,pdb_id,chain_id,location,dssp_location,gene,amino_acid_original,list_amino_acid_variants,variants,baseline_freq_original,description,antigen_name,antigen_chain,antigen_species,resolution,DDG,DDG_antibody,antigen_loc_list,antigen_species_id,groupID
0,4JPV,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody 3bnc117 in complex with hiv-1 gp120,hiv-1 clade a strain 93th057 gp120 with loop d and loopd v5replaced from hiv strain 3415v1,G,human immunodeficiency virus 1,2.827,4.58194,1.56898,"G97,G122,G124,G198,G275,G276,G278,G279,G280,G281,G282,G352,G353,G354,G357,G365,G366,G367,G368,G371,G429,G430,G431,G455,G456,G457,G458,G459,G460,G461,G463,G464,G465,G466,G467,G469,G470,G471,G472,G473,G474",HIV,1
1,4OGX,L,50,50,IGKV1-5,K,['D' 'K'],D,83.73655913978494,Crystal structure of Fab DX-2930 in complex with human plasma kallikrein at 2.4 Angstrom resolution,plasma kallikrein,A,homo sapiens,2.4,1.60285,-1.02401,"A410,A412,A414,A416,A418,A419,A434,A435,A437,A438,A439,A477,A478,A479,A480,A483,A524,A527,A528,A552,A554,A555,A572,A573,A574,A575,A576,A578,A596,A597,A598,A599,A600,A601,A602,A604,A607,A609,A610,A611",Human,2
2,4IDJ,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,S.Aureus a-hemolysin monomer in complex with Fab,alpha-hemolysin,A,staphylococcus aureus,3.36,2.22921,0.390032,"A30,A31,A32,A64,A65,A66,A67,A68,A69,A70,A71,A72,A78,A79,A205,A207,A208,A210,A211,A212,A213,A253,A274,A276",Staphylococcus aureus,3
3,4IDJ,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,S.Aureus a-hemolysin monomer in complex with Fab,alpha-hemolysin,A,staphylococcus aureus,3.36,-1.67275,-0.928692,"A30,A31,A32,A64,A65,A66,A67,A68,A69,A70,A71,A72,A78,A79,A205,A207,A208,A210,A211,A212,A213,A253,A274,A276",Staphylococcus aureus,3
4,4IDJ,H,73,73,IGHV1-69,K,['E' 'K'],E,45.41864139020537,S.Aureus a-hemolysin monomer in complex with Fab,alpha-hemolysin,A,staphylococcus aureus,3.36,0.368753,-0.0337212,"A30,A31,A32,A64,A65,A66,A67,A68,A69,A70,A71,A72,A78,A79,A205,A207,A208,A210,A211,A212,A213,A253,A274,A276",Staphylococcus aureus,3
5,2B1A,L,50,50,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with UG1033 peptide,ug1033 peptide of exterior membrane glycoprotein gp120,P,,2.348,3.70751,3.71906,"P303,P304,P305,P306,P307,P308,P309,P312,P313,P315,P317,P318",,
6,1TJI,H,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal Structure of the broadly neutralizing anti-HIV-1 antibody 2F5 in complex with a gp41 17mer epitope,envelope glycoprotein gp41,P,,2.2,0.587238,0.503417,"P658,P659,P661,P662,P663,P664,P665,P666,P667,P669",,
7,1TJH,H,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal Structure of the broadly neutralizing anti-HIV-1 antibody 2F5 in complex with a gp41 11mer epitope,envelope glycoprotein gp41,P,,2.1,0.955147,-0.236783,"P661,P662,P663,P664,P665,P666,P667,P669",,
8,1TJG,H,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal Structure of the broadly neutralizing anti-HIV-1 antibody 2F5 in complex with a gp41 7mer epitope,envelope glycoprotein gp41,P,,2.0,0.546633,0.490684,"P662,P663,P664,P665,P666,P667,P668",,
9,4TSB,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Structure of a lysozyme antibody complex,lysozyme c,A,gallus gallus,1.95,2.77877,-0.104117,"A21,A22,A23,A24,A27,A99,A101,A102,A103,A104,A106,A107,A109,A111,A112,A113,A114,A116,A117,A118",Chicken,5
10,7RXI,L,50,50,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,Fab234 in complex with the C-terminal alpha-TSR domain of P. falciparum,circumsporozoite protein,A,plasmodium falciparum (isolate 3d7),2.15,8.43987,-0.0798559,"A314,A315,A317,A318,A320,A321,A322,A324,A325,A327,A353,A354,A355,A356,A357,A358,A359,A360,A364",Malaria,6
11,6CMI,D,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody m102.3,glycoprotein g,B,hendra virus,2.72,-0.55853,-0.157082,"B213,B214,B218,B238,B239,B240,B241,B242,B302,B305,B458,B488,B489,B490,B504,B505,B506,B507,B527,B528,B530,B531,B532,B533,B534,B554,B555,B557,B558,B559,B579,B580,B581,B583,B586,B588",Hendra,7
12,6CMI,D,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody m102.3,glycoprotein g,B,hendra virus,2.72,1.32877,1.23096,"B213,B214,B218,B238,B239,B240,B241,B242,B302,B305,B458,B488,B489,B490,B504,B505,B506,B507,B527,B528,B530,B531,B532,B533,B534,B554,B555,B557,B558,B559,B579,B580,B581,B583,B586,B588",Hendra,7
13,6CMG,C,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody m102.3,glycoprotein g,A,hendra virus,2.7,-0.055538,-0.0230831,"A213,A214,A216,A218,A238,A239,A240,A241,A242,A243,A302,A305,A351,A458,A488,A489,A490,A504,A505,A506,A507,A530,A531,A532,A533,A554,A555,A557,A558,A559,A579,A580,A581,A583,A586,A588",Hendra,7
14,6CMG,C,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody m102.3,glycoprotein g,A,hendra virus,2.7,0.531835,0.900011,"A213,A214,A216,A218,A238,A239,A240,A241,A242,A243,A302,A305,A351,A458,A488,A489,A490,A504,A505,A506,A507,A530,A531,A532,A533,A554,A555,A557,A558,A559,A579,A580,A581,A583,A586,A588",Hendra,7
15,6OZ3,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly neutralizing antibody N49P9.1 Fab in complex with HIV-1 Clade A/E strain 93TH057 gp120 core,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,3.15,-2.2361,-2.36491,"G276,G278,G279,G280,G281,G282,G354,G362,G365,G366,G367,G368,G370,G371,G424,G425,G426,G427,G428,G429,G431,G455,G456,G457,G458,G459,G460,G461,G462,G463,G469,G471,G472,G473,G474,G475",HIV,1
16,1H0D,B,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of Human Angiogenin in complex with Fab fragment of its monoclonal antibody mAb 26-2F,angiogenin,C,homo sapiens,2.0,31.3007,-0.355315,"C34,C35,C37,C38,C39,C40,C41,C83,C85,C86,C87,C88,C89,C90,C91,C93",Human,8
17,1H0D,B,52A,52A,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,Crystal structure of Human Angiogenin in complex with Fab fragment of its monoclonal antibody mAb 26-2F,angiogenin,C,homo sapiens,2.0,0.221803,0.215663,"C34,C35,C37,C38,C39,C40,C41,C83,C85,C86,C87,C88,C89,C90,C91,C93",Human,8
18,1H0D,B,53,53,IGHV3-23,G,['S' 'G'],S,0.7007007007007007,Crystal structure of Human Angiogenin in complex with Fab fragment of its monoclonal antibody mAb 26-2F,angiogenin,C,homo sapiens,2.0,0.280769,-0.111111,"C34,C35,C37,C38,C39,C40,C41,C83,C85,C86,C87,C88,C89,C90,C91,C93",Human,8
19,7XNF,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Structure of SARS-CoV-2 antibody P2C-1F11 with GX/P2V/2017 RBD,spike protein s1,A,pangolin coronavirus,2.79,2.64747,-0.166022,"A403,A405,A406,A409,A415,A416,A417,A420,A421,A453,A455,A456,A457,A458,A459,A460,A473,A474,A475,A476,A477,A486,A487,A489,A490,A493,A502,A505",SARS,9
20,6W52,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Prefusion RSV F bound by neutralizing antibody RSB1,fusion glycoprotein f1 fused with fibritin trimerizationdomain  | fusion glycoprotein f0,B | A,"human respiratory syncytial virus a,escherichia phage t2  | human respiratory syncytial virus a (straina2)",3.74,0.304612,-1.32242,"A61,A62,A63,A65,A66,A68,A86,A87,A90,A91,A94,A95,A97,B161,B162,B165,B168,B196,B200,B204,B208,B292,B293,B294,B295",RSV,10
21,4TSA,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Structure of a lysozyme FAb complex,lysozyme c,A,gallus gallus,2.27,3.17194,0.0473323,"A19,A21,A22,A23,A27,A99,A101,A102,A103,A104,A106,A107,A109,A111,A112,A113,A114,A116,A117,A118",Chicken,5
22,4TSC,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Structure of a lysozyme antibody complex,lysozyme c,A,gallus gallus,1.92,2.35122,0.166354,"A19,A21,A22,A23,A24,A27,A101,A102,A103,A104,A106,A107,A109,A111,A112,A113,A114,A116,A117,A118,A120",Chicken,5
23,7E5O,H,50,50,IGHV4-34,E,['E' 'Y'],Y,100.0,Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.8,20.3521,11.9351,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A449,A453,A455,A456,A475,A484,A485,A486,A487,A488,A489,A493,A494,A496,A498,A500,A501,A502,A503,A504,A505",SARS,11
24,7E5O,H,52,52,IGHV4-34,N,['N' 'Y' 'I'],Y,98.8888888888889,Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.8,0.983264,1.89593,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A449,A453,A455,A456,A475,A484,A485,A486,A487,A488,A489,A493,A494,A496,A498,A500,A501,A502,A503,A504,A505",SARS,11
25,7E5O,H,52,52,IGHV4-34,N,['N' 'Y' 'I'],I,98.8888888888889,Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.8,-0.67197,0.392774,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A449,A453,A455,A456,A475,A484,A485,A486,A487,A488,A489,A493,A494,A496,A498,A500,A501,A502,A503,A504,A505",SARS,11
26,7E5O,H,59,59,IGHV4-34,Y,['Y' 'N'],N,100.0,Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.8,2.82259,2.64844,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A449,A453,A455,A456,A475,A484,A485,A486,A487,A488,A489,A493,A494,A496,A498,A500,A501,A502,A503,A504,A505",SARS,11
27,7E5O,L,32,33,IGKV1-17,Y,['D' 'Y'],D,17.73049645390071,Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.8,5.61043,2.2685,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A449,A453,A455,A456,A475,A484,A485,A486,A487,A488,A489,A493,A494,A496,A498,A500,A501,A502,A503,A504,A505",SARS,12
28,7WP2,H,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Cryo-EM structure of SARS-CoV-2 C.1.2 S6P trimer in complex with neutralizing antibody VacW-209 (local refinement),spike protein s1,F,severe acute respiratory syndrome coronavirus2,3.52,0.493481,0.764391,"F369,F370,F371,F372,F374,F377,F378,F379,F380,F381,F382,F383,F384,F385,F403,F405,F406,F407,F408,F409,F411,F412,F413,F414,F415,F416,F417,F420,F421,F427,F428,F429,F455,F460,F505",SARS,13
29,7WP0,H,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Cryo-EM structure of SARS-CoV-2 Delta S6P trimer in complex with neutralizing antibody VacW-209 (local refinement),spike protein s1,F,severe acute respiratory syndrome coronavirus2,0,0.667684,-0.774663,"F369,F370,F371,F372,F374,F377,F378,F379,F380,F381,F382,F383,F384,F385,F386,F403,F405,F406,F407,F408,F409,F411,F412,F413,F414,F415,F416,F417,F420,F427,F428,F429,F505",SARS,13
30,7WP1,H,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Cryo-EM structure of SARS-CoV-2 Mu S6P trimer in complex with neutralizing antibody VacW-209 (local refinement),spike protein s1,F,severe acute respiratory syndrome coronavirus2,3.77,-0.614544,-0.240177,"F368,F369,F370,F371,F372,F374,F377,F378,F379,F380,F381,F383,F384,F385,F386,F403,F405,F406,F408,F409,F410,F411,F412,F413,F414,F415,F416,F417,F420,F421,F427,F428,F429,F460,F502,F505",SARS,13
31,5CD5,C,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of an immature VRC01-class antibody DRVIA7 from a Chinese donor bound to clade A/E HIV-1 gp120 core,93th057 hiv-1 gp120 core,A,human immunodeficiency virus 1,3.3960000000000000,3.24837,1.16563,"A97,A275,A276,A278,A279,A280,A281,A282,A353,A354,A357,A360,A365,A366,A367,A368,A371,A425,A429,A432,A455,A456,A457,A458,A459,A460,A461,A462,A463,A465,A466,A467,A469,A472,A473,A474,A476",HIV,1
32,6OZ4,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly neutralizing antibody N49P6 Fab in complex with HIV-1 BG505 SOSIP.664 Env trimer ectodomain.,envelope glycoprotein gp160,G,human immunodeficiency virus 1,4.05,0.98809,0.0750904,"G97,G102,G198,G275,G276,G278,G279,G280,G281,G282,G283,G360,G364,G365,G366,G367,G368,G370,G371,G428,G430,G455,G456,G457,G458,G459,G460,G461,G465,G467,G469,G472,G473,G474,G476,G480",HIV,1
33,7TLZ,B,26,26,IGHV3-30,G,['G' 'A'],A,100.0,SARS-CoV-2 S NTD B.1.1.529 Omicron variant + S309 Local Refinement,spike glycoprotein,J,homo sapiens,3.3,5.18176,4.74752,"J25,J26,J28,J61,J63,J65,J82,J83,J84,J85,J87,J88,J108,J109,J110,J111,J113,J114,J134,J137,J234,J236,J237,J269,J270,J271,J272",Human,14
34,7TLZ,B,52,52,IGHV3-30,R,['S' 'R'],S,8.548707753479125,SARS-CoV-2 S NTD B.1.1.529 Omicron variant + S309 Local Refinement,spike glycoprotein,J,homo sapiens,3.3,0.357437,1.38355,"J25,J26,J28,J61,J63,J65,J82,J83,J84,J85,J87,J88,J108,J109,J110,J111,J113,J114,J134,J137,J234,J236,J237,J269,J270,J271,J272",Human,14
35,7SU1,H,50,50,IGHV3-30,F,['V' 'F'],V,8.548707753479125,Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.106 in complex with CTLA-4,cytotoxic t-lymphocyte protein 4,C,homo sapiens,2.53,5.12225,3.07854,"C2,C3,C33,C35,C39,C41,C44,C46,C47,C48,C53,C93,C95,C97,C99,C102,C103,C104,C105,C106,C107,C108",Human,15
36,7SU1,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Crystal structure of an acidic pH-selective Ipilimumab variant Ipi.106 in complex with CTLA-4,cytotoxic t-lymphocyte protein 4,C,homo sapiens,2.53,2.27265,0.82962,"C2,C3,C33,C35,C39,C41,C44,C46,C47,C48,C53,C93,C95,C97,C99,C102,C103,C104,C105,C106,C107,C108",Human,15
37,3GO1,H,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal structure of anti-HIV-1 Fab 268-D in complex with V3 peptide MN,envelope glycoprotein gp160,P,,1.89,6.29904,3.33187,"P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P317",,
38,3GO1,H,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,Crystal structure of anti-HIV-1 Fab 268-D in complex with V3 peptide MN,envelope glycoprotein gp160,P,,1.89,7.3062,0.996143,"P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P317",,
39,3GO1,H,58,58,IGHV4-59,N,['N' 'Y'],Y,100.0,Crystal structure of anti-HIV-1 Fab 268-D in complex with V3 peptide MN,envelope glycoprotein gp160,P,,1.89,4.64669,1.40526,"P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P317",,
40,7KRA,I,25,27,IGHV4-34,Y,['Y' 'S'],S,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,0.017905,0.63878,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
41,7KRA,I,26,28,IGHV4-34,G,['G' 'F'],F,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,11.0817,8.57037,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
42,7KRA,I,27,29,IGHV4-34,G,['G' 'S'],S,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,-0.0663109,-0.0572215,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
43,7KRA,I,28,30,IGHV4-34,S,['S' 'T' 'G'],T,99.44444444444446,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,2.19364,1.30033,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
44,7KRA,I,28,30,IGHV4-34,S,['S' 'T' 'G'],G,99.44444444444446,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,-0.17219,-0.807172,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
45,7KRA,I,29,31,IGHV4-34,F,['F' 'V' 'Y'],V,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,2.86511,2.45046,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
46,7KRA,I,29,31,IGHV4-34,F,['F' 'V' 'Y'],Y,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,0.759907,0.751471,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
47,7KRA,I,30,32,IGHV4-34,S,['S' 'Y'],Y,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,-0.970375,-1.19606,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
48,7KRA,I,31,33,IGHV4-34,G,['G' 'W'],W,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,4.59061,1.97528,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
49,7KRA,I,32,34,IGHV4-34,Y,['Y' 'S'],S,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,1.09754,-0.0554912,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
50,7KRA,I,52,54,IGHV4-34,N,['N' 'Y' 'I'],Y,98.8888888888889,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,0.428561,-1.57759,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
51,7KRA,I,52,54,IGHV4-34,N,['N' 'Y' 'I'],I,98.8888888888889,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,1.23575,1.9322,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
52,7KRA,I,53,55,IGHV4-34,H,['H' 'Y'],Y,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to Fab-DH4 in lipid nanodiscs,er membrane protein complex subunit 1,A,saccharomyces cerevisiae,3.2,-1.9399999999998272,-1.3910000000000196,"A42,A43,A44,A45,A62,A63,A64,A88,A89,A90,A135,A136,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A150,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A177,A190,A193,A194,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352",Yeast,16
53,7KET,A,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein,factor h binding protein,C,neisseria meningitidis,2.0,22.9562,9.86104,"C47,C49,C50,C51,C52,C54,C77,C78,C79,C81,C83,C86,C87,C88,C90,C93,C94,C95,C112,C113,C119,C120,C121,C122,C123,C125,C127",Meningococcus,17
54,7KET,A,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein,factor h binding protein,C,neisseria meningitidis,2.0,1.77412,-0.0340134,"C47,C49,C50,C51,C52,C54,C77,C78,C79,C81,C83,C86,C87,C88,C90,C93,C94,C95,C112,C113,C119,C120,C121,C122,C123,C125,C127",Meningococcus,17
55,7KET,A,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein,factor h binding protein,C,neisseria meningitidis,2.0,-0.613251,0.170829,"C47,C49,C50,C51,C52,C54,C77,C78,C79,C81,C83,C86,C87,C88,C90,C93,C94,C95,C112,C113,C119,C120,C121,C122,C123,C125,C127",Meningococcus,17
56,7WRJ,A,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Local CryoEM structure of the SARS-CoV-2 S6P(B.1.1.529) in complex with BD55-4637 Fab,spike protein s1,R,severe acute respiratory syndrome coronavirus2,0,0.476861,-0.0769609,"R372,R373,R374,R375,R376,R377,R378,R380,R403,R404,R405,R407,R408,R410,R414,R433,R435,R436,R437,R439,R440,R496,R498,R499,R500,R501,R502,R503,R504,R505,R506,R508",SARS,18
57,7E3B,B,31,31,IGHV4-59,S,['S' 'Y'],Y,100.0,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,4.2,-0.265597,0.55535,"A345,A346,A347,A348,A349,A351,A352,A354,A441,A442,A444,A445,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A482,A483,A484,A490,A492,A509",SARS,19
58,7E3B,B,32,32,IGHV4-59,Y,['Y' 'W' 'H'],W,92.13483146067416,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,4.2,-0.39235,0.191937,"A345,A346,A347,A348,A349,A351,A352,A354,A441,A442,A444,A445,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A482,A483,A484,A490,A492,A509",SARS,19
59,7E3B,B,32,32,IGHV4-59,Y,['Y' 'W' 'H'],H,92.13483146067416,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,4.2,0.431111,0.434375,"A345,A346,A347,A348,A349,A351,A352,A354,A441,A442,A444,A445,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A482,A483,A484,A490,A492,A509",SARS,19
60,7E3B,B,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,4.2,1.7372,2.51031,"A345,A346,A347,A348,A349,A351,A352,A354,A441,A442,A444,A445,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A482,A483,A484,A490,A492,A509",SARS,19
61,7E3B,B,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,4.2,4.06914,1.54607,"A345,A346,A347,A348,A349,A351,A352,A354,A441,A442,A444,A445,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A482,A483,A484,A490,A492,A509",SARS,19
62,7E3B,B,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,4.2,1.43381,1.71471,"A345,A346,A347,A348,A349,A351,A352,A354,A441,A442,A444,A445,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A482,A483,A484,A490,A492,A509",SARS,19
63,7E3B,B,58,58,IGHV4-59,N,['N' 'Y'],Y,100.0,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,4.2,-1.04981,-1.03194,"A345,A346,A347,A348,A349,A351,A352,A354,A441,A442,A444,A445,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A482,A483,A484,A490,A492,A509",SARS,19
64,7E39,C,31,31,IGHV3-33,S,['S' 'R'],R,99.69788519637464,SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,-0.853576,-0.562046,"A456,A474,A475,A476,A477,A478,A479,A480,A483,A484,A485,A486,A487,A488,A489",SARS,20
65,7E39,C,35,35,IGHV3-33,H,['H' 'Y'],Y,99.69788519637464,SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,2.3759999999999764,2.8057,"A456,A474,A475,A476,A477,A478,A479,A480,A483,A484,A485,A486,A487,A488,A489",SARS,20
66,7E39,C,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,-1.3641,-0.411439,"A456,A474,A475,A476,A477,A478,A479,A480,A483,A484,A485,A486,A487,A488,A489",SARS,20
67,8DLX,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6,spike glycoprotein | spike glycoprotein,C | A,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,5.18703,5.19247,"A113,A372,A374,A375,A376,A377,A378,A379,A380,A404,A405,A407,A408,A411,A414,A439,A499,A500,A501,A502,A503,A504,A506,A508,C349,C351,C444,C446,C447,C448,C449,C450,C452,C455,C468,C470,C471,C472,C473,C480,C481,C482,C483,C486,C487,C488,C489,C490,C492,C493,C494,C496,C498",SARS,21
68,8DLX,H,94,97,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6,spike glycoprotein | spike glycoprotein,C | A,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,1.1262,1.00466,"A113,A372,A374,A375,A376,A377,A378,A379,A380,A404,A405,A407,A408,A411,A414,A439,A499,A500,A501,A502,A503,A504,A506,A508,C349,C351,C444,C446,C447,C448,C449,C450,C452,C455,C468,C470,C471,C472,C473,C480,C481,C482,C483,C486,C487,C488,C489,C490,C492,C493,C494,C496,C498",SARS,21
69,8DLR,H,54,74,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4-8 (focused refinement of NTD and 4-8),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,1.12757,0.265829,"A14,A15,A144,A145,A146,A147,A148,A152,A154,A155,A156,A157,A158,A161,A246,A247,A248,A249,A250,A251,A252,A253,A254",SARS,22
70,7EKB,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of 4E10 modified with pyrene acetamide,mper region of the hiv-1 envelope glycoprotein proteingp41,P,human immunodeficiency virus 1,1.45,2.9453,-0.795012,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
71,7EKB,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of 4E10 modified with pyrene acetamide,mper region of the hiv-1 envelope glycoprotein proteingp41,P,human immunodeficiency virus 1,1.45,16.479,0.702523,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
72,7EKB,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of 4E10 modified with pyrene acetamide,mper region of the hiv-1 envelope glycoprotein proteingp41,P,human immunodeficiency virus 1,1.45,0.780815,-0.098988,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
73,7EKB,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of 4E10 modified with pyrene acetamide,mper region of the hiv-1 envelope glycoprotein proteingp41,P,human immunodeficiency virus 1,1.45,1.5493,1.04683,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
74,7EKK,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Anti-HIV-1 broadly neutralizing antibody delta-loop 4E10 modified with pyrene acetamide,mper region of the envelope glycoprotein gp41 from hiv-1,P,human immunodeficiency virus 1,1.7,2.17213,-0.75198,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
75,7EKK,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Anti-HIV-1 broadly neutralizing antibody delta-loop 4E10 modified with pyrene acetamide,mper region of the envelope glycoprotein gp41 from hiv-1,P,human immunodeficiency virus 1,1.7,13.3295,-1.2246,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
76,7EKK,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Anti-HIV-1 broadly neutralizing antibody delta-loop 4E10 modified with pyrene acetamide,mper region of the envelope glycoprotein gp41 from hiv-1,P,human immunodeficiency virus 1,1.7,0.287765,-0.0332047,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
77,7EKK,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Anti-HIV-1 broadly neutralizing antibody delta-loop 4E10 modified with pyrene acetamide,mper region of the envelope glycoprotein gp41 from hiv-1,P,human immunodeficiency virus 1,1.7,1.33499,1.24295,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
78,7BYR,L,50,50,IGKV1-5,K,['D' 'K'],D,83.73655913978494,BD23-Fab in complex with the S ectodomain trimer,sars-cov-2 spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,3.84,0.713908,0.557206,"B446,B449,B452,B453,B456,B470,B472,B483,B484,B485,B486,B487,B489,B490,B492,B493,B494,B496,B498,B500,B501,B505",SARS,24
79,7N8I,H,33,33,IGHV3-30,G,['A' 'G'],A,68.58846918489066,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3,1.51092,1.55449,"A28,A61,A63,A65,A82,A83,A84,A85,A87,A88,A108,A109,A110,A111,A113,A114,A234,A236,A237,A269,A270,A271,A272",SARS,25
80,7N8I,H,52,52,IGHV3-30,R,['S' 'R'],S,8.548707753479125,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3,-0.40409,-0.280662,"A28,A61,A63,A65,A82,A83,A84,A85,A87,A88,A108,A109,A110,A111,A113,A114,A234,A236,A237,A269,A270,A271,A272",SARS,25
81,6PWU,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,"Structure of full-length, fully glycosylated, non-modified HIV-1 gp160 bound to PG16 Fab",envelope glycoprotein gp160 | envelope glycoprotein gp160 | envelope glycoprotein gp160,A | C | E,human immunodeficiency virus 1 | human immunodeficiency virus 1 | human immunodeficiency virus 1,6.2,5.6728,4.99645,"A158,A160,A163,A167,A168,A169,A170,A171,A172,A173,A308,C167,E128,E185,E186,E187,E188,E189,E190",HIV,26
82,7SBU,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a highly potent antibody J08 Fab,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.53,-1.50031,-0.688759,"A417,A449,A453,A455,A456,A473,A475,A476,A477,A478,A479,A484,A485,A486,A487,A489,A490,A492,A493",SARS,27
83,7SBU,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a highly potent antibody J08 Fab,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.53,5.1156,4.75377,"A417,A449,A453,A455,A456,A473,A475,A476,A477,A478,A479,A484,A485,A486,A487,A489,A490,A492,A493",SARS,27
84,4NHC,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41.,modified fragment of hiv glycoprotein (gp41),P,,2.912,3.55107,-0.280621,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",,
85,4NHC,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41.,modified fragment of hiv glycoprotein (gp41),P,,2.912,16.2928,1.81425,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",,
86,4NHC,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41.,modified fragment of hiv glycoprotein (gp41),P,,2.912,2.08618,1.80423,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",,
87,7AHV,B,50,50,IGKV1-5,K,['D' 'K'],D,83.73655913978494,Anti-FIXa Fab of mim8 in complex with human FIXa,coagulation factor ix,H,homo sapiens,3.11,-0.0812277,-0.756127,"H96,H97,H164,H165,H166,H167,H169,H170,H171,H172,H173,H174,H175,H177,H185,H224",Human,28
88,6C5V,L,50,49,IGLV3-21,Y,['Y' 'D'],D,33.71757925072046,An anti-gH/gL antibody that neutralizes dual-tropic infection defines a site of vulnerability on Epstein-Barr virus,envelope glycoprotein h | glycoprotein 42 | envelope glycoprotein l,A | C | B,human herpesvirus 4 | human herpesvirus 4 | human herpesvirus 4,4.8,3.52081,1.85067,"A66,A69,A70,A72,A73,A74,A76,A77,A78,A79,A80,A81,A214,A215,A232,A233,A235,A236,A239,A240,A243,A285,B123,B124,B125,B126,B127,B128,C168,C171,C172,C183,C184,C185,C186,C200,C201",EBV,29
89,6D2P,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of IOMA-class CLK31 Fab from an HIV-1 naive donor in complex with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.6 A,germline-targeting hiv-1 gp120 engineered outer domain eod-gt8,C,homo sapiens,2.6,3.13865,1.7536,"C25,C26,C27,C28,C29,C30,C31,C35,C36,C37,C39,C42,C43,C44,C47,C79,C81,C82,C83,C84,C85,C86,C135,C138,C139,C140,C141,C143,C144",Human,30
90,6D2P,H,61,62,IGHV1-2,Q,['Q' 'H'],H,94.54314720812184,Crystal structure of IOMA-class CLK31 Fab from an HIV-1 naive donor in complex with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.6 A,germline-targeting hiv-1 gp120 engineered outer domain eod-gt8,C,homo sapiens,2.6,0.622693,0.271916,"C25,C26,C27,C28,C29,C30,C31,C35,C36,C37,C39,C42,C43,C44,C47,C79,C81,C82,C83,C84,C85,C86,C135,C138,C139,C140,C141,C143,C144",Human,30
91,4RFO,H,33,33,IGHV4-31,G,['G' 'S'],S,100.0,Crystal structure of the ADCC-Potent Antibody N60-I3 Fab in complex with HIV-1 Clade A/E gp120 and M48u1,hiv-1 clade a/e gp120,G,human immunodeficiency virus 1,3.2,14.9544,7.21398,"G50,G51,G52,G53,G54,G60,G68,G69,G71,G72,G73,G74,G75,G76,G77,G78,G79,G103,G106,G107,G114,G217,G219,G220,G221",HIV,31
92,4RFO,L,29,29,IGLV2-14,G,['G' 'S'],S,97.74590163934424,Crystal structure of the ADCC-Potent Antibody N60-I3 Fab in complex with HIV-1 Clade A/E gp120 and M48u1,hiv-1 clade a/e gp120,G,human immunodeficiency virus 1,3.2,13.1967,12.8611,"G50,G51,G52,G53,G54,G60,G68,G69,G71,G72,G73,G74,G75,G76,G77,G78,G79,G103,G106,G107,G114,G217,G219,G220,G221",HIV,32
93,4RFO,L,32,32,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,Crystal structure of the ADCC-Potent Antibody N60-I3 Fab in complex with HIV-1 Clade A/E gp120 and M48u1,hiv-1 clade a/e gp120,G,human immunodeficiency virus 1,3.2,3.38149,1.76305,"G50,G51,G52,G53,G54,G60,G68,G69,G71,G72,G73,G74,G75,G76,G77,G78,G79,G103,G106,G107,G114,G217,G219,G220,G221",HIV,32
94,6WO4,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody HC11,envelope glycoprotein e2,E,recombinant hepatitis c virus hk6a/jfh-1,2.349,"-nan
","-nan
","E422,E423,E427,E428,E429,E430,E431,E432,E433,E434,E438,E439,E441,E442,E443,E444,E445,E529,E531",HCV,33
95,6WO4,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody HC11,envelope glycoprotein e2,E,recombinant hepatitis c virus hk6a/jfh-1,2.349,"-nan
","-nan
","E422,E423,E427,E428,E429,E430,E431,E432,E433,E434,E438,E439,E441,E442,E443,E444,E445,E529,E531",HCV,33
96,6WO3,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody U1,envelope glycoprotein e2,E,recombinant hepatitis c virus hk6a/jfh-1,2.382,0.455026,0.118485,"E423,E427,E428,E429,E430,E431,E432,E434,E438,E439,E442,E443,E500,E528,E529,E531,E557",HCV,34
97,6WO3,H,73,73,IGHV1-69,E,['E' 'K'],K,54.58135860979463,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody U1,envelope glycoprotein e2,E,recombinant hepatitis c virus hk6a/jfh-1,2.382,-0.210458,-0.292538,"E423,E427,E428,E429,E430,E431,E432,E434,E438,E439,E442,E443,E500,E528,E529,E531,E557",HCV,34
98,6NMV,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Non-Blocking Fab 218 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1,tyrosine-protein phosphatase non-receptor type substrate 1,S,homo sapiens,2.61,19.6789,-0.339585,"S37,S39,S40,S41,S42,S43,S44,S45,S46,S47,S48,S86,S87,S88,S90,S92,S94,S99,S102,S103,S104,S106,S108,S111",Human,35
99,6NMV,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Non-Blocking Fab 218 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1,tyrosine-protein phosphatase non-receptor type substrate 1,S,homo sapiens,2.61,-0.644603,-0.218659,"S37,S39,S40,S41,S42,S43,S44,S45,S46,S47,S48,S86,S87,S88,S90,S92,S94,S99,S102,S103,S104,S106,S108,S111",Human,35
100,5TE4,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal Structure of Broadly Neutralizing VRC01-class Antibody N6 in Complex with HIV-1 Clade G Strain X2088 gp120 Core,hiv-1 clade g strain x2088 gp120,G,human immunodeficiency virus 1,2.75,6.08481,2.1193,"G97,G124,G198,G275,G276,G278,G279,G280,G281,G282,G283,G355C,G355D,G365,G366,G367,G368,G370,G371,G425,G426,G427,G430,G455,G456,G457,G458,G459,G460,G461,G462,G463,G469,G471,G472,G473,G474,G475,G476",HIV,1
101,6UYN,H,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of influenza A virus hemagglutinin from A/Ohio/09/2015 bound to the stalk-binding CR6261 antibody Fab,hemagglutinin ha1 chain | hemagglutinin ha1 chain,B | A,influenza a virus | influenza a virus,2.85,1.19812,-0.249752,"A25,A45,A47,A48,A49,A306,A307,A308,A333,B362,B363,B364,B365,B382,B385,B386,B389,B390,B392,B393,B396,B397,B400",influenza,36
102,6UYN,H,56,57,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Crystal structure of influenza A virus hemagglutinin from A/Ohio/09/2015 bound to the stalk-binding CR6261 antibody Fab,hemagglutinin ha1 chain | hemagglutinin ha1 chain,B | A,influenza a virus | influenza a virus,2.85,-1.00083,-0.680996,"A25,A45,A47,A48,A49,A306,A307,A308,A333,B362,B363,B364,B365,B382,B385,B386,B389,B390,B392,B393,B396,B397,B400",influenza,36
103,5TE7,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal Structure of Broadly Neutralizing VRC01-class Antibody N6 in Complex with HIV-1 Clade C Strain DU172.17 gp120 Core,hiv-1 gp120 core,G,human immunodeficiency virus 1,2.15,5.52058,2.73647,"G97,G124,G198,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G370,G371,G425,G426,G427,G430,G455,G456,G457,G458,G459,G460,G462,G469,G472,G473,G474,G475,G476",HIV,1
104,6BLH,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,RSV G central conserved region bound to Fab CB017.5,major surface glycoprotein g,G,human respiratory syncytial virus a (strainrsb6256),2.0,3.74841,1.77637,"G164,G165,G166,G167,G168,G169,G170,G172,G174,G175,G188,G189,G190,G191,G192,G193,G194,G195,G196",RSV,37
105,6BLH,H,94,94,IGHV3-33,R,['R' 'K'],K,92.14501510574016,RSV G central conserved region bound to Fab CB017.5,major surface glycoprotein g,G,human respiratory syncytial virus a (strainrsb6256),2.0,3.04532,2.23687,"G164,G165,G166,G167,G168,G169,G170,G172,G174,G175,G188,G189,G190,G191,G192,G193,G194,G195,G196",RSV,37
106,5T85,H,50,50,IGHV3-15,R,['R' 'C'],C,100.0,Crystal structure of 10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidylglycerol (06:0 PG),10e8 epitope scaffold t117v2,G,synthetic construct,2.373,2.20228,2.48784,"G9,G10,G64,G65,G66,G73,G79,G118,G119,G120,G121,G124,G125,G127,G128,G130,G131,G134,G135,G162",Synthetic,38
107,5T80,H,50,50,IGHV3-15,R,['R' 'C'],C,100.0,Crystal structure of 10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidic acid (06:0 PA),10e8 epitope scaffold t117v2,G,synthetic construct,2.62,-0.629457,-0.935666,"G64,G65,G66,G73,G78,G79,G118,G119,G120,G121,G124,G125,G127,G128,G130,G131,G134,G135",Synthetic,38
108,5T80,H,58,58,IGHV3-15,D,['D' 'N'],N,99.45054945054945,Crystal structure of 10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidic acid (06:0 PA),10e8 epitope scaffold t117v2,G,synthetic construct,2.62,0.385893,0.577057,"G64,G65,G66,G73,G78,G79,G118,G119,G120,G121,G124,G125,G127,G128,G130,G131,G134,G135",Synthetic,38
109,7BEH,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,spike glycoprotein,E,severe acute respiratory syndrome coronavirus2,2.3,21.4482,4.28981,"E444,E446,E447,E449,E452,E453,E455,E456,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498",SARS,39
110,7EOW,B,52,53,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,"High-resolution structure of vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine",von willebrand factor,A,homo sapiens,1.6,17.858,13.2807,"A27,A28,A29,A30,A31,A32,A33,A34,A35,A36,A37,A38,A39,A72,A76,A77,A222,A223,A227,A228",Human,40
111,2UZI,H,33,33,IGHV3-48,S,['S' 'E'],E,47.05882352941176,Crystal structure of HRAS(G12V) - anti-RAS Fv complex,gtpase hras,R,homo sapiens,2.0,5.95616,-1.85182,"R12,R17,R21,R25,R27,R29,R31,R32,R33,R34,R35,R36,R37,R38,R39,R40,R56,R61,R63,R64,R67",Human,41
112,6U36,L,69,69,IGKV3-11,T,['T' 'R'],R,99.56958393113344,PCSK9 in complex with a Fab and compound 14,proprotein convertase subtilisin/kexin type 9,B,homo sapiens,2.7,-0.325231,-0.29531,"B153,B155,B193,B194,B195,B197,B237,B238,B239,B369,B374,B375,B376,B377,B378,B379",Human,42
113,4XVJ,H,50,50,IGHV3-23,A,['A' 'V'],V,99.2992992992993,STUCTURE OF THE HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 ANTIGENIC 2 REGION 412-423 BOUND TO THE BROADLY NEUTRALIZING ANTIBODY HC33.1,hcv e2 antigen,A,hepatitis c virus,2.0,8.20891,0.463835,"A1,A412,A413,A414,A415,A416,A417,A418,A419,A420,A421,A422",HCV,43
114,4XVJ,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,STUCTURE OF THE HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 ANTIGENIC 2 REGION 412-423 BOUND TO THE BROADLY NEUTRALIZING ANTIBODY HC33.1,hcv e2 antigen,A,hepatitis c virus,2.0,8.08509,-1.34545,"A1,A412,A413,A414,A415,A416,A417,A418,A419,A420,A421,A422",HCV,43
115,4XVJ,H,52A,53,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,STUCTURE OF THE HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 ANTIGENIC 2 REGION 412-423 BOUND TO THE BROADLY NEUTRALIZING ANTIBODY HC33.1,hcv e2 antigen,A,hepatitis c virus,2.0,-0.327918,-0.131469,"A1,A412,A413,A414,A415,A416,A417,A418,A419,A420,A421,A422",HCV,43
116,4XVJ,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,STUCTURE OF THE HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 ANTIGENIC 2 REGION 412-423 BOUND TO THE BROADLY NEUTRALIZING ANTIBODY HC33.1,hcv e2 antigen,A,hepatitis c virus,2.0,-0.393944,-0.422139,"A1,A412,A413,A414,A415,A416,A417,A418,A419,A420,A421,A422",HCV,43
117,4XVJ,L,50,51,IGLV1-51,D,['D' 'E'],E,83.18318318318319,STUCTURE OF THE HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 ANTIGENIC 2 REGION 412-423 BOUND TO THE BROADLY NEUTRALIZING ANTIBODY HC33.1,hcv e2 antigen,A,hepatitis c virus,2.0,-0.965837,0.8063,"A1,A412,A413,A414,A415,A416,A417,A418,A419,A420,A421,A422",HCV,44
118,4XVS,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of HIV-1 donor 45 d45-01dG5 coreE gp120 with antibody 45-VRC01.H01+07.O-863513/45-VRC01.L01+07.O-110653 (VRC07_1995),donor 45 01dg5 coree gp120,G,human immunodeficiency virus 1,1.9,3.62486,1.74416,"G96,G97,G102,G275,G276,G278,G279,G280,G281,G282,G283,G362,G365,G366,G367,G368,G371,G430,G455,G456,G457,G458,G459,G460,G461,G462,G463,G467,G470,G472,G473,G474,G475,G477,G481",HIV,1
119,4XVS,H,61,62,IGHV1-2,Q,['Q' 'H'],H,94.54314720812184,Crystal structure of HIV-1 donor 45 d45-01dG5 coreE gp120 with antibody 45-VRC01.H01+07.O-863513/45-VRC01.L01+07.O-110653 (VRC07_1995),donor 45 01dg5 coree gp120,G,human immunodeficiency virus 1,1.9,0.0752787,0.259492,"G96,G97,G102,G275,G276,G278,G279,G280,G281,G282,G283,G362,G365,G366,G367,G368,G371,G430,G455,G456,G457,G458,G459,G460,G461,G462,G463,G467,G470,G472,G473,G474,G475,G477,G481",HIV,1
120,4XVT,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of HIV-1 93TH057 coreE gp120 with antibody 45-VRC01.H01+07.O-863513/45-VRC01.L01+07.O-110653 (VRC07_1995),envelope glycoprotein gp120 of hiv-1 clade a/e,G,human immunodeficiency virus 1,1.69,4.23563,1.78946,"G96,G97,G102,G105,G275,G276,G278,G279,G280,G281,G282,G283,G362,G365,G366,G367,G368,G371,G427,G429,G430,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G467,G469,G472,G473,G474,G476,G480",HIV,1
121,4XVT,H,61,62,IGHV1-2,Q,['Q' 'H'],H,94.54314720812184,Crystal structure of HIV-1 93TH057 coreE gp120 with antibody 45-VRC01.H01+07.O-863513/45-VRC01.L01+07.O-110653 (VRC07_1995),envelope glycoprotein gp120 of hiv-1 clade a/e,G,human immunodeficiency virus 1,1.69,-1.12631,0.356627,"G96,G97,G102,G105,G275,G276,G278,G279,G280,G281,G282,G283,G362,G365,G366,G367,G368,G371,G427,G429,G430,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G467,G469,G472,G473,G474,G476,G480",HIV,1
122,7RAL,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains),spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,NOT,4.02114,4.07449,"B369,B370,B371,B372,B373,B374,B375,B376,B377,B378,B379,B380,B381,B382,B383,B384,B385,B404,B405,B407,B408,B414,B437,B501,B502,B503,B504,B505,B506,B508",SARS,45
123,7RAL,H,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains),spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,NOT,0.38,0.2401,"B369,B370,B371,B372,B373,B374,B375,B376,B377,B378,B379,B380,B381,B382,B383,B384,B385,B404,B405,B407,B408,B414,B437,B501,B502,B503,B504,B505,B506,B508",SARS,45
124,5GMQ,B,33,30,IGHV1-69,A,['A' 'T'],T,95.260663507109,Structure of MERS-CoV RBD in complex with a fully human antibody MCA1,s protein,A,middle east respiratory syndrome coronavirus,2.703,3.6636,1.83371,"A502,A506,A508,A510,A511,A513,A528,A529,A531,A533,A535,A536,A538,A539,A540,A541,A542,A543,A544,A553,A555,A557",MERS,46
125,5GMQ,B,50,47,IGHV1-69,R,['G' 'R'],G,16.350710900473935,Structure of MERS-CoV RBD in complex with a fully human antibody MCA1,s protein,A,middle east respiratory syndrome coronavirus,2.703,0.918465,0.491435,"A502,A506,A508,A510,A511,A513,A528,A529,A531,A533,A535,A536,A538,A539,A540,A541,A542,A543,A544,A553,A555,A557",MERS,46
126,5GMQ,B,54,52,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Structure of MERS-CoV RBD in complex with a fully human antibody MCA1,s protein,A,middle east respiratory syndrome coronavirus,2.703,1.28686,0.0703884,"A502,A506,A508,A510,A511,A513,A528,A529,A531,A533,A535,A536,A538,A539,A540,A541,A542,A543,A544,A553,A555,A557",MERS,46
127,5GMQ,B,73,71,IGHV1-69,K,['E' 'K'],E,45.41864139020537,Structure of MERS-CoV RBD in complex with a fully human antibody MCA1,s protein,A,middle east respiratory syndrome coronavirus,2.703,1.71303,0.590729,"A502,A506,A508,A510,A511,A513,A528,A529,A531,A533,A535,A536,A538,A539,A540,A541,A542,A543,A544,A553,A555,A557",MERS,46
128,6O2C,A,33,33,IGHV3-49,A,['A' 'P'],P,100.0,Crystal structure of 4493 Fab in complex with circumsporozoite protein NANP3 and anti-kappa VHH domain,circumsporozoite protein,C,plasmodium falciparum,2.017,-0.884289,-1.73799,"C2,C3,C4,C5,C6,C7,C8,C9,C10,C11,C12",Malaria,47
129,6O26,A,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of 3246 Fab in complex with circumsporozoite protein NANA,circumsporozoite protein,C,plasmodium falciparum,1.8,2.48682,1.96946,"C5,C6,C7,C8,C9,C10,C11,C12,C13",Malaria,48
130,6O24,A,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of 4498 Fab in complex with circumsporozoite protein NANP3 and anti-Kappa VHH domain,circumsporozoite protein,I,plasmodium falciparum,1.4,1.74636,1.92251,"I3,I4,I5,I6,I7,I8,I9,I10,I11,I12",Malaria,48
131,5F45,H,33,33,IGHV3-48,E,['S' 'E'],S,52.94117647058824,Crystal structure of Fab H7.167 in complex with influenza virus hemagglutinin from A/Shanghai/02/2013 (H7N9),hemagglutinin ha1 chain,A,influenza a virus,4.656,-3.65227,-0.476836,"A130,A131,A133,A157,A158,A158A,A158B,A159,A160,A161,A162,A163,A192,A193,A196,A197,A198,A199,A200,A248",influenza,49
132,6CO3,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,aducanumab abeta complex,ala-glu-phe-arg-his-asp,Q,homo sapiens,2.384,5.2926,3.34331,"Q3,Q4,Q5,Q6",Human,50
133,6UCF,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,N123-VRC34_pI4 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519,hiv fusion peptide,A,human immunodeficiency virus 1,1.29,3.41017,2.28464,"A512,A513,A514,A515,A516,A517,A518",HIV,51
134,5VL7,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,PCSK9 complex with Fab33,proprotein convertase subtilisin/kexin type 9,B,homo sapiens,3.5,3.50522,-1.61832,"B194,B195,B197,B233,B237,B238,B239,B241,B243,B340,B341,B342,B343,B364,B366,B367,B368,B369,B374,B375,B376,B377,B378,B379,B380,B381,B391",Human,52
135,5VL7,L,30,30,IGKV1-13,S,['I' 'S'],I,100.0,PCSK9 complex with Fab33,proprotein convertase subtilisin/kexin type 9,B,homo sapiens,3.5,0.135836,1.23252,"B194,B195,B197,B233,B237,B238,B239,B241,B243,B340,B341,B342,B343,B364,B366,B367,B368,B369,B374,B375,B376,B377,B378,B379,B380,B381,B391",Human,53
136,5VL7,L,32,32,IGKV1-13,A,['S' 'A'],S,100.0,PCSK9 complex with Fab33,proprotein convertase subtilisin/kexin type 9,B,homo sapiens,3.5,3.39668,1.06075,"B194,B195,B197,B233,B237,B238,B239,B241,B243,B340,B341,B342,B343,B364,B366,B367,B368,B369,B374,B375,B376,B377,B378,B379,B380,B381,B391",Human,53
137,5MEV,H,50,50,IGHV3-21,S,['S' 'Y'],Y,100.0,MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 21,"induced myeloid leukemia cell differentiation protein mcl-1homolog,induced myeloid leukemia cell differentiation protein mcl-1",A,"mus musculus, homo sapiens",2.94,27.1279,6.92868,"A174,A177,A204,A205,A208,A212,A307,A308,A309,A310,A311,A313,A316,A317,A318,A320,A321,A322",Human,54
138,5MES,H,50,50,IGHV3-21,S,['S' 'Y'],Y,100.0,MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 29,"induced myeloid leukemia cell differentiation protein mcl-1homolog,induced myeloid leukemia cell differentiation protein mcl-1",A,"mus musculus, homo sapiens",2.24,14.476,1.45685,"A174,A177,A204,A205,A208,A307,A308,A309,A310,A311,A312,A313,A314,A316,A317,A318,A320,A322",Human,54
139,4M5Z,L,50,50,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,"Crystal structure of broadly neutralizing antibody 5J8 bound to 2009 pandemic influenza hemagglutinin, HA1 subunit",hemagglutinin ha1 chain,A,influenza a virus,2.25,12.3165,10.0323,"A98,A133,A133A,A134,A135,A136,A137,A140,A142,A143,A144,A145,A153,A155,A183,A187,A188,A189,A190,A192,A193,A194,A222,A225,A226,A227",influenza,55
140,4HS8,H,58,58,IGHV3-11,N,['Y' 'N'],Y,43.54838709677419,Hepatitus C envelope glycoprotein E2 fragment 412-423 with humanized and affinity-matured antibody hu5B3.v3,e2-peptide,A,hepatitis c virus,2.6,5.37507,0.777358,"A413,A414,A415,A416,A417,A418,A419,A420,A421,A422,A423",HCV,56
141,7U9P,H,31,31,IGHV3-33,S,['S' 'R'],R,99.69788519637464,SARS-CoV-2 spike trimer RBD in complex with Fab NA8,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,0.045471,-0.630067,"A345,A346,A347,A348,A349,A351,A352,A354,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A450,A451,A452,A470,A472,A482,A483,A484,A490,A492,A494,A499",SARS,57
142,7U9P,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,SARS-CoV-2 spike trimer RBD in complex with Fab NA8,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,1.75774,-0.112915,"A345,A346,A347,A348,A349,A351,A352,A354,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A450,A451,A452,A470,A472,A482,A483,A484,A490,A492,A494,A499",SARS,57
143,7U9O,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,SARS-CoV-2 spike trimer RBD in complex with Fab NE12,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,4.12368,3.33392,"A351,A445,A446,A449,A450,A452,A455,A470,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A491,A492,A493,A494,A496,A498",SARS,39
144,7DUO,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of daratumumab fab and CD38 complex,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,B,homo sapiens,2.81,13.7603,1.01386,"B76,B77,B91,B95,B97,B98,B158,B159,B161,B192,B193,B195,B197,B208,B210,B211,B219,B228,B229,B230,B231,B232,B233,B235,B240",Human,58
145,7DUO,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of daratumumab fab and CD38 complex,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,B,homo sapiens,2.81,1.83821,1.28481,"B76,B77,B91,B95,B97,B98,B158,B159,B161,B192,B193,B195,B197,B208,B210,B211,B219,B228,B229,B230,B231,B232,B233,B235,B240",Human,58
146,7DUO,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of daratumumab fab and CD38 complex,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,B,homo sapiens,2.81,0.214293,-0.0257936,"B76,B77,B91,B95,B97,B98,B158,B159,B161,B192,B193,B195,B197,B208,B210,B211,B219,B228,B229,B230,B231,B232,B233,B235,B240",Human,58
147,7DUO,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of daratumumab fab and CD38 complex,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,B,homo sapiens,2.81,2.93264,-0.0490743,"B76,B77,B91,B95,B97,B98,B158,B159,B161,B192,B193,B195,B197,B208,B210,B211,B219,B228,B229,B230,B231,B232,B233,B235,B240",Human,58
148,4H8W,H,53,53,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of non-neutralizing and ADCC-potent antibody N5-i5 in complex with HIV-1 clade A/E gp120 and sCD4.,hiv-1 clade a/e 93th057 (h375s) gp120,G,homo sapiens,1.85,0.222577,0.184043,"G51,G52,G53,G54,G56,G58,G59,G60,G61,G68,G69,G71,G72,G73,G74,G75,G76,G77,G78,G79,G80,G103,G106,G107,G110,G114,G219,G220,G221",Human,59
149,7E9B,H,58,59,IGHV3-11,Y,['Y' 'N'],N,56.45161290322581,"Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy",programmed cell death protein 1,C,homo sapiens,1.78,2.52694,1.86478,"C60,C61,C62,C64,C66,C78,C81,C82,C83,C84,C85,C86,C87,C88,C99,C126,C128,C129,C130,C131,C132,C133,C134",Human,60
150,4HPY,L,50,50,IGLV3-10,E,['E' 'K'],K,100.0,Crystal structure of RV144-elicited antibody CH59 in complex with V2 peptide,envelope glycoprotein gp160,P,human immunodeficiency virus 1,1.5,0.455659,-0.398476,"P169,P170,P171,P172,P173,P175,P176,P177,P178",HIV,61
151,2PW2,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKWKSL,peptide epitope,C,,2.55,0.307895,0.129484,"C1,C2,C3,C4,C5",,
152,2PW1,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKWNSL,peptide epitope,C,,2.6,0.491065,-0.070505,"C1,C2,C3,C4,C5,C6,C8",,
153,6VLN,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of 4498 Fab in complex with circumsporozoite protein DND3 and anti-Kappa VHH domain,circumsporozoite protein | anti kappa vhh domain,P | K,plasmodium falciparum | camelidae mixed library,1.63,1.20203,-0.0523401,"K39,K41,K42,K45,K92,K95,K118,K119,K120,P3,P4,P5,P6,P7,P8,P9,P10,P11",Malaria,62
154,5FGC,E,50,50,IGHV3-23,A,['A' 'V'],V,99.2992992992993,Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC33.8,genome polyprotein,A,hepatitis c virus genotype 1a (isolate h),1.9,7.1316,0.458369,"A415,A416,A417,A418,A419,A420,A421,A422",HCV,43
155,5FGC,E,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC33.8,genome polyprotein,A,hepatitis c virus genotype 1a (isolate h),1.9,19.2368,-1.41206,"A415,A416,A417,A418,A419,A420,A421,A422",HCV,43
156,5FGC,E,52A,53,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC33.8,genome polyprotein,A,hepatitis c virus genotype 1a (isolate h),1.9,-0.164716,-0.293001,"A415,A416,A417,A418,A419,A420,A421,A422",HCV,43
157,7S5P,L,50,50,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizing antibody CS23,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.86,0.498667,0.589294,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A453,A455,A456,A457,A458,A459,A460,A473,A474,A475,A476,A477,A484,A486,A487,A489,A490,A493,A495,A500,A501,A502,A504,A505",SARS,63
158,5C6T,H,1,1,IGHV4-39,Q,['Q' 'R'],R,99.61832061068702,Crystal structure of HCMV glycoprotein B in complex with 1G2 Fab,envelope glycoprotein b,A,human cytomegalovirus,3.6,-0.590822,-0.706971,"A275,A280,A281,A282,A283,A285,A286,A290,A291,A292,A293,A294,A295,A297,A298,A299,A300,A301,A321",CMV,64
159,5C6T,L,50,51,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Crystal structure of HCMV glycoprotein B in complex with 1G2 Fab,envelope glycoprotein b,A,human cytomegalovirus,3.6,1.51841,1.47453,"A275,A280,A281,A282,A283,A285,A286,A290,A291,A292,A293,A294,A295,A297,A298,A299,A300,A301,A321",CMV,65
160,2CMR,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of the HIV-1 neutralizing antibody D5 Fab bound to  the gp41 inner-core mimetic 5-helix,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.0,0.544297,0.0185035,"A29,A32,A33,A36,A40,A142,A143,A146,A147,A149,A150,A153,A157,A195,A199,A200,A202,A203,A204,A206,A207,A209,A210,A211,A212,A213,A214",HIV,66
161,2CMR,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of the HIV-1 neutralizing antibody D5 Fab bound to  the gp41 inner-core mimetic 5-helix,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.0,4.51153,0.330635,"A29,A32,A33,A36,A40,A142,A143,A146,A147,A149,A150,A153,A157,A195,A199,A200,A202,A203,A204,A206,A207,A209,A210,A211,A212,A213,A214",HIV,66
162,2CMR,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of the HIV-1 neutralizing antibody D5 Fab bound to  the gp41 inner-core mimetic 5-helix,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.0,2.40285,-0.0618792,"A29,A32,A33,A36,A40,A142,A143,A146,A147,A149,A150,A153,A157,A195,A199,A200,A202,A203,A204,A206,A207,A209,A210,A211,A212,A213,A214",HIV,66
163,2CMR,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Crystal structure of the HIV-1 neutralizing antibody D5 Fab bound to  the gp41 inner-core mimetic 5-helix,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.0,1.54795,-0.971344,"A29,A32,A33,A36,A40,A142,A143,A146,A147,A149,A150,A153,A157,A195,A199,A200,A202,A203,A204,A206,A207,A209,A210,A211,A212,A213,A214",HIV,66
164,2CMR,H,73,73,IGHV1-69,E,['E' 'K'],K,54.58135860979463,Crystal structure of the HIV-1 neutralizing antibody D5 Fab bound to  the gp41 inner-core mimetic 5-helix,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.0,-0.0163896,-0.245989,"A29,A32,A33,A36,A40,A142,A143,A146,A147,A149,A150,A153,A157,A195,A199,A200,A202,A203,A204,A206,A207,A209,A210,A211,A212,A213,A214",HIV,66
165,2CMR,L,50,50,IGKV1-5,K,['D' 'K'],D,83.73655913978494,Crystal structure of the HIV-1 neutralizing antibody D5 Fab bound to  the gp41 inner-core mimetic 5-helix,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.0,2.08238,2.62769,"A29,A32,A33,A36,A40,A142,A143,A146,A147,A149,A150,A153,A157,A195,A199,A200,A202,A203,A204,A206,A207,A209,A210,A211,A212,A213,A214",HIV,67
166,5BVP,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,"The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta",interleukin-1 beta,I,homo sapiens,2.2,4.2217,2.40041,"I19,I20,I21,I22,I23,I24,I25,I27,I29,I31,I32,I34,I35,I37,I38,I39,I40,I41,I63,I64,I65,I66,I86,I87,I88,I129,I153",Human,68
167,5BVP,H,94,98,IGHV3-33,R,['R' 'K'],K,92.14501510574016,"The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta",interleukin-1 beta,I,homo sapiens,2.2,0.920599,0.66831,"I19,I20,I21,I22,I23,I24,I25,I27,I29,I31,I32,I34,I35,I37,I38,I39,I40,I41,I63,I64,I65,I66,I86,I87,I88,I129,I153",Human,68
168,2XTJ,D,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,The crystal structure of PCSK9 in complex with 1D05 Fab,proprotein convertase subtilisin/kexin type 9,A,homo sapiens,2.7,7.67852,0.280798,"A155,A192,A194,A197,A220,A221,A237,A238,A239,A367,A369,A372,A374,A375,A376,A377,A378,A379,A380,A381,A382",Human,69
169,2XTJ,D,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,The crystal structure of PCSK9 in complex with 1D05 Fab,proprotein convertase subtilisin/kexin type 9,A,homo sapiens,2.7,1.11838,0.14223,"A155,A192,A194,A197,A220,A221,A237,A238,A239,A367,A369,A372,A374,A375,A376,A377,A378,A379,A380,A381,A382",Human,69
170,8GV5,C,52,82,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Crystal structure of PN-SIA28 in complex with influenza hemagglutinin A/swine/Guangdong/104/2013 (H1N1),hemagglutinin ha2 chain | hemagglutinin ha1 chain,B | A,influenza a virus(a/swine/guangdong/104/2013(h1n1))  | influenza a virus(a/swine/guangdong/104/2013(h1n1)),3.2,-1.30587,0.303747,"A8,A10,A27,A28,A30,A276,A278,A287,A316,B343,B344,B345,B346,B347,B348,B353,B361,B362,B365,B366,B368,B369,B372,B373,B375,B376,B379,B380,B384,B477,B480",influenza,70
171,8GV7,C,52,82,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Crystal structure of PN-SIA28 in complex with influenza hemagglutinin H18 A/flat-faced bat/Peru/033/2010,hemagglutinin h18-ha2 | hemagglutinin h18-ha1,B | A,influenza a virus (a/flat-facedbat/peru/033/2010(h18n11))  | influenza a virus (a/flat-facedbat/peru/033/2010(h18n11)),2.6,-0.434843,-0.720166,"A18,A20,A37,A38,A40,A322,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B39,B41,B42,B45,B46,B48,B49,B52,B53,B150,B153",influenza,71
172,4S1Q,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,"Crystal structure of a VRC01-lineage antibody, 45-VRC01.H03+06.D-001739, in complex with clade A/E HIV-1 gp120 core",hiv-1 gp120 core,G,homo sapiens,2.4,4.88557,1.75677,"G97,G122,G123,G124,G198,G257,G276,G278,G279,G280,G281,G282,G283,G357,G365,G366,G367,G368,G370,G371,G375,G425,G426,G427,G428,G429,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G472,G473,G474,G475",Human,72
173,4S1Q,H,69,69,IGHV1-2,M,['S' 'M'],S,99.87309644670052,"Crystal structure of a VRC01-lineage antibody, 45-VRC01.H03+06.D-001739, in complex with clade A/E HIV-1 gp120 core",hiv-1 gp120 core,G,homo sapiens,2.4,3.73319,3.81382,"G97,G122,G123,G124,G198,G257,G276,G278,G279,G280,G281,G282,G283,G357,G365,G366,G367,G368,G370,G371,G375,G425,G426,G427,G428,G429,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G472,G473,G474,G475",Human,72
174,4S1R,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,"Crystal structure of a VRC01-lineage antibody, 45-VRC01.H08.F-117225, in complex with clade A/E HIV-1 gp120 core",clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,3.214,3.28262,1.11273,"G96,G97,G99,G102,G105,G106,G109,G113,G275,G276,G278,G279,G280,G281,G282,G283,G357,G365,G366,G367,G368,G371,G427,G428,G429,G430,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G473,G474,G476,G477,G480",HIV,1
175,4S1S,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,"Crystal structure of a VRC01-lineage antibody, 45-VRC01.H5.F-185917, in complex with clade A/E HIV-1 gp120 core",clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,3.39,4.28259,2.17821,"G97,G105,G124,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G371,G427,G428,G429,G430,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G471,G472,G473,G474,G476,G477",HIV,1
176,7E3O,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.51,3.4734,3.16368,"R346,R349,R351,R352,R403,R444,R445,R446,R447,R448,R449,R450,R452,R455,R456,R466,R468,R470,R471,R472,R482,R483,R484,R485,R486,R487,R488,R489,R490,R492,R493,R494,R495,R496",SARS,73
177,7E3O,H,94,97,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.51,1.98992,0.368192,"R346,R349,R351,R352,R403,R444,R445,R446,R447,R448,R449,R450,R452,R455,R456,R466,R468,R470,R471,R472,R482,R483,R484,R485,R486,R487,R488,R489,R490,R492,R493,R494,R495,R496",SARS,73
178,3SE9,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC-PG04 in complex with HIV-1 gp120,hiv-1 clade ae strain 93th057 gp120,G,human immunodeficiency virus 1,2.0,5.27007,2.86843,"G97,G102,G122,G124,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G371,G427,G429,G431,G455,G456,G457,G458,G459,G461,G462,G469,G472,G473,G474,G476",HIV,1
179,5J13,B,50,52,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,Cytokine antibody complex,thymic stromal lymphopoietin,A,homo sapiens,2.298,-1.05407,-1.35558,"A61,A64,A65,A66,A67,A68,A69,A70,A71,A72,A74,A75,A78,A81,A150,A151,A153,A154",Human,74
180,5J13,C,52,55,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Cytokine antibody complex,thymic stromal lymphopoietin,A,homo sapiens,2.298,-0.262298,0.396287,"A61,A64,A65,A66,A67,A68,A69,A70,A71,A72,A74,A75,A78,A81,A150,A151,A153,A154",Human,75
181,5J13,C,94,101,IGHV3-33,R,['R' 'K'],K,92.14501510574016,Cytokine antibody complex,thymic stromal lymphopoietin,A,homo sapiens,2.298,3.05762,0.698951,"A61,A64,A65,A66,A67,A68,A69,A70,A71,A72,A74,A75,A78,A81,A150,A151,A153,A154",Human,75
182,4AL8,L,30,30,IGKV1-17,R,['R' 'S'],S,82.26950354609927,Structure of Dengue virus DIII in complex with Fab 2H12,envelope protein,C,dengue virus,1.66,0.433754,0.345412,"C310,C313,C314,C315,C316,C317,C318,C319,C321,C323,C352,C353,C354,C363,C364,C366,C368,C370",Dengue,76
183,5C0S,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of a generation 4 influenza hemagglutinin stabilized stem in complex with the broadly neutralizing antibody CR6261,"hemagglutinin, envelope glycoprotein, fibritin fusionprotein ",A,"influenza a virus, human immunodeficiency virustype 1 group m subtype b, enterobacteria phage t4",4.3,0.871003,-0.168151,"A8,A28,A30,A31,A32,A40,A66,A67,A68,A69,A86,A89,A90,A93,A94,A97,A98,A100,A101,A104,A105",influenza,77
184,5C0S,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Crystal structure of a generation 4 influenza hemagglutinin stabilized stem in complex with the broadly neutralizing antibody CR6261,"hemagglutinin, envelope glycoprotein, fibritin fusionprotein ",A,"influenza a virus, human immunodeficiency virustype 1 group m subtype b, enterobacteria phage t4",4.3,-1.03425,-0.983483,"A8,A28,A30,A31,A32,A40,A66,A67,A68,A69,A86,A89,A90,A93,A94,A97,A98,A100,A101,A104,A105",influenza,77
185,4DN4,H,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of the complex between cnto888 fab and mcp-1 mutant p8a,c-c motif chemokine 2,M,homo sapiens,2.8,0.207786,0.1616,"M16,M18,M19,M20,M21,M22,M23,M24,M45,M46,M47,M48,M49,M51",Human,78
186,7T01,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,SARS-CoV-2 S-RBD + Fab 54042-4,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.69,-0.23365,-0.478953,"A346,A439,A440,A441,A443,A444,A445,A446,A447,A449,A450,A498,A499,A500",SARS,79
187,7LY0,H,31,31,IGHV3-33,S,['S' 'R'],R,99.69788519637464,SARS-CoV-2 S/S2M11/S2M28 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.6,0.264667,0.0557229,"A14,A15,A16,A17,A18,A19,A20,A77,A140,A142,A144,A145,A146,A147,A148,A155,A156,A158,A246,A247,A248,A249,A250,A251,A252,A253,A254,A255",SARS,80
188,7LY0,H,35,35,IGHV3-33,H,['H' 'Y'],Y,99.69788519637464,SARS-CoV-2 S/S2M11/S2M28 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.6,2.41305,2.06056,"A14,A15,A16,A17,A18,A19,A20,A77,A140,A142,A144,A145,A146,A147,A148,A155,A156,A158,A246,A247,A248,A249,A250,A251,A252,A253,A254,A255",SARS,80
189,7LY0,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,SARS-CoV-2 S/S2M11/S2M28 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.6,2.28422,-0.153672,"A14,A15,A16,A17,A18,A19,A20,A77,A140,A142,A144,A145,A146,A147,A148,A155,A156,A158,A246,A247,A248,A249,A250,A251,A252,A253,A254,A255",SARS,80
190,4J6R,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC23 in complex with HIV-1 gp120,envelope glycoprotein gp160,G,human immunodeficiency virus 1,1.64,4.98913,2.18818,"G97,G122,G124,G198,G257,G275,G276,G278,G279,G280,G281,G282,G283,G356,G365,G366,G367,G368,G370,G371,G425,G426,G427,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G463,G466,G469,G472,G473,G474,G475,G476,G480",HIV,1
191,3U7Y,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Structure of NIH45-46 Fab in complex with gp120 of 93TH057 HIV,envelope glycoprotein gp160,G,human immunodeficiency virus 1,2.4478,3.35759,0.555214,"G49,G96,G97,G98,G99,G102,G122,G123,G124,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G370,G371,G427,G428,G429,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G472,G473,G474,G475,G476,G480",HIV,1
192,3U7Y,H,69,69,IGHV1-2,M,['S' 'M'],S,99.87309644670052,Structure of NIH45-46 Fab in complex with gp120 of 93TH057 HIV,envelope glycoprotein gp160,G,human immunodeficiency virus 1,2.4478,2.57728,2.59077,"G49,G96,G97,G98,G99,G102,G122,G123,G124,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G370,G371,G427,G428,G429,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G472,G473,G474,G475,G476,G480",HIV,1
193,3MLZ,H,30,30,IGHV4-59,S,['S' 'Y'],Y,100.0,Crystal structure of anti-HIV-1 V3 Fab 3074 in complex with a VI191 V3 peptide,hiv-1 gp120 third variable region (v3) crown,P,human immunodeficiency virus 1,2.99,-0.204483,-0.104941,"P303,P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P316,P317,P318,P319,P320,P322,P323",HIV,81
194,3MLZ,H,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal structure of anti-HIV-1 V3 Fab 3074 in complex with a VI191 V3 peptide,hiv-1 gp120 third variable region (v3) crown,P,human immunodeficiency virus 1,2.99,2.73012,1.86022,"P303,P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P316,P317,P318,P319,P320,P322,P323",HIV,81
195,3MLZ,L,50,50,IGLV1-51,E,['D' 'E'],D,16.816816816816818,Crystal structure of anti-HIV-1 V3 Fab 3074 in complex with a VI191 V3 peptide,hiv-1 gp120 third variable region (v3) crown,P,human immunodeficiency virus 1,2.99,1.32395,0.721502,"P303,P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P316,P317,P318,P319,P320,P322,P323",HIV,82
196,6IUT,H,31,30,IGHV4-4,S,['S' 'N'],N,100.0,Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody AVFluIgG01,hemagglutinin,A,influenza a virus (a/anhui/1/2005(h5n1)),2.3,-0.101621,-1.59968,"A115,A116,A117,A118,A120,A121,A122,A123,A124,A125,A158,A159,A160,A161,A162,A163,A164,A165,A167,A168,A240,A241",influenza,83
197,6IUT,H,50,49,IGHV4-4,Y,['E' 'R' 'Y'],E,5.681818181818182,Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody AVFluIgG01,hemagglutinin,A,influenza a virus (a/anhui/1/2005(h5n1)),2.3,6.57854,6.32103,"A115,A116,A117,A118,A120,A121,A122,A123,A124,A125,A158,A159,A160,A161,A162,A163,A164,A165,A167,A168,A240,A241",influenza,83
198,6IUT,H,50,49,IGHV4-4,Y,['E' 'R' 'Y'],R,5.681818181818182,Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody AVFluIgG01,hemagglutinin,A,influenza a virus (a/anhui/1/2005(h5n1)),2.3,3.42239,4.22754,"A115,A116,A117,A118,A120,A121,A122,A123,A124,A125,A158,A159,A160,A161,A162,A163,A164,A165,A167,A168,A240,A241",influenza,83
199,6IUT,H,73,72,IGHV4-4,T,['K' 'T'],K,28.03030303030303,Crystal structure of influenza A virus H5 hemagglutinin globular head in complex with the Fab of antibody AVFluIgG01,hemagglutinin,A,influenza a virus (a/anhui/1/2005(h5n1)),2.3,-0.583657,-1.03561,"A115,A116,A117,A118,A120,A121,A122,A123,A124,A125,A158,A159,A160,A161,A162,A163,A164,A165,A167,A168,A240,A241",influenza,83
200,7ND3,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab,spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,3.7,2.48033,-0.484318,"B403,B405,B409,B415,B416,B417,B420,B421,B449,B453,B455,B456,B457,B458,B459,B460,B473,B474,B475,B476,B477,B486,B487,B489,B493,B494,B495,B496,B497,B498,B500,B501,B502,B503,B504,B505",SARS,9
201,7V27,A,32,34,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,RBD/XG005 local refinement,spike protein s1,C,severe acute respiratory syndrome coronavirus2,0,1.4773,0.102955,"C344,C345,C346,C437,C439,C440,C441,C442,C443,C444,C445,C446,C447,C448,C449,C450,C498,C499,C500,C501,C502,C506",SARS,84
202,7V27,B,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,RBD/XG005 local refinement,spike protein s1,C,severe acute respiratory syndrome coronavirus2,0,0.544024,0.550014,"C344,C345,C346,C437,C439,C440,C441,C442,C443,C444,C445,C446,C447,C448,C449,C450,C498,C499,C500,C501,C502,C506",SARS,79
203,7SD5,H,1,1,IGHV4-39,Q,['Q' 'R'],R,99.61832061068702,Crystallographic structure of neutralizing antibody 10-40 in complex with SARS-CoV-2 spike receptor binding domain,spike protein s1,A,severe acute respiratory syndrome coronavirus2,1.53,-0.983844,-0.48471,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A505",SARS,85
204,7SD5,H,26,26,IGHV4-39,G,['G' 'S'],S,100.0,Crystallographic structure of neutralizing antibody 10-40 in complex with SARS-CoV-2 spike receptor binding domain,spike protein s1,A,severe acute respiratory syndrome coronavirus2,1.53,6.60733,6.75797,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A505",SARS,85
205,7SD5,H,27,27,IGHV4-39,G,['G' 'Y'],Y,100.0,Crystallographic structure of neutralizing antibody 10-40 in complex with SARS-CoV-2 spike receptor binding domain,spike protein s1,A,severe acute respiratory syndrome coronavirus2,1.53,6.03691,3.53046,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A505",SARS,85
206,7SD5,H,28,28,IGHV4-39,S,['S' 'Y'],Y,100.0,Crystallographic structure of neutralizing antibody 10-40 in complex with SARS-CoV-2 spike receptor binding domain,spike protein s1,A,severe acute respiratory syndrome coronavirus2,1.53,0.511308,0.237389,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A505",SARS,85
207,7OXN,H,31,31,IGHV3-33,S,['S' 'R'],R,99.69788519637464,Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide,amyloid-beta precursor protein,A,homo sapiens,2.5,0.0876373,0.125441,"A1,A2,A4,A5,A6,A7,A8,A9,A11,A14",Human,86
208,7OXN,H,35,35,IGHV3-33,H,['H' 'Y'],Y,99.69788519637464,Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide,amyloid-beta precursor protein,A,homo sapiens,2.5,7.4637,0.744024,"A1,A2,A4,A5,A6,A7,A8,A9,A11,A14",Human,86
209,7OXN,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide,amyloid-beta precursor protein,A,homo sapiens,2.5,4.04871,2.81199,"A1,A2,A4,A5,A6,A7,A8,A9,A11,A14",Human,86
210,7T72,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Epitope-based selection of SARS-CoV-2 neutralizing antibodies from convalescent patients,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.177,8.87403,2.87232,"A403,A405,A406,A409,A415,A416,A417,A420,A421,A453,A455,A456,A457,A458,A459,A460,A473,A474,A475,A476,A477,A484,A485,A486,A487,A489,A490,A492,A493,A495,A496,A498,A500,A501,A502,A505",SARS,9
211,7T73,H,52C,52C,IGHV3-15,T,['T' 'A'],A,100.0,HIV-1 Envelope ApexGT2.2MUT in complex with PCT64.LMCA Fab,hiv envelope apexgt2.2mut gp120 | hiv envelope apexgt2.2mut gp120 | hiv envelope apexgt2.2mut gp120,E | A | C,human immunodeficiency virus 1 | human immunodeficiency virus 1 | human immunodeficiency virus 1,4.0,-0.728787,-0.162045,"A127,A128,A160,A162,A166,A167,A168,A169,C121,C123,C124,C160,C162,C166,C167,C168,C169,C186,C187,E124,E162,E166,E167,E168,E169,E171,E173,E313",HIV,87
212,7T73,H,53,53,IGHV3-15,D,['D' 'N'],N,100.0,HIV-1 Envelope ApexGT2.2MUT in complex with PCT64.LMCA Fab,hiv envelope apexgt2.2mut gp120 | hiv envelope apexgt2.2mut gp120 | hiv envelope apexgt2.2mut gp120,E | A | C,human immunodeficiency virus 1 | human immunodeficiency virus 1 | human immunodeficiency virus 1,4.0,0.937275,0.173181,"A127,A128,A160,A162,A166,A167,A168,A169,C121,C123,C124,C160,C162,C166,C167,C168,C169,C186,C187,E124,E162,E166,E167,E168,E169,E171,E173,E313",HIV,87
213,7T76,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,HIV-1 Envelope ApexGT3 in complex with PG9.iGL Fab,hiv envelope apexgt3 gp120 | hiv envelope apexgt3 gp120 | hiv envelope apexgt3 gp120,E | A | C,human immunodeficiency virus 1 | human immunodeficiency virus 1 | human immunodeficiency virus 1,4.43,2.97884,2.76263,"A166,A167,A169,C128,C162,C166,C169,C185,C185h,C186,C190,E158,E160,E165,E166,E167,E168,E169,E170,E171,E172,E173",HIV,88
214,7T76,H,94,94,IGHV3-30,R,['R' 'K'],K,46.91848906560635,HIV-1 Envelope ApexGT3 in complex with PG9.iGL Fab,hiv envelope apexgt3 gp120 | hiv envelope apexgt3 gp120 | hiv envelope apexgt3 gp120,E | A | C,human immunodeficiency virus 1 | human immunodeficiency virus 1 | human immunodeficiency virus 1,4.43,-0.726365,-0.50597,"A166,A167,A169,C128,C162,C166,C169,C185,C185h,C186,C190,E158,E160,E165,E166,E167,E168,E169,E170,E171,E172,E173",HIV,88
215,7T77,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,HIV-1 Envelope ApexGT3.N130 in complex with PG9 Fab,hiv envelope apexgt3.n130 gp120 | hiv envelope apexgt3.n130 gp120 | hiv envelope apexgt3.n130 gp120,E | A | C,human immunodeficiency virus 1 | human immunodeficiency virus 1 | human immunodeficiency virus 1,4.75,3.61194,3.65801,"A166,A167,A169,C128,C169,C184,C185,C185h,C186,E127,E158,E160,E163,E165,E166,E167,E168,E169,E170,E171,E172,E173",HIV,88
216,6DB6,H,51,51,IGHV1-3,I,['I' 'S'],S,100.0,Crystal structure of anti-HIV-1 V3 Fab 311-11D in complex with a HIV-1 gp120 V3 peptide from MN strain,hiv-1 gp120 v3 peptide from mn strain,P,human immunodeficiency virus 1,1.978,2.41986,2.67886,"P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P316,P317,P319",HIV,89
217,6DB6,L,50,50,IGLV3-10,E,['E' 'K'],K,100.0,Crystal structure of anti-HIV-1 V3 Fab 311-11D in complex with a HIV-1 gp120 V3 peptide from MN strain,hiv-1 gp120 v3 peptide from mn strain,P,human immunodeficiency virus 1,1.978,-0.0207364,-0.404428,"P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P316,P317,P319",HIV,90
218,7KQL,H,30,30,IGHV4-39,S,['S' 'G'],G,100.0,Anti-Tim3 antibody Fab complex,hepatitis a virus cellular receptor 2,T,homo sapiens,1.49,1.37194,0.81306,"T29,T30,T31,T38,T39,T40,T41,T42,T43,T44,T45,T46,T47,T48,T49,T50,T51,T53,T90,T91,T92,T95,T96,T97,T99",Human,91
219,3N85,H,58,58,IGHV3-74,S,['S' 'T'],T,92.63803680981596,Crystallographic trimer of HER2 extracellular regions in complex with tryptophan-rich antibody fragment,receptor tyrosine-protein kinase erbb-2,A,homo sapiens,3.2,0.589921,1.13053,"A371,A372,A373,A376,A379,A395,A396,A397,A398,A399,A401,A402,A404,A427,A429,A430,A434,A450,A451,A477,A478,A480,A481,A483,A484,A485,A486,A487,A501,A502,A503,A504,A505",Human,92
220,6WG0,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of Fab366 in complex with NPNA3 peptide from circumsporozoite protein,npna3 peptide,P,plasmodium falciparum,1.599,3.26611,2.79331,"P1,P2,P3,P4,P5,P6,P7,P8,P9,P10,P11",Malaria,93
221,6WGL,A,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Dupilumab fab with Crystal Kappa design complexed with human IL-4 receptor,interleukin-4 receptor subunit alpha,C,homo sapiens,2.82,21.3169,-0.720941,"C37,C38,C39,C40,C41,C42,C43,C44,C45,C47,C64,C66,C67,C69,C71,C72,C73,C74",Human,94
222,6WGL,A,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Dupilumab fab with Crystal Kappa design complexed with human IL-4 receptor,interleukin-4 receptor subunit alpha,C,homo sapiens,2.82,-0.503205,0.207452,"C37,C38,C39,C40,C41,C42,C43,C44,C45,C47,C64,C66,C67,C69,C71,C72,C73,C74",Human,94
223,7MDP,H,26,26,IGHV4-4,G,['G' 'S'],S,100.0,KRas G12C in complex with G-2897,isoform 2b of gtpase kras,A,homo sapiens,1.96,4.11494,3.22532,"A3,A5,A6,A7,A24,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
224,7MDP,H,27,27,IGHV4-4,G,['G' 'I'],I,100.0,KRas G12C in complex with G-2897,isoform 2b of gtpase kras,A,homo sapiens,1.96,5.33508,6.88798,"A3,A5,A6,A7,A24,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
225,7MDP,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,KRas G12C in complex with G-2897,isoform 2b of gtpase kras,A,homo sapiens,1.96,1.68894,-0.0453975,"A3,A5,A6,A7,A24,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
226,7MDP,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],W,71.96969696969697,KRas G12C in complex with G-2897,isoform 2b of gtpase kras,A,homo sapiens,1.96,9.61559,0.375662,"A3,A5,A6,A7,A24,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
227,7MDP,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],Y,71.96969696969697,KRas G12C in complex with G-2897,isoform 2b of gtpase kras,A,homo sapiens,1.96,6.4372,0.262008,"A3,A5,A6,A7,A24,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
228,7MDP,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],W,71.96969696969697,KRas G12C in complex with G-2897,isoform 2b of gtpase kras,A,homo sapiens,1.96,0.327828,0.742316,"A3,A5,A6,A7,A24,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
229,7MDP,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],Y,71.96969696969697,KRas G12C in complex with G-2897,isoform 2b of gtpase kras,A,homo sapiens,1.96,-1.10061,-0.523195,"A3,A5,A6,A7,A24,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
230,7MDP,H,53,53,IGHV4-4,H,['H' 'T'],T,71.96969696969697,KRas G12C in complex with G-2897,isoform 2b of gtpase kras,A,homo sapiens,1.96,0.748565,-0.055306,"A3,A5,A6,A7,A24,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
231,6XZW,L,60,61,IGKV3-20,D,['D' 'A'],A,99.87797437461867,Crystal structure of the meningococcal vaccine antigen fHbp in complex with a cross-reactive human Fab.,lipoprot_c domain-containing protein,D,neisseria meningitidis serogroup b (strainmc58),2.4,-0.0237433,0.0931588,"D141,D142,D144,D145,D146,D147,D149,D169,D171,D173,D174,D175,D176,D178,D194,D195,D196,D197,D198,D199,D200,D204,D213,D216,D218",Meningococcus,96
232,4XI5,D,33,33,IGHV3-30,A,['A' 'G'],G,31.41153081510934,gHgL of varicella-zoster virus in complex with human neutralizing antibodies,envelope glycoprotein l | envelope glycoprotein h,B | A,human herpesvirus 3 strain oka vaccine | human herpesvirus 3 strain oka vaccine,3.9,1.16656,0.841213,"A154,A155,A156,A157,A281,A286,A287,A288,A289,A290,A291,A292,A293,A294,A295,B112,B114,B121,B122,B125,B126,B128,B129,B130,B133,B134",HHV-3,97
233,4XI5,D,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,gHgL of varicella-zoster virus in complex with human neutralizing antibodies,envelope glycoprotein l | envelope glycoprotein h,B | A,human herpesvirus 3 strain oka vaccine | human herpesvirus 3 strain oka vaccine,3.9,10.332,4.30776,"A154,A155,A156,A157,A281,A286,A287,A288,A289,A290,A291,A292,A293,A294,A295,B112,B114,B121,B122,B125,B126,B128,B129,B130,B133,B134",HHV-3,97
234,4XI5,D,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,gHgL of varicella-zoster virus in complex with human neutralizing antibodies,envelope glycoprotein l | envelope glycoprotein h,B | A,human herpesvirus 3 strain oka vaccine | human herpesvirus 3 strain oka vaccine,3.9,-0.00281778,0.654957,"A154,A155,A156,A157,A281,A286,A287,A288,A289,A290,A291,A292,A293,A294,A295,B112,B114,B121,B122,B125,B126,B128,B129,B130,B133,B134",HHV-3,97
235,7ZR8,H,33,33,IGHV1-69,T,['A' 'T'],A,4.739336492890995,OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement),"spike glycoprotein,fibritin",A,"severe acute respiratory syndrome coronavirus2, enterobacteria phage t4",3.7,-0.87471,-1.00547,"A342,A343,A348,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A467,A469,A480,A481,A487,A489,A490,A491,A506",SARS,98
236,7ZR8,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement),"spike glycoprotein,fibritin",A,"severe acute respiratory syndrome coronavirus2, enterobacteria phage t4",3.7,-1.38987,2.26898,"A342,A343,A348,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A467,A469,A480,A481,A487,A489,A490,A491,A506",SARS,98
237,7ZR8,H,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement),"spike glycoprotein,fibritin",A,"severe acute respiratory syndrome coronavirus2, enterobacteria phage t4",3.7,-0.367169,1.01386,"A342,A343,A348,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A467,A469,A480,A481,A487,A489,A490,A491,A506",SARS,98
238,7ZR8,L,50,50,IGKV1-5,D,['D' 'K'],K,16.263440860215052,OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement),"spike glycoprotein,fibritin",A,"severe acute respiratory syndrome coronavirus2, enterobacteria phage t4",3.7,3.66469,-0.440614,"A342,A343,A348,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A467,A469,A480,A481,A487,A489,A490,A491,A506",SARS,99
239,7B3O,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab,surface glycoprotein,E,severe acute respiratory syndrome coronavirus2,2.0,1.50993,-0.377828,"E403,E405,E406,E408,E409,E415,E416,E417,E420,E421,E449,E453,E455,E456,E457,E458,E459,E460,E473,E474,E475,E476,E477,E486,E487,E489,E493,E494,E495,E496,E498,E500,E501,E502,E503,E504,E505",SARS,9
240,6VJT,H,31,31,IGHV3-33,R,['S' 'R'],S,0.3021148036253776,Co-crystals of broadly neutralizing antibody with the linear epitope from Hepatitis B surface antigen,antigenic region 139-148 of hepatitis b surface antigenprotein,P,hepatitis b virus,1.782,0.499228,0.484188,"P140,P141,P142,P143,P144,P145,P146,P147,P148",HBV,100
241,6VJT,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Co-crystals of broadly neutralizing antibody with the linear epitope from Hepatitis B surface antigen,antigenic region 139-148 of hepatitis b surface antigenprotein,P,hepatitis b virus,1.782,1.80886,1.07433,"P140,P141,P142,P143,P144,P145,P146,P147,P148",HBV,100
242,6ULF,A,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of 4498 Fab in complex with circumsporozoite protein NDN3 and anti-Kappa VHH domain,circumsporozoite protein | anti kappa vhh domain,P | K,plasmodium falciparum | camelidae mixed library,1.7,1.12185,1.45743,"K3,K39,K41,K42,K45,K92,K95,K118,K119,K120,P3,P4,P5,P6,P7,P8,P9,P10,P11,P12",Malaria,62
243,6ULC,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,"Structure of full-length, fully glycosylated, non-modified HIV-1 gp160 bound to PG16 Fab at a nominal resolution of 4.6 Angstrom","envelope glycoprotein gp120,envelope glycoprotein gp120 | envelope glycoprotein gp120,envelope glycoprotein gp120",A | E,human immunodeficiency virus 1 | human immunodeficiency virus 1,4.6,5.37072,5.40041,"A158,A160,A166,A167,A168,A169,A170,A171,A172,A173,E128,E160,E167,E169,E185,E186,E187,E188,E189,E190B",HIV,101
244,7YKJ,D,60,61,IGKV3-20,D,['D' 'A'],A,99.87797437461867,Omicron RBDs bound with P3E6 Fab (one up and one down),spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,0,0.399571,0.291517,"C343,C345,C346,C439,C440,C441,C442,C443,C444,C445,C446,C448,C450,C499,C500,C501,C502,C503,C506,C509",SARS,102
245,7T5O,L,50,49,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,VFLIP Spike Trimer with GAR03,spike glycoprotein,C,severe acute respiratory syndrome-relatedcoronavirus ,0,-0.891002,1.62383,"C337,C340,C341,C344,C345,C346,C347,C348,C349,C351,C352,C353,C354,C355,C356,C357,C359,C450,C451,C452,C464,C465,C466,C467,C468,C469,C471,C582",SARS,103
246,7M71,H,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,SARS-CoV-2 Spike:5A6 Fab complex I focused refinement,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,2.66,5.21155,2.90782,"A351,A446,A449,A452,A455,A456,A469,A470,A471,A472,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,B369,B374,B375,B376,B377,B378,B404,B405,B408,B414,B503,B504,B508",SARS,104
247,7M71,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,SARS-CoV-2 Spike:5A6 Fab complex I focused refinement,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,2.66,2.5287,-0.0979049,"A351,A446,A449,A452,A455,A456,A469,A470,A471,A472,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,B369,B374,B375,B376,B377,B378,B404,B405,B408,B414,B503,B504,B508",SARS,104
248,7M71,H,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,SARS-CoV-2 Spike:5A6 Fab complex I focused refinement,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,2.66,1.05391,-0.421249,"A351,A446,A449,A452,A455,A456,A469,A470,A471,A472,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,B369,B374,B375,B376,B377,B378,B404,B405,B408,B414,B503,B504,B508",SARS,104
249,6MLK,H,30,32,IGHV4-34,S,['S' 'Y'],Y,100.0,Structure of Thioesterase from DEBS with a thioesterase-specific antibody,"6-deoxyerythronolide-b synthase erya3, modules 5 and 6",A,saccharopolyspora erythraea,2.45,-0.875723,-0.894731,"A24,A27,A28,A29,A30,A32,A174,A177,A180,A181,A182,A183,A184,A185,A188,A189,A232,A233,A234,A235,A236,A237,A238,A239,A258",Saccharopolyspora erythraea,105
250,6MLK,H,31,33,IGHV4-34,G,['G' 'W'],W,100.0,Structure of Thioesterase from DEBS with a thioesterase-specific antibody,"6-deoxyerythronolide-b synthase erya3, modules 5 and 6",A,saccharopolyspora erythraea,2.45,0.254961,0.37207,"A24,A27,A28,A29,A30,A32,A174,A177,A180,A181,A182,A183,A184,A185,A188,A189,A232,A233,A234,A235,A236,A237,A238,A239,A258",Saccharopolyspora erythraea,105
251,6MLK,H,32,34,IGHV4-34,Y,['Y' 'S'],S,100.0,Structure of Thioesterase from DEBS with a thioesterase-specific antibody,"6-deoxyerythronolide-b synthase erya3, modules 5 and 6",A,saccharopolyspora erythraea,2.45,0.419413,0.326996,"A24,A27,A28,A29,A30,A32,A174,A177,A180,A181,A182,A183,A184,A185,A188,A189,A232,A233,A234,A235,A236,A237,A238,A239,A258",Saccharopolyspora erythraea,105
252,6MLK,H,52,54,IGHV4-34,N,['N' 'Y' 'I'],Y,98.8888888888889,Structure of Thioesterase from DEBS with a thioesterase-specific antibody,"6-deoxyerythronolide-b synthase erya3, modules 5 and 6",A,saccharopolyspora erythraea,2.45,12.8436,10.9231,"A24,A27,A28,A29,A30,A32,A174,A177,A180,A181,A182,A183,A184,A185,A188,A189,A232,A233,A234,A235,A236,A237,A238,A239,A258",Saccharopolyspora erythraea,105
253,6MLK,H,52,54,IGHV4-34,N,['N' 'Y' 'I'],I,98.8888888888889,Structure of Thioesterase from DEBS with a thioesterase-specific antibody,"6-deoxyerythronolide-b synthase erya3, modules 5 and 6",A,saccharopolyspora erythraea,2.45,0.610017,1.49805,"A24,A27,A28,A29,A30,A32,A174,A177,A180,A181,A182,A183,A184,A185,A188,A189,A232,A233,A234,A235,A236,A237,A238,A239,A258",Saccharopolyspora erythraea,105
254,6MLK,H,53,55,IGHV4-34,H,['H' 'Y'],Y,100.0,Structure of Thioesterase from DEBS with a thioesterase-specific antibody,"6-deoxyerythronolide-b synthase erya3, modules 5 and 6",A,saccharopolyspora erythraea,2.45,-1.34269,-1.40683,"A24,A27,A28,A29,A30,A32,A174,A177,A180,A181,A182,A183,A184,A185,A188,A189,A232,A233,A234,A235,A236,A237,A238,A239,A258",Saccharopolyspora erythraea,105
255,7D5B,D,58,218,IGHV3-74,T,['S' 'T'],S,7.361963190184049,"BACE2 xaperone complex with N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide",beta-secretase 2,A,homo sapiens,1.31,-0.159553,-0.196012,"A75,A77,A78,A79,A81,A98,A100,A109,A110,A111,A112,A113,A114,A140,A147,A148,A150,A154,A157,A158,A159,A161,A162,A163,A164",Human,106
256,7D5U,D,58,218,IGHV3-74,T,['S' 'T'],S,7.361963190184049,"BACE2 xaperone complex with N-{3-[(9S)-7-amino-2,2-difluoro-9-(prop-1-yn-1-yl)-6-oxa-8-azaspiro[3.5]non-7-en-9-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide",beta-secretase 2,A,homo sapiens,2.04,-0.287599,-0.195118,"A75,A77,A78,A79,A81,A98,A100,A110,A112,A113,A114,A140,A146,A147,A148,A150,A154,A157,A158,A159,A161,A162,A163,A164",Human,106
257,7EY4,H,58,59,IGHV3-11,Y,['Y' 'N'],N,56.45161290322581,Local CryoEM of the SARS-CoV-2 S6PV2 in complex with BD-667,spike glycoprotein | ntd,R | N,severe acute respiratory syndrome coronavirus2  | homo sapiens,3.69,0.422076,0.910004,"R340,R345,R346,R347,R348,R349,R351,R352,R353,R354,R355,R356,R357,R396,R444,R448,R449,R450,R451,R452,R464,R466,R468,R469,R470,R471,R482,R483,R484,R490,R492,R493,R494,N163,N164,N165,N166",SARS,107
258,6E4X,Z,34,34,IGHV4-61,Y,['Y' 'W'],W,100.0,Human antibody S5V2-29 in complex with influenza hemagglutinin A/Texas/50/2012 (H3N2),hemagglutinin,B,influenza a virus (a/texas/50/2012(h3n2)),2.25,0.556105,-1.54431,"B65,B89,B90,B91,B93,B94,B95,B99,B100,B101,B102,B105,B216,B217,B218,B219,B220,B221,B222,B223,B224,B225,B229,B269",influenza,108
259,2EKS,B,31,31,IGHV4-59,S,['S' 'Y'],Y,100.0,Crystal structure of humanized HyHEL-10 FV-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.0,0.98496,-0.169989,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C76,C77,C89,C93,C96,C97,C100,C101,C102,C103",Chicken,109
260,2EKS,B,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal structure of humanized HyHEL-10 FV-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.0,5.67699,1.06682,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C76,C77,C89,C93,C96,C97,C100,C101,C102,C103",Chicken,109
261,2EKS,B,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,Crystal structure of humanized HyHEL-10 FV-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.0,6.3145,3.77642,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C76,C77,C89,C93,C96,C97,C100,C101,C102,C103",Chicken,109
262,2EKS,B,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal structure of humanized HyHEL-10 FV-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.0,2.37751,0.330403,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C76,C77,C89,C93,C96,C97,C100,C101,C102,C103",Chicken,109
263,2EKS,B,58,58,IGHV4-59,Y,['N' 'Y'],N,0.0,Crystal structure of humanized HyHEL-10 FV-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.0,0.919307,0.321175,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C76,C77,C89,C93,C96,C97,C100,C101,C102,C103",Chicken,109
264,7SJS,H,50,50,IGHV3-23,A,['A' 'V'],V,99.2992992992993,Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40.8,stem helix peptide of spike protein s2',C,severe acute respiratory syndrome coronavirus2,1.612,2.08111,1.89551,"C1142,C1143,C1144,C1145,C1146,C1148,C1149,C1150,C1151,C1152,C1153,C1154,C1155,C1156,C1158,C1159,C1160,C1161",SARS,110
265,7SJS,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40.8,stem helix peptide of spike protein s2',C,severe acute respiratory syndrome coronavirus2,1.612,0.824669,-0.902031,"C1142,C1143,C1144,C1145,C1146,C1148,C1149,C1150,C1151,C1152,C1153,C1154,C1155,C1156,C1158,C1159,C1160,C1161",SARS,110
266,7SJS,H,53,53,IGHV3-23,G,['S' 'G'],S,0.7007007007007007,Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40.8,stem helix peptide of spike protein s2',C,severe acute respiratory syndrome coronavirus2,1.612,1.50345,1.40253,"C1142,C1143,C1144,C1145,C1146,C1148,C1149,C1150,C1151,C1152,C1153,C1154,C1155,C1156,C1158,C1159,C1160,C1161",SARS,110
267,7SJS,H,55,55,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40.8,stem helix peptide of spike protein s2',C,severe acute respiratory syndrome coronavirus2,1.612,3.71748,3.76113,"C1142,C1143,C1144,C1145,C1146,C1148,C1149,C1150,C1151,C1152,C1153,C1154,C1155,C1156,C1158,C1159,C1160,C1161",SARS,110
268,7SJS,L,50,50,IGLV3-10,E,['E' 'K'],K,100.0,Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40.8,stem helix peptide of spike protein s2',C,severe acute respiratory syndrome coronavirus2,1.612,-3.65994,-1.0895,"C1142,C1143,C1144,C1145,C1146,C1148,C1149,C1150,C1151,C1152,C1153,C1154,C1155,C1156,C1158,C1159,C1160,C1161",SARS,111
269,7SJS,L,96,96,IGLV3-10,A,['T' 'A'],T,0.0,Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40.8,stem helix peptide of spike protein s2',C,severe acute respiratory syndrome coronavirus2,1.612,5.90503,6.42312,"C1142,C1143,C1144,C1145,C1146,C1148,C1149,C1150,C1151,C1152,C1153,C1154,C1155,C1156,C1158,C1159,C1160,C1161",SARS,111
270,4OT1,L,50,51,IGLV1-51,D,['D' 'E'],E,83.18318318318319,Structural Basis for the Recognition of Human Cytomegalovirus Glycoprotein B by the Neutralizing Human Antibody SM5-1,envelope glycoprotein b,A,human cytomegalovirus,2.11,0.477661,0.173672,"A121,A131,A133,A358,A359,A360,A361,A362,A364,A379,A380,A381,A382,A383,A384,A386,A388,A389,A415,A422,A428",CMV,112
271,7VNG,L,90,90,IGKV1-39,Q,['Q' 'C'],C,99.92498124531132,Crystal structure of human coronavirus 229E spike protein receptor-binding domain in complex with S11 Fab,spike glycoprotein s1,D,human coronavirus 229e,3.8,-0.0231737,-0.759707,"D334,D335,D336,D337,D338,D340,D341,D342,D343,D383,D384,D386,D390,D391,D392,D393,D394,D395,D418,D419,D420,D421,D422,D424,D425",229E,113
272,4HHA,B,33,33,IGHV3-30,G,['A' 'G'],A,68.58846918489066,Anti-Human Cytomegalovirus (HCMV) Fab KE5 with epitope peptide AD-2S1,glycoprotein b,P,human herpesvirus 5,1.6,-0.731017,-0.861041,"P1,P2,P3,P4,P5,P6,P7,P8,P9,P10",CMV,114
273,4HHA,B,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Anti-Human Cytomegalovirus (HCMV) Fab KE5 with epitope peptide AD-2S1,glycoprotein b,P,human herpesvirus 5,1.6,9.69995,-0.201126,"P1,P2,P3,P4,P5,P6,P7,P8,P9,P10",CMV,114
274,4HHA,B,94,94,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Anti-Human Cytomegalovirus (HCMV) Fab KE5 with epitope peptide AD-2S1,glycoprotein b,P,human herpesvirus 5,1.6,0.530477,1.0445,"P1,P2,P3,P4,P5,P6,P7,P8,P9,P10",CMV,114
275,6PZE,L,50,50,IGLV1-51,D,['D' 'E'],E,83.18318318318319,Crystal structure of human NA-45 Fab in complex with neuraminidase Y169aH mutant from A/Shanghai/2/2013 (H7N9),neuraminidase,A,influenza a virus (a/shanghai/02/2013(h7n9)),2.3,-1.7714,-1.25834,"A118,A146,A149,A150,A151,A152,A197,A198,A199,A220,A221,A222,A224,A246,A247,A276,A277,A292,A294,A326,A344,A345,A346,A347,A369,A371,A406,A430,A431,A432,A434,A435,A437,A439",influenza,115
276,6B0G,C,27D,27D,IGKV2-30,Y,['Y' 'H'],H,60.664819944598335,Crystal structure of Pfs25 in complex with the transmission blocking antibody 1245,25 kda ookinete surface antigen,E,plasmodium falciparum,1.9,1.09334,2.65797,"E13,E15,E17,E22,E24,E25,E26,E27,E28,E40,E55,E81,E82,E83,E93,E95,E96,E97,E98,E115,E116,E129,E148,E149,E150,E151,E152,E153,E155,E157,E158",Malaria,116
277,6B0A,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of Pfs25 in complex with the transmission blocking antibody 1269,25 kda ookinete surface antigen,A,plasmodium falciparum,2.5,16.7422,0.0626021,"A18,A19,A87,A88,A91,A92,A93,A100,A102,A104,A105,A106,A107,A108,A109,A110,A111,A112,A113,A119,A120,A122,A123,A125,A126,A127,A130,A134",Malaria,117
278,6B0A,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of Pfs25 in complex with the transmission blocking antibody 1269,25 kda ookinete surface antigen,A,plasmodium falciparum,2.5,0.36442,1.24038,"A18,A19,A87,A88,A91,A92,A93,A100,A102,A104,A105,A106,A107,A108,A109,A110,A111,A112,A113,A119,A120,A122,A123,A125,A126,A127,A130,A134",Malaria,117
279,6B0A,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of Pfs25 in complex with the transmission blocking antibody 1269,25 kda ookinete surface antigen,A,plasmodium falciparum,2.5,-0.474055,-0.170936,"A18,A19,A87,A88,A91,A92,A93,A100,A102,A104,A105,A106,A107,A108,A109,A110,A111,A112,A113,A119,A120,A122,A123,A125,A126,A127,A130,A134",Malaria,117
280,6B08,B,50,50,IGLV3-21,Y,['Y' 'D'],D,33.71757925072046,Crystal structure of Pfs25 in complex with the transmission blocking antibody 1276,pfs25,A,plasmodium falciparum,2.2,6.70018,0.961288,"A76,A78,A87,A88,A90,A91,A92,A93,A102,A104,A105,A106,A107,A108,A109,A110,A111,A112,A122,A123,A124,A125,A126,A127",Malaria,118
281,6B08,C,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of Pfs25 in complex with the transmission blocking antibody 1276,pfs25,A,plasmodium falciparum,2.2,2.59554,2.06921,"A76,A78,A87,A88,A90,A91,A92,A93,A102,A104,A105,A106,A107,A108,A109,A110,A111,A112,A122,A123,A124,A125,A126,A127",Malaria,119
282,7MF1,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.092,0.806963,0.360129,"A346,A351,A444,A446,A449,A450,A452,A470,A471,A472,A481,A482,A483,A484,A490,A492,A493,A494",SARS,120
283,7MF1,H,73,73,IGHV1-69,E,['E' 'K'],K,54.58135860979463,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.092,-0.570801,-0.234676,"A346,A351,A444,A446,A449,A450,A452,A470,A471,A472,A481,A482,A483,A484,A490,A492,A493,A494",SARS,120
284,7MF1,L,50,50,IGLV2-14,D,['E' 'D'],E,43.44262295081968,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.092,0.38632,0.218745,"A346,A351,A444,A446,A449,A450,A452,A470,A471,A472,A481,A482,A483,A484,A490,A492,A493,A494",SARS,121
285,6AOD,A,30,30,IGKV1-17,R,['R' 'S'],S,82.26950354609927,FXIa antibody complex,coagulation factor xi,C,homo sapiens,1.8,2.27921,0.888481,"C392,C395,C396,C397,C413,C414,C416,C454,C456,C457,C458,C459,C462,C503,C504,C505,C506,C507,C508,C509,C510,C534,C551,C552,C553,C554,C555,C557,C575,C576,C577,C578,C579,C580,C581,C588,C589",Human,122
286,6AOD,A,32,32,IGKV1-17,D,['D' 'Y'],Y,82.26950354609927,FXIa antibody complex,coagulation factor xi,C,homo sapiens,1.8,7.52431,-0.477544,"C392,C395,C396,C397,C413,C414,C416,C454,C456,C457,C458,C459,C462,C503,C504,C505,C506,C507,C508,C509,C510,C534,C551,C552,C553,C554,C555,C557,C575,C576,C577,C578,C579,C580,C581,C588,C589",Human,122
287,6AOD,A,34,34,IGKV1-17,G,['G' 'A'],A,82.26950354609927,FXIa antibody complex,coagulation factor xi,C,homo sapiens,1.8,-1.06425,-0.0144782,"C392,C395,C396,C397,C413,C414,C416,C454,C456,C457,C458,C459,C462,C503,C504,C505,C506,C507,C508,C509,C510,C534,C551,C552,C553,C554,C555,C557,C575,C576,C577,C578,C579,C580,C581,C588,C589",Human,122
288,6AOD,B,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,FXIa antibody complex,coagulation factor xi,C,homo sapiens,1.8,4.02728,1.77562,"C392,C395,C396,C397,C413,C414,C416,C454,C456,C457,C458,C459,C462,C503,C504,C505,C506,C507,C508,C509,C510,C534,C551,C552,C553,C554,C555,C557,C575,C576,C577,C578,C579,C580,C581,C588,C589",Human,123
289,6AOD,B,61,62,IGHV1-2,Q,['Q' 'H'],H,94.54314720812184,FXIa antibody complex,coagulation factor xi,C,homo sapiens,1.8,0.545025,0.380589,"C392,C395,C396,C397,C413,C414,C416,C454,C456,C457,C458,C459,C462,C503,C504,C505,C506,C507,C508,C509,C510,C534,C551,C552,C553,C554,C555,C557,C575,C576,C577,C578,C579,C580,C581,C588,C589",Human,123
290,3PGF,H,54,54,IGHV3-11,S,['G' 'S'],G,43.54838709677419,Crystal structure of maltose bound MBP with a conformationally specific synthetic antigen binder (sAB),maltose-binding periplasmic protein,A,escherichia coli,2.1,2.74377,0.733007,"A64,A83,A86,A87,A90,A91,A92,A93,A95,A96,A98,A101,A110,A256,A259,A261,A301,A302,A303,A305,A306,A308,A309,A313,A321,A324,A325,A327,A328,A329,A330,A331,A332",E Coli,124
291,3PGF,H,56,56,IGHV3-11,Y,['T' 'Y'],T,43.54838709677419,Crystal structure of maltose bound MBP with a conformationally specific synthetic antigen binder (sAB),maltose-binding periplasmic protein,A,escherichia coli,2.1,1.74475,0.361485,"A64,A83,A86,A87,A90,A91,A92,A93,A95,A96,A98,A101,A110,A256,A259,A261,A301,A302,A303,A305,A306,A308,A309,A313,A321,A324,A325,A327,A328,A329,A330,A331,A332",E Coli,124
292,6FGB,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,Human FcRn extra-cellular domain complexed with Fab fragment of Rozanolixizumab,igg receptor fcrn large subunit p51 | beta-2-microglobulin,A | B,homo sapiens | homo sapiens,2.9,1.2703,1.06006,"A93,A97,A99,A100,A103,A105,A106,A107,A108,A109,A112,A113,A115,A116,A117,A118,A119,A120,A121,A122,A123,A124,A128,A129,A130,A131,A132,A133,A135,B1,B58",Human,125
293,6FGB,L,32,37,IGKV1-17,Y,['D' 'Y'],D,17.73049645390071,Human FcRn extra-cellular domain complexed with Fab fragment of Rozanolixizumab,igg receptor fcrn large subunit p51 | beta-2-microglobulin,A | B,homo sapiens | homo sapiens,2.9,3.07433,-0.425923,"A93,A97,A99,A100,A103,A105,A106,A107,A108,A109,A112,A113,A115,A116,A117,A118,A119,A120,A121,A122,A123,A124,A128,A129,A130,A131,A132,A133,A135,B1,B58",Human,126
294,3GRW,H,52,52,IGHV3-23,Y,['S' 'Y'],S,1.6016016016016017,FGFR3 in complex with a Fab,fibroblast growth factor receptor 3,A,homo sapiens,2.1,2.95146,2.49226,"A155,A158,A159,A161,A162,A163,A164,A165,A166,A167,A168,A169,A170,A171,A172,A173,A174,A175,A177,A202,A205,A207,A210,A214,A216,A217,A241,A246,A247,A248,A278,A279,A280,A281,A282,A283,A314,A315,A316,A317,A318",Human,127
295,7VNC,V,52,52,IGHV3-23,Y,['S' 'Y'],S,1.6016016016016017,"Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113 (UDD-state, state 1)",spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,3.7,2.50864,1.03021,"C346,C347,C348,C349,C352,C354,C441,C442,C444,C448,C449,C450,C451,C452,C466,C468,C469,C470,C471,C472,C484,C490,C491,C492,C493,C494",SARS,128
296,7VNB,A,52,52,IGHV3-23,Y,['S' 'Y'],S,1.6016016016016017,Crystal structure of the SARS-CoV-2 RBD in complex with a human single domain antibody n3113,spike protein s1,B,severe acute respiratory syndrome coronavirus2,2.27,3.32149,1.35892,"B340,B344,B345,B346,B347,B348,B349,B351,B352,B354,B356,B399,B444,B449,B450,B452,B468,B470,B471,B472,B482,B484,B490,B492,B493,B494",SARS,129
297,5CIN,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal Structure of non-neutralizing version of 4E10 (DeltaLoop) with epitope bound,peptide from mper region of hiv-1 env,P,human immunodeficiency virus 1,1.7,2.70358,-0.83237,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
298,5CIN,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal Structure of non-neutralizing version of 4E10 (DeltaLoop) with epitope bound,peptide from mper region of hiv-1 env,P,human immunodeficiency virus 1,1.7,16.4633,0.922668,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
299,5CIN,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal Structure of non-neutralizing version of 4E10 (DeltaLoop) with epitope bound,peptide from mper region of hiv-1 env,P,human immunodeficiency virus 1,1.7,0.845451,-0.0306391,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
300,5CIN,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal Structure of non-neutralizing version of 4E10 (DeltaLoop) with epitope bound,peptide from mper region of hiv-1 env,P,human immunodeficiency virus 1,1.7,1.00794,0.848578,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
301,5CIL,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal Structure of non-neutralizing version of 4E10 (WDWD) with epitope bound,peptide from the mper region of the env protein of hiv-1,P,human immunodeficiency virus 1,1.81,2.77399,-0.633987,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
302,5CIL,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal Structure of non-neutralizing version of 4E10 (WDWD) with epitope bound,peptide from the mper region of the env protein of hiv-1,P,human immunodeficiency virus 1,1.81,8.26942,0.900837,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
303,5CIL,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal Structure of non-neutralizing version of 4E10 (WDWD) with epitope bound,peptide from the mper region of the env protein of hiv-1,P,human immunodeficiency virus 1,1.81,1.52507,-0.253892,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
304,5CIL,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal Structure of non-neutralizing version of 4E10 (WDWD) with epitope bound,peptide from the mper region of the env protein of hiv-1,P,human immunodeficiency virus 1,1.81,1.63205,1.01448,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
305,6VJN,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],W,92.13483146067416,Structure of NHP D11A.B5Fab in complex with 16055 V2b peptide,v2b peptide | v2b peptide,G | F,homo sapiens | homo sapiens,2.0,0.282342,-0.169556,"G182,G183,G184,G185,G186,G186A,G186B,G186C,G186D,G187,G190,G192,F186,F186A,F186B,F189,F194",Human,130
306,6VJN,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],H,92.13483146067416,Structure of NHP D11A.B5Fab in complex with 16055 V2b peptide,v2b peptide | v2b peptide,G | F,homo sapiens | homo sapiens,2.0,1.43841,1.02234,"G182,G183,G184,G185,G186,G186A,G186B,G186C,G186D,G187,G190,G192,F186,F186A,F186B,F189,F194",Human,130
307,6VJN,H,50,50,IGHV4-59,R,['Y' 'R'],Y,0.0,Structure of NHP D11A.B5Fab in complex with 16055 V2b peptide,v2b peptide | v2b peptide,G | F,homo sapiens | homo sapiens,2.0,19.0704,14.3338,"G182,G183,G184,G185,G186,G186A,G186B,G186C,G186D,G187,G190,G192,F186,F186A,F186B,F189,F194",Human,130
308,6VJN,H,58,58,IGHV4-59,Y,['N' 'Y'],N,0.0,Structure of NHP D11A.B5Fab in complex with 16055 V2b peptide,v2b peptide | v2b peptide,G | F,homo sapiens | homo sapiens,2.0,2.57894,2.66528,"G182,G183,G184,G185,G186,G186A,G186B,G186C,G186D,G187,G190,G192,F186,F186A,F186B,F189,F194",Human,130
309,7FCQ,L,50,52,IGLV2-14,E,['E' 'D'],D,56.55737704918033,Crystallographic structure of neutralizing antibody P14-44 in complex with SARS-CoV-2 spike receptor-binding Domain (RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,1.89,2.21543,1.74998,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A412,A413,A414,A415,A426,A427,A428,A429,A460",SARS,131
310,7F62,H,56,57,IGHV3-11,Y,['T' 'Y'],T,43.54838709677419,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.6,0.339502,0.202504,"A403,A405,A447,A449,A453,A455,A456,A489,A493,A494,A495,A496,A497,A498,A499,A500,A501,A502,A503,A504,A505,A506",SARS,132
311,7F62,H,58,59,IGHV3-11,N,['Y' 'N'],Y,43.54838709677419,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.6,-0.142799,0.205844,"A403,A405,A447,A449,A453,A455,A456,A489,A493,A494,A495,A496,A497,A498,A499,A500,A501,A502,A503,A504,A505,A506",SARS,132
312,7F62,L,96,97,IGKV3D-20,Y,['Y' 'R'],R,48.333333333333336,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.6,2.12933,5.76624,"A403,A405,A447,A449,A453,A455,A456,A489,A493,A494,A495,A496,A497,A498,A499,A500,A501,A502,A503,A504,A505,A506",SARS,133
313,5GGT,H,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,PD-L1 in complex with BMS-936559 Fab,programmed cell death 1 ligand 1,A,homo sapiens,2.8,1.13736,-0.0921048,"A19,A47,A49,A50,A51,A52,A54,A56,A58,A63,A66,A68,A69,A71,A75,A113,A115,A116,A117,A119,A120,A121,A122,A123",Human,134
314,5GGV,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,CTLA-4 in complex with tremelimumab Fab,cytotoxic t-lymphocyte protein 4,Y,homo sapiens,1.998,4.08126,2.06105,"Y1,Y2,Y3,Y28,Y33,Y35,Y39,Y41,Y44,Y45,Y46,Y48,Y91,Y93,Y95,Y97,Y99,Y100,Y102,Y103,Y104,Y105,Y106,Y107,Y108,Y109,Y110",Human,135
315,2WUC,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Crystal structure of HGFA in complex with the allosteric non- inhibitory antibody Fab40.deltaTrp and Ac-KQLR-chloromethylketone,hepatocyte growth factor activator long chain,A,homo sapiens,2.7,8.16767,1.53011,"A59,A60,A60B,A60C,A60D,A61,A87,A88,A89,A90,A91,A92,A93,A94,A95,A96,A97,A98,A100,A101,A176,A177,A178,A179,A233,A236,A237,A240,A241,A243",Human,136
316,6DFI,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],W,92.13483146067416,Crystal structure of anti-Zika antibody Z021 bound to Zika virus envelope protein DIII,zika virus envelope protein diii,E,zika virus,2.48,0.257926,-0.137265,"E304,E305,E306,E307,E309,E310,E334,E335,E336,E337,E338,E366,E368,E369,E370,E391,E392,E394",Zika,137
317,6DFI,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],H,92.13483146067416,Crystal structure of anti-Zika antibody Z021 bound to Zika virus envelope protein DIII,zika virus envelope protein diii,E,zika virus,2.48,1.89291,0.986322,"E304,E305,E306,E307,E309,E310,E334,E335,E336,E337,E338,E366,E368,E369,E370,E391,E392,E394",Zika,137
318,6DFI,H,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal structure of anti-Zika antibody Z021 bound to Zika virus envelope protein DIII,zika virus envelope protein diii,E,zika virus,2.48,5.15614,3.30746,"E304,E305,E306,E307,E309,E310,E334,E335,E336,E337,E338,E366,E368,E369,E370,E391,E392,E394",Zika,137
319,6DFJ,H,27,27,IGHV4-59,G,['G' 'I'],I,100.0,Crystal structure of anti-Zika antibody Z021 bound to DENV-1 envelope protein DIII,dengue 1 envelope diii domain,E,dengue virus 1,2.07,0.95562,0.868929,"E298,E299,E300,E301,E303,E304,E327,E328,E329,E330,E331,E332,E334,E360,E361,E362,E382,E383,E384,E385",Dengue,138
320,6DFJ,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],W,92.13483146067416,Crystal structure of anti-Zika antibody Z021 bound to DENV-1 envelope protein DIII,dengue 1 envelope diii domain,E,dengue virus 1,2.07,-0.516859,-0.177596,"E298,E299,E300,E301,E303,E304,E327,E328,E329,E330,E331,E332,E334,E360,E361,E362,E382,E383,E384,E385",Dengue,138
321,6DFJ,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],H,92.13483146067416,Crystal structure of anti-Zika antibody Z021 bound to DENV-1 envelope protein DIII,dengue 1 envelope diii domain,E,dengue virus 1,2.07,1.87138,0.876387,"E298,E299,E300,E301,E303,E304,E327,E328,E329,E330,E331,E332,E334,E360,E361,E362,E382,E383,E384,E385",Dengue,138
322,6DFJ,H,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal structure of anti-Zika antibody Z021 bound to DENV-1 envelope protein DIII,dengue 1 envelope diii domain,E,dengue virus 1,2.07,5.24485,2.41757,"E298,E299,E300,E301,E303,E304,E327,E328,E329,E330,E331,E332,E334,E360,E361,E362,E382,E383,E384,E385",Dengue,138
323,7LSS,H,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7,spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,3.72,0.276757,-0.355588,"B345,B346,B437,B439,B440,B441,B443,B444,B445,B446,B447,B448,B449,B450,B498,B499,B500,B501,B502,B503,B506",SARS,79
324,7LSS,L,32,32,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7,spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,3.72,-0.989174,0.331015,"B345,B346,B437,B439,B440,B441,B443,B444,B445,B446,B447,B448,B449,B450,B498,B499,B500,B501,B502,B503,B506",SARS,84
325,7LSS,L,50,50,IGLV2-14,D,['E' 'D'],E,43.44262295081968,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7,spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,3.72,0.618602,0.327705,"B345,B346,B437,B439,B440,B441,B443,B444,B445,B446,B447,B448,B449,B450,B498,B499,B500,B501,B502,B503,B506",SARS,84
326,1U8P,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ECDKWCS,gp41 peptide,C,human immunodeficiency virus 1,3.23,0.807691,0.173597,"C1,C2,C3,C4,C5,C6",HIV,139
327,1U8Q,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELEKWAS,gp41 peptide,C,human immunodeficiency virus 1,2.24,0.821641,0.170852,"C1,C2,C3,C4,C5,C6,C7",HIV,139
328,1U8J,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKWAG,gp41 peptide,C,human immunodeficiency virus 1,2.24,0.259222,0.174079,"C1,C2,C3,C4,C5,C6",HIV,139
329,1U8K,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide LELDKWASL,gp41 peptide,C,human immunodeficiency virus 1,2.24,-0.0324271,-0.138771,"C0,C1,C2,C3,C4,C5,C6,C7,C8",HIV,139
330,1U8H,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ALDKWAS,gp41 peptide,C,human immunodeficiency virus 1,2.1,0.399932,0.173714,"C1,C2,C3,C4,C5,C6",HIV,139
331,1U8I,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKWAN,gp41 peptide,C,human immunodeficiency virus 1,2.0,0.397746,0.170884,"C1,C2,C3,C4,C5,C6",HIV,139
332,1U8N,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKFAS,gp41 peptide,C,human immunodeficiency virus 1,2.56,0.477036,0.169467,"C1,C2,C3,C4,C5,C6",HIV,139
333,1U8O,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKHAS,gp41 peptide,C,human immunodeficiency virus 1,3.02,0.307883,0.167166,"C1,C2,C3,C4,C5,C6",HIV,139
334,1U8L,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide DLDRWAS,gp41 peptide,C,human immunodeficiency virus 1,2.6,0.507835,0.167884,"C1,C2,C3,C4,C5,C6",HIV,139
335,7SN2,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,4.3,1.97583,0.0551839,"A366,A367,A369,A370,A371,A372,A373,A374,A375,A376,A377,A378,A379,A380,A382,A383,A384,A385,A386,A437,A438,A439,A440,A502,A503,A506,A508",SARS,140
336,6OZ2,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of the broadly neutralizing antibody N49P6 Fab in complex with HIV-1 Clade A/E strain 93TH057 gp120 core.,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.55,2.79462,0.345599,"G96,G97,G102,G124,G275,G276,G278,G279,G280,G281,G282,G365,G366,G367,G368,G371,G429,G430,G431,G455,G456,G457,G458,G459,G460,G461,G465,G467,G469,G473,G474,G476,G480",HIV,1
337,7WBZ,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Crystal structure of the SARS-Cov-2 RBD in complex with Fab 2303,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.42,-0.774858,-0.290866,"A403,A405,A406,A415,A416,A417,A420,A421,A449,A453,A455,A456,A457,A458,A459,A460,A473,A474,A475,A476,A477,A484,A486,A487,A489,A490,A493,A494,A495,A496,A498,A500,A501,A502,A503,A504,A505",SARS,9
338,4R8W,L,60,61,IGKV3-20,D,['D' 'A'],A,99.87797437461867,Crystal structure of H7 hemagglutinin from A/Anhui/1/2013 in complex with a neutralizing antibody CT149,hemagglutinin | hemagglutinin,B | A,influenza a virus (a/anhui/1-balf_rg45/2013(h7n9))  | influenza a virus (a/anhui/1-balf_rg45/2013(h7n9)),2.795,0.637186,0.92141,"A28,A30,A44,A45,A269,A282,A309,B340,B341,B342,B359,B360,B362,B363,B366,B367,B369,B370,B371,B373,B374,B375,B377,B378,B381",influenza,141
339,5HHV,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide,interleukin-17a,A,homo sapiens,2.2,1.16519,-1.23684,"A70,A74,A84,A85,A86,A87,A88,A91,A93,A124,A125,A126,A127,A128",Human,142
340,5HHV,H,53,53,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide,interleukin-17a,A,homo sapiens,2.2,0.629534,0.83595,"A70,A74,A84,A85,A86,A87,A88,A91,A93,A124,A125,A126,A127,A128",Human,142
341,5HHV,H,55,55,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide,interleukin-17a,A,homo sapiens,2.2,0.152187,-0.0774458,"A70,A74,A84,A85,A86,A87,A88,A91,A93,A124,A125,A126,A127,A128",Human,142
342,5HHX,H,53,53,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide,interleukin-17a,A,homo sapiens,3.0,-0.25181,-0.312648,"A70,A74,A85,A86,A87,A88,A91,A93,A124,A125,A126,A127",Human,142
343,5HHX,H,55,55,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide,interleukin-17a,A,homo sapiens,3.0,-0.478836,-0.189836,"A70,A74,A85,A86,A87,A88,A91,A93,A124,A125,A126,A127",Human,142
344,1U8M,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDKYAS,gp41 peptide,C,human immunodeficiency virus 1,2.4,0.500899,0.175296,"C1,C2,C3,C4,C5,C6",HIV,139
345,2B1H,L,50,50,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with UG29 peptide,ug29 peptide of exterior membrane glycoprotein gp120,P,,2.0,2.82974,3.94399,"P303,P304,P305,P306,P307,P308,P309,P312,P313,P317,P318",,
346,5Y2L,I,26,45,IGHV3-30,G,['G' 'A'],A,100.0,Crystal structure of a group 2 HA binding antibody AF4H1K1 Fab in complex with the 1968 H3N2 pandemic (H3-AC/68) hemagglutinin,hemagglutinin | hemagglutinin,B | A,influenza a virus (strain a/aichi/2/1968 h3n2) | influenza a virus (strain a/aichi/2/1968 h3n2),2.902,7.82586,7.8148,"A38,A40,A48,A52,A275,A276,A277,A278,A279,A280,A289,A290,A291,A318,B18,B19,B20,B21,B38,B41,B42,B45,B46,B48,B49,B52,B53,B56,B57,B58",influenza,143
347,2EIZ,B,31,31,IGHV4-59,S,['S' 'Y'],Y,100.0,Crystal structure of humanized HYHEL-10 fv mutant(HW47Y)-hen lysozyme complex,lysozyme c,C,gallus gallus,1.9,0.184,-0.394686,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C77,C89,C93,C96,C97,C100,C101,C102",Chicken,109
348,2EIZ,B,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal structure of humanized HYHEL-10 fv mutant(HW47Y)-hen lysozyme complex,lysozyme c,C,gallus gallus,1.9,4.1423,1.5346,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C77,C89,C93,C96,C97,C100,C101,C102",Chicken,109
349,2EIZ,B,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,Crystal structure of humanized HYHEL-10 fv mutant(HW47Y)-hen lysozyme complex,lysozyme c,C,gallus gallus,1.9,5.66072,4.02759,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C77,C89,C93,C96,C97,C100,C101,C102",Chicken,109
350,2EIZ,B,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal structure of humanized HYHEL-10 fv mutant(HW47Y)-hen lysozyme complex,lysozyme c,C,gallus gallus,1.9,3.12257,0.352496,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C77,C89,C93,C96,C97,C100,C101,C102",Chicken,109
351,2EIZ,B,58,58,IGHV4-59,Y,['N' 'Y'],N,0.0,Crystal structure of humanized HYHEL-10 fv mutant(HW47Y)-hen lysozyme complex,lysozyme c,C,gallus gallus,1.9,0.16511,0.179714,"C13,C14,C15,C16,C18,C19,C20,C21,C62,C63,C73,C75,C77,C89,C93,C96,C97,C100,C101,C102",Chicken,109
352,7FG2,D,52,53,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,"Minor cryo-EM structure of S protein trimer of SARS-CoV2 with K-874A VHH, composite map",spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,4.4,-0.0980892,-0.933198,"A346,A348,A349,A352,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A473,A487,A488,A489,A490,A494,A496",SARS,144
353,7FG2,D,60,62,IGHV3-23,G,['A' 'G'],A,0.0,"Minor cryo-EM structure of S protein trimer of SARS-CoV2 with K-874A VHH, composite map",spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,4.4,3.29412,2.88918,"A346,A348,A349,A352,A446,A447,A448,A449,A450,A451,A452,A466,A468,A470,A472,A473,A487,A488,A489,A490,A494,A496",SARS,144
354,7FG3,D,52,53,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,"Major cryo-EM structure of S protein trimer of SARS-CoV2 with K-874, composite map",spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.9,0.800856,1.77324,"A346,A347,A348,A349,A351,A352,A354,A356,A449,A450,A451,A466,A468,A470,A472,A473,A487,A488,A490,A492,A493,A494,A495,A496",SARS,145
355,7Z0Y,H,33,33,IGHV3-30,A,['A' 'G'],G,31.41153081510934,THSC20.HVTR04 Fab bound to SARS-CoV-2 Receptor Binding Domain,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.95,1.76035,1.05043,"R439,R440,R441,R443,R444,R445,R446,R447,R448,R449,R450,R498,R499,R500,R501,R502,R506",SARS,146
356,7Z0Y,H,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,THSC20.HVTR04 Fab bound to SARS-CoV-2 Receptor Binding Domain,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.95,7.89209,4.265,"R439,R440,R441,R443,R444,R445,R446,R447,R448,R449,R450,R498,R499,R500,R501,R502,R506",SARS,146
357,7Z0Y,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,THSC20.HVTR04 Fab bound to SARS-CoV-2 Receptor Binding Domain,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.95,12.2158,-0.0963094,"R439,R440,R441,R443,R444,R445,R446,R447,R448,R449,R450,R498,R499,R500,R501,R502,R506",SARS,146
358,4G7V,L,30,30,IGKV1-13,S,['I' 'S'],I,100.0,"Crystal structure of voltage sensing domain of Ci-VSP with fragment antibody (R217E, 2.5 A)",voltage-sensor containing phosphatase,S,ciona intestinalis,2.5,1.59117,0.945897,"S144,S200,S204,S205,S207,S208,S209,S211,S212,S213,S214,S215,S216,S217,S218,S219,S220",Ciona intestinalis,147
359,4G7V,L,32,32,IGKV1-13,A,['S' 'A'],S,100.0,"Crystal structure of voltage sensing domain of Ci-VSP with fragment antibody (R217E, 2.5 A)",voltage-sensor containing phosphatase,S,ciona intestinalis,2.5,1.68468,1.435,"S144,S200,S204,S205,S207,S208,S209,S211,S212,S213,S214,S215,S216,S217,S218,S219,S220",Ciona intestinalis,147
360,4NGH,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety.,modified fragment of hiv glycoprotein (gp41),P,,2.68,3.82348,0.012379,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P684",,
361,4NGH,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety.,modified fragment of hiv glycoprotein (gp41),P,,2.68,15.2616,1.2792,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P684",,
362,4NGH,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of the HIV-1 neutralizing antibody 4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety.,modified fragment of hiv glycoprotein (gp41),P,,2.68,1.74035,1.35577,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P684",,
363,4JKP,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Restricting HIV-1 Pathways for Escape using Rationally-Designed Anti-HIV-1 Antibodies,gp120,G,human immunodeficiency virus 1,2.82,3.67697,0.882404,"G49,G96,G97,G99,G102,G105,G122,G124,G257,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G370,G371,G375,G425,G426,G427,G428,G429,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G463,G465,G467,G469,G472,G473,G474,G475,G476,G480",HIV,1
364,7RU4,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,-0.33665,-0.531351,"A332,A333,A334,A335,A336,A337,A338,A339,A340,A342,A343,A344,A345,A362,A363,A364,A365,A367,A368,A441,A513,A527,A529",SARS,148
365,7RU4,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,4.91817,0.272025,"A332,A333,A334,A335,A336,A337,A338,A339,A340,A342,A343,A344,A345,A362,A363,A364,A365,A367,A368,A441,A513,A527,A529",SARS,148
366,7RU4,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,0.34235,0.286478,"A332,A333,A334,A335,A336,A337,A338,A339,A340,A342,A343,A344,A345,A362,A363,A364,A365,A367,A368,A441,A513,A527,A529",SARS,148
367,7RU4,H,73,73,IGHV1-69,K,['E' 'K'],E,45.41864139020537,CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,0.479218,0.59078,"A332,A333,A334,A335,A336,A337,A338,A339,A340,A342,A343,A344,A345,A362,A363,A364,A365,A367,A368,A441,A513,A527,A529",SARS,148
368,6CBV,H,54,58,IGHV3-48,S,['S' 'G'],G,47.05882352941176,Crystal strutcure of BRIL bound to an affinity matured synthetic antibody.,bril,B,escherichia coli,1.872,1.87194,2.05003,"B27,B28,B31,B32,B34,B35,B36,B38,B39,B41,B42,B66,B69,B70,B73,B76,B77,B80",E Coli,149
369,5X08,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,"Crystal structure of broadly neutralizing anti-HIV-1 antibody 4E10, mutant Npro, with peptide bound",envelope glycoprotein gp160,P,human immunodeficiency virus type 1 (malisolate),1.49,1.69114,-0.691498,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
370,5X08,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,"Crystal structure of broadly neutralizing anti-HIV-1 antibody 4E10, mutant Npro, with peptide bound",envelope glycoprotein gp160,P,human immunodeficiency virus type 1 (malisolate),1.49,16.3326,0.261855,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
371,5X08,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"Crystal structure of broadly neutralizing anti-HIV-1 antibody 4E10, mutant Npro, with peptide bound",envelope glycoprotein gp160,P,human immunodeficiency virus type 1 (malisolate),1.49,1.33452,0.0707284,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
372,5X08,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,"Crystal structure of broadly neutralizing anti-HIV-1 antibody 4E10, mutant Npro, with peptide bound",envelope glycoprotein gp160,P,human immunodeficiency virus type 1 (malisolate),1.49,0.864278,1.0748,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P683",HIV,23
373,7LQW,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spike,spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,4.47,0.257651,0.320099,"C14,C15,C16,C17,C18,C19,C20,C75,C76,C77,C78,C79,C143,C144,C244,C247",SARS,150
374,7LQW,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spike,spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,4.47,-0.405728,-0.0382501,"C14,C15,C16,C17,C18,C19,C20,C75,C76,C77,C78,C79,C143,C144,C244,C247",SARS,150
375,7TAS,H,52A,53,IGHV3-43,W,['W' 'G'],G,44.776119402985074,SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (local refinement of the RBD and S2K146),spike glycoprotein,E,severe acute respiratory syndrome coronavirus2,3.2,0.111365,0.205494,"E403,E406,E409,E417,E421,E449,E452,E455,E456,E473,E475,E476,E477,E478,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E500,E501,E502,E505",SARS,151
376,5L6Y,L,50,50,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,il13 in complex with tralokinumab,interleukin-13,C,homo sapiens,1.99,5.63503,-1.38231,"C6,C10,C13,C14,C17,C20,C21,C22,C99,C100,C103,C104,C106,C107,C108,C109,C111",Human,152
377,8DWA,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of neutralizing antibody P1D9 Fab in complex with SARS-CoV-2 spike receptor binding domain (RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.2,17.2235,7.66433,"A340,A343,A344,A345,A346,A349,A351,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A450,A452,A468,A470,A484,A490,A492,A493,A494,A509",SARS,153
378,5UWE,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,"CRYSTAL STRUCTURE OF THE ADCC-POTENT, WEAKLY NEUTRALIZING HIV ENV CO-RECEPTOR BINDING SITE ANTIBODY N12-I2 FAB IN COMPLEX WITH HIV-1 CLADE A/E GP120 AND M48U1",clade a/e 93th057 hiv-1 gp120 core | m48u1 cd4 mimetic peptide,G | N,human immunodeficiency virus 1 | synthetic construct,3.19,0.861132,0.600541,"G119,G120,G122,G200,G202,G203,G205,G206,G207,G298,G300,G301,G324,G325,G326,G327,G419,G421,G422,G423,G432,G434,G435,G436,G437,G438,G439,G440,G441,N5,N9",HIV,154
379,4G7Y,L,30,30,IGKV1-13,S,['I' 'S'],I,100.0,"Crystal structure of voltage sensing domain of Ci-VSP with fragment antibody (R217E, 2.8 A)",voltage-sensor containing phosphatase,S,ciona intestinalis,2.8,3.08254,0.759116,"S144,S200,S204,S205,S207,S208,S209,S211,S212,S213,S214,S215,S216,S217,S218,S219,S220",Ciona intestinalis,147
380,4G7Y,L,32,32,IGKV1-13,A,['S' 'A'],S,100.0,"Crystal structure of voltage sensing domain of Ci-VSP with fragment antibody (R217E, 2.8 A)",voltage-sensor containing phosphatase,S,ciona intestinalis,2.8,1.84793,1.60542,"S144,S200,S204,S205,S207,S208,S209,S211,S212,S213,S214,S215,S216,S217,S218,S219,S220",Ciona intestinalis,147
381,4DAG,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Structure of the Human Metapneumovirus Fusion Protein with Neutralizing Antibody Identifies a Pneumovirus Antigenic Site,fusion glycoprotein f0,A,human metapneumovirus,3.3904,0.816504,0.290256,"A18,A19,A20,A21,A22,A23,A24,A25,A26,A31,A33,A34,A282,A284,A312,A345,A346,A348,A349,A351,A352,A353,A356,A358,A378,A409,A411,A413,A414",hMPV,155
382,7WP5,H,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Cryo-EM structure of SARS-CoV-2 Omicron S6P trimer in complex with neutralizing antibody VacW-209 (local refinement),spikeprotein s1,F,severe acute respiratory syndrome coronavirus2,3.9,1.69426,1.18558,"F369,F370,F371,F372,F373,F375,F377,F378,F379,F380,F381,F382,F383,F384,F385,F403,F405,F406,F408,F409,F411,F412,F413,F414,F415,F416,F417,F420,F421,F427,F428,F455,F456,F505",SARS,13
383,6JSZ,D,58,218,IGHV3-74,T,['S' 'T'],S,7.361963190184049,"BACE2 xaperone complex with N-{3-[(5R)-3-amino-5-methyl-9,9-dioxo-2,9lambda6-dithia-4-azaspiro[5.5]undec-3-en-5-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide",beta-secretase 2,A,homo sapiens,1.53,0.254046,-0.0467928,"A75,A77,A78,A79,A81,A98,A100,A110,A112,A113,A114,A140,A147,A148,A150,A154,A157,A158,A159,A161,A162,A163,A164",Human,106
384,6UJ9,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide in complex with Fab,"hla class i histocompatibility antigen, b-7 alpha chain | isocitrate dehydrogenase [nadp], mitochondrial",A | C,homo sapiens | homo sapiens,2.9,8.66038,-0.901659,"A62,A65,A66,A68,A69,A72,A73,A76,A79,A80,A82,A83,A84,A86,A87,A88,A89,A142,A145,A146,A149,A150,A151,A152,A154,A155,C4,C5,C6,C7,C8,C9",Human,156
385,6UJ9,H,53,54,IGHV3-23,G,['S' 'G'],S,0.7007007007007007,Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide in complex with Fab,"hla class i histocompatibility antigen, b-7 alpha chain | isocitrate dehydrogenase [nadp], mitochondrial",A | C,homo sapiens | homo sapiens,2.9,5.73029,3.84974,"A62,A65,A66,A68,A69,A72,A73,A76,A79,A80,A82,A83,A84,A86,A87,A88,A89,A142,A145,A146,A149,A150,A151,A152,A154,A155,C4,C5,C6,C7,C8,C9",Human,156
386,6MJZ,H,31,31,IGHV4-59,S,['S' 'Y'],Y,100.0,Cryo-EM structure of Human Parainfluenza Virus Type 3 (hPIV3) in complex with antibody PIA174,fusion glycoprotein f0 | fusion glycoprotein f0 | fusion glycoprotein f0,C | A | B,human parainfluenza virus 3 | human parainfluenza virus 3 | human parainfluenza virus 3,4.3,0.441657,0.119713,"A58,A59,A61,A62,A186,A187,A188,A189,A190,A191,A192,A193,A194,B188,B189,B190,B191,B193,B194,B197,C59,C60,C186,C187,C188,C189,C190,C191,C192,C193,C194",HPIV,157
387,6MJZ,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],W,92.13483146067416,Cryo-EM structure of Human Parainfluenza Virus Type 3 (hPIV3) in complex with antibody PIA174,fusion glycoprotein f0 | fusion glycoprotein f0 | fusion glycoprotein f0,C | A | B,human parainfluenza virus 3 | human parainfluenza virus 3 | human parainfluenza virus 3,4.3,0.126274,0.0534411,"A58,A59,A61,A62,A186,A187,A188,A189,A190,A191,A192,A193,A194,B188,B189,B190,B191,B193,B194,B197,C59,C60,C186,C187,C188,C189,C190,C191,C192,C193,C194",HPIV,157
388,6MJZ,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],H,92.13483146067416,Cryo-EM structure of Human Parainfluenza Virus Type 3 (hPIV3) in complex with antibody PIA174,fusion glycoprotein f0 | fusion glycoprotein f0 | fusion glycoprotein f0,C | A | B,human parainfluenza virus 3 | human parainfluenza virus 3 | human parainfluenza virus 3,4.3,-0.403754,-0.348494,"A58,A59,A61,A62,A186,A187,A188,A189,A190,A191,A192,A193,A194,B188,B189,B190,B191,B193,B194,B197,C59,C60,C186,C187,C188,C189,C190,C191,C192,C193,C194",HPIV,157
389,6MJZ,H,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Cryo-EM structure of Human Parainfluenza Virus Type 3 (hPIV3) in complex with antibody PIA174,fusion glycoprotein f0 | fusion glycoprotein f0 | fusion glycoprotein f0,C | A | B,human parainfluenza virus 3 | human parainfluenza virus 3 | human parainfluenza virus 3,4.3,0.500015,0.19945,"A58,A59,A61,A62,A186,A187,A188,A189,A190,A191,A192,A193,A194,B188,B189,B190,B191,B193,B194,B197,C59,C60,C186,C187,C188,C189,C190,C191,C192,C193,C194",HPIV,157
390,6MJZ,H,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,Cryo-EM structure of Human Parainfluenza Virus Type 3 (hPIV3) in complex with antibody PIA174,fusion glycoprotein f0 | fusion glycoprotein f0 | fusion glycoprotein f0,C | A | B,human parainfluenza virus 3 | human parainfluenza virus 3 | human parainfluenza virus 3,4.3,0.819778,1.05314,"A58,A59,A61,A62,A186,A187,A188,A189,A190,A191,A192,A193,A194,B188,B189,B190,B191,B193,B194,B197,C59,C60,C186,C187,C188,C189,C190,C191,C192,C193,C194",HPIV,157
391,6W4M,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,"CRYSTAL STRUCTURE OF THE ADCC-POTENT, WEAKLY NEUTRALIZING HIV ENV CO-RECEPTOR BINDING SITE ANTIBODY N12-I2 FAB IN COMPLEX WITH HIV-1 CLADE A/E GP120 AND M48U1",clade a/e 93th057 hiv-1 gp120 core | m48u1 cd4 mimetic peptide,G | N,human immunodeficiency virus 1 | synthetic construct,3.2,0.78576,0.368947,"G119,G120,G122,G200,G202,G203,G205,G206,G207,G298,G300,G301,G324,G325,G326,G327,G419,G421,G422,G423,G432,G434,G435,G436,G437,G438,G439,G440,G441,N5,N9",HIV,154
392,5ERW,A,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Structure of HCV E2 glycoprotein antigenic Epitope II bound to the broadly neutralizing antibody HC84-26,hcv e2 glycoprotein epitope ii,C,hepatitis c virus,2.9,15.787,-1.98818,"C439,C440,C441,C442,C443,C444,C445,C446",HCV,158
393,5ERW,A,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of HCV E2 glycoprotein antigenic Epitope II bound to the broadly neutralizing antibody HC84-26,hcv e2 glycoprotein epitope ii,C,hepatitis c virus,2.9,0.683027,-0.161001,"C439,C440,C441,C442,C443,C444,C445,C446",HCV,158
394,5ERW,A,56,57,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Structure of HCV E2 glycoprotein antigenic Epitope II bound to the broadly neutralizing antibody HC84-26,hcv e2 glycoprotein epitope ii,C,hepatitis c virus,2.9,-1.53892,-0.719825,"C439,C440,C441,C442,C443,C444,C445,C446",HCV,158
395,5ERW,B,50,49,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,Structure of HCV E2 glycoprotein antigenic Epitope II bound to the broadly neutralizing antibody HC84-26,hcv e2 glycoprotein epitope ii,C,hepatitis c virus,2.9,-1.16386,-0.275296,"C439,C440,C441,C442,C443,C444,C445,C446",HCV,159
396,7M7B,H,53,53,IGHV4-34,H,['H' 'Y'],Y,100.0,SARS-CoV-2 Spike:Fab 3D11 complex focused refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.95,-0.424991,-0.408104,"A366,A369,A370,A371,A372,A374,A375,A376,A377,A378,A379,A382,A383,A384,A385,A386,A387,A388,A408,A414",SARS,160
397,7M7E,C,31,33,IGHV3-49,D,['D' 'Y'],Y,100.0,6-Deoxyerythronolide B synthase (DEBS) hybrid module (M3/1) in complex with antibody fragment 1B2,"6-deoxyerythronolide-b synthase erya2, modules 3 and 4,eryai,6-deoxyerythronolide-b synthase erya3, modules 5 and 6 chimera  | 6-deoxyerythronolide-b synthase erya2, modules 3 and 4,eryai,6-deoxyerythronolide-b synthase erya3, modules 5 and 6 chimera",A | B,saccharopolyspora erythraea | saccharopolyspora erythraea,3.2,-0.461009,-0.181896,"B5,B7,B10,B11,B13,B14,B17,B20,B21,B24,B28,B327,B328,B329,B332,A4,A5,A6,A7,A8,A9,A10,A11,A12,A14,A15,A16,A18,A19,A22,A776,A778,A795",Saccharopolyspora erythraea,161
398,7M7E,C,33,35,IGHV3-49,A,['A' 'P'],P,100.0,6-Deoxyerythronolide B synthase (DEBS) hybrid module (M3/1) in complex with antibody fragment 1B2,"6-deoxyerythronolide-b synthase erya2, modules 3 and 4,eryai,6-deoxyerythronolide-b synthase erya3, modules 5 and 6 chimera  | 6-deoxyerythronolide-b synthase erya2, modules 3 and 4,eryai,6-deoxyerythronolide-b synthase erya3, modules 5 and 6 chimera",A | B,saccharopolyspora erythraea | saccharopolyspora erythraea,3.2,-1.58658,-1.32099,"B5,B7,B10,B11,B13,B14,B17,B20,B21,B24,B28,B327,B328,B329,B332,A4,A5,A6,A7,A8,A9,A10,A11,A12,A14,A15,A16,A18,A19,A22,A776,A778,A795",Saccharopolyspora erythraea,161
399,4XAW,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid (08:0 PA),fragment of hiv glycoprotein (gp41) including the mperregion 671-683,P,human immunodeficiency virus 1,1.47,1.75603,-0.649454,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
400,4XAW,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid (08:0 PA),fragment of hiv glycoprotein (gp41) including the mperregion 671-683,P,human immunodeficiency virus 1,1.47,11.3787,-0.838103,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
401,4XAW,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid (08:0 PA),fragment of hiv glycoprotein (gp41) including the mperregion 671-683,P,human immunodeficiency virus 1,1.47,0.893064,0.050354,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
402,4XAW,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid (08:0 PA),fragment of hiv glycoprotein (gp41) including the mperregion 671-683,P,human immunodeficiency virus 1,1.47,1.35937,1.09635,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
403,7THE,B,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,Structure of RBD directed antibody DH1042 in complex with SARS-CoV-2 spike: Local refinement of RBD-Fab interface,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.79,4.35863,1.94294,"A351,A444,A445,A446,A448,A449,A450,A452,A455,A456,A468,A470,A471,A472,A478,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,162
404,7THE,B,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of RBD directed antibody DH1042 in complex with SARS-CoV-2 spike: Local refinement of RBD-Fab interface,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.79,2.13154,-0.71718,"A351,A444,A445,A446,A448,A449,A450,A452,A455,A456,A468,A470,A471,A472,A478,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,162
405,7THE,B,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Structure of RBD directed antibody DH1042 in complex with SARS-CoV-2 spike: Local refinement of RBD-Fab interface,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.79,0.875146,0.357891,"A351,A444,A445,A446,A448,A449,A450,A452,A455,A456,A468,A470,A471,A472,A478,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,162
406,7THE,B,73,73,IGHV1-69,K,['E' 'K'],E,45.41864139020537,Structure of RBD directed antibody DH1042 in complex with SARS-CoV-2 spike: Local refinement of RBD-Fab interface,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.79,0.0409798,0.05362,"A351,A444,A445,A446,A448,A449,A450,A452,A455,A456,A468,A470,A471,A472,A478,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,162
407,8DXT,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Fab arm of antibody GAR12 bound to the receptor binding domain of SARS-CoV-2.,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.25,2.84593,2.82866,"R345,R346,R347,R348,R349,R351,R354,R440,R441,R442,R443,R444,R445,R446,R447,R448,R449,R450,R451,R452,R470,R472,R481,R482,R483,R484,R490,R492,R494,R509",SARS,163
408,8DXT,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Fab arm of antibody GAR12 bound to the receptor binding domain of SARS-CoV-2.,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.25,0.384467,0.0329247,"R345,R346,R347,R348,R349,R351,R354,R440,R441,R442,R443,R444,R445,R446,R447,R448,R449,R450,R451,R452,R470,R472,R481,R482,R483,R484,R490,R492,R494,R509",SARS,163
409,8DXT,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Fab arm of antibody GAR12 bound to the receptor binding domain of SARS-CoV-2.,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.25,-0.271426,-0.246718,"R345,R346,R347,R348,R349,R351,R354,R440,R441,R442,R443,R444,R445,R446,R447,R448,R449,R450,R451,R452,R470,R472,R481,R482,R483,R484,R490,R492,R494,R509",SARS,163
410,8DXT,L,50,50,IGKV1-5,D,['D' 'K'],K,16.263440860215052,Fab arm of antibody GAR12 bound to the receptor binding domain of SARS-CoV-2.,spike protein s1,R,severe acute respiratory syndrome coronavirus2,2.25,6.59131,0.284615,"R345,R346,R347,R348,R349,R351,R354,R440,R441,R442,R443,R444,R445,R446,R447,R448,R449,R450,R451,R452,R470,R472,R481,R482,R483,R484,R490,R492,R494,R509",SARS,164
411,7YXU,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of agonistic antibody 1618 fab domain bound to human 4-1BB.,tumor necrosis factor receptor superfamily member 9,A,homo sapiens,2.31,0.312906,-1.49318,"A32,A33,A34,A35,A38,A40,A41,A42,A44,A45,A46,A47,A48,A49,A50,A51,A52,A65,A78,A79,A80,A81",Human,165
412,7YXU,H,52A,53,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,Crystal structure of agonistic antibody 1618 fab domain bound to human 4-1BB.,tumor necrosis factor receptor superfamily member 9,A,homo sapiens,2.31,-0.084937,-0.313314,"A32,A33,A34,A35,A38,A40,A41,A42,A44,A45,A46,A47,A48,A49,A50,A51,A52,A65,A78,A79,A80,A81",Human,165
413,7YXU,H,53,54,IGHV3-23,G,['S' 'G'],S,0.7007007007007007,Crystal structure of agonistic antibody 1618 fab domain bound to human 4-1BB.,tumor necrosis factor receptor superfamily member 9,A,homo sapiens,2.31,3.88703,1.52641,"A32,A33,A34,A35,A38,A40,A41,A42,A44,A45,A46,A47,A48,A49,A50,A51,A52,A65,A78,A79,A80,A81",Human,165
414,2XQB,L,50,50,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Crystal Structure of anti-IL-15 Antibody in Complex with human IL-15,interleukin 15,A,homo sapiens,2.6,4.32414,0.573746,"A22,A23,A24,A25,A26,A38,A41,A44,A45,A46,A48,A49,A52,A53,A55,A60,A63,A64,A67,A68,A71,A72,A74,A75,A87,A88,A89,A93",Human,166
415,5F9O,H,30,30,IGHV1-46,N,['T' 'N'],T,6.774193548387098,Crystal structure of broadly neutralizing VH1-46 germline-derived CD4-binding site-directed antibody CH235.09 in complex with HIV-1 clade A/E 93TH057 gp120,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,1.86,-0.0113653,0.313989,"G96,G102,G274,G275,G276,G277,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G371,G425,G426,G429,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G469,G470,G471,G472,G473,G474,G477,G480",HIV,167
416,4HF5,H,31,31,IGHV3-33,S,['S' 'R'],R,99.69788519637464,Crystal structure of Fab 8F8 in complex a H2N2 influenza virus hemagglutinin,hemagglutinin ha1,A,influenza a virus,3.004,16.8887,-1.04334,"A98,A131,A133,A134,A135,A136,A137,A140,A142,A143,A144,A145,A153,A155,A156,A157,A158,A159,A187,A188,A189,A190,A192,A193,A194,A225,A226",influenza,168
417,3FN0,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],W,92.13483146067416,Crystal structure of HIV-1 neutralizing human Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41,envelope polyprotein gp160,P,,1.8,0.463665,0.284263,"P670,P671,P672,P673,P674,P675,P676,P677",,
418,3FN0,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],H,92.13483146067416,Crystal structure of HIV-1 neutralizing human Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41,envelope polyprotein gp160,P,,1.8,0.558294,0.564292,"P670,P671,P672,P673,P674,P675,P676,P677",,
419,3FN0,H,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal structure of HIV-1 neutralizing human Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41,envelope polyprotein gp160,P,,1.8,6.4512,2.65314,"P670,P671,P672,P673,P674,P675,P676,P677",,
420,3FN0,H,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal structure of HIV-1 neutralizing human Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41,envelope polyprotein gp160,P,,1.8,2.01741,1.09969,"P670,P671,P672,P673,P674,P675,P676,P677",,
421,6OZ9,H,32,32,IGHV4-4,Y,['S' 'W' 'Y'],S,28.03030303030303,Ebola virus glycoprotein in complex with EBOV-520 Fab,envelope glycoprotein | small secreted glycoprotein sgp,B | A,ebola virus | ebola virus,3.462,4.9792,2.7952,"A71,A72,A74,A75,A76,A77,A78,A79,A104,A106,A107,A134,A136,A137,A139,B510,B511,B512,B513,B514,B516,B545,B546,B547,B549,B550,B551,B552,B556",Ebola,169
422,6OZ9,H,32,32,IGHV4-4,Y,['S' 'W' 'Y'],W,28.03030303030303,Ebola virus glycoprotein in complex with EBOV-520 Fab,envelope glycoprotein | small secreted glycoprotein sgp,B | A,ebola virus | ebola virus,3.462,1.89086,1.48416,"A71,A72,A74,A75,A76,A77,A78,A79,A104,A106,A107,A134,A136,A137,A139,B510,B511,B512,B513,B514,B516,B545,B546,B547,B549,B550,B551,B552,B556",Ebola,169
423,6OZ9,H,50,50,IGHV4-4,Y,['E' 'R' 'Y'],E,5.681818181818182,Ebola virus glycoprotein in complex with EBOV-520 Fab,envelope glycoprotein | small secreted glycoprotein sgp,B | A,ebola virus | ebola virus,3.462,-1.10627,-1.70733,"A71,A72,A74,A75,A76,A77,A78,A79,A104,A106,A107,A134,A136,A137,A139,B510,B511,B512,B513,B514,B516,B545,B546,B547,B549,B550,B551,B552,B556",Ebola,169
424,6OZ9,H,50,50,IGHV4-4,Y,['E' 'R' 'Y'],R,5.681818181818182,Ebola virus glycoprotein in complex with EBOV-520 Fab,envelope glycoprotein | small secreted glycoprotein sgp,B | A,ebola virus | ebola virus,3.462,-0.891084,-0.886149,"A71,A72,A74,A75,A76,A77,A78,A79,A104,A106,A107,A134,A136,A137,A139,B510,B511,B512,B513,B514,B516,B545,B546,B547,B549,B550,B551,B552,B556",Ebola,169
425,7RQQ,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Structure of chimeric antibody F10heavy_L9light with PfCSP peptide NANPNVDP,pfcsp peptide nanpnvdp,P,plasmodium falciparum 3d7,1.89,4.52396,3.12173,"P107,P108,P109,P110,P111",Malaria,170
426,7N3D,H,31,31,IGHV4-59,S,['S' 'Y'],Y,100.0,Crystal Structure of Human Fab S24-1564 in the complex with the N-teminal Domain of Nucleocapsid protein from SARS CoV-2,nucleoprotein,C,severe acute respiratory syndrome coronavirus2,1.53,0.230133,-0.104703,"C68,C69,C80,C81,C84,C113,C114,C119,C120,C121,C122,C123,C124,C132,C134,C135,C136,C137,C138,C139,C140,C141,C142,C144",SARS,171
427,7N3D,H,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal Structure of Human Fab S24-1564 in the complex with the N-teminal Domain of Nucleocapsid protein from SARS CoV-2,nucleoprotein,C,severe acute respiratory syndrome coronavirus2,1.53,2.70374,2.46697,"C68,C69,C80,C81,C84,C113,C114,C119,C120,C121,C122,C123,C124,C132,C134,C135,C136,C137,C138,C139,C140,C141,C142,C144",SARS,171
428,7N3D,H,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,Crystal Structure of Human Fab S24-1564 in the complex with the N-teminal Domain of Nucleocapsid protein from SARS CoV-2,nucleoprotein,C,severe acute respiratory syndrome coronavirus2,1.53,1.78004,1.32032,"C68,C69,C80,C81,C84,C113,C114,C119,C120,C121,C122,C123,C124,C132,C134,C135,C136,C137,C138,C139,C140,C141,C142,C144",SARS,171
429,5F96,H,30,30,IGHV1-46,N,['T' 'N'],T,6.774193548387098,Crystal structure of broadly neutralizing VH1-46 germline-derived CD4-binding site-directed antibody CH235.12 in complex with HIV-1 clade A/E 93TH057 gp120,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.2407,0.738004,-0.542829,"G96,G97,G124,G275,G276,G277,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G371,G425,G426,G429,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G469,G471,G472,G473,G474,G477,G480",HIV,167
430,4KHT,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Triple helix bundle of GP41 complexed with fab 8066,gp41 helix,A,human immunodeficiency virus 1,2.8170000000000000,4.10175,1.57625,"A49,A50,A51,A53,A54,A55,A57,A58,A60,A61,A62,A64,A65",HIV,172
431,4KHT,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Triple helix bundle of GP41 complexed with fab 8066,gp41 helix,A,human immunodeficiency virus 1,2.8170000000000000,0.673552,0.391456,"A49,A50,A51,A53,A54,A55,A57,A58,A60,A61,A62,A64,A65",HIV,172
432,4KHT,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Triple helix bundle of GP41 complexed with fab 8066,gp41 helix,A,human immunodeficiency virus 1,2.8170000000000000,-2.30803,-0.945568,"A49,A50,A51,A53,A54,A55,A57,A58,A60,A61,A62,A64,A65",HIV,172
433,4KHX,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of gp41 helix complexed with antibody 8062,gp41 helix,A,human immunodeficiency virus 1,2.9210000000000000,1.85252,1.75881,"A49,A50,A51,A53,A54,A55,A57,A58,A60,A61,A62,A63,A64,A65",HIV,172
434,4KHX,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of gp41 helix complexed with antibody 8062,gp41 helix,A,human immunodeficiency virus 1,2.9210000000000000,1.79914,0.238965,"A49,A50,A51,A53,A54,A55,A57,A58,A60,A61,A62,A63,A64,A65",HIV,172
435,4HFU,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of Fab 8M2 in complex with a H2N2 influenza virus hemagglutinin,hemagglutinin ha1,A,influenza a virus,3.106,1.65629,-0.0567608,"A98,A131,A133,A134,A135,A136,A137,A138,A143,A144,A145,A153,A155,A156,A157,A158,A159,A186,A187,A188,A189,A190,A192,A193,A194,A222,A224,A225,A226,A227,A228",influenza,173
436,4HFU,H,73,73,IGHV1-69,E,['E' 'K'],K,54.58135860979463,Crystal structure of Fab 8M2 in complex with a H2N2 influenza virus hemagglutinin,hemagglutinin ha1,A,influenza a virus,3.106,-0.679094,-0.731255,"A98,A131,A133,A134,A135,A136,A137,A138,A143,A144,A145,A153,A155,A156,A157,A158,A159,A186,A187,A188,A189,A190,A192,A193,A194,A222,A224,A225,A226,A227,A228",influenza,173
437,7CR5,H,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,Complex structure of a human monoclonal antibody with SARS-CoV-2 nucleocapsid protein NTD,nucleoprotein,A,severe acute respiratory syndrome coronavirus2,2.08,23.9629,3.40834,"A55,A56,A57,A58,A59,A60,A64,A65,A66,A67,A70,A74,A158,A159,A160,A161,A162,A163,A164,A165,A166,A167,A168,A169,A170,A171,A172",SARS,174
438,7CR5,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Complex structure of a human monoclonal antibody with SARS-CoV-2 nucleocapsid protein NTD,nucleoprotein,A,severe acute respiratory syndrome coronavirus2,2.08,-2.2126,-1.05555,"A55,A56,A57,A58,A59,A60,A64,A65,A66,A67,A70,A74,A158,A159,A160,A161,A162,A163,A164,A165,A166,A167,A168,A169,A170,A171,A172",SARS,174
439,6VBO,L,27D,27D,IGKV2-30,H,['Y' 'H'],Y,39.33518005540167,Crystal structure of anti-HIV-1 antibody DH813 bound to gp120 V2 peptide,envelope glycoprotein gp160,C,human immunodeficiency virus 1,1.683,-1.02853,-0.777028,"C170,C171,C172,C174,C175,C176,C177,C178,C179,C180,C181,C182,C183",HIV,175
440,5WHK,H,52A,53,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,Crystal structure of Fab fragment of antibody DX-2507 bound to FcRn-B2M,igg receptor fcrn large subunit p51 | beta-2-microglobulin,A | B,homo sapiens | homo sapiens,2.5,-0.242212,0.460014,"A81,A82,A83,A84,A85,A86,A87,A88,A112,A113,A115,A116,A129,A130,A131,A132,A133,A135,A136,A139,B1,B2,B32,B85",Human,176
441,5WHK,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of Fab fragment of antibody DX-2507 bound to FcRn-B2M,igg receptor fcrn large subunit p51 | beta-2-microglobulin,A | B,homo sapiens | homo sapiens,2.5,0.494535,-0.139147,"A81,A82,A83,A84,A85,A86,A87,A88,A112,A113,A115,A116,A129,A130,A131,A132,A133,A135,A136,A139,B1,B2,B32,B85",Human,176
442,5WHK,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of Fab fragment of antibody DX-2507 bound to FcRn-B2M,igg receptor fcrn large subunit p51 | beta-2-microglobulin,A | B,homo sapiens | homo sapiens,2.5,-1.06719,-0.443632,"A81,A82,A83,A84,A85,A86,A87,A88,A112,A113,A115,A116,A129,A130,A131,A132,A133,A135,A136,A139,B1,B2,B32,B85",Human,176
443,7DJZ,A,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab,spike protein s1,C,severe acute respiratory syndrome coronavirus2,2.397,5.0613,3.04829,"C351,C403,C417,C444,C445,C446,C447,C449,C450,C452,C453,C455,C456,C470,C472,C481,C482,C483,C484,C485,C486,C487,C489,C490,C492,C493,C494,C505",SARS,162
444,7DJZ,A,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab,spike protein s1,C,severe acute respiratory syndrome coronavirus2,2.397,3.9387,-0.537375,"C351,C403,C417,C444,C445,C446,C447,C449,C450,C452,C453,C455,C456,C470,C472,C481,C482,C483,C484,C485,C486,C487,C489,C490,C492,C493,C494,C505",SARS,162
445,7DJZ,A,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab,spike protein s1,C,severe acute respiratory syndrome coronavirus2,2.397,1.58453,0.771876,"C351,C403,C417,C444,C445,C446,C447,C449,C450,C452,C453,C455,C456,C470,C472,C481,C482,C483,C484,C485,C486,C487,C489,C490,C492,C493,C494,C505",SARS,162
446,7DJZ,A,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab,spike protein s1,C,severe acute respiratory syndrome coronavirus2,2.397,0.155809,0.29968,"C351,C403,C417,C444,C445,C446,C447,C449,C450,C452,C453,C455,C456,C470,C472,C481,C482,C483,C484,C485,C486,C487,C489,C490,C492,C493,C494,C505",SARS,162
447,2NXZ,D,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"HIV-1 gp120 Envelope Glycoprotein (T257S, S334A, S375W) Complexed with CD4 and Antibody 17b",envelope glycoprotein gp120,A,human immunodeficiency virus 1,2.04,0.445088,-0.451637,"A119,A120,A122,A200,A202,A203,A204,A205,A419,A420,A421,A422,A423,A432,A434,A435,A436,A437",HIV,177
448,7UAQ,H,54,54,IGHV3-48,G,['S' 'G'],S,52.94117647058824,"Structure of the SARS-CoV-2 NTD in complex with C1520, local refinement",spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.1,2.00302,2.64667,"A96,A97,A98,A99,A102,A121,A122,A123,A124,A143,A148,A149,A150,A151,A152,A153,A154,A173,A174,A176,A177,A178,A179,A180,A181,A182,A183,A184,A245,A261",SARS,178
449,5DWU,H,52A,53,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,Beta common receptor in complex with a Fab,cytokine receptor common subunit beta | cytokine receptor common subunit beta,A | B,homo sapiens | homo sapiens,3.97,-1.43308,-1.11906,"A39,A64,A65,A66,A101,A102,A104,A105,A106,A107,A108,A109,B335,B364,B365,B366,B367,B419,B420,B421",Human,179
450,5DWU,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Beta common receptor in complex with a Fab,cytokine receptor common subunit beta | cytokine receptor common subunit beta,A | B,homo sapiens | homo sapiens,3.97,-0.571351,-0.508291,"A39,A64,A65,A66,A101,A102,A104,A105,A106,A107,A108,A109,B335,B364,B365,B366,B367,B419,B420,B421",Human,179
451,5DWU,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Beta common receptor in complex with a Fab,cytokine receptor common subunit beta | cytokine receptor common subunit beta,A | B,homo sapiens | homo sapiens,3.97,0.0988262,0.307174,"A39,A64,A65,A66,A101,A102,A104,A105,A106,A107,A108,A109,B335,B364,B365,B366,B367,B419,B420,B421",Human,179
452,5XKU,C,33,29,IGHV4-31,G,['G' 'S'],S,100.0,Crystal structure of hemagglutinin globular head from an H7N9 influenza virus in complex with a neutralizing antibody HNIgGA6,influenza a virus,A,influenza a virus,1.78,-0.739592,-0.589806,"A98,A131,A135,A136,A137,A140,A143,A144,A145,A153,A155,A158A,A158B,A183,A186,A187,A189,A190,A193,A194,A219,A220,A221,A222,A225,A226,A227,A228",influenza,180
453,6YWD,A,33,41,IGHV2-70,G,['G' 'E'],E,100.0,De novo designed protein 4H_01 in complex with Mota antibody,de novo designed protein 4h_01,C,synthetic construct,3.2,19.8657,4.80134,"C12,C15,C16,C18,C19,C20,C24,C25,C26,C28,C29,C30,C32,C33,C36",Synthetic,181
454,6YWD,A,58,68,IGHV2-70,H,['Y' 'F' 'H'],Y,0.0,De novo designed protein 4H_01 in complex with Mota antibody,de novo designed protein 4h_01,C,synthetic construct,3.2,-0.736631,-0.23699999999999477,"C12,C15,C16,C18,C19,C20,C24,C25,C26,C28,C29,C30,C32,C33,C36",Synthetic,181
455,6YWD,A,58,68,IGHV2-70,H,['Y' 'F' 'H'],F,0.0,De novo designed protein 4H_01 in complex with Mota antibody,de novo designed protein 4h_01,C,synthetic construct,3.2,-1.52055,-0.5649999999999977,"C12,C15,C16,C18,C19,C20,C24,C25,C26,C28,C29,C30,C32,C33,C36",Synthetic,181
456,6YWD,B,50,57,IGKV1-5,D,['D' 'K'],K,16.263440860215052,De novo designed protein 4H_01 in complex with Mota antibody,de novo designed protein 4h_01,C,synthetic construct,3.2,1.41243,-1.0191,"C12,C15,C16,C18,C19,C20,C24,C25,C26,C28,C29,C30,C32,C33,C36",Synthetic,182
457,6DC3,L,29,29,IGLV2-14,G,['G' 'S'],S,97.74590163934424,RSV prefusion F bound to RSD5 Fab,rsv fusion glycoprotein,F,"human respiratory syncytial virus a (straina2), human immunodeficiency virus 1, unidentified",3.501,2.73878,2.45472,"F60,F63,F64,F65,F66,F68,F165,F168,F169,F172,F196,F200,F201,F204,F205,F206,F208,F209,F210,F211,F293,F294,F295",RSV,183
458,6DC3,L,32,32,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,RSV prefusion F bound to RSD5 Fab,rsv fusion glycoprotein,F,"human respiratory syncytial virus a (straina2), human immunodeficiency virus 1, unidentified",3.501,-0.537025,-0.406175,"F60,F63,F64,F65,F66,F68,F165,F168,F169,F172,F196,F200,F201,F204,F205,F206,F208,F209,F210,F211,F293,F294,F295",RSV,183
459,6DC3,L,50,50,IGLV2-14,D,['E' 'D'],E,43.44262295081968,RSV prefusion F bound to RSD5 Fab,rsv fusion glycoprotein,F,"human respiratory syncytial virus a (straina2), human immunodeficiency virus 1, unidentified",3.501,-0.760258,-0.915345,"F60,F63,F64,F65,F66,F68,F165,F168,F169,F172,F196,F200,F201,F204,F205,F206,F208,F209,F210,F211,F293,F294,F295",RSV,183
460,6DC3,L,51,51,IGLV2-14,V,['V' 'G'],G,97.74590163934424,RSV prefusion F bound to RSD5 Fab,rsv fusion glycoprotein,F,"human respiratory syncytial virus a (straina2), human immunodeficiency virus 1, unidentified",3.501,0.664905,0.819621,"F60,F63,F64,F65,F66,F68,F165,F168,F169,F172,F196,F200,F201,F204,F205,F206,F208,F209,F210,F211,F293,F294,F295",RSV,183
461,4PS4,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the complex between IL-13 and M1295 FAB,interleukin-13,A,homo sapiens,2.8,2.48531,-0.394853,"A7,A8,A11,A12,A14,A15,A18,A101,A104,A105,A107,A108,A109,A110",Human,184
462,6XPY,B,26,26,IGHV4-4,G,['G' 'S'],S,100.0,Human antibody S1V2-58 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2),hemagglutinin,A,influenza a virus,3.603,0.594734,0.594217,"A65,A67,A89,A90,A91,A93,A94,A95,A99,A100,A101,A102,A105,A109,A216,A217,A218,A219,A220,A221,A222,A223,A224,A225,A229,A269",influenza,185
463,6XPY,B,27,27,IGHV4-4,G,['G' 'I'],I,100.0,Human antibody S1V2-58 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2),hemagglutinin,A,influenza a virus,3.603,2.84819,3.6276,"A65,A67,A89,A90,A91,A93,A94,A95,A99,A100,A101,A102,A105,A109,A216,A217,A218,A219,A220,A221,A222,A223,A224,A225,A229,A269",influenza,185
464,6XPY,B,32,32,IGHV4-4,Y,['S' 'W' 'Y'],S,28.03030303030303,Human antibody S1V2-58 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2),hemagglutinin,A,influenza a virus,3.603,1.05922,0.953671,"A65,A67,A89,A90,A91,A93,A94,A95,A99,A100,A101,A102,A105,A109,A216,A217,A218,A219,A220,A221,A222,A223,A224,A225,A229,A269",influenza,185
465,6XPY,B,32,32,IGHV4-4,Y,['S' 'W' 'Y'],W,28.03030303030303,Human antibody S1V2-58 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2),hemagglutinin,A,influenza a virus,3.603,1.44743,0.509917,"A65,A67,A89,A90,A91,A93,A94,A95,A99,A100,A101,A102,A105,A109,A216,A217,A218,A219,A220,A221,A222,A223,A224,A225,A229,A269",influenza,185
466,6XPQ,B,2,2,IGHV4-61,V,['V' 'L'],L,100.0,Human antibody D1 H1-17/H3-14 in complex with the influenza hemagglutinin head domain of A/Texas/50/2012(H3N2),hemagglutinin,A,influenza a virus (a/texas/50/2012(h3n2)),4.2,-0.31842,-1.11195,"A65,A91,A92,A93,A94,A99,A100,A101,A102,A105,A216,A219,A220,A221,A222,A223,A224,A225,A229",influenza,108
467,4XC1,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate,modified fragment of hiv-1 glycoprotein (gp41) includingthe mper region 671-683,P,human immunodeficiency virus 1,1.63,0.427928,-0.59794,"P671,P672,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
468,4XC1,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate,modified fragment of hiv-1 glycoprotein (gp41) includingthe mper region 671-683,P,human immunodeficiency virus 1,1.63,5.01849,0.383834,"P671,P672,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
469,4XC1,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate,modified fragment of hiv-1 glycoprotein (gp41) includingthe mper region 671-683,P,human immunodeficiency virus 1,1.63,0.614342,-0.112808,"P671,P672,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
470,4XC1,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate,modified fragment of hiv-1 glycoprotein (gp41) includingthe mper region 671-683,P,human immunodeficiency virus 1,1.63,1.23187,0.580865,"P671,P672,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
471,4XC3,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate,modified fragment of hiv-1 glycoprotein (gp41) includingthe mper region 671-683,P,human immunodeficiency virus 1,1.63,2.81982,-0.623393,"P671,P672,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
472,4XC3,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate,modified fragment of hiv-1 glycoprotein (gp41) includingthe mper region 671-683,P,human immunodeficiency virus 1,1.63,8.8974,-0.607565,"P671,P672,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
473,4XC3,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate,modified fragment of hiv-1 glycoprotein (gp41) includingthe mper region 671-683,P,human immunodeficiency virus 1,1.63,1.35634,-0.520465,"P671,P672,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
474,4XC3,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate,modified fragment of hiv-1 glycoprotein (gp41) includingthe mper region 671-683,P,human immunodeficiency virus 1,1.63,1.25993,0.352037,"P671,P672,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
475,6IW0,H,26,27,IGHV4-59,G,['G' 'S'],S,100.0,Crystal structure of 5A ScFv in complex with YFV-17D sE in postfusion state,envelope protein e,A,yellow fever virus (strain 17d vaccine),3.6,6.45712,6.09615,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A99,A101,A102,A103,A104,A105,A106,A238,A239,A240,A241,A242,A243,A244",YFV,186
476,6IW0,H,27,28,IGHV4-59,G,['G' 'I'],I,100.0,Crystal structure of 5A ScFv in complex with YFV-17D sE in postfusion state,envelope protein e,A,yellow fever virus (strain 17d vaccine),3.6,-0.0166825,-0.306615,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A99,A101,A102,A103,A104,A105,A106,A238,A239,A240,A241,A242,A243,A244",YFV,186
477,6IW0,H,30,31,IGHV4-59,Y,['S' 'Y'],S,0.0,Crystal structure of 5A ScFv in complex with YFV-17D sE in postfusion state,envelope protein e,A,yellow fever virus (strain 17d vaccine),3.6,2.43829,1.2253,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A99,A101,A102,A103,A104,A105,A106,A238,A239,A240,A241,A242,A243,A244",YFV,186
478,6IW0,H,32,33,IGHV4-59,H,['Y' 'W' 'H'],Y,7.865168539325842,Crystal structure of 5A ScFv in complex with YFV-17D sE in postfusion state,envelope protein e,A,yellow fever virus (strain 17d vaccine),3.6,-0.917981,-0.965313,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A99,A101,A102,A103,A104,A105,A106,A238,A239,A240,A241,A242,A243,A244",YFV,186
479,6IW0,H,32,33,IGHV4-59,H,['Y' 'W' 'H'],W,7.865168539325842,Crystal structure of 5A ScFv in complex with YFV-17D sE in postfusion state,envelope protein e,A,yellow fever virus (strain 17d vaccine),3.6,2.67371,2.57027,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A99,A101,A102,A103,A104,A105,A106,A238,A239,A240,A241,A242,A243,A244",YFV,186
480,6IW0,H,53,54,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal structure of 5A ScFv in complex with YFV-17D sE in postfusion state,envelope protein e,A,yellow fever virus (strain 17d vaccine),3.6,1.99819,2.11303,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A99,A101,A102,A103,A104,A105,A106,A238,A239,A240,A241,A242,A243,A244",YFV,186
481,6U1N,L,30,31,IGKV1-13,S,['I' 'S'],I,100.0,GPCR-Beta arrestin structure in lipid bilayer,"beta-arrestin-1 | muscarinic acetylcholine receptor m2, vasopressin v2receptor chimera",C | R,rattus norvegicus | homo sapiens,4,6.22477,1.50073,"C7,C169,C173,C209,C210,C211,C212,C213,C275,C276,C277,C278,C279,C282,C290,C297,C298,C299,C300,C353,C354,C356,C357,C358,C359,C360,C361,C363,C364",Rat,187
482,6U1N,L,32,33,IGKV1-13,A,['S' 'A'],S,100.0,GPCR-Beta arrestin structure in lipid bilayer,"beta-arrestin-1 | muscarinic acetylcholine receptor m2, vasopressin v2receptor chimera",C | R,rattus norvegicus | homo sapiens,4,1.73085,1.66808,"C7,C169,C173,C209,C210,C211,C212,C213,C275,C276,C277,C278,C279,C282,C290,C297,C298,C299,C300,C353,C354,C356,C357,C358,C359,C360,C361,C363,C364",Rat,187
483,7OLY,H,28,28,IGHV4-39,S,['S' 'Y'],Y,100.0,Structure of activin A in complex with an ActRIIB-Alk4 fusion reveal insight into activin receptor interactions,activin receptor type-2b,C,homo sapiens,3.265,-0.911998,-0.0371119,"C26,C28,C30,C32,C43,C44,C45,C46,C48,C70,C72,C75,C88,C89,C107,C108,C109,C111,C112,C113,C114",Human,188
484,7OLY,H,30,30,IGHV4-39,S,['S' 'G'],G,100.0,Structure of activin A in complex with an ActRIIB-Alk4 fusion reveal insight into activin receptor interactions,activin receptor type-2b,C,homo sapiens,3.265,-0.348257,-0.0430535,"C26,C28,C30,C32,C43,C44,C45,C46,C48,C70,C72,C75,C88,C89,C107,C108,C109,C111,C112,C113,C114",Human,188
485,7WLC,H,33,33,IGHV1-69,T,['A' 'T'],A,4.739336492890995,SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265,spike protein s1,E,severe acute respiratory syndrome coronavirus2,4,-1.46226,-1.74823,"E346,E351,E439,E440,E441,E443,E444,E445,E446,E449,E450,E451,E452,E470,E490,E492,E493,E494,E498,E499,E500",SARS,189
486,7WLC,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265,spike protein s1,E,severe acute respiratory syndrome coronavirus2,4,0.910862,3.33696,"E346,E351,E439,E440,E441,E443,E444,E445,E446,E449,E450,E451,E452,E470,E490,E492,E493,E494,E498,E499,E500",SARS,189
487,7RU8,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement),spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,0,2.05966,1.93725,"C351,C445,C446,C447,C449,C452,C455,C456,C470,C472,C475,C477,C481,C482,C483,C484,C485,C486,C487,C489,C490,C492,C493,C494",SARS,162
488,7RU8,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement),spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,0,6.06713,4.91238,"C351,C445,C446,C447,C449,C452,C455,C456,C470,C472,C475,C477,C481,C482,C483,C484,C485,C486,C487,C489,C490,C492,C493,C494",SARS,162
489,7AZB,B,52,74,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Structure of DDR2 DS domain in complex with VHH,discoidin domain-containing receptor 2,A,homo sapiens,2.62,-0.343096,0.5151,"A53,A55,A56,A57,A70,A74,A77,A78,A106,A107,A108,A109,A110,A111,A112,A113,A114,A115,A146,A147,A148,A149,A150,A151,A176,A178",Human,190
490,7AZB,B,60,84,IGHV3-23,A,['A' 'G'],G,100.0,Structure of DDR2 DS domain in complex with VHH,discoidin domain-containing receptor 2,A,homo sapiens,2.62,1.83895,1.63889,"A53,A55,A56,A57,A70,A74,A77,A78,A106,A107,A108,A109,A110,A111,A112,A113,A114,A115,A146,A147,A148,A149,A150,A151,A176,A178",Human,190
491,2XWT,B,50,50,IGLV1-51,D,['D' 'E'],E,83.18318318318319,Crystal structure of the TSH receptor in complex with a blocking type  TSHR autoantibody,thyrotropin receptor,C,homo sapiens,1.9,0.618406,-0.200336,"C34,C35,C36,C37,C38,C40,C42,C55,C56,C58,C60,C61,C79,C80,C82,C83,C84,C85,C102,C104,C105,C107,C109,C110,C127,C129,C130,C134,C151,C152,C153,C155,C157,C181,C183,C203,C206",Human,191
492,2NY6,D,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) Complexed with CD4 and Antibody 17b",envelope glycoprotein gp120,A,human immunodeficiency virus 1,2.8,-0.469585,-0.170685,"A119,A120,A122,A200,A202,A203,A204,A205,A419,A420,A421,A422,A423,A432,A433,A434,A435,A436,A437",HIV,177
493,2NY5,H,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) Complexed with CD4 and Antibody 17b",envelope glycoprotein gp120,G,human immunodeficiency virus 1,2.5,0.671262,-0.326734,"G119,G120,G122,G200,G202,G203,G204,G205,G419,G420,G421,G422,G423,G432,G433,G434,G435,G436,G437",HIV,177
494,2NY4,D,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E268C, S334A, S375W) Complexed with CD4 and Antibody 17b",envelope glycoprotein gp120,A,human immunodeficiency virus 1,2.0,0.900403,-0.389353,"A119,A120,A122,A200,A202,A203,A204,A205,A419,A420,A421,A422,A423,A432,A434,A435,A436,A437",HIV,177
495,2NY1,D,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"HIV-1 gp120 Envelope Glycoprotein (I109C, T257S, S334A, S375W, Q428C) Complexed with CD4 and Antibody 17b",envelope glycoprotein gp120,A,human immunodeficiency virus 1,1.99,-0.312444,-0.228566,"A119,A120,A122,A200,A202,A203,A204,A205,A419,A420,A421,A422,A423,A432,A434,A435,A436,A437",HIV,177
496,2NY0,D,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, T257S, V275C, S334A, S375W, A433M) Complexed with CD4 and Antibody 17b",envelope glycoprotein gp120,A,human immunodeficiency virus 1,2.2,1.03118,-0.355694,"A119,A120,A122,A200,A202,A203,A204,A205,A419,A420,A421,A422,A423,A432,A434,A435,A436,A437",HIV,177
497,6QB6,H,50,50,IGHV3-21,S,['S' 'Y'],Y,100.0,Mcl1 in complex with a Fab,induced myeloid leukemia cell differentiation protein mcl-1,A,homo sapiens,2.24,14.9845,7.09375,"A174,A177,A204,A205,A208,A307,A308,A309,A310,A311,A312,A313,A316,A317,A318,A320,A322",Human,54
498,6BCK,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal Structure of Broadly Neutralizing Antibody N49P7 in Complex with HIV-1 Clade AE strain 93TH057 gp120 core.,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.7,4.10785,1.31587,"G96,G97,G102,G105,G124,G275,G276,G278,G279,G280,G281,G282,G283,G364,G365,G366,G367,G368,G370,G371,G427,G428,G429,G455,G456,G457,G458,G459,G460,G461,G463,G469,G470,G471,G473,G474,G476,G477,G480",HIV,1
499,6MF7,H,51,52,IGHV4-30-4,I,['I' 'F'],F,100.0,Structure of parvovirus B19 decorated with Fab molecules from a human antibody,vp2,A,human parvovirus b19,3.2,1.17396,-0.397622,"A48,A50,A51,A57,A58,A59,A60,A61,A62,A133,A183,A195,A196,A197,A198,A200,A202,A475,A477,A479",Parvovirus B19,192
500,7DHA,C,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,crystal structure of CD38 in complex with daratumumab,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,A,homo sapiens,2.55,11.2278,1.79941,"A76,A77,A91,A95,A97,A98,A158,A159,A161,A192,A193,A195,A197,A208,A210,A228,A229,A230,A231,A232,A233,A235,A240,A243,A244,A247,A248,A251,A252,A253,A255,A256",Human,58
501,7DHA,C,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,crystal structure of CD38 in complex with daratumumab,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,A,homo sapiens,2.55,1.71154,1.50808,"A76,A77,A91,A95,A97,A98,A158,A159,A161,A192,A193,A195,A197,A208,A210,A228,A229,A230,A231,A232,A233,A235,A240,A243,A244,A247,A248,A251,A252,A253,A255,A256",Human,58
502,7DHA,C,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,crystal structure of CD38 in complex with daratumumab,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,A,homo sapiens,2.55,0.157667,-0.0974841,"A76,A77,A91,A95,A97,A98,A158,A159,A161,A192,A193,A195,A197,A208,A210,A228,A229,A230,A231,A232,A233,A235,A240,A243,A244,A247,A248,A251,A252,A253,A255,A256",Human,58
503,7DHA,C,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,crystal structure of CD38 in complex with daratumumab,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,A,homo sapiens,2.55,3.09473,0.0481924,"A76,A77,A91,A95,A97,A98,A158,A159,A161,A192,A193,A195,A197,A208,A210,A228,A229,A230,A231,A232,A233,A235,A240,A243,A244,A247,A248,A251,A252,A253,A255,A256",Human,58
504,7K8U,H,26,26,IGHV4-34,G,['G' 'F'],F,100.0,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,4.07605,4.43434,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
505,7K8U,H,27,27,IGHV4-34,G,['G' 'S'],S,100.0,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,1.22258,1.30477,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
506,7K8U,H,28,28,IGHV4-34,S,['S' 'T' 'G'],T,99.44444444444446,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,-0.055468,-0.12323,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
507,7K8U,H,28,28,IGHV4-34,S,['S' 'T' 'G'],G,99.44444444444446,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,-0.149054,-0.120958,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
508,7K8U,H,31,31,IGHV4-34,G,['G' 'W'],W,100.0,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,-1.01807,0.270353,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
509,7K8U,H,32,32,IGHV4-34,Y,['Y' 'S'],S,100.0,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,1.39803,0.642312,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
510,7K8U,H,50,50,IGHV4-34,E,['E' 'Y'],Y,100.0,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,-1.8634,0.0626104,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
511,7K8U,H,52,52,IGHV4-34,N,['N' 'Y' 'I'],Y,98.8888888888889,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,-1.059,-1.05032,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
512,7K8U,H,52,52,IGHV4-34,N,['N' 'Y' 'I'],I,98.8888888888889,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,-0.0575661,-0.384232,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
513,7K8U,H,53,53,IGHV4-34,H,['H' 'Y'],Y,100.0,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.8,7.380000000000109,-0.349265,"A351,A444,A449,A450,A452,A470,A483,A484,A486,A490,A492,A494,B378,B404,B405,B407,B408,B414,B503,B504,B505,B508",SARS,193
514,7K8Y,G,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 2)",spike glycoprotein | spike glycoprotein,B | D,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,4.4,2.95601,4.01795,"B444,B446,B447,B449,B450,B452,B453,B455,B456,B475,B483,B484,B485,B486,B487,B489,B490,B492,B493,B494,B496,B498,D378,D404,D405,D408,D409,D411,D412,D413,D414,D415,D503,D504",SARS,194
515,7L3N,D,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,SARS-CoV 2 Spike Protein bound to LY-CoV555,spike glycoprotein | spike glycoprotein,B | C,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,0.961042,0.873845,"B351,B403,B446,B447,B449,B450,B452,B453,B456,B470,B472,B478,B479,B481,B482,B483,B484,B485,B486,B487,B488,B489,B490,B492,B493,B494,B495,B496,C372,C373,C436,C437,C439,C440,C441",SARS,195
516,7L3N,D,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,SARS-CoV 2 Spike Protein bound to LY-CoV555,spike glycoprotein | spike glycoprotein,B | C,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,2.27251,0.739474,"B351,B403,B446,B447,B449,B450,B452,B453,B456,B470,B472,B478,B479,B481,B482,B483,B484,B485,B486,B487,B488,B489,B490,B492,B493,B494,B495,B496,C372,C373,C436,C437,C439,C440,C441",SARS,195
517,7L3N,D,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,SARS-CoV 2 Spike Protein bound to LY-CoV555,spike glycoprotein | spike glycoprotein,B | C,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,3.52906,-0.624115,"B351,B403,B446,B447,B449,B450,B452,B453,B456,B470,B472,B478,B479,B481,B482,B483,B484,B485,B486,B487,B488,B489,B490,B492,B493,B494,B495,B496,C372,C373,C436,C437,C439,C440,C441",SARS,195
518,7L3N,D,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,SARS-CoV 2 Spike Protein bound to LY-CoV555,spike glycoprotein | spike glycoprotein,B | C,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,2.43965,1.51536,"B351,B403,B446,B447,B449,B450,B452,B453,B456,B470,B472,B478,B479,B481,B482,B483,B484,B485,B486,B487,B488,B489,B490,B492,B493,B494,B495,B496,C372,C373,C436,C437,C439,C440,C441",SARS,195
519,7L3N,D,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,SARS-CoV 2 Spike Protein bound to LY-CoV555,spike glycoprotein | spike glycoprotein,B | C,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,0.467414,0.450222,"B351,B403,B446,B447,B449,B450,B452,B453,B456,B470,B472,B478,B479,B481,B482,B483,B484,B485,B486,B487,B488,B489,B490,B492,B493,B494,B495,B496,C372,C373,C436,C437,C439,C440,C441",SARS,195
520,6W00,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of Fab239 in complex with NPNA2 peptide from circumsporozoite protein,npna2 peptide,P,plasmodium falciparum,1.853,3.80503,2.25513,"P2,P3,P4,P5,P6,P7,P8,P9",Malaria,48
521,4P59,H,50,50,IGHV3-23,A,['A' 'V'],V,99.2992992992993,HER3 extracellular domain in complex with Fab fragment of MOR09825,receptor tyrosine-protein kinase erbb-3,A,homo sapiens,3.4,-0.4579,-0.072362,"A263,A265,A266,A267,A268,A269,A270,A271,A272,A273,A274,A275,A276,A277,A314,A315,A321,A571,A582,A583,A584,A596,A597,A600,A601,A602,A603,A609,A611,A612,A613,A614,A615,A624",Human,196
522,4P59,H,52A,53,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,HER3 extracellular domain in complex with Fab fragment of MOR09825,receptor tyrosine-protein kinase erbb-3,A,homo sapiens,3.4,0.18429,0.418695,"A263,A265,A266,A267,A268,A269,A270,A271,A272,A273,A274,A275,A276,A277,A314,A315,A321,A571,A582,A583,A584,A596,A597,A600,A601,A602,A603,A609,A611,A612,A613,A614,A615,A624",Human,196
523,7UCX,L,27D,31,IGKV2-30,Y,['Y' 'H'],H,60.664819944598335,LRP8 11H1 Fab complexed to a cyclized CR1 peptide,cyclized cr1 peptide,B,homo sapiens,1.72,1.2161,1.01089,"B1,B2,B3,B4,B5,B6,B7,B8,B9,B10,B11,B14",Human,197
524,1ADQ,L,50,50,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,CRYSTAL STRUCTURE OF A HUMAN IGM RHEUMATOID FACTOR FAB IN COMPLEX WITH ITS AUTOANTIGEN IGG FC,igg4 rea fc,A,homo sapiens,3.15,-1.09649,-0.591058,"A251,A252,A253,A254,A255,A256,A311,A382,A383,A384,A385,A386,A422,A424,A428,A433,A434,A435,A436,A437,A438,A439,A440",Human,198
525,6XPX,B,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,Human antibody S1V2-51 in complex with the influenza hemagglutinin head domain of A/Aichi/2/1968 (X-31)(H3N2),hemagglutinin,A,influenza a virus,2.598,16.7834,4.59237,"A96,A136,A137,A138,A140,A143,A216,A217,A218,A219,A220,A221,A222,A223,A224,A225,A226,A227,A229",influenza,199
526,6XPX,B,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Human antibody S1V2-51 in complex with the influenza hemagglutinin head domain of A/Aichi/2/1968 (X-31)(H3N2),hemagglutinin,A,influenza a virus,2.598,5.84149,0.804218,"A96,A136,A137,A138,A140,A143,A216,A217,A218,A219,A220,A221,A222,A223,A224,A225,A226,A227,A229",influenza,199
527,7YDY,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,4.75,0.563265,0.542007,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,200
528,7YDY,H,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,4.75,3.67294,-0.292056,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,200
529,7YDY,H,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,4.75,1.37697,0.940042,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,200
530,7YDY,H,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,4.75,0.488571,0.21604,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,200
531,7YDY,L,69,71,IGLV1-40,T,['T' 'A'],A,99.57081545064378,SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,4.75,-0.885588,-0.450759,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,201
532,7YDI,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,"SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2, focused refinement of RBD region",spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.98,0.23274,0.145204,"E340,E344,E345,E346,E348,E351,E352,E353,E354,E355,E356,E357,E396,E449,E450,E452,E457,E461,E462,E463,E464,E465,E466,E467,E468,E469,E470,E471,E472,E482,E483,E484,E490,E492,E493,E494",SARS,200
533,7YDI,H,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2, focused refinement of RBD region",spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.98,9.43603,0.213927,"E340,E344,E345,E346,E348,E351,E352,E353,E354,E355,E356,E357,E396,E449,E450,E452,E457,E461,E462,E463,E464,E465,E466,E467,E468,E469,E470,E471,E472,E482,E483,E484,E490,E492,E493,E494",SARS,200
534,7YDI,H,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,"SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2, focused refinement of RBD region",spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.98,1.46821,0.412807,"E340,E344,E345,E346,E348,E351,E352,E353,E354,E355,E356,E357,E396,E449,E450,E452,E457,E461,E462,E463,E464,E465,E466,E467,E468,E469,E470,E471,E472,E482,E483,E484,E490,E492,E493,E494",SARS,200
535,7YDI,L,69,71,IGLV1-40,T,['T' 'A'],A,99.57081545064378,"SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2, focused refinement of RBD region",spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.98,-0.0300203,-0.0901004,"E340,E344,E345,E346,E348,E351,E352,E353,E354,E355,E356,E357,E396,E449,E450,E452,E457,E461,E462,E463,E464,E465,E466,E467,E468,E469,E470,E471,E472,E482,E483,E484,E490,E492,E493,E494",SARS,201
536,6Q18,H,26,26,IGHV4-4,G,['G' 'S'],S,100.0,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,2.98405,3.06421,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
537,6Q18,H,27,27,IGHV4-4,G,['G' 'I'],I,100.0,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,4.73768,4.54346,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
538,6Q18,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,8.97601,1.37105,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
539,6Q18,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],W,71.96969696969697,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,22.7879,0.222461,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
540,6Q18,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],Y,71.96969696969697,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,22.1965,-0.0309702,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
541,6Q18,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],W,71.96969696969697,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,14.0929,1.7429,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
542,6Q18,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],Y,71.96969696969697,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,6.51878,-0.419696,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
543,6Q18,H,34,34,IGHV4-4,W,['W' 'S'],S,100.0,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,1.23498,2.65173,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
544,6Q18,H,53,54,IGHV4-4,H,['H' 'T'],T,71.96969696969697,Human antibody H1244 in complex with the influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.55,-1.4909999999999854,-1.1620000000000061,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
545,6OCB,H,34,34,IGHV4-61,Y,['Y' 'W'],W,100.0,Crystal structure of FluA-20 Fab in complex with the head domain of H3 (A/Hong Kong/1/1968),hemagglutinin,A,influenza a virus,2.1,"-nan
","-nan
","A91,A92,A95,A99,A100,A101,A216,A217,A218,A219,A220,A221,A222,A223,A224,A225,A229",influenza,203
546,6VY6,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of Hendra receptor binding protein head domain in complex with human neutralizing antibody HENV-26,receptor binding protein,A,hendra henipavirus,2.6,9.98923,-1.73792,"A242,A305,A351,A389,A391,A393,A394,A397,A401,A402,A403,A404,A458,A488,A489,A490,A491,A492,A494,A495,A496,A497,A501,A502,A504,A505,A506,A507,A528,A529,A530,A531,A532,A533,A553,A555,A556,A557,A559,A581,A583,A584",Hendra,204
547,6VY6,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of Hendra receptor binding protein head domain in complex with human neutralizing antibody HENV-26,receptor binding protein,A,hendra henipavirus,2.6,3.31821,3.46006,"A242,A305,A351,A389,A391,A393,A394,A397,A401,A402,A403,A404,A458,A488,A489,A490,A491,A492,A494,A495,A496,A497,A501,A502,A504,A505,A506,A507,A528,A529,A530,A531,A532,A533,A553,A555,A556,A557,A559,A581,A583,A584",Hendra,204
548,6VY6,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of Hendra receptor binding protein head domain in complex with human neutralizing antibody HENV-26,receptor binding protein,A,hendra henipavirus,2.6,1.13899,0.0936464,"A242,A305,A351,A389,A391,A393,A394,A397,A401,A402,A403,A404,A458,A488,A489,A490,A491,A492,A494,A495,A496,A497,A501,A502,A504,A505,A506,A507,A528,A529,A530,A531,A532,A533,A553,A555,A556,A557,A559,A581,A583,A584",Hendra,204
549,6VY6,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of Hendra receptor binding protein head domain in complex with human neutralizing antibody HENV-26,receptor binding protein,A,hendra henipavirus,2.6,-0.990218,-0.347072,"A242,A305,A351,A389,A391,A393,A394,A397,A401,A402,A403,A404,A458,A488,A489,A490,A491,A492,A494,A495,A496,A497,A501,A502,A504,A505,A506,A507,A528,A529,A530,A531,A532,A533,A553,A555,A556,A557,A559,A581,A583,A584",Hendra,204
550,6VY5,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of Nipah receptor binding protein head domain in complex with human neutralizing antibody HENV-26,receptor binding protein,A,nipah henipavirus,3.4,10.8844,0.498124,"A305,A389,A394,A401,A402,A403,A404,A458,A488,A489,A490,A491,A492,A494,A497,A501,A502,A504,A505,A506,A507,A527,A528,A529,A530,A531,A532,A533,A553,A554,A555,A556,A557,A581,A583,A586",Nipah,205
551,6VY5,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of Nipah receptor binding protein head domain in complex with human neutralizing antibody HENV-26,receptor binding protein,A,nipah henipavirus,3.4,1.29248,1.51503,"A305,A389,A394,A401,A402,A403,A404,A458,A488,A489,A490,A491,A492,A494,A497,A501,A502,A504,A505,A506,A507,A527,A528,A529,A530,A531,A532,A533,A553,A554,A555,A556,A557,A581,A583,A586",Nipah,205
552,6VY5,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of Nipah receptor binding protein head domain in complex with human neutralizing antibody HENV-26,receptor binding protein,A,nipah henipavirus,3.4,0.312069,-0.0148002,"A305,A389,A394,A401,A402,A403,A404,A458,A488,A489,A490,A491,A492,A494,A497,A501,A502,A504,A505,A506,A507,A527,A528,A529,A530,A531,A532,A533,A553,A554,A555,A556,A557,A581,A583,A586",Nipah,205
553,6VY5,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of Nipah receptor binding protein head domain in complex with human neutralizing antibody HENV-26,receptor binding protein,A,nipah henipavirus,3.4,-0.233488,0.126649,"A305,A389,A394,A401,A402,A403,A404,A458,A488,A489,A490,A491,A492,A494,A497,A501,A502,A504,A505,A506,A507,A527,A528,A529,A530,A531,A532,A533,A553,A554,A555,A556,A557,A581,A583,A586",Nipah,205
554,5GRJ,H,52,52,IGHV3-23,Y,['S' 'Y'],S,1.6016016016016017,Crystal structure of human PD-L1 with monoclonal antibody avelumab,programmed cell death 1 ligand 1,A,homo sapiens,3.2060000000000000,5.87167,2.24473,"A54,A56,A58,A60,A61,A62,A63,A66,A68,A69,A73,A75,A76,A78,A111,A113,A115,A116,A117,A121,A122,A123,A125",Human,206
555,5GRJ,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of human PD-L1 with monoclonal antibody avelumab,programmed cell death 1 ligand 1,A,homo sapiens,3.2060000000000000,0.398182,0.193435,"A54,A56,A58,A60,A61,A62,A63,A66,A68,A69,A73,A75,A76,A78,A111,A113,A115,A116,A117,A121,A122,A123,A125",Human,206
556,5GRJ,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of human PD-L1 with monoclonal antibody avelumab,programmed cell death 1 ligand 1,A,homo sapiens,3.2060000000000000,2.22775,2.19283,"A54,A56,A58,A60,A61,A62,A63,A66,A68,A69,A73,A75,A76,A78,A111,A113,A115,A116,A117,A121,A122,A123,A125",Human,206
557,5GRJ,L,32,34,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,Crystal structure of human PD-L1 with monoclonal antibody avelumab,programmed cell death 1 ligand 1,A,homo sapiens,3.2060000000000000,2.64448,0.128124,"A54,A56,A58,A60,A61,A62,A63,A66,A68,A69,A73,A75,A76,A78,A111,A113,A115,A116,A117,A121,A122,A123,A125",Human,207
558,5GRJ,L,50,52,IGLV2-14,D,['E' 'D'],E,43.44262295081968,Crystal structure of human PD-L1 with monoclonal antibody avelumab,programmed cell death 1 ligand 1,A,homo sapiens,3.2060000000000000,-0.729201,-0.519911,"A54,A56,A58,A60,A61,A62,A63,A66,A68,A69,A73,A75,A76,A78,A111,A113,A115,A116,A117,A121,A122,A123,A125",Human,207
559,7XCP,H,31,31,IGHV3-13,S,['S' 'N'],N,100.0,Cryo-EM structure of Omicron RBD complexed with ACE2 and 304 Fab,spike protein s1,B,severe acute respiratory syndrome coronavirus2,0,-0.862717,-0.733355,"B366,B369,B373,B375,B376,B377,B378,B379,B380,B381,B382,B383,B384,B385,B386,B388,B390,B392,B411,B412,B413,B414,B427,B428,B429,B430,B517",SARS,208
560,7XCP,H,57,57,IGHV3-13,T,['T' 'P'],P,95.18072289156626,Cryo-EM structure of Omicron RBD complexed with ACE2 and 304 Fab,spike protein s1,B,severe acute respiratory syndrome coronavirus2,0,0.653622,0.702542,"B366,B369,B373,B375,B376,B377,B378,B379,B380,B381,B382,B383,B384,B385,B386,B388,B390,B392,B411,B412,B413,B414,B427,B428,B429,B430,B517",SARS,208
561,6GV4,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,High-resolution Cryo-EM of Fab-labeled human parechovirus 3,vp1 | vp0,B | A,human parechovirus 3 | human parechovirus 3,2.8,-0.328719,0.521412,"A285,A289,B85,B87,B88,B92,B135,B136,B137,B138,B140,B141,B142,B184",HPeV,209
562,5T33,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,"Crystal structure of strain-specific glycan-dependent CD4 binding site-directed neutralizing antibody CAP257-RH1, in complex with HIV-1 strain RHPA gp120 core with an oligomannose N276 glycan.",rhpa gp120 core,G,human immunodeficiency virus,3.2092,3.52973,3.35584,"G279,G280,G281,G282,G354,G357,G365,G366,G367,G368,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G469",HIV,210
563,5T33,L,50,50,IGLV3-10,E,['E' 'K'],K,100.0,"Crystal structure of strain-specific glycan-dependent CD4 binding site-directed neutralizing antibody CAP257-RH1, in complex with HIV-1 strain RHPA gp120 core with an oligomannose N276 glycan.",rhpa gp120 core,G,human immunodeficiency virus,3.2092,-0.578911,-0.550859,"G279,G280,G281,G282,G354,G357,G365,G366,G367,G368,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G469",HIV,211
564,5CZV,H,33,33,IGHV1-69,T,['A' 'T'],A,4.739336492890995,Crystal structure of Notch3 NRR in complex with 20350 Fab,neurogenic locus notch homolog protein 3,A,homo sapiens,3.19,0.423294,0.709622,"A1427,A1429,A1442,A1444,A1445,A1447,A1448,A1449,A1450,A1453,A1458,A1459,A1461,A1462,A1464,A1507,A1508,A1509,A1510,A1592,A1594,A1595,A1596,A1597,A1598,A1599,A1600,A1602,A1603,A1606",Human,212
565,2H32,H,42,42,IGHV5-51,G,['G' 'R'],R,100.0,Crystal structure of the pre-B cell receptor,immunoglobulin omega chain,B,homo sapiens,2.7,3.69954,3.63323,"B56,B57,B58,B59,B60,B61,B62,B63,B64,B65,B66,B67,B68,B69,B70,B71,B78,B80,B81,B82,B83,B84,B85,B86,B87,B88,B93,B95,B97,B99,B101,B105,B107,B124,B125,B126,B127,B129,B131,B132,B133,B136,B137,B138,B139,B141,B143,B168,B170,B171",Human,213
566,2F5B,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH ITS GP41 EPITOPE,protein (gp41 epitope),P,,2.0,0.875929,-0.719103,"P1,P2,P3,P4,P5,P6",,
567,7WH8,B,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (focused refinement on Fab-RBD),spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,0,1.45567,1.25137,"C351,C417,C444,C445,C446,C449,C450,C452,C455,C456,C470,C472,C482,C483,C484,C485,C486,C487,C488,C489,C490,C492,C493,C494,C496,C498,C500,C501,C505",SARS,162
568,7WH8,B,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (focused refinement on Fab-RBD),spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,0,1.22154,0.60075,"C351,C417,C444,C445,C446,C449,C450,C452,C455,C456,C470,C472,C482,C483,C484,C485,C486,C487,C488,C489,C490,C492,C493,C494,C496,C498,C500,C501,C505",SARS,162
569,7WH8,B,56,57,IGHV1-69,T,['T' 'I'],I,86.8878357030016,SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (focused refinement on Fab-RBD),spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,0,-1.27428,-0.822623,"C351,C417,C444,C445,C446,C449,C450,C452,C455,C456,C470,C472,C482,C483,C484,C485,C486,C487,C488,C489,C490,C492,C493,C494,C496,C498,C500,C501,C505",SARS,162
570,4FQY,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of broadly neutralizing antibody CR9114 bound to H3 influenza hemagglutinin,hemagglutinin ha2 | hemagglutinin ha1,B | A,influenza a virus | influenza a virus,5.253000000000000,-3.13503,0.031629,"A18,A38,A40,A41,A42,A291,A292,A318,B18,B19,B20,B21,B36,B38,B41,B42,B45,B46,B48,B49,B52,B53,B56",influenza,214
571,4FQI,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal Structure of Fab CR9114 in Complex with a H5N1 influenza virus hemagglutinin,hemagglutinin ha2 | hemagglutinin ha1,B | A,influenza a virus | influenza a virus,1.71,0.558701,0.936792,"A18,A38,A40,A42,A291,A292,A293,A318,B18,B19,B20,B21,B36,B38,B41,B42,B45,B46,B48,B49,B52,B53,B56",influenza,214
572,6UYF,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of Hepatitis C Virus Envelope Glycoprotein E2mc3-v1 redesigned core from genotype 6a bound to broadly neutralizing antibody AR3B,envelope glycoprotein e2,E,recombinant hepatitis c virus hk6a/jfh-1,2.06,1.11352,0.110078,"E422,E425,E427,E428,E429,E430,E431,E432,E434,E435,E436,E437,E438,E439,E441,E442,E443,E500,E505,E529,E531,E613",HCV,33
573,5TE6,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal Structure of Broadly Neutralizing VRC01-class Antibody N6 in Complex with HIV-1 Clade AE Strain 93TH057 gp120 Core,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.4,4.66363,2.08968,"G96,G97,G122,G257,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G370,G371,G375,G425,G426,G427,G429,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G469,G472,G473,G474,G475,G476,G480",HIV,1
574,7STR,H,31,31,IGHV4-59,S,['S' 'Y'],Y,100.0,Crystal Structure of Human Fab S24-1063 in the Complex with the N-teminal Domain of Nucleocapsid Protein from SARS CoV-2,nucleoprotein,C,severe acute respiratory syndrome coronavirus2,1.5,-0.263933,0.293834,"C68,C69,C79,C80,C81,C82,C84,C113,C114,C119,C120,C121,C122,C123,C124,C134,C135,C136,C137,C138,C139,C140,C141,C142,C144,C145",SARS,171
575,7STR,H,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal Structure of Human Fab S24-1063 in the Complex with the N-teminal Domain of Nucleocapsid Protein from SARS CoV-2,nucleoprotein,C,severe acute respiratory syndrome coronavirus2,1.5,3.85234,2.06796,"C68,C69,C79,C80,C81,C82,C84,C113,C114,C119,C120,C121,C122,C123,C124,C134,C135,C136,C137,C138,C139,C140,C141,C142,C144,C145",SARS,171
576,7STR,H,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,Crystal Structure of Human Fab S24-1063 in the Complex with the N-teminal Domain of Nucleocapsid Protein from SARS CoV-2,nucleoprotein,C,severe acute respiratory syndrome coronavirus2,1.5,3.34675,1.12481,"C68,C69,C79,C80,C81,C82,C84,C113,C114,C119,C120,C121,C122,C123,C124,C134,C135,C136,C137,C138,C139,C140,C141,C142,C144,C145",SARS,171
577,7STR,H,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal Structure of Human Fab S24-1063 in the Complex with the N-teminal Domain of Nucleocapsid Protein from SARS CoV-2,nucleoprotein,C,severe acute respiratory syndrome coronavirus2,1.5,3.01394,3.17346,"C68,C69,C79,C80,C81,C82,C84,C113,C114,C119,C120,C121,C122,C123,C124,C134,C135,C136,C137,C138,C139,C140,C141,C142,C144,C145",SARS,171
578,2NY2,D,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"HIV-1 gp120 Envelope Glycoprotein (T123C, T257S, S334A, S375W, G431C) Complexed with CD4 and Antibody 17b",envelope glycoprotein gp120,A,human immunodeficiency virus 1,2.0,0.77909,-0.230811,"A119,A120,A122,A200,A202,A203,A204,A205,A419,A420,A421,A422,A423,A432,A433,A434,A435,A436,A437",HIV,177
579,5U3J,H,53,53,IGHV3-15,D,['D' 'N'],N,100.0,Crystal Structure of DH511.1 Fab in Complex with HIV-1 gp41 MPER Peptide,gp41 mper peptide,A,human immunodeficiency virus 1,2.74,2.20094,0.650998,"A656,A657,A668,A669,A670,A671,A672,A673,A674,A675,A676,A679,A680,A682,A683",HIV,215
580,5U3O,H,53,53,IGHV3-15,D,['D' 'N'],N,100.0,Crystal Structure of DH511.2_K3 Fab in Complex with HIV-1 gp41 MPER Peptide,gp41 mper peptide,A,human immunodeficiency virus 1,1.761,1.69076,1.32664,"A669,A670,A671,A672,A673,A674,A675,A676,A677,A679,A680,A682,A683",HIV,215
581,5U3N,H,53,53,IGHV3-15,D,['D' 'N'],N,100.0,Crystal Structure of DH511.12P Fab in Complex with HIV-1 gp41 MPER Peptide,gp41 mper peptide,A,human immunodeficiency virus 1,2.0,1.32583,0.537857,"A669,A670,A671,A672,A673,A674,A675,A676,A677,A679,A680,A682,A683",HIV,215
582,5U3M,H,53,53,IGHV3-15,D,['D' 'N'],N,100.0,Crystal Structure of DH511.11P Fab in Complex with HIV-1 gp41 MPER Peptide,gp41 mper peptide,A,human immunodeficiency virus 1,2.418,0.349851,-0.0994324,"A669,A670,A671,A672,A673,A674,A675,A676,A677,A679,A680,A682,A683,A685",HIV,215
583,4UV7,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,The complex structure of extracellular domain of EGFR and GC1118A,epidermal growth factor receptor,A,homo sapiens,2.1,2.74871,1.45013,"A325,A348,A349,A350,A353,A354,A355,A356,A357,A358,A359,A360,A361,A362",Human,216
584,4UV7,H,53,54,IGHV3-23,G,['S' 'G'],S,0.7007007007007007,The complex structure of extracellular domain of EGFR and GC1118A,epidermal growth factor receptor,A,homo sapiens,2.1,0.344874,0.349221,"A325,A348,A349,A350,A353,A354,A355,A356,A357,A358,A359,A360,A361,A362",Human,216
585,4UV7,L,27D,31,IGKV2-30,H,['Y' 'H'],Y,39.33518005540167,The complex structure of extracellular domain of EGFR and GC1118A,epidermal growth factor receptor,A,homo sapiens,2.1,0.0474721,0.0692202,"A325,A348,A349,A350,A353,A354,A355,A356,A357,A358,A359,A360,A361,A362",Human,217
586,5I8C,A,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal Structure of HIV-1 Clade A BG505 Fusion Peptide (residue 512-520) in Complex with Broadly Neutralizing Antibody VRC34.01 Fab,hiv-1 clade a bg505 fusion peptide (residue 512-520),C,human immunodeficiency virus 1,1.54,4.17896,2.61673,"C512,C513,C514,C515,C516,C517,C518,C519",HIV,51
587,5WT9,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Complex structure of PD-1 and nivolumab-Fab,programmed cell death protein 1,G,homo sapiens,2.401,2.36079,2.32177,"G25,G26,G27,G28,G29,G30,G31,G59,G60,G61,G62,G127,G128,G129,G130,G131,G132",Human,218
588,2NY3,D,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E267C, S334A, S375W) Complexed with CD4 and Antibody 17b",envelope glycoprotein gp120,A,human immunodeficiency virus 1,2.0,0.0153322,-0.343704,"A119,A120,A122,A200,A202,A203,A204,A205,A419,A420,A421,A422,A423,A432,A434,A435,A437",HIV,177
589,3K2U,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Crystal structure of HGFA in complex with the allosteric inhibitory antibody Fab40,hepatocyte growth factor activator long chain,A,homo sapiens,2.35,6.17939,-0.453708,"A59,A60,A60B,A60C,A61,A87,A88,A89,A90,A91,A92,A93,A94,A95,A96,A97,A100,A101,A176,A177,A178,A179,A233,A234,A237,A240,A241,A243",Human,136
590,7E23,B,23,23,IGHV4-34,A,['A' 'G'],G,100.0,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.3,0.234566,0.0925331,"A417,A446,A449,A450,A452,A453,A455,A456,A473,A475,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498",SARS,219
591,7E23,B,24,24,IGHV4-34,V,['V' 'G'],G,100.0,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.3,3.41609,1.66128,"A417,A446,A449,A450,A452,A453,A455,A456,A473,A475,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498",SARS,219
592,7E23,B,25,25,IGHV4-34,Y,['Y' 'S'],S,100.0,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.3,2.0772,0.617668,"A417,A446,A449,A450,A452,A453,A455,A456,A473,A475,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498",SARS,219
593,7E23,B,26,26,IGHV4-34,G,['G' 'F'],F,100.0,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.3,16.335,2.59334,"A417,A446,A449,A450,A452,A453,A455,A456,A473,A475,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498",SARS,219
594,7E23,B,29,29,IGHV4-34,F,['F' 'V' 'Y'],V,100.0,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.3,2.55436,0.991843,"A417,A446,A449,A450,A452,A453,A455,A456,A473,A475,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498",SARS,219
595,7E23,B,29,29,IGHV4-34,F,['F' 'V' 'Y'],Y,100.0,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.3,0.663093,0.216043,"A417,A446,A449,A450,A452,A453,A455,A456,A473,A475,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498",SARS,219
596,7E23,B,30,30,IGHV4-34,S,['S' 'Y'],Y,100.0,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.3,0.206971,0.170479,"A417,A446,A449,A450,A452,A453,A455,A456,A473,A475,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498",SARS,219
597,7E23,B,32,32,IGHV4-34,Y,['Y' 'S'],S,100.0,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.3,0.248421,0.126735,"A417,A446,A449,A450,A452,A453,A455,A456,A473,A475,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498",SARS,219
598,7ZBU,H,33,33,IGHV3-30,G,['A' 'G'],A,68.58846918489066,CryoEM structure of SARS-CoV-2 spike monomer in complex with neutralising antibody P008_60,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,0.223118,0.764721,"A518,A519,A554,A556,A557,A558,A559,A560,A561,A562,A563,A565,A566,A567,A574,A575,A577,A579,A580,A581,A582,A583,A584",SARS,220
599,7ZBU,H,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,CryoEM structure of SARS-CoV-2 spike monomer in complex with neutralising antibody P008_60,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,10.3587,-0.945115,"A518,A519,A554,A556,A557,A558,A559,A560,A561,A562,A563,A565,A566,A567,A574,A575,A577,A579,A580,A581,A582,A583,A584",SARS,220
600,7ZBU,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,CryoEM structure of SARS-CoV-2 spike monomer in complex with neutralising antibody P008_60,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,12.1541,0.444569,"A518,A519,A554,A556,A557,A558,A559,A560,A561,A562,A563,A565,A566,A567,A574,A575,A577,A579,A580,A581,A582,A583,A584",SARS,220
601,4WY7,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of recombinant 4E10 expressed in Escherichia coli with epitope bound,envelope glycoprotein gp160,P,human immunodeficiency virus type 1 group msubtype b,2.1,2.9365,-0.938606,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
602,4WY7,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of recombinant 4E10 expressed in Escherichia coli with epitope bound,envelope glycoprotein gp160,P,human immunodeficiency virus type 1 group msubtype b,2.1,18.3576,2.00351,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
603,4WY7,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of recombinant 4E10 expressed in Escherichia coli with epitope bound,envelope glycoprotein gp160,P,human immunodeficiency virus type 1 group msubtype b,2.1,0.691075,-0.121666,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
604,4WY7,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of recombinant 4E10 expressed in Escherichia coli with epitope bound,envelope glycoprotein gp160,P,human immunodeficiency virus type 1 group msubtype b,2.1,1.47895,0.937331,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P683",HIV,23
605,5XXY,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Complex structure of PD-L1 with atezolizumab Fab,programmed cell death 1 ligand 1,A,homo sapiens,2.9,3.56253,-1.79674,"A19,A49,A51,A52,A54,A56,A58,A59,A60,A61,A62,A63,A66,A68,A69,A111,A113,A115,A117,A118,A119,A120,A121,A122,A123,A125",Human,221
606,5OCC,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of CD32b (Fc Gamma Receptor IIb) in complex with Human IgG1 Fab fragment (6G08),low affinity immunoglobulin gamma fc region receptor ii-b,A,homo sapiens,2.5,5.68464,-0.309153,"A55,A56,A58,A64,A65,A66,A102,A132,A151,A153,A156,A157,A158,A159,A160,A161,A176,A177,A178,A179,A180,A200,A201,A202",Human,222
607,5OCC,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of CD32b (Fc Gamma Receptor IIb) in complex with Human IgG1 Fab fragment (6G08),low affinity immunoglobulin gamma fc region receptor ii-b,A,homo sapiens,2.5,5.06801,4.31941,"A55,A56,A58,A64,A65,A66,A102,A132,A151,A153,A156,A157,A158,A159,A160,A161,A176,A177,A178,A179,A180,A200,A201,A202",Human,222
608,5OCC,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of CD32b (Fc Gamma Receptor IIb) in complex with Human IgG1 Fab fragment (6G08),low affinity immunoglobulin gamma fc region receptor ii-b,A,homo sapiens,2.5,-0.00277664,-0.401486,"A55,A56,A58,A64,A65,A66,A102,A132,A151,A153,A156,A157,A158,A159,A160,A161,A176,A177,A178,A179,A180,A200,A201,A202",Human,222
609,5OCC,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of CD32b (Fc Gamma Receptor IIb) in complex with Human IgG1 Fab fragment (6G08),low affinity immunoglobulin gamma fc region receptor ii-b,A,homo sapiens,2.5,0.306165,0.413259,"A55,A56,A58,A64,A65,A66,A102,A132,A151,A153,A156,A157,A158,A159,A160,A161,A176,A177,A178,A179,A180,A200,A201,A202",Human,222
610,7F9W,B,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,CD25 in complex with Fab,interleukin-2 receptor subunit alpha,A,homo sapiens,3.2,0.193214,-0.154019,"A18,A128,A129,A130,A131,A133,A134,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A161,A164,A165",Human,223
611,7F9W,B,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,CD25 in complex with Fab,interleukin-2 receptor subunit alpha,A,homo sapiens,3.2,0.614526,2.0096,"A18,A128,A129,A130,A131,A133,A134,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A161,A164,A165",Human,223
612,7F9W,B,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,CD25 in complex with Fab,interleukin-2 receptor subunit alpha,A,homo sapiens,3.2,1.03321,-0.173722,"A18,A128,A129,A130,A131,A133,A134,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A161,A164,A165",Human,223
613,7LO8,H,52,78,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,NorA in complex with Fab36,quinolone resistance protein nora,Z,staphylococcus aureus,3.16,-0.514185,0.297972,"Z19,Z22,Z23,Z24,Z25,Z26,Z27,Z28,Z30,Z31,Z32,Z36,Z37,Z38,Z40,Z41,Z42,Z44,Z45,Z47,Z49,Z98,Z137,Z140,Z141,Z144,Z147,Z148,Z150,Z151,Z152,Z155,Z219,Z222,Z223,Z224,Z225,Z226,Z227,Z230,Z231,Z234,Z235,Z236,Z237,Z238,Z240,Z241,Z244,Z247,Z248,Z303,Z307,Z310,Z340,Z341,Z344,Z345,Z348,Z349,Z350,Z351,Z352,Z353,Z354,Z355",Staphylococcus aureus,224
614,7LO8,H,53,80,IGHV3-23,S,['S' 'G'],G,99.2992992992993,NorA in complex with Fab36,quinolone resistance protein nora,Z,staphylococcus aureus,3.16,0.232166,0.203323,"Z19,Z22,Z23,Z24,Z25,Z26,Z27,Z28,Z30,Z31,Z32,Z36,Z37,Z38,Z40,Z41,Z42,Z44,Z45,Z47,Z49,Z98,Z137,Z140,Z141,Z144,Z147,Z148,Z150,Z151,Z152,Z155,Z219,Z222,Z223,Z224,Z225,Z226,Z227,Z230,Z231,Z234,Z235,Z236,Z237,Z238,Z240,Z241,Z244,Z247,Z248,Z303,Z307,Z310,Z340,Z341,Z344,Z345,Z348,Z349,Z350,Z351,Z352,Z353,Z354,Z355",Staphylococcus aureus,224
615,7LO8,L,90,114,IGKV1-39,Q,['Q' 'C'],C,99.92498124531132,NorA in complex with Fab36,quinolone resistance protein nora,Z,staphylococcus aureus,3.16,1.66484,0.421354,"Z19,Z22,Z23,Z24,Z25,Z26,Z27,Z28,Z30,Z31,Z32,Z36,Z37,Z38,Z40,Z41,Z42,Z44,Z45,Z47,Z49,Z98,Z137,Z140,Z141,Z144,Z147,Z148,Z150,Z151,Z152,Z155,Z219,Z222,Z223,Z224,Z225,Z226,Z227,Z230,Z231,Z234,Z235,Z236,Z237,Z238,Z240,Z241,Z244,Z247,Z248,Z303,Z307,Z310,Z340,Z341,Z344,Z345,Z348,Z349,Z350,Z351,Z352,Z353,Z354,Z355",Staphylococcus aureus,225
616,4PY8,I,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Crystal structure of Fab 3.1 in complex with the 1918 influenza virus hemagglutinin,hemagglutinin ha2 chain | hemagglutinin ha1 chain,B | A,influenza a virus | influenza a virus,2.91,-0.342026,-0.653713,"A18,A20,A38,A39,A40,A41,A42,A44,A288,A297,A298,A299,A300,A301,A326,B18,B19,B20,B21,B38,B39,B41,B42,B45,B46,B48,B49,B50,B52,B53,B56,B57,B150",influenza,226
617,4R4F,H,31,31,IGHV4-34,G,['G' 'W'],W,100.0,"Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 YU2 gp120",hiv-1 env gp120,A,human immunodeficiency virus 1,3.514,2.50619,1.39494,"A51,A52,A53,A54,A57,A58,A59,A60,A61,A71,A72,A73,A74,A75,A76,A77,A78,A79,A80,A114,A218,A219,A220,A221,A246",HIV,227
618,4R4F,H,50,50,IGHV4-34,E,['E' 'Y'],Y,100.0,"Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 YU2 gp120",hiv-1 env gp120,A,human immunodeficiency virus 1,3.514,13.6696,4.92494,"A51,A52,A53,A54,A57,A58,A59,A60,A61,A71,A72,A73,A74,A75,A76,A77,A78,A79,A80,A114,A218,A219,A220,A221,A246",HIV,227
619,4R4F,H,59,59,IGHV4-34,Y,['Y' 'N'],N,100.0,"Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 YU2 gp120",hiv-1 env gp120,A,human immunodeficiency virus 1,3.514,3.53519,1.71774,"A51,A52,A53,A54,A57,A58,A59,A60,A61,A71,A72,A73,A74,A75,A76,A77,A78,A79,A80,A114,A218,A219,A220,A221,A246",HIV,227
620,6VUG,D,52,55,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Diabody bound to a Reverse Transcriptase Aptamer Complex,reverse transcriptase p51,B,human immunodeficiency virus 1,3.0,4.74848,3.1625,"B195,B196,B199,B220,B221,B223,B224,B225,B226,B227,B228,B229,B230,B231,B233,B356,B357,B358,B359,B360,B361,B362,B366,B374",HIV,228
621,7OW1,H,31,31,IGHV3-33,S,['S' 'R'],R,99.69788519637464,Crystal Structure of TAP01 in complex with amyloid beta peptide,amyloid-beta precursor protein,A,homo sapiens,1.4,-0.656006,-0.799496,"A4,A5,A6,A7,A8,A9,A11",Human,86
622,7OW1,H,35,35,IGHV3-33,H,['H' 'Y'],Y,99.69788519637464,Crystal Structure of TAP01 in complex with amyloid beta peptide,amyloid-beta precursor protein,A,homo sapiens,1.4,6.52994,2.11944,"A4,A5,A6,A7,A8,A9,A11",Human,86
623,7OW1,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal Structure of TAP01 in complex with amyloid beta peptide,amyloid-beta precursor protein,A,homo sapiens,1.4,3.11495,1.71877,"A4,A5,A6,A7,A8,A9,A11",Human,86
624,5GHW,H,50,50,IGHV3-15,R,['R' 'C'],C,100.0,Crystal structure of broad neutralizing antibody 10E8 with long epitope bound,endogenous retrovirus group k member 8 env polyprotein,P,human immunodeficiency virus 1,2.4,-1.02545,-1.18746,"P669,P670,P671,P672,P673,P674,P676,P677,P679,P680,P682,P683,P686,P687",HIV,215
625,1GC1,H,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,HIV-1 GP120 CORE COMPLEXED WITH CD4 AND A NEUTRALIZING HUMAN ANTIBODY,envelope protein gp120,G,human immunodeficiency virus 1,2.5,1.71895,-0.461348,"G119,G121,G200,G202,G203,G204,G205,G419,G420,G421,G422,G423,G432,G433,G434,G435,G437",HIV,177
626,5D70,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,"Crystal structure of MOR03929, a neutralizing anti-human GM-CSF antibody Fab fragment in complex with human GM-CSF",granulocyte-macrophage colony-stimulating factor,A,homo sapiens,2.06,8.7916,-1.21175,"A10,A11,A12,A13,A15,A16,A17,A20,A21,A23,A24,A83,A86,A87,A89,A119,A120,A121,A122",Human,229
627,5D71,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,"Crystal structure of MOR04302, a neutralizing anti-human GM-CSF antibody Fab fragment in complex with human GM-CSF",granulocyte-macrophage colony-stimulating factor,A,homo sapiens,2.25,11.3006,-0.226902,"A10,A11,A12,A13,A15,A16,A17,A20,A21,A23,A24,A83,A86,A87,A89,A119,A120,A121",Human,229
628,3B2V,H,32,32,IGHV4-30-4,G,['G' 'Y'],Y,100.0,Crystal structure of the extracellular region of the epidermal growth factor receptor in complex with the Fab fragment of IMC-11F8,epidermal growth factor receptor,A,homo sapiens,3.3,1.81544,-0.353363,"A348,A349,A350,A353,A382,A384,A385,A388,A408,A409,A411,A412,A415,A417,A418,A419,A420,A438,A440,A441,A443,A449,A464,A465,A466,A467,A468,A469,A470,A471,A472,A473",Human,230
629,3B2V,H,33,33,IGHV4-30-4,D,['D' 'Y' 'G'],Y,95.49549549549548,Crystal structure of the extracellular region of the epidermal growth factor receptor in complex with the Fab fragment of IMC-11F8,epidermal growth factor receptor,A,homo sapiens,3.3,-0.0241235,-0.0888374,"A348,A349,A350,A353,A382,A384,A385,A388,A408,A409,A411,A412,A415,A417,A418,A419,A420,A438,A440,A441,A443,A449,A464,A465,A466,A467,A468,A469,A470,A471,A472,A473",Human,230
630,3B2V,H,33,33,IGHV4-30-4,D,['D' 'Y' 'G'],G,95.49549549549548,Crystal structure of the extracellular region of the epidermal growth factor receptor in complex with the Fab fragment of IMC-11F8,epidermal growth factor receptor,A,homo sapiens,3.3,0.531451,-0.247497,"A348,A349,A350,A353,A382,A384,A385,A388,A408,A409,A411,A412,A415,A417,A418,A419,A420,A438,A440,A441,A443,A449,A464,A465,A466,A467,A468,A469,A470,A471,A472,A473",Human,230
631,3B2V,H,35,35,IGHV4-30-4,Y,['Y' 'S'],S,95.49549549549548,Crystal structure of the extracellular region of the epidermal growth factor receptor in complex with the Fab fragment of IMC-11F8,epidermal growth factor receptor,A,homo sapiens,3.3,-32.5757,-9.38318,"A348,A349,A350,A353,A382,A384,A385,A388,A408,A409,A411,A412,A415,A417,A418,A419,A420,A438,A440,A441,A443,A449,A464,A465,A466,A467,A468,A469,A470,A471,A472,A473",Human,230
632,7L5B,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystallographic structure of neutralizing antibody 2-15 in complex with SARS-CoV-2 spike receptor-binding Domain (RBD).,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.18,0.0412484,0.49149,"A446,A449,A450,A452,A453,A455,A456,A470,A472,A478,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A496,A498,A505",SARS,39
633,7X92,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab445,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,-1.09445,-1.05838,"A403,A405,A408,A409,A415,A416,A417,A420,A421,A446,A449,A453,A455,A456,A484,A485,A486,A489,A493,A494,A495,A496,A497,A498,A501,A503,A504,A505",SARS,231
634,7ND8,H,56,57,IGHV3-11,T,['T' 'Y'],Y,56.45161290322581,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab,spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,3.5,-0.490834,-1.0142,"B417,B449,B452,B455,B456,B472,B481,B482,B483,B484,B485,B486,B488,B489,B490,B492,B493,B494",SARS,232
635,7ND8,H,58,59,IGHV3-11,Y,['Y' 'N'],N,56.45161290322581,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab,spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,3.5,4.70883,1.28407,"B417,B449,B452,B455,B456,B472,B481,B482,B483,B484,B485,B486,B488,B489,B490,B492,B493,B494",SARS,232
636,7ND0,H,50,50,IGHV3-21,Y,['S' 'Y'],S,0.0,lateral-open conformation of the wild-type BAM complex (BamABCDE) bound to a bactericidal Fab fragment,outer membrane protein assembly factor bama,A,escherichia coli k-12,5.2,0.234562,-0.825732,"A539,A547,A550,A551,A552,A553,A554,A555,A556,A557,A558,A559,A562,A563,A564,A565,A642,A643,A644,A675,A676,A698,A699,A752,A753,A757",E Coli,233
637,7WSL,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,PD-1 in complex with Dostarlimab,programmed cell death protein 1,D,homo sapiens,1.534,10.9656,-0.468497,"D59,D60,D61,D62,D63,D64,D66,D78,D81,D82,D83,D84,D85,D86,D87,D88,D126,D128,D129,D130,D131,D132,D134",Human,234
638,7WSL,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,PD-1 in complex with Dostarlimab,programmed cell death protein 1,D,homo sapiens,1.534,1.70847,1.42407,"D59,D60,D61,D62,D63,D64,D66,D78,D81,D82,D83,D84,D85,D86,D87,D88,D126,D128,D129,D130,D131,D132,D134",Human,234
639,7WSL,H,53,54,IGHV3-23,G,['S' 'G'],S,0.7007007007007007,PD-1 in complex with Dostarlimab,programmed cell death protein 1,D,homo sapiens,1.534,0.322059,0.0202787,"D59,D60,D61,D62,D63,D64,D66,D78,D81,D82,D83,D84,D85,D86,D87,D88,D126,D128,D129,D130,D131,D132,D134",Human,234
640,7WSL,H,55,56,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,PD-1 in complex with Dostarlimab,programmed cell death protein 1,D,homo sapiens,1.534,-0.140465,-0.0103581,"D59,D60,D61,D62,D63,D64,D66,D78,D81,D82,D83,D84,D85,D86,D87,D88,D126,D128,D129,D130,D131,D132,D134",Human,234
641,5GJS,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.9,-0.27827,-0.462474,"A18,A20,A21,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B146,B153",influenza,235
642,5GJS,H,32,32,IGHV4-4,Y,['S' 'W' 'Y'],S,28.03030303030303,Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.9,0.790061,0.494353,"A18,A20,A21,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B146,B153",influenza,235
643,5GJS,H,32,32,IGHV4-4,Y,['S' 'W' 'Y'],W,28.03030303030303,Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.9,-0.0200191,-0.0395966,"A18,A20,A21,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B146,B153",influenza,235
644,5GJS,H,33,33,IGHV4-4,Y,['N' 'W' 'Y'],N,28.03030303030303,Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.9,3.52991,1.64,"A18,A20,A21,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B146,B153",influenza,235
645,5GJS,H,33,33,IGHV4-4,Y,['N' 'W' 'Y'],W,28.03030303030303,Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.9,3.07553,0.858728,"A18,A20,A21,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B146,B153",influenza,235
646,5GJS,H,50,50,IGHV4-4,R,['E' 'R' 'Y'],E,22.348484848484848,Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.9,4.16753,2.73287,"A18,A20,A21,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B146,B153",influenza,235
647,5GJS,H,50,50,IGHV4-4,R,['E' 'R' 'Y'],Y,22.348484848484848,Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.9,6.05845,7.05628,"A18,A20,A21,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B146,B153",influenza,235
648,5GJS,L,50,50,IGKV1-5,K,['D' 'K'],D,83.73655913978494,Crystal structure of H1 hemagglutinin from A/California/04/2009 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.9,2.1915,1.0065,"A18,A20,A21,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B146,B153",influenza,236
649,5GJT,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,3.1,-0.151538,-0.240092,"A18,A20,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B53",influenza,235
650,5GJT,H,32,32,IGHV4-4,Y,['S' 'W' 'Y'],S,28.03030303030303,Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,3.1,1.81352,1.08972,"A18,A20,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B53",influenza,235
651,5GJT,H,32,32,IGHV4-4,Y,['S' 'W' 'Y'],W,28.03030303030303,Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,3.1,-0.134737,-0.340013,"A18,A20,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B53",influenza,235
652,5GJT,H,33,33,IGHV4-4,Y,['N' 'W' 'Y'],N,28.03030303030303,Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,3.1,1.74457,0.957032,"A18,A20,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B53",influenza,235
653,5GJT,H,33,33,IGHV4-4,Y,['N' 'W' 'Y'],W,28.03030303030303,Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,3.1,0.0436033,-0.646304,"A18,A20,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B53",influenza,235
654,5GJT,H,50,50,IGHV4-4,R,['E' 'R' 'Y'],E,22.348484848484848,Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,3.1,4.98213,3.91058,"A18,A20,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B53",influenza,235
655,5GJT,H,50,50,IGHV4-4,R,['E' 'R' 'Y'],Y,22.348484848484848,Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,3.1,4.8791,5.29127,"A18,A20,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B53",influenza,235
656,5GJT,L,50,50,IGKV1-5,K,['D' 'K'],D,83.73655913978494,Crystal structure of H1 hemagglutinin from A/Washington/05/2011 in complex with a neutralizing antibody 3E1,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,3.1,1.01812,0.0985789,"A18,A20,A38,A40,A326,B15,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B41,B42,B45,B46,B48,B49,B52,B53",influenza,236
657,2R0K,H,94,94,IGHV3-64,R,['R' 'K'],K,100.0,Protease domain of HGFA with inhibitor Fab58,hepatocyte growth factor activator,A,homo sapiens,3.51,-0.783401,-1.18868,"A57,A60,A60A,A95,A96,A97,A98,A99A,A99,A100,A101,A146,A147,A172,A174,A175,A180,A192,A195,A214,A215,A216,A217,A219,A221,A224",Human,237
658,7X26,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,S41 neutralizing antibody Fab(MERS-CoV),spike glycoprotein,I,severe acute respiratory syndrome coronavirus2,3.685,1.48969,1.05137,"I501,I502,I504,I506,I510,I511,I513,I535,I536,I537,I538,I539,I540,I541,I542,I553,I555,I556,I557,I559",SARS,238
659,7X26,H,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,S41 neutralizing antibody Fab(MERS-CoV),spike glycoprotein,I,severe acute respiratory syndrome coronavirus2,3.685,3.5413,-0.30357,"I501,I502,I504,I506,I510,I511,I513,I535,I536,I537,I538,I539,I540,I541,I542,I553,I555,I556,I557,I559",SARS,238
660,7X26,H,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,S41 neutralizing antibody Fab(MERS-CoV),spike glycoprotein,I,severe acute respiratory syndrome coronavirus2,3.685,2.12783,0.844181,"I501,I502,I504,I506,I510,I511,I513,I535,I536,I537,I538,I539,I540,I541,I542,I553,I555,I556,I557,I559",SARS,238
661,7X26,H,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,S41 neutralizing antibody Fab(MERS-CoV),spike glycoprotein,I,severe acute respiratory syndrome coronavirus2,3.685,2.39852,0.439127,"I501,I502,I504,I506,I510,I511,I513,I535,I536,I537,I538,I539,I540,I541,I542,I553,I555,I556,I557,I559",SARS,238
662,6BKD,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3D,polyprotein,E,recombinant hepatitis c virus hk6a/jfh-1,3.25,2.10129,-0.194687,"E422,E425,E427,E428,E429,E430,E431,E432,E434,E435,E436,E438,E439,E441,E442,E443,E528,E529,E531,E613",HCV,33
663,6BKD,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3D,polyprotein,E,recombinant hepatitis c virus hk6a/jfh-1,3.25,-1.89324,-0.851877,"E422,E425,E427,E428,E429,E430,E431,E432,E434,E435,E436,E438,E439,E441,E442,E443,E528,E529,E531,E613",HCV,33
664,4R4H,H,31,31,IGHV4-34,G,['G' 'W'],W,100.0,"Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 Env gp120",hiv-1 env gp120,A,human immunodeficiency virus 1,4.28,2.82773,2.17163,"A53,A54,A57,A58,A59,A60,A61,A63,A71,A72,A73,A74,A75,A76,A77,A78,A79,A80,A114,A218,A219,A220,A221,A246,A247",HIV,227
665,4R4H,H,50,50,IGHV4-34,E,['E' 'Y'],Y,100.0,"Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 Env gp120",hiv-1 env gp120,A,human immunodeficiency virus 1,4.28,2.10003,1.60691,"A53,A54,A57,A58,A59,A60,A61,A63,A71,A72,A73,A74,A75,A76,A77,A78,A79,A80,A114,A218,A219,A220,A221,A246,A247",HIV,227
666,4R4H,H,53,53,IGHV4-34,H,['H' 'Y'],Y,100.0,"Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 Env gp120",hiv-1 env gp120,A,human immunodeficiency virus 1,4.28,-0.484379,-0.712389,"A53,A54,A57,A58,A59,A60,A61,A63,A71,A72,A73,A74,A75,A76,A77,A78,A79,A80,A114,A218,A219,A220,A221,A246,A247",HIV,227
667,4R4H,H,59,59,IGHV4-34,Y,['Y' 'N'],N,100.0,"Crystal structure of non-neutralizing, A32-like antibody 2.2c in complex with HIV-1 Env gp120",hiv-1 env gp120,A,human immunodeficiency virus 1,4.28,3.88877,3.46616,"A53,A54,A57,A58,A59,A60,A61,A63,A71,A72,A73,A74,A75,A76,A77,A78,A79,A80,A114,A218,A219,A220,A221,A246,A247",HIV,227
668,7S0E,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,4.9,-2.8746,-1.65959,"A555,A556,A557,A558,A560,A561,A562,A563,A564,A565,A567,A568,A569,A574,A586",SARS,239
669,6BKC,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3B,polyprotein,E,recombinant hepatitis c virus hk6a/jfh-1,2.6,1.23674,0.0245388,"E422,E425,E427,E428,E429,E430,E431,E432,E434,E435,E436,E438,E439,E441,E442,E500,E505,E528,E529,E531,E613",HCV,33
670,6BKB,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3A,polyprotein,E,recombinant hepatitis c virus hk6a/jfh-1,2.799,"-nan
","-nan
","E422,E423,E427,E428,E429,E430,E431,E432,E433,E434,E435,E436,E438,E439,E441,E442,E443,E529,E531",HCV,33
671,6BKB,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3A,polyprotein,E,recombinant hepatitis c virus hk6a/jfh-1,2.799,"-nan
","-nan
","E422,E423,E427,E428,E429,E430,E431,E432,E433,E434,E435,E436,E438,E439,E441,E442,E443,E529,E531",HCV,33
672,3W9E,A,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of Human Monoclonal Antibody E317 Fab Complex with HSV-2 gD,envelope glycoprotein d,C,human herpesvirus 2,2.3,2.08661,0.878593,"C25,C26,C27,C28,C29,C30,C35,C36,C38,C39,C132,C134,C137,C139,C140,C193,C194,C196,C198,C215,C216,C217,C218,C220,C221,C222,C223,C224,C227,C230,C231,C234,C235,C238,C239",HSV-2,240
673,3W9E,A,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,Structure of Human Monoclonal Antibody E317 Fab Complex with HSV-2 gD,envelope glycoprotein d,C,human herpesvirus 2,2.3,0.236235,0.2869,"C25,C26,C27,C28,C29,C30,C35,C36,C38,C39,C132,C134,C137,C139,C140,C193,C194,C196,C198,C215,C216,C217,C218,C220,C221,C222,C223,C224,C227,C230,C231,C234,C235,C238,C239",HSV-2,240
674,7X2A,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,MERS-CoV spike complex with S41 neutralizing antibody Fab Class1 (1u2d RBD with 1Fab),mers-cov spike glycoprotein,A,middle east respiratory syndrome-relatedcoronavirus ,2.49,1.26216,1.09981,"A501,A502,A504,A506,A510,A511,A513,A535,A536,A538,A539,A540,A541,A542,A553,A555,A556,A557,A559",MERS,241
675,7X2A,H,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,MERS-CoV spike complex with S41 neutralizing antibody Fab Class1 (1u2d RBD with 1Fab),mers-cov spike glycoprotein,A,middle east respiratory syndrome-relatedcoronavirus ,2.49,9.55626,0.697921,"A501,A502,A504,A506,A510,A511,A513,A535,A536,A538,A539,A540,A541,A542,A553,A555,A556,A557,A559",MERS,241
676,7X2A,H,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,MERS-CoV spike complex with S41 neutralizing antibody Fab Class1 (1u2d RBD with 1Fab),mers-cov spike glycoprotein,A,middle east respiratory syndrome-relatedcoronavirus ,2.49,1.0219,0.750631,"A501,A502,A504,A506,A510,A511,A513,A535,A536,A538,A539,A540,A541,A542,A553,A555,A556,A557,A559",MERS,241
677,7X2A,H,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,MERS-CoV spike complex with S41 neutralizing antibody Fab Class1 (1u2d RBD with 1Fab),mers-cov spike glycoprotein,A,middle east respiratory syndrome-relatedcoronavirus ,2.49,1.25455,0.30905,"A501,A502,A504,A506,A510,A511,A513,A535,A536,A538,A539,A540,A541,A542,A553,A555,A556,A557,A559",MERS,241
678,3GBN,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal Structure of Fab CR6261 in Complex with the 1918 H1N1 influenza virus hemagglutinin,hemagglutinin | hemagglutinin,B | A,influenza a virus (a/brevigmission/1/1918(h1n1))  | influenza a virus (a/brevigmission/1/1918(h1n1)),2.2,1.43037,-0.307834,"A18,A38,A40,A41,A42,A291,A292,A293,A318,B18,B19,B20,B21,B36,B38,B41,B42,B45,B46,B48,B49,B52,B53,B56",influenza,214
679,3GBN,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Crystal Structure of Fab CR6261 in Complex with the 1918 H1N1 influenza virus hemagglutinin,hemagglutinin | hemagglutinin,B | A,influenza a virus (a/brevigmission/1/1918(h1n1))  | influenza a virus (a/brevigmission/1/1918(h1n1)),2.2,-1.62164,-1.47962,"A18,A38,A40,A41,A42,A291,A292,A293,A318,B18,B19,B20,B21,B36,B38,B41,B42,B45,B46,B48,B49,B52,B53,B56",influenza,214
680,3IDX,H,33,33,IGHV3-30,A,['A' 'G'],G,31.41153081510934,"Crystal structure of HIV-gp120 core in complex with CD4-binding site antibody b13, space group C222",hiv-1 hxbc2 gp120 core,G,human immunodeficiency virus 1,2.5,1.24872,1.19171,"G281,G283,G364,G365,G366,G367,G368,G369,G370,G371,G372,G373,G375,G384,G386,G419,G421,G425,G426,G455,G472,G473,G474,G476,G477",HIV,242
681,6Y97,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,Structure of full-length CD20 in complex with Obinutuzumab Fab,b-lymphocyte antigen cd20 | b-lymphocyte antigen cd20,A | B,homo sapiens | homo sapiens,4.33,0.934647,2.1988,"A170,A171,A172,A173,A174,A175,A176,A177,A178,A179,B76,B160,B161,B163,B171,B173,B174,B177,B178,B179",Human,243
682,6Y97,H,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,Structure of full-length CD20 in complex with Obinutuzumab Fab,b-lymphocyte antigen cd20 | b-lymphocyte antigen cd20,A | B,homo sapiens | homo sapiens,4.33,0.526663,0.587644,"A170,A171,A172,A173,A174,A175,A176,A177,A178,A179,B76,B160,B161,B163,B171,B173,B174,B177,B178,B179",Human,243
683,5CJQ,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of a trimeric influenza hemagglutinin stem in complex with an broadly neutralizing antibody CR9114,"designed influenza hemagglutinin stem #4900, ha2 | designed influenza hemagglutinin stem #4900, ha1",B | A,synthetic construct | synthetic construct,3.6,0.0898117,-0.421255,"A18,A20,A37,A38,A40,A41,A42,A318,B18,B19,B20,B21,B34,B35,B36,B38,B41,B42,B45,B46,B48,B49,B52,B53,B56",Synthetic,244
684,6Y9A,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,Structure of full-length CD20 in complex with Obinutuzumab Fab,b-lymphocyte antigen cd20 | b-lymphocyte antigen cd20,A | B,homo sapiens | homo sapiens,4.2,1.54986,1.06266,"A168,A169,A170,A171,A172,A173,A174,A175,A176,A177,A178,B76,B77,B160,B161,B171,B173,B174,B177,B178,B179",Human,243
685,5VOB,H,50,50,IGHV3-30,F,['V' 'F'],V,8.548707753479125,Crystal structure of HCMV Pentamer in complex with neutralizing antibody 8I21,envelope glycoprotein ul130 | envelope glycoprotein l,D | B,human cytomegalovirus (strain merlin) | human cytomegalovirus (strain 5508),3.02,2.29806,3.54556,"B156,B157,B158,D46,D47,D48,D49,D51,D52,D72,D73,D74,D75,D76,D77,D78,D89,D90,D92,D93,D96,D98,D114,D115,D118,D119,D120,D123,D124,D137,D138,D139,D140,D141,D142,D143,D146",CMV,245
686,5VOB,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Crystal structure of HCMV Pentamer in complex with neutralizing antibody 8I21,envelope glycoprotein ul130 | envelope glycoprotein l,D | B,human cytomegalovirus (strain merlin) | human cytomegalovirus (strain 5508),3.02,2.94367,-0.449581,"B156,B157,B158,D46,D47,D48,D49,D51,D52,D72,D73,D74,D75,D76,D77,D78,D89,D90,D92,D93,D96,D98,D114,D115,D118,D119,D120,D123,D124,D137,D138,D139,D140,D141,D142,D143,D146",CMV,245
687,5VOC,H,50,50,IGHV3-30,F,['V' 'F'],V,8.548707753479125,Crystal structure of HCMV Pentamer in complex with neutralizing antibody 8I21 - Low resolution dataset for initial phasing by SAD,envelope glycoprotein ul130 | envelope glycoprotein l,D | B,human cytomegalovirus (strain merlin) | human cytomegalovirus (strain 5508),3.99,2.80489,2.44243,"B156,B157,B158,D46,D47,D48,D49,D50,D51,D52,D72,D73,D74,D75,D76,D78,D89,D90,D92,D93,D96,D98,D114,D115,D118,D119,D120,D123,D124,D137,D138,D139,D140,D141,D142,D143,D146",CMV,245
688,5VOC,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Crystal structure of HCMV Pentamer in complex with neutralizing antibody 8I21 - Low resolution dataset for initial phasing by SAD,envelope glycoprotein ul130 | envelope glycoprotein l,D | B,human cytomegalovirus (strain merlin) | human cytomegalovirus (strain 5508),3.99,13.0446,-0.88716,"B156,B157,B158,D46,D47,D48,D49,D50,D51,D52,D72,D73,D74,D75,D76,D78,D89,D90,D92,D93,D96,D98,D114,D115,D118,D119,D120,D123,D124,D137,D138,D139,D140,D141,D142,D143,D146",CMV,245
689,5VOD,L,27D,31,IGKV2-30,Y,['Y' 'H'],H,60.664819944598335,Crystal structure of HCMV Pentamer in complex with neutralizing antibody 9I6,envelope glycoprotein ul128 | envelope glycoprotein ul131a,C | E,human cytomegalovirus (strain ad169) | human cytomegalovirus (strain merlin),5.9,-0.329902,0.0600792,"C32,C47,C48,C49,C50,C51,C52,C70,C92,C93,C95,C106,C108,C109,C110,E23,E24,E27,E28,E29,E30,E31",CMV,246
690,7TPJ,H,94,101,IGHV3-64,R,['R' 'K'],K,100.0,Single-Particle Cryo-EM Structure of the WaaL O-antigen ligase in its apo state,putative cell surface polysaccharide polymerase/ligase,B,cupriavidus metallidurans,3.46,0.649185,0.416956,"B131,B132,B135,B136,B137,B138,B139,B141,B142,B145,B146,B147,B186,B190,B191,B192,B241,B242,B244,B245,B248,B249,B257,B259,B260,B261,B264,B265,B268,B303,B305,B308,B309,B310,B313",Cupriavidus metallidurans,247
691,7ENF,P,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30,spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,2.76,4.41805,2.59488,"B343,B344,B345,B346,B347,B348,B349,B351,B352,B354,B439,B440,B441,B442,B443,B444,B445,B448,B450,B451,B452,B466,B468,B499,B509",SARS,248
692,7ENG,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30 (local refinement of the RBD and Fab30),spike glycoprotein,B,severe acute respiratory syndrome coronavirus2,3.59,2.32217,0.00767486,"B340,B345,B346,B347,B348,B349,B351,B352,B354,B439,B440,B441,B442,B443,B444,B445,B448,B450,B451,B452,B466,B468,B499,B509",SARS,248
693,7TPG,H,94,101,IGHV3-64,R,['R' 'K'],K,100.0,Single-Particle Cryo-EM Structure of the WaaL O-antigen ligase in its ligand bound state,putative cell surface polysaccharide polymerase/ligase,B,cupriavidus metallidurans,3.23,-0.246892,-0.676715,"B131,B132,B135,B136,B137,B138,B139,B141,B142,B145,B146,B147,B186,B189,B190,B241,B242,B244,B245,B248,B249,B252,B259,B260,B261,B264,B265,B303,B304,B305,B308,B309,B310,B313",Cupriavidus metallidurans,247
694,7X90,E,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab326,spike glycoprotein,G,severe acute respiratory syndrome coronavirus2,0,10.4541,4.79254,"G351,G446,G449,G450,G452,G455,G468,G469,G470,G471,G472,G480,G481,G482,G483,G484,G485,G486,G487,G488,G489,G490,G492,G493,G494,G495,G496,G498",SARS,249
695,7X90,E,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab326,spike glycoprotein,G,severe acute respiratory syndrome coronavirus2,0,1.48363,-0.0110886,"G351,G446,G449,G450,G452,G455,G468,G469,G470,G471,G472,G480,G481,G482,G483,G484,G485,G486,G487,G488,G489,G490,G492,G493,G494,G495,G496,G498",SARS,249
696,3IDI,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide ALDKWNQ,gp41 mper peptide,C,,2.1,0.430972,-0.120023,"C1,C2,C3,C4,C5",,
697,3IDJ,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide analog ELD(Orn)WAS,gp41 mper peptide analog,C,,2.24,0.0160209,0.0558375,"C1,C2,C3,C5,C6",,
698,3IDN,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 Fab' fragment in complex with gp41 Peptide analog ELD(Paf)WAS,gp41 mper peptide analog,C,,2.25,0.0752324,0.211414,"C1,C2,C3,C5,C6",,
699,4O58,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of broadly neutralizing antibody F045-092 in complex with A/Victoria/3/1975 (H3N2) influenza hemagglutinin,hemagglutinin ha1 chain,A,influenza a virus,2.7501,0.912263,1.1344,"A98,A131,A132,A133,A134,A135,A136,A137,A144,A145,A153,A155,A156,A157,A158,A159,A189,A190,A193,A194,A226,A255",influenza,250
700,1G9N,H,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B,envelope glycoprotein gp120,G,human immunodeficiency virus 1,2.9,3.73249,-0.315957,"G119,G120,G122,G200,G202,G203,G204,G205,G419,G420,G421,G422,G423,G432,G433,G434,G437",HIV,177
701,6O39,B,52,52,IGHV3-23,Y,['S' 'Y'],S,1.6016016016016017,Crystal structure of Frizzled 5 CRD in complex with F2.I Fab,frizzled-5,C,homo sapiens,1.8,5.1675,4.17488,"C39,C55,C56,C57,C61,C62,C64,C65,C66,C68,C69,C70,C71,C72,C73,C75,C76,C90,C120,C123,C124,C125,C126,C128,C130",Human,251
702,6O39,B,52A,52A,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,Crystal structure of Frizzled 5 CRD in complex with F2.I Fab,frizzled-5,C,homo sapiens,1.8,0.989215,0.160715,"C39,C55,C56,C57,C61,C62,C64,C65,C66,C68,C69,C70,C71,C72,C73,C75,C76,C90,C120,C123,C124,C125,C126,C128,C130",Human,251
703,6O39,B,53,53,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of Frizzled 5 CRD in complex with F2.I Fab,frizzled-5,C,homo sapiens,1.8,0.642342,0.021493,"C39,C55,C56,C57,C61,C62,C64,C65,C66,C68,C69,C70,C71,C72,C73,C75,C76,C90,C120,C123,C124,C125,C126,C128,C130",Human,251
704,6O39,B,55,55,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of Frizzled 5 CRD in complex with F2.I Fab,frizzled-5,C,homo sapiens,1.8,2.88666,2.40488,"C39,C55,C56,C57,C61,C62,C64,C65,C66,C68,C69,C70,C71,C72,C73,C75,C76,C90,C120,C123,C124,C125,C126,C128,C130",Human,251
705,6W05,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of Fab356 in complex with NPNA2 peptide from circumsporozoite protein,npna2 peptide,P,plasmodium falciparum,2.516,1.99321,0.492363,"P1,P2,P3,P4,P5,P6,P7,P8",Malaria,48
706,7S6L,H,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (conformation 3),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,4,1.35375,1.482,"A417,A449,A453,A455,A456,A473,A475,A476,A477,A478,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,27
707,7S6L,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (conformation 3),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,4,2.09571,6.63728,"A417,A449,A453,A455,A456,A473,A475,A476,A477,A478,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,27
708,7CM4,H,33,33,IGHV2-70,G,['G' 'E'],E,100.0,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.71,9.54147,3.76529,"A349,A351,A403,A406,A417,A446,A449,A450,A452,A453,A455,A456,A478,A483,A484,A485,A486,A488,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,252
709,7CM4,H,58,60,IGHV2-70,Y,['Y' 'F' 'H'],F,81.11111111111111,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.71,0.916164,0.868513,"A349,A351,A403,A406,A417,A446,A449,A450,A452,A453,A455,A456,A478,A483,A484,A485,A486,A488,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,252
710,7CM4,H,58,60,IGHV2-70,Y,['Y' 'F' 'H'],H,81.11111111111111,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.71,2.93678,2.69886,"A349,A351,A403,A406,A417,A446,A449,A450,A452,A453,A455,A456,A478,A483,A484,A485,A486,A488,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,252
711,7CM4,H,64,66,IGHV2-70,K,['K' 'N'],N,100.0,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.71,0.209501,0.241598,"A349,A351,A403,A406,A417,A446,A449,A450,A452,A453,A455,A456,A478,A483,A484,A485,A486,A488,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,252
712,7CM4,H,94,99,IGHV2-70,R,['R' 'H'],H,100.0,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.71,3.90008,3.80134,"A349,A351,A403,A406,A417,A446,A449,A450,A452,A453,A455,A456,A478,A483,A484,A485,A486,A488,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,252
713,7CM4,L,50,51,IGLV1-51,D,['D' 'E'],E,83.18318318318319,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.71,3.37281,0.790441,"A349,A351,A403,A406,A417,A446,A449,A450,A452,A453,A455,A456,A478,A483,A484,A485,A486,A488,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,253
714,7VUX,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Complex structure of PD1 and 609A-Fab,programmed cell death protein 1,A,homo sapiens,1.64,1.69924,-1.24647,"A59,A60,A61,A62,A63,A64,A78,A81,A82,A83,A84,A85,A86,A87,A88,A89,A126,A128,A129,A130,A131,A132,A133,A134",Human,234
715,7LCV,A,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein,factor h binding protein,C,neisseria meningitidis,1.7,18.7668,11.0235,"C47,C49,C50,C51,C52,C53,C54,C75,C77,C78,C79,C81,C87,C88,C89,C90,C93,C94,C95,C112,C113,C121,C122,C123,C125,C127",Meningococcus,17
716,7LCV,A,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein,factor h binding protein,C,neisseria meningitidis,1.7,1.10646,0.328248,"C47,C49,C50,C51,C52,C53,C54,C75,C77,C78,C79,C81,C87,C88,C89,C90,C93,C94,C95,C112,C113,C121,C122,C123,C125,C127",Meningococcus,17
717,7LCV,A,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Factor H enhancing human antibody fragment (Fab) to meningococcal Factor H binding protein,factor h binding protein,C,neisseria meningitidis,1.7,0.225055,-0.335671,"C47,C49,C50,C51,C52,C53,C54,C75,C77,C78,C79,C81,C87,C88,C89,C90,C93,C94,C95,C112,C113,C121,C122,C123,C125,C127",Meningococcus,17
718,6OKM,H,30,30,IGHV1-46,T,['T' 'N'],N,93.22580645161293,Human OX40R (TNFRSF4) bound to Fab 3C8,tumor necrosis factor receptor superfamily member 4,R,homo sapiens,2.1,-0.617588,-0.62592,"R66,R67,R68,R69,R70,R71,R81,R82,R83,R84,R86,R87,R88,R89,R90,R95,R96,R97,R98,R99,R100,R101",Human,254
719,2P8L,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELLELDKWASLWN,gp41 peptide,C,,2.44,0.763514,-0.135328,"C0,C1,C2,C3,C4,C5,C6,C7,C8,C10",,
720,2P8M,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELLELDKWASLWN in new crystal form,gp41 peptide,C,,2.7,0.193125,0.222861,"C-2,C0,C1,C2,C3,C4,C5,C6",,
721,6O3A,B,50,50,IGHV3-21,Y,['S' 'Y'],S,0.0,Crystal structure of Frizzled 7 CRD in complex with F7.B Fab,frizzled-7,E,homo sapiens,2.1,1.3372,1.54275,"E55,E56,E81,E84,E85,E86,E87,E88,E89,E91,E92,E134,E135,E136,E137,E138,E139,E140,E141",Human,255
722,2P8P,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide LELDKWASLW[N-Ac],gp41 peptide,C,,2.7,-0.128392,-0.194946,"C0,C1,C2,C3,C4,C5,C6,C8",,
723,5O4G,B,30,30,IGHV1-46,T,['T' 'N'],N,93.22580645161293,HER2 in complex with Fab MF3958,receptor tyrosine-protein kinase erbb-2,C,homo sapiens,3.0,0.678275,-0.0782377,"C141,C143,C144,C145,C146,C160,C162,C164,C165,C166,C167,C168,C169,C170,C171,C172,C173,C175,C178,C179,C180,C181",Human,256
724,7EPU,A,50,773,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,Crystal structure of HsALC1,chromodomain-helicase-dna-binding protein 1-like,B,homo sapiens,3.5,-1.00532,-0.348503,"B104,B105,B107,B108,B111,B125,B127,B128,B129,B130,B131,B132,B136,B152,B154,B155,B158,B308,B312,B371,B394,B421,B422,B423,B425,B426,B442,B443,B444,B446,B447,B450,B486,B493",Human,257
725,6D0X,A,31,31,IGHV3-33,S,['S' 'R'],R,99.69788519637464,Crystal structure of chimeric H.2140 / K.1210 Fab in complex with circumsporozoite protein NANP3,nanp3,C,plasmodium falciparum,1.849,-0.709123,-0.24314,"C2,C3,C4,C5,C6,C7,C8,C9,C10,C11",Malaria,48
726,6D0X,A,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of chimeric H.2140 / K.1210 Fab in complex with circumsporozoite protein NANP3,nanp3,C,plasmodium falciparum,1.849,3.91612,1.70707,"C2,C3,C4,C5,C6,C7,C8,C9,C10,C11",Malaria,48
727,7U8L,H,55,55,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of chimeric hemagglutinin cH15/3 in complex with broad protective antibody 31.a.83,hemagglutinin ha2 subunit | hemagglutinin ha1 subunit,B | A,influenza a virus | influenza a virus,4.56,0.716218,0.353044,"A18,A38,A40,A54,A55,A83,A85,A261E,A261F,A261H,A261I,A262,A276,A280,A290,A318,B18,B19,B20,B21,B38,B41,B42,B45,B46,B48,B49,B50,B52,B53,B56,B57,B58,B59,B60,B61",influenza,258
728,7U8J,H,55,55,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of chimeric hemagglutinin cH4/3 in complex with broad protective antibody 31.a.83,hemagglutinin ha2 subunit | hemagglutinin ha1 subunit,B | A,influenza a virus | influenza a virus,4.9,0.635202,0.349577,"A18,A38,A40,A278,A280,A290,A291,A304,A318,B18,B19,B20,B21,B38,B41,B42,B45,B46,B48,B49,B50,B52,B53,B56,B57,B58,B59,B60,B61",influenza,258
729,2DD8,H,33,33,IGHV1-69,T,['A' 'T'],A,4.739336492890995,Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody,spike glycoprotein,S,sars coronavirus,2.3,2.1316,1.59525,"S359,S361,S362,S363,S365,S390,S391,S392,S394,S395,S426,S432,S436,S440,S482,S484,S485,S486,S487,S488,S489,S490,S491,S492,S494",SARS,259
730,2DD8,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody,spike glycoprotein,S,sars coronavirus,2.3,5.29627,2.04004,"S359,S361,S362,S363,S365,S390,S391,S392,S394,S395,S426,S432,S436,S440,S482,S484,S485,S486,S487,S488,S489,S490,S491,S492,S494",SARS,259
731,2DD8,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody,spike glycoprotein,S,sars coronavirus,2.3,2.3778,0.00557447,"S359,S361,S362,S363,S365,S390,S391,S392,S394,S395,S426,S432,S436,S440,S482,S484,S485,S486,S487,S488,S489,S490,S491,S492,S494",SARS,259
732,2DD8,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody,spike glycoprotein,S,sars coronavirus,2.3,0.935967,0.230281,"S359,S361,S362,S363,S365,S390,S391,S392,S394,S395,S426,S432,S436,S440,S482,S484,S485,S486,S487,S488,S489,S490,S491,S492,S494",SARS,259
733,6NN3,H,66,68,IGHV4-31,R,['L' 'R'],L,97.40932642487049,Structure of parvovirus B19 decorated with Fab molecules from a human antibody,vp2 of b19 parvovirus,A,human parvovirus b19,3.22,-0.189888,-0.339512,"A48,A50,A51,A57,A58,A59,A60,A61,A62,A80,A88,A133,A138,A183,A195,A196,A197,A198,A200,A202,A475,A477,A479",Parvovirus B19,260
734,7E8M,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Crystal structure of SARS-CoV-2 antibody P2C-1F11 with mutated RBD,spike protein s1,E,severe acute respiratory syndrome coronavirus2,2.09,0.114385,0.00326141,"E403,E405,E408,E409,E415,E416,E417,E420,E421,E453,E455,E456,E457,E458,E459,E460,E473,E474,E475,E476,E477,E486,E487,E489,E490,E493,E494,E495,E498,E500,E501,E502,E505",SARS,9
735,8DI5,H,52,52,IGHV3-23,Y,['S' 'Y'],S,1.6016016016016017,Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with VH domain F6 (focused refinement of RBD and VH F6),spike glycoprotein,C,severe acute respiratory syndrome coronavirus2,0,0.401614,-0.611154,"C351,C444,C446,C447,C449,C450,C452,C453,C455,C470,C472,C480,C481,C482,C483,C484,C486,C487,C488,C489,C490,C492,C493,C494,C498",SARS,261
736,7XW7,B,50,50,IGLV1-51,D,['D' 'E'],E,83.18318318318319,TSHR-K1-70 complex,thyrotropin receptor,R,homo sapiens,0,0.792375,-0.416908,"R35,R40,R58,R60,R82,R84,R153,R155,R181,R204",Human,262
737,3EGS,B,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 scrambledFP-MPER scrHyb3K construct GIGAFGLLGFLAAGSKK-Ahx-K656NEQELLELDKWASLWN671 soaked in ammonium sulfate,gp41 scrfp-mper construct,C,,3.6,0.0115106,0.0415198,"C3,C4,C5,C6,C7,C8",,
738,5UEK,L,30,30,IGKV1-13,S,['I' 'S'],I,100.0,Structure of antigen-Fab 12E complex with Histone chaperone ASF1,histone chaperone asf1,A,saccharomyces cerevisiae,1.7,2.18324,0.624874,"A5,A6,A7,A8,A9,A45,A47,A48,A49,A50,A51,A52,A91,A92,A93,A94,A96,A108,A110,A111,A112,A113,A114,A138,A140,A141,A142,A143,A144,A145,A146,A147,A148,A149",Yeast,263
739,5UEK,L,32,32,IGKV1-13,A,['S' 'A'],S,100.0,Structure of antigen-Fab 12E complex with Histone chaperone ASF1,histone chaperone asf1,A,saccharomyces cerevisiae,1.7,-0.329674,-0.373127,"A5,A6,A7,A8,A9,A45,A47,A48,A49,A50,A51,A52,A91,A92,A93,A94,A96,A108,A110,A111,A112,A113,A114,A138,A140,A141,A142,A143,A144,A145,A146,A147,A148,A149",Yeast,263
740,4XWG,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal Structure of LCAT (C31Y) in complex with Fab1,phosphatidylcholine-sterol acyltransferase,A,homo sapiens,2.65,2.47929,1.22748,"A40,A48,A49,A50,A51,A52,A53,A54,A58,A59,A60,A63,A65,A66,A68,A69,A70,A71,A74,A75,A78,A238,A239,A240",Human,264
741,6APB,H,33,33,IGHV2-70,G,['G' 'E'],E,100.0,Crystal Structure of Non-Neutralizing Infant Antibody ADI-14359 in Complex with Postfusion RSV F Glycoprotein,"fusion glycoprotein f0,fusion glycoprotein f0 | fusion glycoprotein f0,fusion glycoprotein f0",C | A,human respiratory syncytial virus | human respiratory syncytial virus,3.0,3.59469,2.96938,"A399,A400,A401,A419,C31,C32,C33,C34,C35,C40,C42,C43,C312,C313,C314,C344,C377,C378,C380,C381,C383,C384,C385,C389,C390",RSV,265
742,6APB,H,50,50,IGHV2-70,R,['L' 'R'],L,54.44444444444445,Crystal Structure of Non-Neutralizing Infant Antibody ADI-14359 in Complex with Postfusion RSV F Glycoprotein,"fusion glycoprotein f0,fusion glycoprotein f0 | fusion glycoprotein f0,fusion glycoprotein f0",C | A,human respiratory syncytial virus | human respiratory syncytial virus,3.0,-1.75856,-1.751,"A399,A400,A401,A419,C31,C32,C33,C34,C35,C40,C42,C43,C312,C313,C314,C344,C377,C378,C380,C381,C383,C384,C385,C389,C390",RSV,265
743,6APB,H,58,58,IGHV2-70,Y,['Y' 'F' 'H'],F,81.11111111111111,Crystal Structure of Non-Neutralizing Infant Antibody ADI-14359 in Complex with Postfusion RSV F Glycoprotein,"fusion glycoprotein f0,fusion glycoprotein f0 | fusion glycoprotein f0,fusion glycoprotein f0",C | A,human respiratory syncytial virus | human respiratory syncytial virus,3.0,0.607642,0.924598,"A399,A400,A401,A419,C31,C32,C33,C34,C35,C40,C42,C43,C312,C313,C314,C344,C377,C378,C380,C381,C383,C384,C385,C389,C390",RSV,265
744,6APB,H,58,58,IGHV2-70,Y,['Y' 'F' 'H'],H,81.11111111111111,Crystal Structure of Non-Neutralizing Infant Antibody ADI-14359 in Complex with Postfusion RSV F Glycoprotein,"fusion glycoprotein f0,fusion glycoprotein f0 | fusion glycoprotein f0,fusion glycoprotein f0",C | A,human respiratory syncytial virus | human respiratory syncytial virus,3.0,2.20469,2.13145,"A399,A400,A401,A419,C31,C32,C33,C34,C35,C40,C42,C43,C312,C313,C314,C344,C377,C378,C380,C381,C383,C384,C385,C389,C390",RSV,265
745,5W42,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of human monoclonal antibody H3v-47 in complex with influenza virus hemagglutinin from A/Minnesota/11/2010 (H3N2),hemagglutinin,A,influenza a virus(a/swine/minnesota/a01134337/2010(h3n2)),3.569,2.13958,1.47183,"A57,A59,A62,A77,A78,A80,A81,A82,A83,A119,A120,A121,A122,A123,A124,A133,A134,A135,A141,A142,A144,A145,A146,A147,A148,A149,A171,A172,A173,A174,A255,A257,A259",influenza,266
746,2VH5,H,33,33,IGHV3-48,S,['S' 'E'],E,47.05882352941176,CRYSTAL STRUCTURE OF HRAS(G12V) - ANTI-RAS FV (disulfide free mutant)  COMPLEX,gtpase hras,R,homo sapiens,2.7,4.54273,-1.86207,"R12,R17,R21,R25,R27,R29,R31,R32,R33,R34,R35,R36,R37,R38,R39,R40,R56,R57,R61,R63,R64,R67",Human,41
747,3Q1S,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],W,92.13483146067416,HIV-1 neutralizing antibody Z13e1 in complex with epitope display protein,interleukin-22,I,homo sapiens,2.15,0.0880587,0.172613,"I61,I62,I64,I65,I66,I67,I68,I69,I70,I71,I73,I75,I76,I77,I80,I88,I169,I172,I173",Human,267
748,3Q1S,H,32,32,IGHV4-59,Y,['Y' 'W' 'H'],H,92.13483146067416,HIV-1 neutralizing antibody Z13e1 in complex with epitope display protein,interleukin-22,I,homo sapiens,2.15,0.721072,0.47919,"I61,I62,I64,I65,I66,I67,I68,I69,I70,I71,I73,I75,I76,I77,I80,I88,I169,I172,I173",Human,267
749,3Q1S,H,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,HIV-1 neutralizing antibody Z13e1 in complex with epitope display protein,interleukin-22,I,homo sapiens,2.15,6.79091,2.26917,"I61,I62,I64,I65,I66,I67,I68,I69,I70,I71,I73,I75,I76,I77,I80,I88,I169,I172,I173",Human,267
750,3Q1S,H,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,HIV-1 neutralizing antibody Z13e1 in complex with epitope display protein,interleukin-22,I,homo sapiens,2.15,2.00721,1.17827,"I61,I62,I64,I65,I66,I67,I68,I69,I70,I71,I73,I75,I76,I77,I80,I88,I169,I172,I173",Human,267
751,6U38,L,69,69,IGKV3-11,T,['T' 'R'],R,99.56958393113344,PCSK9 in complex with a Fab and compound 8,proprotein convertase subtilisin/kexin type 9,B,homo sapiens,2.73,-0.770104,-0.0385476,"B153,B154,B155,B193,B194,B195,B197,B237,B238,B239,B369,B374,B375,B376,B377,B378,B379",Human,42
752,7JV2,L,76,78,IGLV7-46,S,['S' 'L'],L,100.0,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of the receptor-binding motif and Fab variable domains),sars-cov-2 spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.5,-0.253947,-0.546619,"A444,A445,A446,A449,A479,A480,A481,A482,A483,A484,A485,A486,A488,A489,A490,A493,A494,A498",SARS,268
753,7TTY,H,1,1,IGHV4-39,Q,['Q' 'R'],R,99.61832061068702,Crystal structure of potent neutralizing antibody 10-40 in complex with bat WIV1 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus wiv1,3.11,-0.0905386,0.00438466,"A369,A370,A371,A372,A374,A376,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A504",SARS,85
754,7TTY,H,26,26,IGHV4-39,G,['G' 'S'],S,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with bat WIV1 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus wiv1,3.11,7.03766,6.69506,"A369,A370,A371,A372,A374,A376,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A504",SARS,85
755,7TTY,H,27,27,IGHV4-39,G,['G' 'Y'],Y,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with bat WIV1 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus wiv1,3.11,8.87325,2.37422,"A369,A370,A371,A372,A374,A376,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A504",SARS,85
756,7TTY,H,28,28,IGHV4-39,S,['S' 'Y'],Y,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with bat WIV1 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus wiv1,3.11,-0.0901053,-0.165235,"A369,A370,A371,A372,A374,A376,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A504",SARS,85
757,7TTY,H,30,30,IGHV4-39,S,['S' 'G'],G,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with bat WIV1 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus wiv1,3.11,0.1701,0.171116,"A369,A370,A371,A372,A374,A376,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A430,A460,A504",SARS,85
758,7TTX,H,1,1,IGHV4-39,Q,['Q' 'R'],R,99.61832061068702,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat RaGT13 receptor-binding domain,spike glycoprotein,A,bat coronavirus ratg13,2.8,-0.276134,-0.0888826,"A368,A369,A370,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A386,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A417,A427,A428,A429,A460,A505",SARS,85
759,7TTX,H,26,26,IGHV4-39,G,['G' 'S'],S,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat RaGT13 receptor-binding domain,spike glycoprotein,A,bat coronavirus ratg13,2.8,5.76473,5.761,"A368,A369,A370,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A386,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A417,A427,A428,A429,A460,A505",SARS,85
760,7TTX,H,27,27,IGHV4-39,G,['G' 'Y'],Y,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat RaGT13 receptor-binding domain,spike glycoprotein,A,bat coronavirus ratg13,2.8,4.9107,2.97533,"A368,A369,A370,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A386,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A417,A427,A428,A429,A460,A505",SARS,85
761,7TTX,H,28,28,IGHV4-39,S,['S' 'Y'],Y,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat RaGT13 receptor-binding domain,spike glycoprotein,A,bat coronavirus ratg13,2.8,-0.0394452,-0.202851,"A368,A369,A370,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A386,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A417,A427,A428,A429,A460,A505",SARS,85
762,7TTX,H,30,30,IGHV4-39,S,['S' 'G'],G,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat RaGT13 receptor-binding domain,spike glycoprotein,A,bat coronavirus ratg13,2.8,0.961902,0.895365,"A368,A369,A370,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A386,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A417,A427,A428,A429,A460,A505",SARS,85
763,7F15,B,51,51,IGHV1-3,I,['I' 'S'],S,100.0,A SARS-CoV-2 neutralizing antibody,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.65,4.53896,4.62229,"A456,A458,A473,A474,A475,A476,A477,A478,A479,A481,A486,A487,A488,A489,A493",SARS,269
764,3L5X,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the complex between IL-13 and H2L6 FAB,interleukin-13,A,homo sapiens,1.9,3.01059,-0.0176976,"A8,A11,A14,A15,A18,A101,A104,A105,A107,A108,A109,A110",Human,184
765,3L5Y,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the complex between IL-13 and M1295 FAB,interleukin-13,A,homo sapiens,2.8,2.75441,-0.227745,"A7,A8,A11,A14,A15,A18,A101,A104,A105,A107,A108,A109,A110",Human,184
766,4OQT,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,LINGO-1/Li81 Fab complex,leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1,A,homo sapiens,3.23,0.0187402,-0.0260314,"A97,A121,A122,A125,A128,A146,A149,A150,A152,A170,A173,A174,A176,A197,A198,A199,A200,A201",Human,270
767,4OQT,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,LINGO-1/Li81 Fab complex,leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1,A,homo sapiens,3.23,-0.0496168,-0.309163,"A97,A121,A122,A125,A128,A146,A149,A150,A152,A170,A173,A174,A176,A197,A198,A199,A200,A201",Human,270
768,7TTM,H,1,1,IGHV4-39,Q,['Q' 'R'],R,99.61832061068702,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat SHC014 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus rsshc014,2.24,-0.0655204,-0.252903,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A460,A504",SARS,85
769,7TTM,H,26,26,IGHV4-39,G,['G' 'S'],S,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat SHC014 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus rsshc014,2.24,6.44439,6.79776,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A460,A504",SARS,85
770,7TTM,H,27,27,IGHV4-39,G,['G' 'Y'],Y,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat SHC014 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus rsshc014,2.24,5.74004,2.32467,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A460,A504",SARS,85
771,7TTM,H,28,28,IGHV4-39,S,['S' 'Y'],Y,100.0,Crystal structure of potent neutralizing antibody 10-40 in complex with Sarbecovirus bat SHC014 receptor-binding domain,spike protein s1,A,bat sars-like coronavirus rsshc014,2.24,-0.427396,-0.43833,"A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A404,A405,A408,A409,A411,A412,A413,A414,A415,A416,A427,A428,A429,A460,A504",SARS,85
772,5EA0,H,33,33,IGHV3-30,G,['A' 'G'],A,68.58846918489066,Structure of the antibody 7968 with human complement factor H-derived peptide,complement factor h-related protein 2,P,homo sapiens,2.0,1.07585,-1.10941,"P1112,P1113,P1114,P1115,P1116,P1117,P1118,P1119,P1120,P1121,P1122",Human,271
773,5EA0,H,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,Structure of the antibody 7968 with human complement factor H-derived peptide,complement factor h-related protein 2,P,homo sapiens,2.0,20.9531,1.23412,"P1112,P1113,P1114,P1115,P1116,P1117,P1118,P1119,P1120,P1121,P1122",Human,271
774,5EA0,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Structure of the antibody 7968 with human complement factor H-derived peptide,complement factor h-related protein 2,P,homo sapiens,2.0,2.6219,-0.274921,"P1112,P1113,P1114,P1115,P1116,P1117,P1118,P1119,P1120,P1121,P1122",Human,271
775,3KR3,H,50,50,IGHV3-23,V,['A' 'V'],A,0.7007007007007007,Crystal structure of IGF-II antibody complex,insulin-like growth factor ii,D,homo sapiens,2.2,2.56552,2.14545,"D7,D9,D10,D11,D12,D13,D14,D15,D17,D18,D26,D31,D34,D35,D37,D39,D40,D41,D43,D44,D45,D47,D48,D49,D59",Human,272
776,3KR3,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Crystal structure of IGF-II antibody complex,insulin-like growth factor ii,D,homo sapiens,2.2,22.5416,-1.50919,"D7,D9,D10,D11,D12,D13,D14,D15,D17,D18,D26,D31,D34,D35,D37,D39,D40,D41,D43,D44,D45,D47,D48,D49,D59",Human,272
777,3KR3,H,52A,53,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,Crystal structure of IGF-II antibody complex,insulin-like growth factor ii,D,homo sapiens,2.2,-0.487299,-0.362099,"D7,D9,D10,D11,D12,D13,D14,D15,D17,D18,D26,D31,D34,D35,D37,D39,D40,D41,D43,D44,D45,D47,D48,D49,D59",Human,272
778,3KR3,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Crystal structure of IGF-II antibody complex,insulin-like growth factor ii,D,homo sapiens,2.2,-0.234531,-0.201123,"D7,D9,D10,D11,D12,D13,D14,D15,D17,D18,D26,D31,D34,D35,D37,D39,D40,D41,D43,D44,D45,D47,D48,D49,D59",Human,272
779,3KR3,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of IGF-II antibody complex,insulin-like growth factor ii,D,homo sapiens,2.2,-0.36907,-0.0732202,"D7,D9,D10,D11,D12,D13,D14,D15,D17,D18,D26,D31,D34,D35,D37,D39,D40,D41,D43,D44,D45,D47,D48,D49,D59",Human,272
780,7F1G,D,58,218,IGHV3-74,T,['S' 'T'],S,7.361963190184049,"BACE2 xaperone complex with N-{3-[(4R,5R,6R)-2-amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-2H,3H-[1,4]dioxino[2,3-c]pyridine-7-carboxamide",beta-secretase 2,A,homo sapiens,1.5,0.0624257,-0.0346014,"A75,A77,A78,A79,A81,A98,A100,A110,A111,A112,A113,A114,A140,A146,A147,A148,A150,A151,A154,A157,A158,A159,A161,A162,A163,A164",Human,106
781,7FJC,L,50,50,IGKV1-5,D,['D' 'K'],K,16.263440860215052,Crystal structure of SARS-CoV-2 Beta RBD complexed with P36-5D2 Fab,spike protein s1,E,severe acute respiratory syndrome coronavirus2,2.96,5.33086,0.648273,"E345,E346,E347,E348,E351,E354,E440,E441,E442,E443,E444,E445,E446,E447,E448,E449,E450,E451,E452,E470,E472,E490,E492,E493,E509",SARS,164
782,6BQB,H,35,35,IGHV3-33,H,['H' 'Y'],Y,99.69788519637464,MGG4 Fab in complex with peptide,n-terminal junction peptide,P,plasmodium falciparum,1.769,5.28278,4.29338,"P7,P8,P9,P10,P11,P12",Malaria,48
783,6BQB,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,MGG4 Fab in complex with peptide,n-terminal junction peptide,P,plasmodium falciparum,1.769,4.04293,2.56615,"P7,P8,P9,P10,P11,P12",Malaria,48
784,6BQB,H,94,94,IGHV3-33,K,['R' 'K'],R,7.854984894259819,MGG4 Fab in complex with peptide,n-terminal junction peptide,P,plasmodium falciparum,1.769,0.185864,0.231369,"P7,P8,P9,P10,P11,P12",Malaria,48
785,6MTO,H,33,33,IGHV1-69,T,['A' 'T'],A,4.739336492890995,Crystal structure of VRC42.01 Fab in complex with T117-F MPER scaffold,vrc42 epitope t117-f scaffold,T,human immunodeficiency virus 1,2.634,-1.351,0.0713438,"T56,T60,T61,T62,T64,T73,T75,T76,T77,T78,T100,T101,T118,T119,T120,T121,T122,T123,T124,T125,T127,T128,T131,T165,T166,T167",HIV,273
786,6MTO,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of VRC42.01 Fab in complex with T117-F MPER scaffold,vrc42 epitope t117-f scaffold,T,human immunodeficiency virus 1,2.634,7.31601,-2.76817,"T56,T60,T61,T62,T64,T73,T75,T76,T77,T78,T100,T101,T118,T119,T120,T121,T122,T123,T124,T125,T127,T128,T131,T165,T166,T167",HIV,273
787,6MTO,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of VRC42.01 Fab in complex with T117-F MPER scaffold,vrc42 epitope t117-f scaffold,T,human immunodeficiency virus 1,2.634,-0.337918,0.400806,"T56,T60,T61,T62,T64,T73,T75,T76,T77,T78,T100,T101,T118,T119,T120,T121,T122,T123,T124,T125,T127,T128,T131,T165,T166,T167",HIV,273
788,6MTT,H,33,33,IGHV1-69,T,['A' 'T'],A,4.739336492890995,Crystal structure of VRC46.01 Fab in complex with gp41 peptide,rv217 founder virus gp41 peptide,P,human immunodeficiency virus 1,1.7,1.99185,0.623838,"P665,P666,P667,P668,P669,P670,P671,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,274
789,6MTT,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of VRC46.01 Fab in complex with gp41 peptide,rv217 founder virus gp41 peptide,P,human immunodeficiency virus 1,1.7,15.0836,4.82141,"P665,P666,P667,P668,P669,P670,P671,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,274
790,6MTT,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of VRC46.01 Fab in complex with gp41 peptide,rv217 founder virus gp41 peptide,P,human immunodeficiency virus 1,1.7,1.02677,0.214987,"P665,P666,P667,P668,P669,P670,P671,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,274
791,6MTT,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of VRC46.01 Fab in complex with gp41 peptide,rv217 founder virus gp41 peptide,P,human immunodeficiency virus 1,1.7,2.73176,0.762688,"P665,P666,P667,P668,P669,P670,P671,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,274
792,6MTT,H,71,71,IGHV1-69,A,['A' 'T'],T,98.73617693522904,Crystal structure of VRC46.01 Fab in complex with gp41 peptide,rv217 founder virus gp41 peptide,P,human immunodeficiency virus 1,1.7,0.873899,0.906403,"P665,P666,P667,P668,P669,P670,P671,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,274
793,6MTQ,H,33,33,IGHV1-69,T,['A' 'T'],A,4.739336492890995,Crystal structure of VRC42.N1 Fab in complex with T117-F MPER scaffold,vrc42 epitope t117-f scaffold,T,human immunodeficiency virus 1,2.7,0.0616758,0.49575,"T56,T60,T61,T62,T64,T73,T75,T77,T78,T84,T100,T101,T103,T118,T119,T120,T121,T122,T123,T124,T125,T127,T128,T129,T131,T132,T134,T135,T162",HIV,273
794,6MTQ,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of VRC42.N1 Fab in complex with T117-F MPER scaffold,vrc42 epitope t117-f scaffold,T,human immunodeficiency virus 1,2.7,1.30281,0.0323547,"T56,T60,T61,T62,T64,T73,T75,T77,T78,T84,T100,T101,T103,T118,T119,T120,T121,T122,T123,T124,T125,T127,T128,T129,T131,T132,T134,T135,T162",HIV,273
795,6MTQ,H,73,73,IGHV1-69,K,['E' 'K'],E,45.41864139020537,Crystal structure of VRC42.N1 Fab in complex with T117-F MPER scaffold,vrc42 epitope t117-f scaffold,T,human immunodeficiency virus 1,2.7,0.845235,0.288618,"T56,T60,T61,T62,T64,T73,T75,T77,T78,T84,T100,T101,T103,T118,T119,T120,T121,T122,T123,T124,T125,T127,T128,T129,T131,T132,T134,T135,T162",HIV,273
796,5UCB,L,30,30,IGKV1-13,S,['I' 'S'],I,100.0,Structure of antigen-Fab complex with engineered switch residue region.,histone chaperone asf1,B,saccharomyces cerevisiae (strain atcc 204508 /s288c),1.521,1.60674,-0.363237,"B4,B5,B6,B7,B8,B9,B10,B28,B44,B46,B47,B48,B49,B50,B51,B91,B92,B93,B95,B107,B109,B110,B111,B113,B137,B139,B140,B141,B142,B143,B144,B145,B146,B147,B148",Yeast,275
797,5UCB,L,32,32,IGKV1-13,A,['S' 'A'],S,100.0,Structure of antigen-Fab complex with engineered switch residue region.,histone chaperone asf1,B,saccharomyces cerevisiae (strain atcc 204508 /s288c),1.521,0.150982,0.140224,"B4,B5,B6,B7,B8,B9,B10,B28,B44,B46,B47,B48,B49,B50,B51,B91,B92,B93,B95,B107,B109,B110,B111,B113,B137,B139,B140,B141,B142,B143,B144,B145,B146,B147,B148",Yeast,275
798,7A3O,L,50,50,IGLV2-14,D,['E' 'D'],E,43.44262295081968,Crystal structure of dengue 1 virus envelope glycoprotein in complex with the scFv fragment of the broadly neutralizing human antibody EDE1 C10,core protein,A,dengue virus 1,2.8,0.0689073,-1.15975,"A2,A6,A28,A44,A46,A140,A148,A149,A150,A151,A309,A310,A323,A325,A362,A363,A364",Dengue,276
799,6GG0,H,33,33,IGHV4-31,G,['G' 'S'],S,100.0,Cryo-EM structure of BK polyomavirus like particle in complex with single chain antibody ScFv41F17,capsid protein vp1 | capsid protein vp1,4 | 3,bk polyomavirus | bk polyomavirus,4.24,1.00347,0.741294,"352,354,356,357,358,359,360,361,363,381,382,383,392,394,3174,3175,3199,3201,4168,4181,4182,4183,4184,4185,4192",BKV,277
800,4XNY,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC08C in complex with HIV-1 clade A strain Q842.d12 gp120,"envelope glycoprotein gp160,envelope glycoprotein gp160,envelope glycoprotein gp160",G,human immunodeficiency virus 1,2.3,2.32337,1.61208,"G49,G96,G97,G99,G102,G105,G106,G109,G275,G276,G278,G279,G280,G281,G282,G283,G357,G365,G366,G367,G368,G371,G425,G426,G427,G428,G429,G430,G431,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G474,G476,G480",HIV,1
801,4XNY,H,61,61,IGHV1-2,Q,['Q' 'H'],H,94.54314720812184,Crystal structure of broadly and potently neutralizing antibody VRC08C in complex with HIV-1 clade A strain Q842.d12 gp120,"envelope glycoprotein gp160,envelope glycoprotein gp160,envelope glycoprotein gp160",G,human immunodeficiency virus 1,2.3,-0.328988,0.563651,"G49,G96,G97,G99,G102,G105,G106,G109,G275,G276,G278,G279,G280,G281,G282,G283,G357,G365,G366,G367,G368,G371,G425,G426,G427,G428,G429,G430,G431,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G474,G476,G480",HIV,1
802,4XNY,H,69,69,IGHV1-2,M,['S' 'M'],S,99.87309644670052,Crystal structure of broadly and potently neutralizing antibody VRC08C in complex with HIV-1 clade A strain Q842.d12 gp120,"envelope glycoprotein gp160,envelope glycoprotein gp160,envelope glycoprotein gp160",G,human immunodeficiency virus 1,2.3,5.1336,5.43752,"G49,G96,G97,G99,G102,G105,G106,G109,G275,G276,G278,G279,G280,G281,G282,G283,G357,G365,G366,G367,G368,G371,G425,G426,G427,G428,G429,G430,G431,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G474,G476,G480",HIV,1
803,7YUE,A,50,52,IGHV3-23,A,['A' 'V'],V,99.2992992992993,Epitope-directed anti-SARS CoV 2 scFv engineered against the key spike protein region.,spike protein s2,C,severe acute respiratory syndrome coronavirus2,2.35,-0.0532381,-0.924109,"C4,C5,C6,C7,C8,C9,C10,C11",SARS,278
804,7YUE,A,52,54,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Epitope-directed anti-SARS CoV 2 scFv engineered against the key spike protein region.,spike protein s2,C,severe acute respiratory syndrome coronavirus2,2.35,2.22748,0.207391,"C4,C5,C6,C7,C8,C9,C10,C11",SARS,278
805,5VAG,C,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of H7-specific antibody m826 in complex with the HA1 domain of hemagglutinin from H7N9 influenza virus,hemagglutinin,A,influenza a virus,1.9,1.76516,0.303814,"A109,A111,A112,A113,A114,A115,A118,A119,A122,A182,A183,A184,A189,A193,A217,A218,A219,A220,A221,A222,A223,A240,A242,A243,A244,A245,A247,A248,A269",influenza,279
806,5VAG,C,56,57,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Crystal structure of H7-specific antibody m826 in complex with the HA1 domain of hemagglutinin from H7N9 influenza virus,hemagglutinin,A,influenza a virus,1.9,-1.37237,-1.07889,"A109,A111,A112,A113,A114,A115,A118,A119,A122,A182,A183,A184,A189,A193,A217,A218,A219,A220,A221,A222,A223,A240,A242,A243,A244,A245,A247,A248,A269",influenza,279
807,7VKE,B,60,61,IGHV3-30,A,['A' 'T'],T,100.0,Crystal structure of human CD38 ECD in complex with UniDab(TM) F11A,adp-ribosyl cyclase/cyclic adp-ribose hydrolase 1,A,homo sapiens,1.9,-0.372328,-0.392578,"A120,A121,A135,A139,A142,A202,A203,A205,A236,A237,A239,A241,A252,A254,A255,A272,A273,A274,A275,A276,A277,A278,A279,A284,A287,A288,A291,A292,A293,A294,A296,A297,A299,A300",Human,280
808,6UCE,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,N123-VRC34_pI3 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519,hiv fusion peptide,C,human immunodeficiency virus 1,1.382,4.41051,2.65868,"C512,C513,C514,C515,C516,C517,C518,C519",HIV,51
809,8ERQ,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,SARS-CoV-2 BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fab fragment (local refinement of the RBD and S2X324),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.3,0.322387,-0.85914,"A345,A439,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A450,A498,A499,A500,A501,A502,A506,A509",SARS,79
810,8ERQ,L,32,35,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,SARS-CoV-2 BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fab fragment (local refinement of the RBD and S2X324),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.3,0.635402,-0.127537,"A345,A439,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A450,A498,A499,A500,A501,A502,A506,A509",SARS,84
811,8ERQ,L,50,53,IGLV2-14,E,['E' 'D'],D,56.55737704918033,SARS-CoV-2 BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fab fragment (local refinement of the RBD and S2X324),spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.3,0.419601,0.90503,"A345,A439,A440,A441,A442,A443,A444,A445,A446,A447,A448,A449,A450,A498,A499,A500,A501,A502,A506,A509",SARS,84
812,7T0Z,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Complex of GABA-A synaptic receptor with autoimmune antibody Fab175,gamma-aminobutyric acid receptor subunit alpha-1 | gamma-aminobutyric acid receptor subunit gamma-2,D | E,homo sapiens | homo sapiens,0,16.4098,1.00861,"D29,D30,D31,D34,D35,D36,D37,D38,D163,D164,D165,D166,D168,D204,D208,D209,E26,E27,E92,E93,E94,E95,E96,E97,E98",Human,281
813,7T0Z,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Complex of GABA-A synaptic receptor with autoimmune antibody Fab175,gamma-aminobutyric acid receptor subunit alpha-1 | gamma-aminobutyric acid receptor subunit gamma-2,D | E,homo sapiens | homo sapiens,0,-0.58812,-0.168479,"D29,D30,D31,D34,D35,D36,D37,D38,D163,D164,D165,D166,D168,D204,D208,D209,E26,E27,E92,E93,E94,E95,E96,E97,E98",Human,281
814,7T0Z,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Complex of GABA-A synaptic receptor with autoimmune antibody Fab175,gamma-aminobutyric acid receptor subunit alpha-1 | gamma-aminobutyric acid receptor subunit gamma-2,D | E,homo sapiens | homo sapiens,0,-0.232855,-0.158006,"D29,D30,D31,D34,D35,D36,D37,D38,D163,D164,D165,D166,D168,D204,D208,D209,E26,E27,E92,E93,E94,E95,E96,E97,E98",Human,281
815,3GHE,L,29,29,IGLV2-14,G,['G' 'S'],S,97.74590163934424,Crystal structure of anti-HIV-1 Fab 537-10D in complex with V3 peptide MN,envelope glycoprotein,P,,2.4,6.39945,0.368399,"P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P316,P317,P319",,
816,3GHE,L,32,32,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,Crystal structure of anti-HIV-1 Fab 537-10D in complex with V3 peptide MN,envelope glycoprotein,P,,2.4,3.67033,2.00458,"P304,P305,P306,P307,P308,P309,P312,P313,P314,P315,P316,P317,P319",,
817,7PRZ,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with beta-22 Fabs,surface glycoprotein,E,severe acute respiratory syndrome coronavirus2,3.2,7.2316,5.65953,"E403,E405,E408,E415,E416,E417,E420,E421,E449,E453,E455,E456,E457,E460,E473,E475,E486,E487,E489,E490,E493,E494,E495,E496,E498,E500,E501,E502,E503,E505,E506",SARS,282
818,7PRZ,H,94,98,IGHV3-30,K,['R' 'K'],R,53.081510934393634,Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in complex with beta-22 Fabs,surface glycoprotein,E,severe acute respiratory syndrome coronavirus2,3.2,1.98247,0.949482,"E403,E405,E408,E415,E416,E417,E420,E421,E449,E453,E455,E456,E457,E460,E473,E475,E486,E487,E489,E490,E493,E494,E495,E496,E498,E500,E501,E502,E503,E505,E506",SARS,282
819,3IDG,A,32,32,IGKV1-13,A,['S' 'A'],S,100.0,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ALDKWD,gp41 mper peptide,C,,1.86,0.610419,0.774781,"C1,C2,C3,C4,C5,C6",,
820,3IDG,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ALDKWD,gp41 mper peptide,C,,1.86,0.815838,0.185001,"C1,C2,C3,C4,C5,C6",,
821,6WHK,B,50,51,IGLV1-51,D,['D' 'E'],E,83.18318318318319,Minimally mutated anti-influenza broadly neutralizing antibody,hemagglutinin ha1 chain,A,influenza a virus (a/beijing/262/1995(h1n1)),2.6,-1.39018,-1.514,"A95,A133,A134,A135,A136,A137,A140,A143,A144,A145,A153,A155,A156,A158,A159,A160,A187,A189,A190,A192,A193,A194,A196,A197,A198,A226",influenza,283
822,7WVG,C,52,82,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Crystal structure of H18 complexed with SIA28,hemagglutinin | hemagglutinin,B | A,influenza a virus | influenza a virus,2.6,-0.483374,-0.767768,"A18,A20,A37,A38,A40,A322,B16,B18,B19,B20,B21,B26,B32,B33,B34,B35,B38,B39,B41,B42,B45,B46,B48,B49,B52,B53,B150,B153",influenza,71
823,7KPG,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Blocking Fab 25 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1,tyrosine-protein phosphatase non-receptor type substrate 1,S,homo sapiens,2.27,36.6913,-0.0392772,"S30,S31,S32,S33,S34,S35,S52,S53,S65,S66,S67,S68,S69,S70,S72,S96,S97,S98,S99,S101",Human,284
824,7KPG,H,53,53,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Blocking Fab 25 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1,tyrosine-protein phosphatase non-receptor type substrate 1,S,homo sapiens,2.27,-0.900002,-0.673803,"S30,S31,S32,S33,S34,S35,S52,S53,S65,S66,S67,S68,S69,S70,S72,S96,S97,S98,S99,S101",Human,284
825,7D0B,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.9,-0.771118,-0.484371,"A416,A417,A421,A455,A456,A473,A475,A483,A484,A485,A486,A487,A489,A490,A492,A493,A505",SARS,285
826,7BBG,H,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,CRYSTAL STRUCTURE OF HLA-A2-WT1-RMF AND FAB 11D06,mhc class i antigen | wilms tumor 1 (wt1) derived peptide,A | C,homo sapiens | homo sapiens,2.64,1.48282,0.339369,"A55,A57,A58,A59,A61,A62,A65,A66,A69,A73,A149,A150,A151,A152,A154,A155,A158,A159,A162,A163,A166,A167,A170,C1,C2,C4,C5,C6,C7,C8",Human,286
827,7BBG,H,56,57,IGHV1-69,T,['T' 'I'],I,86.8878357030016,CRYSTAL STRUCTURE OF HLA-A2-WT1-RMF AND FAB 11D06,mhc class i antigen | wilms tumor 1 (wt1) derived peptide,A | C,homo sapiens | homo sapiens,2.64,-1.5136,-0.922968,"A55,A57,A58,A59,A61,A62,A65,A66,A69,A73,A149,A150,A151,A152,A154,A155,A158,A159,A162,A163,A166,A167,A170,C1,C2,C4,C5,C6,C7,C8",Human,286
828,7BBG,L,50,50,IGKV1-5,D,['D' 'K'],K,16.263440860215052,CRYSTAL STRUCTURE OF HLA-A2-WT1-RMF AND FAB 11D06,mhc class i antigen | wilms tumor 1 (wt1) derived peptide,A | C,homo sapiens | homo sapiens,2.64,2.74662,0.0295896,"A55,A57,A58,A59,A61,A62,A65,A66,A69,A73,A149,A150,A151,A152,A154,A155,A158,A159,A162,A163,A166,A167,A170,C1,C2,C4,C5,C6,C7,C8",Human,287
829,7DX4,H,33,34,IGHV1-69,A,['A' 'T'],T,95.260663507109,The structure of FC08 Fab-hA.CE2-RBD complex,spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.6,0.502353,0.183301,"E346,E348,E351,E352,E353,E354,E355,E356,E357,E359,E396,E449,E450,E452,E457,E462,E463,E464,E465,E466,E467,E468,E469,E470,E471,E472,E481,E482,E483,E484,E490,E492,E494",SARS,200
830,7DX4,H,56,58,IGHV1-69,I,['T' 'I'],T,13.11216429699842,The structure of FC08 Fab-hA.CE2-RBD complex,spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.6,1.23499,0.679724,"E346,E348,E351,E352,E353,E354,E355,E356,E357,E359,E396,E449,E450,E452,E457,E462,E463,E464,E465,E466,E467,E468,E469,E470,E471,E472,E481,E482,E483,E484,E490,E492,E494",SARS,200
831,7DX4,H,73,75,IGHV1-69,K,['E' 'K'],E,45.41864139020537,The structure of FC08 Fab-hA.CE2-RBD complex,spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.6,0.762763,0.413718,"E346,E348,E351,E352,E353,E354,E355,E356,E357,E359,E396,E449,E450,E452,E457,E462,E463,E464,E465,E466,E467,E468,E469,E470,E471,E472,E481,E482,E483,E484,E490,E492,E494",SARS,200
832,7DX4,L,69,71,IGLV1-40,T,['T' 'A'],A,99.57081545064378,The structure of FC08 Fab-hA.CE2-RBD complex,spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.6,-0.200486,-0.0437785,"E346,E348,E351,E352,E353,E354,E355,E356,E357,E359,E396,E449,E450,E452,E457,E462,E463,E464,E465,E466,E467,E468,E469,E470,E471,E472,E481,E482,E483,E484,E490,E492,E494",SARS,201
833,7LXW,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,SARS-CoV-2 S/S2M11/S2X333 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.8,2.91981,1.58875,"A14,A15,A16,A17,A18,A140,A142,A143,A144,A145,A146,A147,A148,A152,A154,A156,A158,A244,A245,A246,A249,A250,A251",SARS,288
834,7LXW,L,50,49,IGLV3-21,D,['Y' 'D'],Y,66.28242074927954,SARS-CoV-2 S/S2M11/S2X333 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,2.8,0.491486,-0.12458,"A14,A15,A16,A17,A18,A140,A142,A143,A144,A145,A146,A147,A148,A152,A154,A156,A158,A244,A245,A246,A249,A250,A251",SARS,289
835,3DVG,A,30,30,IGKV1-13,S,['I' 'S'],I,100.0,Crystal structure of K63-specific fab Apu.3A8 bound to K63-linked di-ubiquitin,ubiquitin | ubiquitin d77,Y | X,homo sapiens | homo sapiens,2.6,0.400762,0.0190247,"X-1,X1,X18,X19,X20,X21,X22,X25,X55,X57,X58,X59,X60,X61,X62,Y7,Y8,Y9,Y33,Y34,Y35,Y36,Y37,Y39,Y40,Y69,Y71,Y72,Y73,Y74,Y75,Y76",Human,290
836,3DVG,A,32,32,IGKV1-13,A,['S' 'A'],S,100.0,Crystal structure of K63-specific fab Apu.3A8 bound to K63-linked di-ubiquitin,ubiquitin | ubiquitin d77,Y | X,homo sapiens | homo sapiens,2.6,0.44134,0.137873,"X-1,X1,X18,X19,X20,X21,X22,X25,X55,X57,X58,X59,X60,X61,X62,Y7,Y8,Y9,Y33,Y34,Y35,Y36,Y37,Y39,Y40,Y69,Y71,Y72,Y73,Y74,Y75,Y76",Human,290
837,4JB9,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of antibody VRC06 in complex with HIV-1 gp120 core,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.6,3.58795,1.93968,"G94,G97,G123,G124,G198,G199,G257,G275,G276,G278,G279,G280,G281,G282,G283,G354,G365,G366,G367,G368,G370,G371,G375,G425,G426,G427,G429,G430,G431,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G472,G473,G475",HIV,1
838,6YIO,L,50,50,IGKV1-5,K,['D' 'K'],D,83.73655913978494,CRYSTAL STRUCTURE OF FAB RG6292 IN COMPLEX WITH CD25 ECD,interleukin-2 receptor subunit alpha,B,homo sapiens,1.83,-0.391098,0.954714,"B14,B15,B16,B17,B18,B100,B128,B129,B130,B131,B135,B136,B137,B138,B139,B140,B141,B142,B143,B144,B161,B164",Human,291
839,1NL0,H,33,33,IGHV3-30,A,['A' 'G'],G,31.41153081510934,"Crystal structure of human factor IX Gla domain in complex of an inhibitory antibody, 10C12",factor ix,G,,2.2,1.52709,1.06221,"G4,G5,G6,G9,G10,G11,G12,G16",,
840,1NL0,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,"Crystal structure of human factor IX Gla domain in complex of an inhibitory antibody, 10C12",factor ix,G,,2.2,2.74747,-0.0104567,"G4,G5,G6,G9,G10,G11,G12,G16",,
841,7CE2,Z,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,The Crystal structure of TeNT Hc complexed with neutralizing antibody,tetanus toxin,A,clostridium tetani,2.01,3.84571,0.565995,"A1135,A1219,A1220,A1221,A1222,A1223,A1263,A1264,A1270,A1271,A1272,A1282,A1287,A1288,A1289,A1290,A1291,A1292,A1293,A1294,A1295,A1296,A1297,A1298,A1299,A1300",Clostridium tetani,292
842,7CE2,Z,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,The Crystal structure of TeNT Hc complexed with neutralizing antibody,tetanus toxin,A,clostridium tetani,2.01,2.13684,1.21796,"A1135,A1219,A1220,A1221,A1222,A1223,A1263,A1264,A1270,A1271,A1272,A1282,A1287,A1288,A1289,A1290,A1291,A1292,A1293,A1294,A1295,A1296,A1297,A1298,A1299,A1300",Clostridium tetani,292
843,7CE2,Z,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,The Crystal structure of TeNT Hc complexed with neutralizing antibody,tetanus toxin,A,clostridium tetani,2.01,0.561018,0.570219,"A1135,A1219,A1220,A1221,A1222,A1223,A1263,A1264,A1270,A1271,A1272,A1282,A1287,A1288,A1289,A1290,A1291,A1292,A1293,A1294,A1295,A1296,A1297,A1298,A1299,A1300",Clostridium tetani,292
844,7CE2,Z,58,58,IGHV4-59,N,['N' 'Y'],Y,100.0,The Crystal structure of TeNT Hc complexed with neutralizing antibody,tetanus toxin,A,clostridium tetani,2.01,0.428732,-0.515009,"A1135,A1219,A1220,A1221,A1222,A1223,A1263,A1264,A1270,A1271,A1272,A1282,A1287,A1288,A1289,A1290,A1291,A1292,A1293,A1294,A1295,A1296,A1297,A1298,A1299,A1300",Clostridium tetani,292
845,5WB9,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of CD4 binding site antibody N60P23 in complex with HIV-1 clade A/E strain 93TH057 gp120 core,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.4,3.66695,1.5246,"G123,G275,G276,G278,G279,G280,G281,G282,G354,G365,G366,G367,G368,G370,G371,G425,G427,G430,G431,G432,G455,G456,G457,G458,G459,G461,G469,G472,G473,G474",HIV,293
846,3D0L,A,32,32,IGKV1-13,A,['S' 'A'],S,100.0,Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 FP-MPER Hyb3K construct 514GIGALFLGFLGAAGS528KK-Ahx-655KNEQELLELDKWASLWN671,hyb3k peptide construct,C,,2.35,0.26081,0.394657,"C2,C3,C4,C5,C6,C7,C8,C10,C11",,
847,3D0L,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 FP-MPER Hyb3K construct 514GIGALFLGFLGAAGS528KK-Ahx-655KNEQELLELDKWASLWN671,hyb3k peptide construct,C,,2.35,0.164057,0.0413211,"C2,C3,C4,C5,C6,C7,C8,C10,C11",,
848,6YIO,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,CRYSTAL STRUCTURE OF FAB RG6292 IN COMPLEX WITH CD25 ECD,interleukin-2 receptor subunit alpha,B,homo sapiens,1.83,1.12422,1.13498,"B14,B15,B16,B17,B18,B100,B128,B129,B130,B131,B135,B136,B137,B138,B139,B140,B141,B142,B143,B144,B161,B164",Human,223
849,6YIO,H,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,CRYSTAL STRUCTURE OF FAB RG6292 IN COMPLEX WITH CD25 ECD,interleukin-2 receptor subunit alpha,B,homo sapiens,1.83,0.674693,-0.365728,"B14,B15,B16,B17,B18,B100,B128,B129,B130,B131,B135,B136,B137,B138,B139,B140,B141,B142,B143,B144,B161,B164",Human,223
850,6YIO,H,73,74,IGHV1-69,E,['E' 'K'],K,54.58135860979463,CRYSTAL STRUCTURE OF FAB RG6292 IN COMPLEX WITH CD25 ECD,interleukin-2 receptor subunit alpha,B,homo sapiens,1.83,1.12922,0.702996,"B14,B15,B16,B17,B18,B100,B128,B129,B130,B131,B135,B136,B137,B138,B139,B140,B141,B142,B143,B144,B161,B164",Human,223
851,6WFY,H,31,31,IGHV3-49,D,['D' 'Y'],Y,100.0,Crystal structure of Fab224 in complex with NPNA4 peptide from circumsporozoite protein,npna4 peptide,P,plasmodium falciparum,1.226,0.0799693,0.111389,"P1,P2,P3,P4,P5,P6,P7,P8,P9,P10,P11,P12",Malaria,47
852,6WFY,H,33,33,IGHV3-49,A,['A' 'P'],P,100.0,Crystal structure of Fab224 in complex with NPNA4 peptide from circumsporozoite protein,npna4 peptide,P,plasmodium falciparum,1.226,-2.42016,-2.51625,"P1,P2,P3,P4,P5,P6,P7,P8,P9,P10,P11,P12",Malaria,47
853,6WFX,H,31,31,IGHV3-33,S,['S' 'R'],R,99.69788519637464,Crystal structure of Fab395 in complex with NPNA2 peptide from circumsporozoite protein,npna2 peptide,P,plasmodium falciparum,2.59,-0.0284701,-0.131911,"P2,P3,P4,P5,P6",Malaria,294
854,6WFX,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of Fab395 in complex with NPNA2 peptide from circumsporozoite protein,npna2 peptide,P,plasmodium falciparum,2.59,3.7913,2.07917,"P2,P3,P4,P5,P6",Malaria,294
855,7X8W,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab354,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,0,1.09699,1.5636,"A444,A446,A447,A449,A452,A453,A455,A456,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A495,A496,A498",SARS,39
856,5VZY,H,52A,52A,IGHV3-23,S,['G' 'S'],G,1.6016016016016017,Crystal structure of crenezumab Fab in complex with Abeta,amyloid beta,A,homo sapiens,2.32,0.572024,0.363259,"A13,A14,A15,A16,A17,A18,A19,A20,A21,A22,A23,A24",Human,295
857,2B4C,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of HIV-1 JR-FL gp120 core protein containing the third variable region (V3) complexed with CD4 and the X5 antibody,envelope glycoprotein | t-cell surface glycoprotein cd4,G | C,human immunodeficiency virus 1 | homo sapiens,3.3,0.970369,0.27291,"G119,G120,G122,G200,G202,G203,G316,G319,G320,G321,G322,G323,G326,G327,G369,G370,G419,G421,G422,G423,G432,G433,G434,G435,G436,G437,G438,C58",HIV,296
858,2B4C,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Crystal structure of HIV-1 JR-FL gp120 core protein containing the third variable region (V3) complexed with CD4 and the X5 antibody,envelope glycoprotein | t-cell surface glycoprotein cd4,G | C,human immunodeficiency virus 1 | homo sapiens,3.3,-1.01571,-0.679737,"G119,G120,G122,G200,G202,G203,G316,G319,G320,G321,G322,G323,G326,G327,G369,G370,G419,G421,G422,G423,G432,G433,G434,G435,G436,G437,G438,C58",HIV,296
859,8DCE,H,32,190,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,SARS-CoV-2 Receptor-Binding Domain SPEEDesign Immunogen 1 Bound to C144 scFv,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2,1.60538,1.24387,"A417,A449,A450,A452,A453,A455,A456,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494,A495,A496,A498",SARS,297
860,7F7E,C,53,68,IGHV3-23,S,['S' 'G'],G,99.2992992992993,SARS-CoV-2 S protein RBD in complex with A5-10 Fab,spike protein s1,E,severe acute respiratory syndrome coronavirus2,2.49,0.115778,0.0783962,"E343,E345,E346,E439,E440,E441,E442,E443,E444,E445,E448,E450,E451,E499,E500,E509",SARS,298
861,3UJJ,L,50,50,IGLV3-10,E,['E' 'K'],K,100.0,Crystal structure of anti-HIV-1 V3 Fab 4025 in complex with Con A peptide,gp120,P,human immunodeficiency virus 1,2.0,2.49279,-0.5157,"P304,P305,P306,P307,P308,P309,P312,P313,P315,P317,P318,P319,P320",HIV,90
862,6AL5,H,73,74,IGHV1-69,E,['E' 'K'],K,54.58135860979463,COMPLEX BETWEEN CD19 (N138Q MUTANT) AND B43 FAB,b-lymphocyte antigen cd19,A,homo sapiens,3.0,-0.00842498,-0.378788,"A96,A102,A103,A105,A107,A120,A155,A157,A159,A162,A163,A164,A165,A166,A168,A215,A217,A218,A219,A220,A221,A222,A223,A224",Human,299
863,4YDI,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,"Crystal structure of broad and potently neutralizing VRC01-class antibody Z258-VRC27.01, isolated from human donor Z258, in complex with HIV-1 gp120 from clade A strain Q23.17",envelope glycoprotein gp160,G,human immunodeficiency virus 1,3.452,20.0285,1.09838,"G97,G102,G122,G124,G257,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G370,G371,G425,G426,G427,G429,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G469,G472,G473,G474,G475,G476,G480",HIV,1
864,4YDI,H,61,61,IGHV1-2,H,['Q' 'H'],Q,5.456852791878172,"Crystal structure of broad and potently neutralizing VRC01-class antibody Z258-VRC27.01, isolated from human donor Z258, in complex with HIV-1 gp120 from clade A strain Q23.17",envelope glycoprotein gp160,G,human immunodeficiency virus 1,3.452,-0.520052,-0.3019999999999641,"G97,G102,G122,G124,G257,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G370,G371,G425,G426,G427,G429,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G462,G469,G472,G473,G474,G475,G476,G480",HIV,1
865,4YDK,H,55,55,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal structure of broadly and potently neutralizing antibody C38-VRC16.01 in complex with HIV-1 clade AE strain 93TH057 gp120,"envelope glycoprotein gp160,envelope glycoprotein gp160",G,human immunodeficiency virus 1,2.051,8.03642,0.128599,"G105,G122,G123,G124,G198,G199,G257,G275,G279,G280,G281,G282,G283,G364,G365,G366,G367,G368,G369,G370,G371,G375,G425,G426,G427,G428,G429,G431,G432,G455,G456,G457,G458,G459,G460,G463,G467,G469,G470,G471,G472,G473,G474,G475,G477",HIV,300
866,5Y9J,H,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,BAFF in complex with belimumab,tumor necrosis factor ligand superfamily member 13b,A,homo sapiens,2.05,2.30574,1.15517,"A160,A161,A162,A163,A205,A206,A207,A208,A209,A210,A211,A213,A215,A219,A221,A222,A223,A224,A225,A226,A228,A231,A233,A264,A265,A266",Human,301
867,5Y9J,H,56,57,IGHV1-69,T,['T' 'I'],I,86.8878357030016,BAFF in complex with belimumab,tumor necrosis factor ligand superfamily member 13b,A,homo sapiens,2.05,1.41027,0.0275751,"A160,A161,A162,A163,A205,A206,A207,A208,A209,A210,A211,A213,A215,A219,A221,A222,A223,A224,A225,A226,A228,A231,A233,A264,A265,A266",Human,301
868,5IGX,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120,426c.tm1deltav1-3 gp120,G,human immunodeficiency virus 1,3.39,3.41347,0.821927,"G96,G124,G275,G276,G278,G279,G280,G281,G282,G364,G365,G366,G367,G370,G425,G426,G427,G429,G430,G455,G456,G457,G458,G459,G460,G461,G465,G466,G467,G469,G473,G480",HIV,1
869,5IGX,H,61,61,IGHV1-2,Q,['Q' 'H'],H,94.54314720812184,Crystal structure of NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120,426c.tm1deltav1-3 gp120,G,human immunodeficiency virus 1,3.39,0.813161,0.579462,"G96,G124,G275,G276,G278,G279,G280,G281,G282,G364,G365,G366,G367,G370,G425,G426,G427,G429,G430,G455,G456,G457,G458,G459,G460,G461,G465,G466,G467,G469,G473,G480",HIV,1
870,7SK9,F,52,55,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,"Cryo-EM structure of human ACKR3 in complex with a small molecule partial agonist CCX662, and an intracellular Fab",atypical chemokine receptor 3,A,homo sapiens,0,22.1936,-1.00301,"A65,A68,A69,A72,A73,A74,A75,A76,A77,A78,A79,A80,A83,A138,A141,A142,A143,A144,A145,A146,A147,A148,A150,A151,A152,A153,A154,A155,A156,A157,A158,A162,A235,A238,A239,A241,A242,A243,A244,A245,A248,A249,A315,A316,A319,A320,A321,A322",Human,302
871,7SK9,F,53,57,IGHV3-23,S,['S' 'G'],G,99.2992992992993,"Cryo-EM structure of human ACKR3 in complex with a small molecule partial agonist CCX662, and an intracellular Fab",atypical chemokine receptor 3,A,homo sapiens,0,1.11655,0.370723,"A65,A68,A69,A72,A73,A74,A75,A76,A77,A78,A79,A80,A83,A138,A141,A142,A143,A144,A145,A146,A147,A148,A150,A151,A152,A153,A154,A155,A156,A157,A158,A162,A235,A238,A239,A241,A242,A243,A244,A245,A248,A249,A315,A316,A319,A320,A321,A322",Human,302
872,7SK6,F,52,55,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Cryo-EM structure of human ACKR3 in complex with chemokine N-terminal mutant CXCL12_LRHQ and an intracellular Fab,atypical chemokine receptor 3,A,homo sapiens,4.0,18.4297,-0.0974801,"A65,A68,A69,A72,A73,A74,A75,A76,A77,A78,A79,A80,A83,A138,A141,A142,A143,A144,A145,A146,A147,A148,A150,A151,A152,A153,A154,A155,A156,A157,A158,A162,A235,A239,A241,A242,A243,A244,A245,A248,A249,A315,A316,A319,A320,A321,A322,A325",Human,302
873,7SK6,F,53,57,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Cryo-EM structure of human ACKR3 in complex with chemokine N-terminal mutant CXCL12_LRHQ and an intracellular Fab,atypical chemokine receptor 3,A,homo sapiens,4.0,0.00339765,0.312341,"A65,A68,A69,A72,A73,A74,A75,A76,A77,A78,A79,A80,A83,A138,A141,A142,A143,A144,A145,A146,A147,A148,A150,A151,A152,A153,A154,A155,A156,A157,A158,A162,A235,A239,A241,A242,A243,A244,A245,A248,A249,A315,A316,A319,A320,A321,A322,A325",Human,302
874,5KJR,H,33,33,IGHV4-31,G,['G' 'S'],S,100.0,Crystal structure of the ADCC-potent antibody N60-i3 Fab in complex with HIV-1 Clade A/E gp120 W69A/S115W mutant and M48U1.,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.98,15.0419,4.92453,"G50,G51,G52,G53,G54,G60,G68,G71,G72,G73,G74,G75,G76,G77,G78,G79,G103,G106,G107,G114,G115,G217,G219,G220,G221,G246",HIV,31
875,5KJR,L,29,29,IGLV2-14,G,['G' 'S'],S,97.74590163934424,Crystal structure of the ADCC-potent antibody N60-i3 Fab in complex with HIV-1 Clade A/E gp120 W69A/S115W mutant and M48U1.,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.98,12.9716,11.3166,"G50,G51,G52,G53,G54,G60,G68,G71,G72,G73,G74,G75,G76,G77,G78,G79,G103,G106,G107,G114,G115,G217,G219,G220,G221,G246",HIV,32
876,5KJR,L,32,32,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,Crystal structure of the ADCC-potent antibody N60-i3 Fab in complex with HIV-1 Clade A/E gp120 W69A/S115W mutant and M48U1.,clade a/e 93th057 hiv-1 gp120 core,G,human immunodeficiency virus 1,2.98,2.38234,1.62906,"G50,G51,G52,G53,G54,G60,G68,G71,G72,G73,G74,G75,G76,G77,G78,G79,G103,G106,G107,G114,G115,G217,G219,G220,G221,G246",HIV,32
877,6UOE,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,3-25 Fab germline-reversion variant bound to an HCMV gB-derived peptide,envelope glycoprotein b,P,human betaherpesvirus 5,1.8,17.8189,0.790417,"P69,P70,P71,P72,P73,P74,P75,P76,P77,P78",CMV,303
878,6UOE,H,94,94,IGHV3-30,R,['R' 'K'],K,46.91848906560635,3-25 Fab germline-reversion variant bound to an HCMV gB-derived peptide,envelope glycoprotein b,P,human betaherpesvirus 5,1.8,1.14288,0.375099,"P69,P70,P71,P72,P73,P74,P75,P76,P77,P78",CMV,303
879,3MOD,H,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the neutralizing HIV antibody 2F5 Fab fragment (recombinantly produced IgG) with 11 aa gp41 MPER-derived peptide,gp41 mper-derived peptide,P,homo sapiens,2.2,0.562883,0.396638,"P661,P662,P663,P664,P665,P666,P667,P669",Human,304
880,3MOA,H,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the neutralizing HIV antibody 2F5 Fab fragment (recombinantly produced Fab) with 17 aa gp41 MPER-derived peptide,gp41 mper-derived peptide,P,,2.3,0.532567,0.394659,"P659,P661,P662,P663,P664,P665,P666,P667,P669",,
881,3MOB,H,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the neutralizing HIV antibody 2F5 Fab fragment (recombinantly produced Fab) with 11 aa gp41 MPER-derived peptide,gp41 mper-derived peptide,P,,2.6,0.532468,0.314454,"P661,P662,P663,P664,P665,P666,P667,P669",,
882,4LSU,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC-PG20 in complex with HIV-1 clade A/E 93TH057 gp120,hiv-1 clade a/e strain 93th057 gp120,G,human immunodeficiency virus 1,2.3,3.99736,1.72677,"G97,G122,G123,G124,G255,G257,G275,G276,G278,G279,G280,G281,G282,G365,G366,G367,G368,G370,G371,G375,G425,G426,G427,G430,G431,G432,G455,G456,G457,G458,G459,G460,G461,G463,G465,G466,G467,G469,G470,G471,G472,G473,G474,G475",HIV,1
883,4LSV,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody 3BNC117 in complex with HIV-1 clade C C1086 gp120,envelope glycoprotein gp120,G,human immunodeficiency virus 1,3.0,3.0194,1.79548,"G97,G123,G124,G198,G275,G276,G278,G279,G280,G281,G282,G283,G352,G353,G354,G357,G360,G362,G364,G365,G366,G367,G368,G371,G428,G430,G431,G455,G456,G457,G458,G459,G460,G463,G465,G466,G467,G469,G470,G471,G472,G473,G474,G476",HIV,1
884,4LSQ,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC-CH31 in complex with HIV-1 clade A/E gp120 93TH057 with LOOP D and Loop V5 from clade A strain 3415_v1_c1,envelope glycoprotein gp120 with loop d and v5 from strain3415_v1_c1,G,human immunodeficiency virus 1,2.25,3.92627,2.80017,"G97,G276,G278,G279,G280,G281,G282,G353,G354,G357,G365,G366,G367,G368,G371,G429,G432,G455,G456,G457,G458,G459,G460,G461,G463,G466,G467,G472,G473,G476",HIV,1
885,4LSP,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC-CH31 in complex with HIV-1 clade A/E gp120 93TH057,hiv-1 clade a/e strain 93th057 gp120,G,human immunodeficiency virus 1,2.15,4.86214,2.83016,"G275,G276,G278,G279,G280,G281,G282,G353,G354,G357,G365,G366,G367,G368,G371,G429,G432,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G473,G474,G476",HIV,1
886,4LSR,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC-CH31 in complex with HIV-1 clade A/E stran 93TH057 gp120 with LOOP D and Loop V5 from clade A strain KER_2018_11,envelope glycoprotein gp120 with loop d and v5 from strainker_2018_11,G,human immunodeficiency virus 1,2.28,5.63844,2.47834,"G97,G276,G278,G279,G280,G281,G282,G352,G353,G354,G357,G365,G366,G367,G368,G371,G429,G430,G432,G455,G456,G457,G458,G459,G460,G461,G463,G464,G465,G466,G469,G475,G476,G477,G479,G483",HIV,1
887,7DAA,L,50,51,IGKV1-5,D,['D' 'K'],K,16.263440860215052,Crystal structure of basigin complexed with anti-basigin Fab fragment,isoform 2 of basigin,A,homo sapiens,2.51,3.72476,0.305151,"A110,A111,A114,A115,A116,A120,A121,A122,A123,A124,A125,A127,A128,A135,A159,A160,A161,A162,A163,A164,A165,A166,A168,A170,A172",Human,305
888,7CDJ,H,54,55,IGHV3-11,G,['G' 'S'],S,56.45161290322581,Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD,spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.396,4.31002,2.98087,"E445,E446,E449,E452,E455,E456,E472,E476,E478,E479,E480,E481,E482,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E500,E501",SARS,306
889,7CDJ,H,56,57,IGHV3-11,T,['T' 'Y'],Y,56.45161290322581,Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD,spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.396,-0.743955,-0.82853,"E445,E446,E449,E452,E455,E456,E472,E476,E478,E479,E480,E481,E482,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E500,E501",SARS,306
890,7CDJ,H,58,59,IGHV3-11,Y,['Y' 'N'],N,56.45161290322581,Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD,spike protein s1,E,severe acute respiratory syndrome coronavirus2,3.396,0.510412,0.554506,"E445,E446,E449,E452,E455,E456,E472,E476,E478,E479,E480,E481,E482,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E500,E501",SARS,306
891,7CDI,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD,spike protein s1,E,severe acute respiratory syndrome coronavirus2,2.96,0.282454,-0.108086,"E403,E405,E406,E408,E415,E416,E417,E420,E421,E449,E453,E455,E456,E457,E458,E459,E460,E473,E474,E475,E476,E477,E484,E486,E487,E489,E490,E493,E494,E496,E500,E502,E505",SARS,9
892,7MZL,H,26,26,IGHV4-34,G,['G' 'F'],F,100.0,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,1.96691,1.94267,"A403,A421,A446,A449,A452,A453,A455,A456,A457,A458,A473,A475,A476,A477,A478,A484,A485,A486,A487,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,307
893,7MZL,H,28,28,IGHV4-34,T,['S' 'T' 'G'],S,0.5555555555555556,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,-0.522426,-0.0205629,"A403,A421,A446,A449,A452,A453,A455,A456,A457,A458,A473,A475,A476,A477,A478,A484,A485,A486,A487,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,307
894,7MZL,H,28,28,IGHV4-34,T,['S' 'T' 'G'],G,0.5555555555555556,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,-0.0769746,0.0553779,"A403,A421,A446,A449,A452,A453,A455,A456,A457,A458,A473,A475,A476,A477,A478,A484,A485,A486,A487,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,307
895,7MZL,H,30,30,IGHV4-34,S,['S' 'Y'],Y,100.0,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,4.20707,-0.612544,"A403,A421,A446,A449,A452,A453,A455,A456,A457,A458,A473,A475,A476,A477,A478,A484,A485,A486,A487,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,307
896,7MZL,H,31,31,IGHV4-34,G,['G' 'W'],W,100.0,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,1.71484,1.01018,"A403,A421,A446,A449,A452,A453,A455,A456,A457,A458,A473,A475,A476,A477,A478,A484,A485,A486,A487,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,307
897,7MZL,H,32,32,IGHV4-34,Y,['Y' 'S'],S,100.0,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,3.21886,2.98322,"A403,A421,A446,A449,A452,A453,A455,A456,A457,A458,A473,A475,A476,A477,A478,A484,A485,A486,A487,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,307
898,7MZL,H,50,50,IGHV4-34,E,['E' 'Y'],Y,100.0,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.7,7.01802,0.751723,"A403,A421,A446,A449,A452,A453,A455,A456,A457,A458,A473,A475,A476,A477,A478,A484,A485,A486,A487,A489,A490,A492,A493,A494,A495,A496,A498,A501,A505",SARS,307
899,7MZM,H,54,55,IGHV3-11,S,['G' 'S'],G,43.54838709677419,SARS-CoV-2 receptor binding domain bound to Fab PDI 215,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.3,-3.15688,-1.83081,"A340,A341,A344,A345,A346,A347,A348,A349,A351,A352,A354,A355,A356,A357,A359,A399,A444,A447,A448,A449,A450,A452,A466,A468,A469,A470,A471,A472,A484,A490,A492,A494",SARS,308
900,7MZM,H,57,58,IGHV3-11,T,['I' 'T'],I,43.54838709677419,SARS-CoV-2 receptor binding domain bound to Fab PDI 215,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.3,-1.57302,-1.03434,"A340,A341,A344,A345,A346,A347,A348,A349,A351,A352,A354,A355,A356,A357,A359,A399,A444,A447,A448,A449,A450,A452,A466,A468,A469,A470,A471,A472,A484,A490,A492,A494",SARS,308
901,7MZM,H,58,59,IGHV3-11,N,['Y' 'N'],Y,43.54838709677419,SARS-CoV-2 receptor binding domain bound to Fab PDI 215,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.3,-0.688984,0.0129914,"A340,A341,A344,A345,A346,A347,A348,A349,A351,A352,A354,A355,A356,A357,A359,A399,A444,A447,A448,A449,A450,A452,A466,A468,A469,A470,A471,A472,A484,A490,A492,A494",SARS,308
902,4NZR,H,1,1,IGHV4-39,Q,['Q' 'R'],R,99.61832061068702,Crystal structure of the antibody-binding region of Protein M (Protein M TD) in complex with anti-HIV antibody PGT135 Fab,protein m td,M,mycoplasma genitalium,1.65,0.91636,-0.237529,"M95,M99,M102,M103,M105,M106,M107,M109,M110,M114,M116,M117,M118,M119,M144,M158,M160,M161,M162,M163,M177,M178,M179,M180,M181,M186,M187,M188,M191,M321,M338,M340,M341,M345,M384,M388,M389,M390,M391,M392,M393,M394,M396,M397,M426,M427,M429,M431,M436,M438,M439,M440,M441,M442,M444,M445,M446,M447,M449,M452,M453,M456,M457,M462,M466",Mycoplasma genitalium,309
903,4NZR,H,26,26,IGHV4-39,G,['G' 'S'],S,100.0,Crystal structure of the antibody-binding region of Protein M (Protein M TD) in complex with anti-HIV antibody PGT135 Fab,protein m td,M,mycoplasma genitalium,1.65,5.3636,5.92761,"M95,M99,M102,M103,M105,M106,M107,M109,M110,M114,M116,M117,M118,M119,M144,M158,M160,M161,M162,M163,M177,M178,M179,M180,M181,M186,M187,M188,M191,M321,M338,M340,M341,M345,M384,M388,M389,M390,M391,M392,M393,M394,M396,M397,M426,M427,M429,M431,M436,M438,M439,M440,M441,M442,M444,M445,M446,M447,M449,M452,M453,M456,M457,M462,M466",Mycoplasma genitalium,309
904,4NZT,L,43,43,IGLV1-44,A,['A' 'G'],G,100.0,Crystal structure of the antibody-binding region of Protein M (Protein M TD) in complex with anti-infleunza hemagglutinin antibody CR9114 Fab,protein m td,M,mycoplasma genitalium,2.497,1.03253,0.952098,"M95,M96,M99,M102,M103,M106,M107,M109,M110,M114,M118,M119,M144,M158,M160,M161,M162,M163,M177,M178,M179,M180,M181,M187,M188,M191,M192,M193,M247,M269,M319,M321,M338,M340,M341,M347,M384,M388,M389,M390,M391,M392,M393,M394,M395,M396,M426,M427,M429,M438,M439,M440,M441,M442,M444,M445,M447,M449,M452,M453",Mycoplasma genitalium,310
905,4NZT,L,59,59,IGLV1-44,P,['P' 'L'],L,100.0,Crystal structure of the antibody-binding region of Protein M (Protein M TD) in complex with anti-infleunza hemagglutinin antibody CR9114 Fab,protein m td,M,mycoplasma genitalium,2.497,4.69187,1.85392,"M95,M96,M99,M102,M103,M106,M107,M109,M110,M114,M118,M119,M144,M158,M160,M161,M162,M163,M177,M178,M179,M180,M181,M187,M188,M191,M192,M193,M247,M269,M319,M321,M338,M340,M341,M347,M384,M388,M389,M390,M391,M392,M393,M394,M395,M396,M426,M427,M429,M438,M439,M440,M441,M442,M444,M445,M447,M449,M452,M453",Mycoplasma genitalium,310
906,3DRO,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Antibody 2F5 in complex with gp41 Peptide ELLELDKWASLWN grown in ammonium sulfate,elleldkwaslwn gp41 peptide,P,,3.9,-0.0929093,-0.0516229,"P2,P3,P4,P5,P6,P7,P8",,
907,3DRQ,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 FP-MPER Hyb3K construct 514GIGALFLGFLGAAGS528KK-Ahx-655KNEQELLELDKWASLWN671 soaked in PEG/2-propanol solution,gp41 peptide epitope,C,,2.0,0.0435232,-0.00226922,"C2,C3,C4,C5,C6,C7,C8",,
908,3DRT,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 broadly neutralizing antibody 2F5 in complex with the gp41 scrambledFP-MPER scrHyb3K construct GIGAFGLLGFLAAGSKK-Ahx-K656NEQELLELDKWASLWN671,scrhyb3k construct,C,,3.3,0.557092,0.524826,"C3,C4,C5,C6,C7,C8",,
909,7WE8,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265,spike glycoprotein | spike glycoprotein | spike glycoprotein,A | C | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.5,0.155258,-0.17765,"A342,A343,A436,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A495,A496,A497,A498,A503,A506,B412,B414,B418,B453,B456,B457,B470,B472,B473,B474,C437,C442",SARS,311
910,7WE8,L,29,32,IGLV2-14,G,['G' 'S'],S,97.74590163934424,SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265,spike glycoprotein | spike glycoprotein | spike glycoprotein,A | C | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.5,0.255379,-0.026884,"A342,A343,A436,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A495,A496,A497,A498,A503,A506,B412,B414,B418,B453,B456,B457,B470,B472,B473,B474,C437,C442",SARS,312
911,7WE8,L,32,35,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265,spike glycoprotein | spike glycoprotein | spike glycoprotein,A | C | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.5,1.07179,-0.144611,"A342,A343,A436,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A495,A496,A497,A498,A503,A506,B412,B414,B418,B453,B456,B457,B470,B472,B473,B474,C437,C442",SARS,312
912,7WE8,L,50,53,IGLV2-14,E,['E' 'D'],D,56.55737704918033,SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265,spike glycoprotein | spike glycoprotein | spike glycoprotein,A | C | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.5,0.327932,-0.0158072,"A342,A343,A436,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A495,A496,A497,A498,A503,A506,B412,B414,B418,B453,B456,B457,B470,B472,B473,B474,C437,C442",SARS,312
913,7WE8,L,60,63,IGLV2-14,N,['N' 'D'],D,100.0,SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265,spike glycoprotein | spike glycoprotein | spike glycoprotein,A | C | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,3.5,-0.0652082,-0.366483,"A342,A343,A436,A437,A438,A439,A440,A441,A442,A443,A444,A445,A446,A447,A495,A496,A497,A498,A503,A506,B412,B414,B418,B453,B456,B457,B470,B472,B473,B474,C437,C442",SARS,312
914,6XY2,H,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,Crystal structure of CTLA-4 complexed with the Fab of HL32 antibody,cytotoxic t-lymphocyte protein 4,A,homo sapiens,3.05,3.54187,3.27615,"A3,A4,A26,A27,A28,A29,A30,A100,A101,A102,A103,A104,A105,A106,A107,A108",Human,313
915,6XY2,H,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal structure of CTLA-4 complexed with the Fab of HL32 antibody,cytotoxic t-lymphocyte protein 4,A,homo sapiens,3.05,1.27653,1.35474,"A3,A4,A26,A27,A28,A29,A30,A100,A101,A102,A103,A104,A105,A106,A107,A108",Human,313
916,6XY2,H,58,58,IGHV4-59,N,['N' 'Y'],Y,100.0,Crystal structure of CTLA-4 complexed with the Fab of HL32 antibody,cytotoxic t-lymphocyte protein 4,A,homo sapiens,3.05,0.392339,0.454657,"A3,A4,A26,A27,A28,A29,A30,A100,A101,A102,A103,A104,A105,A106,A107,A108",Human,313
917,7WEE,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv265,spike glycoprotein,E,severe acute respiratory syndrome coronavirus2,4,0.197804,-0.21844,"E345,E346,E439,E440,E441,E442,E443,E444,E445,E446,E447,E448,E449,E450,E451,E498,E499,E500,E509",SARS,79
918,7WEE,L,32,35,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv265,spike glycoprotein,E,severe acute respiratory syndrome coronavirus2,4,0.322704,0.0732736,"E345,E346,E439,E440,E441,E442,E443,E444,E445,E446,E447,E448,E449,E450,E451,E498,E499,E500,E509",SARS,84
919,5IES,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of VRC01c-HuGL2 Fab from an HIV-1 naive donor in complex with with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.16 A,germline-targeting hiv-1 gp120 engineered outer domain eod-gt8,C,homo sapiens,2.16,4.85076,2.05063,"C25,C26,C27,C28,C29,C30,C35,C36,C37,C39,C42,C43,C44,C45,C47,C79,C81,C82,C83,C84,C85,C127,C135,C138,C139,C140,C141,C144",Human,30
920,5IES,H,61,61,IGHV1-2,Q,['Q' 'H'],H,94.54314720812184,Crystal structure of VRC01c-HuGL2 Fab from an HIV-1 naive donor in complex with with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.16 A,germline-targeting hiv-1 gp120 engineered outer domain eod-gt8,C,homo sapiens,2.16,0.371131,0.0657966,"C25,C26,C27,C28,C29,C30,C35,C36,C37,C39,C42,C43,C44,C45,C47,C79,C81,C82,C83,C84,C85,C127,C135,C138,C139,C140,C141,C144",Human,30
921,4EDW,H,32,32,IGHV4-4,Y,['S' 'W' 'Y'],S,28.03030303030303,Nerve Growth Factor in Complex with Fab from humanized version of mouse mAb 911 (tanezumab),beta-nerve growth factor,V,homo sapiens,2.48,-0.176639,-0.762419,"V8,V9,V10,V11,V12,V13,V15,V17,V18,V19,V20,V21,V23,V24,V49,V50,V52,V54,V56,V59,V106,V107,V108,V109",Human,314
922,4EDW,H,32,32,IGHV4-4,Y,['S' 'W' 'Y'],W,28.03030303030303,Nerve Growth Factor in Complex with Fab from humanized version of mouse mAb 911 (tanezumab),beta-nerve growth factor,V,homo sapiens,2.48,-0.539689,-0.324126,"V8,V9,V10,V11,V12,V13,V15,V17,V18,V19,V20,V21,V23,V24,V49,V50,V52,V54,V56,V59,V106,V107,V108,V109",Human,314
923,7KTX,I,25,27,IGHV4-34,Y,['Y' 'S'],S,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,1.00174,0.25807,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
924,7KTX,I,26,28,IGHV4-34,G,['G' 'F'],F,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,2.70152,3.14704,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
925,7KTX,I,27,29,IGHV4-34,G,['G' 'S'],S,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,2.98858,0.662471,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
926,7KTX,I,28,30,IGHV4-34,S,['S' 'T' 'G'],T,99.44444444444446,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,1.28577,1.49166,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
927,7KTX,I,28,30,IGHV4-34,S,['S' 'T' 'G'],G,99.44444444444446,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,-1.4198,-0.746379,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
928,7KTX,I,29,31,IGHV4-34,F,['F' 'V' 'Y'],V,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,3.97982,4.02132,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
929,7KTX,I,29,31,IGHV4-34,F,['F' 'V' 'Y'],Y,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,0.621263,0.874545,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
930,7KTX,I,30,32,IGHV4-34,S,['S' 'Y'],Y,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,-1.5963,-1.09089,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
931,7KTX,I,31,33,IGHV4-34,G,['G' 'W'],W,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,3.17079,2.66829,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
932,7KTX,I,32,34,IGHV4-34,Y,['Y' 'S'],S,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,0.202034,0.277882,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
933,7KTX,I,52,54,IGHV4-34,N,['N' 'Y' 'I'],Y,98.8888888888889,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,3.70258,-0.272813,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
934,7KTX,I,52,54,IGHV4-34,N,['N' 'Y' 'I'],I,98.8888888888889,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,3.64482,3.81921,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
935,7KTX,I,53,55,IGHV4-34,H,['H' 'Y'],Y,100.0,Cryo-EM structure of Saccharomyces cerevisiae ER membrane protein complex bound to a Fab in DDM detergent,er membrane protein complex subunit 1,A,saccharomyces cerevisiae by4743,4.3,-1.99769,-0.48500000000001364,"A42,A43,A44,A45,A62,A64,A88,A89,A90,A135,A136,A137,A138,A139,A140,A141,A142,A143,A144,A146,A147,A148,A149,A151,A156,A158,A161,A169,A171,A172,A173,A174,A175,A190,A192,A193,A196,A308,A309,A310,A327,A328,A329,A331,A332,A351,A352,A378",Yeast,16
936,7MZF,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,SARS-CoV-2 receptor binding domain bound to Fab PDI 37,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.493,0.500133,-0.224618,"A403,A405,A408,A409,A415,A416,A417,A420,A421,A453,A455,A456,A457,A458,A459,A460,A473,A474,A475,A476,A477,A478,A486,A487,A489,A493,A494,A495,A496,A498,A499,A500,A501,A502,A505",SARS,9
937,7MZG,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,SARS-CoV-2 receptor binding domain bound to Fab PDI 42,spike protein s1,A,severe acute respiratory syndrome coronavirus2,2.0,3.14533,-0.354386,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A453,A455,A456,A457,A458,A459,A460,A473,A474,A475,A476,A477,A484,A486,A487,A489,A493,A495,A496,A497,A498,A500,A501,A502,A505",SARS,9
938,7MZI,H,50,50,IGHV3-23,A,['A' 'V'],V,99.2992992992993,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129,spike protein s1,A,severe acute respiratory syndrome coronavirus2,1.85,7.73654,0.486273,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A453,A455,A456,A457,A458,A459,A473,A475,A476,A477,A478,A485,A486,A487,A489,A490,A492,A493,A505",SARS,315
939,7MZI,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129,spike protein s1,A,severe acute respiratory syndrome coronavirus2,1.85,-0.111052,0.254516,"A403,A405,A406,A408,A409,A415,A416,A417,A420,A421,A453,A455,A456,A457,A458,A459,A473,A475,A476,A477,A478,A485,A486,A487,A489,A490,A492,A493,A505",SARS,315
940,7SIX,H,73,75,IGHV4-31,T,['T' 'K' 'P'],K,99.4818652849741,Antibody N3-1 bound to RBDs in the up and down conformations,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,-0.85107,-0.665394,"A368,A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A406,A408,A409,A412,A413,A414,A415,A416,A420,A427,A428,A429,A430,A460,A505,B446,B447,B449,B453,B455,B456,B477,B478,B479,B480,B483,B484,B485,B486,B487,B489,B490,B493,B498,B500,B501,B505",SARS,316
941,7SIX,H,73,75,IGHV4-31,T,['T' 'K' 'P'],P,99.4818652849741,Antibody N3-1 bound to RBDs in the up and down conformations,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,0,-1.32091,-1.17725,"A368,A369,A370,A371,A372,A374,A377,A378,A379,A380,A381,A382,A383,A384,A385,A405,A406,A408,A409,A412,A413,A414,A415,A416,A420,A427,A428,A429,A430,A460,A505,B446,B447,B449,B453,B455,B456,B477,B478,B479,B480,B483,B484,B485,B486,B487,B489,B490,B493,B498,B500,B501,B505",SARS,316
942,3LEV,H,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,HIV-1 antibody 2F5 in complex with epitope scaffold ES2,rna polymerase sigma factor,A,thermus aquaticus,2.5,1.00208,0.0632804,"A105,A107,A108,A109,A110,A111,A112,A113,A114,A115,A116,A206,A208,A244,A245,A249,A251",Thermus aquaticus,317
943,6PDU,L,27D,30A,IGKV2-30,H,['Y' 'H'],Y,39.33518005540167,Vaccine-elicited NHP FP-targeting antibody 13N024-a.01 in complex with HIV fusion peptide (residue 512-519),hiv-1 fusion peptide residue 512-519,C,human immunodeficiency virus 1,1.953,49.4869,-0.614833,"C512,C513,C514,C515,C516,C517,C518,C519",HIV,318
944,4JDT,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 of 93TH057 HIV-1,gp120,G,human immunodeficiency virus 1,3.26,7.15661,2.33651,"G124,G276,G278,G279,G280,G281,G282,G283,G354,G357,G365,G366,G367,G368,G371,G430,G455,G456,G457,G458,G459,G460,G461,G464,G465,G466,G467,G469,G473,G474",HIV,1
945,4JDT,H,61,61,IGHV1-2,Q,['Q' 'H'],H,94.54314720812184,Crystal structure of chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 of 93TH057 HIV-1,gp120,G,human immunodeficiency virus 1,3.26,0.302825,0.955506,"G124,G276,G278,G279,G280,G281,G282,G283,G354,G357,G365,G366,G367,G368,G371,G430,G455,G456,G457,G458,G459,G460,G461,G464,G465,G466,G467,G469,G473,G474",HIV,1
946,4JDT,H,69,69,IGHV1-2,M,['S' 'M'],S,99.87309644670052,Crystal structure of chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 of 93TH057 HIV-1,gp120,G,human immunodeficiency virus 1,3.26,4.41107,4.24209,"G124,G276,G278,G279,G280,G281,G282,G283,G354,G357,G365,G366,G367,G368,G371,G430,G455,G456,G457,G458,G459,G460,G461,G464,G465,G466,G467,G469,G473,G474",HIV,1
947,1RZK,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B,envelope glycoprotein gp120,G,human immunodeficiency virus 1,2.9,1.89324,-0.492865,"G119,G120,G122,G200,G202,G203,G204,G205,G419,G420,G421,G422,G423,G432,G433,G434,G437",HIV,177
948,1RZJ,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B,envelope glycoprotein gp120,G,human immunodeficiency virus 1,2.2,-0.829418,-0.320958,"G119,G120,G122,G200,G202,G203,G204,G205,G369,G419,G420,G421,G422,G423,G432,G434,G435,G437",HIV,177
949,2XRA,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,crystal structure of the HK20 Fab in complex with a gp41 mimetic 5- Helix,transmembrane protein gp41,A,synthetic construct,2.3,0.10819,-0.429905,"A561,A564,A565,A567,A568,A569,A570,A571,A572,A574,A575,A576,A578,A579,A582,A1629,A1632,A1635,A1636,A1639,A1643,A4563,A4567,A4570,A4573,A4574,A4577",Synthetic,319
950,2XRA,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,crystal structure of the HK20 Fab in complex with a gp41 mimetic 5- Helix,transmembrane protein gp41,A,synthetic construct,2.3,1.94075,0.269497,"A561,A564,A565,A567,A568,A569,A570,A571,A572,A574,A575,A576,A578,A579,A582,A1629,A1632,A1635,A1636,A1639,A1643,A4563,A4567,A4570,A4573,A4574,A4577",Synthetic,319
951,2XRA,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,crystal structure of the HK20 Fab in complex with a gp41 mimetic 5- Helix,transmembrane protein gp41,A,synthetic construct,2.3,2.76105,1.26853,"A561,A564,A565,A567,A568,A569,A570,A571,A572,A574,A575,A576,A578,A579,A582,A1629,A1632,A1635,A1636,A1639,A1643,A4563,A4567,A4570,A4573,A4574,A4577",Synthetic,319
952,4FQJ,L,50,50,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Influenza B/Florida/4/2006 hemagglutinin Fab CR8071 complex,hemagglutinin,A,influenza b virus,2.5,-0.230803,1.52284,"A35,A36,A37,A38,A39,A40,A41,A52,A58,A59,A60,A61,A62,A85,A86,A90,A92,A282,A283,A284,A285,A287,A296",influenza,320
953,7CHZ,H,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Crystal Structure Of Human Il-1beta In Complex With Antibody Binding Fragment Of IgG26A,interleukin-1 beta,I,homo sapiens,2.5,3.14137,3.12003,"I130,I131,I132,I133,I136,I144,I146,I147,I148,I149,I152,I155,I243,I244,I245,I246,I247,I248,I257,I258,I259,I260",Human,321
954,6Q0L,H,26,26,IGHV4-4,G,['G' 'S'],S,100.0,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,3.14586,3.12217,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
955,6Q0L,H,27,27,IGHV4-4,G,['G' 'I'],I,100.0,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,2.47137,3.57066,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
956,6Q0L,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,2.11095,-0.452142,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
957,6Q0L,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],W,71.96969696969697,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,30.0623,-0.282829,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
958,6Q0L,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],Y,71.96969696969697,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,35.3677,0.542482,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
959,6Q0L,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],W,71.96969696969697,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,6.41722,2.14472,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
960,6Q0L,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],Y,71.96969696969697,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,2.8796,1.23705,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
961,6Q0L,H,34,34,IGHV4-4,W,['W' 'S'],S,100.0,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,3.48796,3.42404,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
962,6Q0L,H,53,54,IGHV4-4,H,['H' 'T'],T,71.96969696969697,Inferred intermediate I-7 (I-7-1) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.5,0.09899999999998954,0.214647,"A95,A131,A133,A134,A135,A136,A137,A143,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
963,4N0Y,H,51,51,IGHV1-3,I,['I' 'S'],S,100.0,Structure of the Hepatitis C Envelope Glycoprotein E1 antigenic region 314-324 bound to the cross-neutralizing antibody IGH526,hcv e1 peptide,A,hepatitis c virus,1.749,4.05792,4.1639,"A314,A315,A316,A317,A319,A320,A322,A323,A324",HCV,322
964,6W7S,H,26,28,IGHV3-30,G,['G' 'A'],A,100.0,Ketoreductase from module 1 of the 6-deoxyerythronolide B synthase (KR1) in complex with antibody fragment (Fab) 2G10,eryai,A,saccharopolyspora erythraea,2.25,5.52471,4.75133,"A1460,A1461,A1580,A1581,A1649,A1828,A1829,A1830,A1831,A1909,A1911",Saccharopolyspora erythraea,323
965,5TFW,H,50,50,IGHV3-15,R,['R' 'C'],C,100.0,"Crystal structure of 10E8 Fab light chain mutant2 against the MPER region of the HIV-1 Env, in complex with T117v2 epitope scaffold",10e8 epitope scaffold t117v2,O,synthetic construct,2.168,2.06637,2.33127,"O64,O65,O66,O73,O77,O78,O79,O118,O119,O120,O121,O124,O125,O127,O128,O130,O131,O134,O135",Synthetic,38
966,1U95,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELDHWAS,gp41 peptide,C,human immunodeficiency virus 1,2.24,-0.988388,0.167288,"C1,C2,C3,C4,C5,C6",HIV,139
967,1U91,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide Analog ENDKW-[Dap]-S (cyclic),gp41 peptide analog,C,human immunodeficiency virus 1,2.24,0.335568,0.17805,"C1,C2,C3,C4,C5,C6",HIV,139
968,1U93,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide Analog EQDKW-[Dap]-S (cyclic),gp41 peptide analog,C,human immunodeficiency virus 1,2.37,0.491714,0.177745,"C1,C2,C3,C4,C5,C6",HIV,139
969,1U92,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide Analog E-[Dap]-DKWQS (cyclic),gp41 peptide analog,C,human immunodeficiency virus 1,2.24,0.742659,0.233008,"C1,C2,C3,C4,C5,C6",HIV,139
970,4G6J,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of human IL-1beta in complex with the therapeutic antibody binding fragment of canakinumab,interleukin-1 beta,A,homo sapiens,2.03,4.5501,2.57278,"A19,A20,A21,A22,A23,A24,A25,A27,A29,A30,A31,A34,A35,A37,A38,A39,A40,A41,A63,A64,A65,A66,A84,A86,A87,A88,A129",Human,68
971,4G6J,H,94,98,IGHV3-33,R,['R' 'K'],K,92.14501510574016,Crystal structure of human IL-1beta in complex with the therapeutic antibody binding fragment of canakinumab,interleukin-1 beta,A,homo sapiens,2.03,1.00243,0.0284289,"A19,A20,A21,A22,A23,A24,A25,A27,A29,A30,A31,A34,A35,A37,A38,A39,A40,A41,A63,A64,A65,A66,A84,A86,A87,A88,A129",Human,68
972,4G6M,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal strucure of human IL-1beta in complex with therapeutic antibody binding fragment of gevokizumab,interleukin-1 beta,A,homo sapiens,1.81,1.01508,-0.154191,"A24,A48,A49,A72,A73,A74,A75,A76,A81,A83,A84,A85,A86,A89,A90,A92,A94,A95,A96,A97,A98,A100,A115,A116,A117,A118",Human,324
973,7SOD,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.2,5.42571,4.80808,"A23,A24,A25,A26,A28,A61,A63,A65,A82,A83,A84,A85,A87,A88,A108,A109,A110,A111,A113,A114,A134,A137,A234,A236,A237,A269,A270,A271,A272",SARS,25
974,7SOD,H,33,33,IGHV3-30,G,['A' 'G'],A,68.58846918489066,SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.2,1.54588,1.59732,"A23,A24,A25,A26,A28,A61,A63,A65,A82,A83,A84,A85,A87,A88,A108,A109,A110,A111,A113,A114,A134,A137,A234,A236,A237,A269,A270,A271,A272",SARS,25
975,7SOD,H,52,52,IGHV3-30,R,['S' 'R'],S,8.548707753479125,SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.2,1.00751,0.865005,"A23,A24,A25,A26,A28,A61,A63,A65,A82,A83,A84,A85,A87,A88,A108,A109,A110,A111,A113,A114,A134,A137,A234,A236,A237,A269,A270,A271,A272",SARS,25
976,7SO5,H,30,30,IGHV4-34,S,['S' 'Y'],Y,100.0,Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B,toxin b,A,clostridioides difficile r20291,1.797,-2.51204,-1.02083,"A6,A14,A17,A18,A19,A20,A21,A22,A23,A25,A26,A29,A32,A33,A55,A58,A61,A62,A63",Clostridioides difficile,325
977,7SO5,H,52,52,IGHV4-34,N,['N' 'Y' 'I'],Y,98.8888888888889,Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B,toxin b,A,clostridioides difficile r20291,1.797,1.46747,-1.84834,"A6,A14,A17,A18,A19,A20,A21,A22,A23,A25,A26,A29,A32,A33,A55,A58,A61,A62,A63",Clostridioides difficile,325
978,7SO5,H,52,52,IGHV4-34,N,['N' 'Y' 'I'],I,98.8888888888889,Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B,toxin b,A,clostridioides difficile r20291,1.797,1.25883,0.281953,"A6,A14,A17,A18,A19,A20,A21,A22,A23,A25,A26,A29,A32,A33,A55,A58,A61,A62,A63",Clostridioides difficile,325
979,7SO5,H,53,53,IGHV4-34,Y,['H' 'Y'],H,0.0,Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B,toxin b,A,clostridioides difficile r20291,1.797,2.10215,0.937942,"A6,A14,A17,A18,A19,A20,A21,A22,A23,A25,A26,A29,A32,A33,A55,A58,A61,A62,A63",Clostridioides difficile,325
980,4RQS,D,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of fully glycosylated HIV-1 gp120 core bound to CD4 and 17b Fab,hiv-1 yu2 gp120 core chimeric protein,G,homo sapiens,4.493,0.0270145,-0.450219,"G119,G120,G122,G200,G202,G203,G204,G205,G419,G420,G421,G422,G423,G434,G435,G436,G437",Human,326
981,4DGY,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,"Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the broadly neutralizing antibody HCV1, C2 form",e2 peptide,A,hepatitis c virus,1.798,4.82864,2.47673,"A412,A413,A414,A415,A418,A419,A420,A421,A422",HCV,327
982,4DGV,H,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,"Structure of the Hepatitis C virus envelope glycoprotein E2 antigenic region 412-423 bound to the broadly neutralizing antibody HCV1, P2(1) form",e2 peptide,A,hepatitis c virus,1.805,4.19263,2.81693,"A1,A412,A413,A414,A415,A417,A418,A419,A420,A421,A422",HCV,327
983,6R2S,A,50,69,IGKV1-5,K,['D' 'K'],D,83.73655913978494,The structure of Plasmodium vivax Duffy binding protein (PvDBP) bound to human antibody DB9,duffy receptor,C,plasmodium vivax (strain salvador i),3.04,1.72797,1.44306,"C404,C408,C412,C416,C418,C421,C424,C472,C475,C476,C479,C484,C486,C487,C488,C489,C491,C492,C493,C495,C497,C498,C499,C500,C502,C503,C504",Malaria,328
984,6R2S,B,26,45,IGHV4-39,G,['G' 'S'],S,100.0,The structure of Plasmodium vivax Duffy binding protein (PvDBP) bound to human antibody DB9,duffy receptor,C,plasmodium vivax (strain salvador i),3.04,8.49483,8.78687,"C404,C408,C412,C416,C418,C421,C424,C472,C475,C476,C479,C484,C486,C487,C488,C489,C491,C492,C493,C495,C497,C498,C499,C500,C502,C503,C504",Malaria,329
985,6R2S,B,27,46,IGHV4-39,G,['G' 'Y'],Y,100.0,The structure of Plasmodium vivax Duffy binding protein (PvDBP) bound to human antibody DB9,duffy receptor,C,plasmodium vivax (strain salvador i),3.04,2.11725,2.30484,"C404,C408,C412,C416,C418,C421,C424,C472,C475,C476,C479,C484,C486,C487,C488,C489,C491,C492,C493,C495,C497,C498,C499,C500,C502,C503,C504",Malaria,329
986,4RWY,H,30,30,IGHV1-46,N,['T' 'N'],T,6.774193548387098,Crystal structure of VH1-46 germline-derived CD4-binding site-directed antibody 8ANC131 in complex with HIV-1 clade B YU2 gp120,hiv-1 yu2 gp120,A,human immunodeficiency virus 1,2.128,0.538257,0.738329,"A96,A97,A98,A99,A102,A105,A122,A124,A275,A276,A278,A279,A280,A281,A282,A283,A365,A366,A367,A368,A371,A425,A426,A427,A428,A429,A430,A431,A432,A455,A456,A457,A459,A460,A461,A472,A473,A474,A476,A477,A480",HIV,167
987,2YSS,B,31,31,IGHV4-59,S,['S' 'Y'],Y,100.0,Crystal structure of Humanized HYHEL-10 FV mutant(HQ39KW47Y)-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.4,-1.42362,-0.536068,"C13,C14,C15,C16,C18,C19,C20,C21,C22,C62,C63,C72,C73,C74,C75,C76,C77,C89,C93,C96,C97,C98,C99,C100,C101,C102,C103,C104,C107",Chicken,109
988,2YSS,B,33,33,IGHV4-59,Y,['Y' 'S'],S,100.0,Crystal structure of Humanized HYHEL-10 FV mutant(HQ39KW47Y)-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.4,0.756648,2.07018,"C13,C14,C15,C16,C18,C19,C20,C21,C22,C62,C63,C72,C73,C74,C75,C76,C77,C89,C93,C96,C97,C98,C99,C100,C101,C102,C103,C104,C107",Chicken,109
989,2YSS,B,50,50,IGHV4-59,Y,['Y' 'R'],R,100.0,Crystal structure of Humanized HYHEL-10 FV mutant(HQ39KW47Y)-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.4,5.94985,3.4583,"C13,C14,C15,C16,C18,C19,C20,C21,C22,C62,C63,C72,C73,C74,C75,C76,C77,C89,C93,C96,C97,C98,C99,C100,C101,C102,C103,C104,C107",Chicken,109
990,2YSS,B,53,53,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal structure of Humanized HYHEL-10 FV mutant(HQ39KW47Y)-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.4,0.0672127,0.429483,"C13,C14,C15,C16,C18,C19,C20,C21,C22,C62,C63,C72,C73,C74,C75,C76,C77,C89,C93,C96,C97,C98,C99,C100,C101,C102,C103,C104,C107",Chicken,109
991,2YSS,B,58,58,IGHV4-59,Y,['N' 'Y'],N,0.0,Crystal structure of Humanized HYHEL-10 FV mutant(HQ39KW47Y)-HEN lysozyme complex,lysozyme c,C,gallus gallus,2.4,1.05153,1.01322,"C13,C14,C15,C16,C18,C19,C20,C21,C22,C62,C63,C72,C73,C74,C75,C76,C77,C89,C93,C96,C97,C98,C99,C100,C101,C102,C103,C104,C107",Chicken,109
992,7DK0,A,50,50,IGHV1-69,R,['G' 'R'],G,16.350710900473935,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab,spike protein s1,C,severe acute respiratory syndrome coronavirus2,3.199,-0.469914,-1.45138,"C351,C444,C445,C446,C447,C448,C449,C450,C452,C453,C455,C456,C468,C470,C472,C483,C484,C485,C486,C488,C489,C490,C492,C493,C494,C498,C505",SARS,162
993,7DK0,A,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab,spike protein s1,C,severe acute respiratory syndrome coronavirus2,3.199,1.71898,0.519122,"C351,C444,C445,C446,C447,C448,C449,C450,C452,C453,C455,C456,C468,C470,C472,C483,C484,C485,C486,C488,C489,C490,C492,C493,C494,C498,C505",SARS,162
994,6MEH,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design,e2 glycoprotein,C,hepacivirus c,1.99,"-nan
","-nan
","C420,C421,C427,C428,C429,C430,C431,C432,C433,C434,C435,C436,C437,C438,C439,C440,C442,C443,C445,C446,C447,C448,C449,C529,C531,C555,C616,C619",HCV,330
995,6MEI,H,73,73,IGHV1-69,E,['E' 'K'],K,54.58135860979463,Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design,e2 glycoprotein,C,hepacivirus c,2.9,"-nan
","-nan
","C414,C417,C418,C419,C420,C427,C428,C429,C430,C431,C432,C434,C435,C436,C437,C438,C439,C440,C441,C442,C443,C445,C446,C447,C448,C449,C529,C531",HCV,330
996,7XXL,C,32,34,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,RBD in complex with Fab14,spike protein s1,B,severe acute respiratory syndrome coronavirus2,0,1.56805,-0.107715,"B479,B481,B483,B484,B485,B486,B489",SARS,331
997,7N0A,B,29,29,IGHV3-15,F,['F' 'C'],C,100.0,Structure of Human Leukaemia Inhibitory Factor with Fab MSC1,leukemia inhibitory factor,C,homo sapiens,3.1,4.12882,3.95598,"C12,C13,C14,C15,C16,C17,C18,C19,C20,C25,C28,C29,C32,C120,C121,C123,C124,C127,C128,C130,C131,C134,C135,C138,C140",Human,332
998,7N0A,B,52,52,IGHV3-15,K,['K' 'E'],E,98.9010989010989,Structure of Human Leukaemia Inhibitory Factor with Fab MSC1,leukemia inhibitory factor,C,homo sapiens,3.1,4.21345,2.70262,"C12,C13,C14,C15,C16,C17,C18,C19,C20,C25,C28,C29,C32,C120,C121,C123,C124,C127,C128,C130,C131,C134,C135,C138,C140",Human,332
999,7N0A,B,53,56,IGHV3-15,D,['D' 'N'],N,100.0,Structure of Human Leukaemia Inhibitory Factor with Fab MSC1,leukemia inhibitory factor,C,homo sapiens,3.1,0.0132135,-0.324988,"C12,C13,C14,C15,C16,C17,C18,C19,C20,C25,C28,C29,C32,C120,C121,C123,C124,C127,C128,C130,C131,C134,C135,C138,C140",Human,332
1000,2B0S,L,50,50,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with MN peptide,mn peptide of exterior membrane glycoprotein gp120,P,,2.3,3.3159,3.31406,"P303,P304,P305,P306,P307,P308,P309,P312,P313,P315,P317,P318",,
1001,7SSC,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,TRL345 lineage ancestor I8 Fab bound to an HCMV gB-derived peptide,envelope glycoprotein b peptide,P,human betaherpesvirus 5,1.8,3.04735,0.20051,"P69,P70,P71,P72,P73,P74,P75,P76,P77,P78",CMV,303
1002,7SSC,H,94,94,IGHV3-30,R,['R' 'K'],K,46.91848906560635,TRL345 lineage ancestor I8 Fab bound to an HCMV gB-derived peptide,envelope glycoprotein b peptide,P,human betaherpesvirus 5,1.8,0.0262296,-0.266614,"P69,P70,P71,P72,P73,P74,P75,P76,P77,P78",CMV,303
1003,5XWD,D,50,50,IGLV3-21,Y,['Y' 'D'],D,33.71757925072046,Crystal structure of the complex of 059-152-Fv and EGFR-ECD,epidermal growth factor receptor,A,homo sapiens,2.8940000000000000,3.60178,0.659546,"A322,A323,A324,A325,A344,A346,A348,A349,A350,A353,A355,A356,A357,A358,A380,A382,A384,A407,A408,A409,A410,A412,A415,A417,A418,A420,A438,A440,A441,A443,A444,A465,A467,A468",Human,333
1004,5XWD,H,30,30,IGHV4-39,S,['S' 'G'],G,100.0,Crystal structure of the complex of 059-152-Fv and EGFR-ECD,epidermal growth factor receptor,A,homo sapiens,2.8940000000000000,0.0225554,-0.0227197,"A322,A323,A324,A325,A344,A346,A348,A349,A350,A353,A355,A356,A357,A358,A380,A382,A384,A407,A408,A409,A410,A412,A415,A417,A418,A420,A438,A440,A441,A443,A444,A465,A467,A468",Human,334
1005,2FX7,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with a 16-residue peptide encompassing the 4e10 epitope on gp41,fragment of hiv glycoprotein (gp41),P,,1.76,2.17177,0.0871605,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P681,P683",,
1006,2FX7,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with a 16-residue peptide encompassing the 4e10 epitope on gp41,fragment of hiv glycoprotein (gp41),P,,1.76,13.6876,0.368359,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P681,P683",,
1007,2FX7,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with a 16-residue peptide encompassing the 4e10 epitope on gp41,fragment of hiv glycoprotein (gp41),P,,1.76,0.738938,-0.0844053,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P681,P683",,
1008,2FX7,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with a 16-residue peptide encompassing the 4e10 epitope on gp41,fragment of hiv glycoprotein (gp41),P,,1.76,1.37001,0.997072,"P671,P672,P673,P674,P675,P676,P677,P679,P680,P681,P683",,
1009,2NXY,D,54,3055,IGHV1-69,L,['F' 'L'],F,15.323854660347552,HIV-1 gp120 Envelope Glycoprotein(S334A) Complexed with CD4 and Antibody 17b,envelope glycoprotein gp120,A,human immunodeficiency virus 1,2.0,-0.0930695,-0.347459,"A119,A120,A122,A200,A202,A203,A204,A205,A419,A420,A421,A422,A423,A432,A434,A435,A436,A437",HIV,177
1010,7KCR,H,50,50,IGHV3-30,F,['V' 'F'],V,8.548707753479125,Cryo-EM structure of Zika virus in complex with E protein cross-linking human monoclonal antibody ADI30056,envelope protein e | envelope protein e | envelope protein e,C | A | E,zika virus zikv/h.sapiens/frenchpolynesia/10087pf/2013  | zika virus zikv/h.sapiens/frenchpolynesia/10087pf/2013  | zika virus zikv/h.sapiens/frenchpolynesia/10087pf/2013,4,3.61844,2.83123,"A67,A81,A83,A84,A86,A87,A89,A90,A118,C64,C65,C66,C67,C68,C69,C83,C84,C86,C87,C89,C90,C118,C119,C120,C121,C122,C124,C231,C232,C233,C234,C235,C236,C252,C254,C255,C256,E207,E208,E209,E276,E277,E278,E279,E283",Zika,335
1011,7KCR,H,52,52,IGHV3-30,R,['S' 'R'],S,8.548707753479125,Cryo-EM structure of Zika virus in complex with E protein cross-linking human monoclonal antibody ADI30056,envelope protein e | envelope protein e | envelope protein e,C | A | E,zika virus zikv/h.sapiens/frenchpolynesia/10087pf/2013  | zika virus zikv/h.sapiens/frenchpolynesia/10087pf/2013  | zika virus zikv/h.sapiens/frenchpolynesia/10087pf/2013,4,3.88658,0.400773,"A67,A81,A83,A84,A86,A87,A89,A90,A118,C64,C65,C66,C67,C68,C69,C83,C84,C86,C87,C89,C90,C118,C119,C120,C121,C122,C124,C231,C232,C233,C234,C235,C236,C252,C254,C255,C256,E207,E208,E209,E276,E277,E278,E279,E283",Zika,335
1012,6TOU,A,33,33,IGHV4-31,S,['G' 'S'],G,0.0,Rabies virus glycoprotein PH domain in complex with the scFv fragment of broadly neutralizing human antibody RVC20,"glycoprotein,glycoprotein",G,rabies lyssavirus,2.587,1.17935,1.14336,"G42,G44,G47,G187,G188,G189,G190,G191,G192,G193,G194,G225,G226,G227,G228,G229,G230,G231,G242,G244,G251",Rabies,336
1013,6TOU,A,50,50,IGHV4-31,Y,['Y' 'C'],C,100.0,Rabies virus glycoprotein PH domain in complex with the scFv fragment of broadly neutralizing human antibody RVC20,"glycoprotein,glycoprotein",G,rabies lyssavirus,2.587,1.23358,0.705441,"G42,G44,G47,G187,G188,G189,G190,G191,G192,G193,G194,G225,G226,G227,G228,G229,G230,G231,G242,G244,G251",Rabies,336
1014,4XBE,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin (02:0 SM (d18:1/2:0)).,peptide fragment of hiv glycoprotein (gp41) including theregion 671-683 of the mper,P,human immunodeficiency virus 1,1.756,1.34067,-0.676843,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,23
1015,4XBE,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin (02:0 SM (d18:1/2:0)).,peptide fragment of hiv glycoprotein (gp41) including theregion 671-683 of the mper,P,human immunodeficiency virus 1,1.756,11.4942,-1.07598,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,23
1016,4XBE,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin (02:0 SM (d18:1/2:0)).,peptide fragment of hiv glycoprotein (gp41) including theregion 671-683 of the mper,P,human immunodeficiency virus 1,1.756,0.697137,0.110624,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,23
1017,4XBE,H,56,56,IGHV1-69,I,['T' 'I'],T,13.11216429699842,Crystal structure of human 4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin (02:0 SM (d18:1/2:0)).,peptide fragment of hiv glycoprotein (gp41) including theregion 671-683 of the mper,P,human immunodeficiency virus 1,1.756,1.36998,1.02578,"P671,P672,P673,P674,P675,P676,P677,P678,P679,P680,P681,P683",HIV,23
1018,4JHW,H,54,54,IGHV1-69,L,['F' 'L'],F,15.323854660347552,Crystal Structure of Respiratory Syncytial Virus Fusion Glycoprotein Stabilized in the Prefusion Conformation by Human Antibody D25,fusion glycoprotein f0,F,human respiratory syncytial virus,3.6,3.0357,3.68338,"F62,F63,F64,F65,F66,F67,F68,F69,F70,F83,F196,F197,F198,F200,F201,F202,F204,F205,F206,F207,F208,F209,F210,F211,F212,F216,F219",RSV,337
1019,7WON,H,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,Cryo-EM structure of SARS-CoV-2 S2P trimer in complex with neutralizing antibody VacW-209 (local refinement),spike protein s1,F,severe acute respiratory syndrome coronavirus2,3.9,-0.514585,-0.718842,"F368,F369,F370,F371,F372,F374,F375,F377,F378,F379,F380,F381,F382,F383,F384,F385,F403,F405,F406,F408,F409,F411,F412,F413,F414,F415,F416,F417,F420,F421,F427,F428,F455,F460,F505",SARS,13
1020,7WOG,A,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,SARS-CoV-2 Omicron S monomer complexed with 553-49,spike protein s1,C,severe acute respiratory syndrome coronavirus2,0,2.65351,0.384163,"C334,C335,C337,C340,C344,C345,C346,C347,C348,C349,C351,C352,C353,C354,C355,C356,C357,C358,C359,C360,C361,C393,C394,C396,C457,C462,C464,C465,C466,C467,C468,C469,C470,C471,C520,C521,C523",SARS,338
1021,7WOG,A,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,SARS-CoV-2 Omicron S monomer complexed with 553-49,spike protein s1,C,severe acute respiratory syndrome coronavirus2,0,-0.294279,-0.118547,"C334,C335,C337,C340,C344,C345,C346,C347,C348,C349,C351,C352,C353,C354,C355,C356,C357,C358,C359,C360,C361,C393,C394,C396,C457,C462,C464,C465,C466,C467,C468,C469,C470,C471,C520,C521,C523",SARS,338
1022,7WOG,A,55,56,IGHV3-23,G,['G' 'S'],S,98.3983983983984,SARS-CoV-2 Omicron S monomer complexed with 553-49,spike protein s1,C,severe acute respiratory syndrome coronavirus2,0,2.03069,0.28717,"C334,C335,C337,C340,C344,C345,C346,C347,C348,C349,C351,C352,C353,C354,C355,C356,C357,C358,C359,C360,C361,C393,C394,C396,C457,C462,C464,C465,C466,C467,C468,C469,C470,C471,C520,C521,C523",SARS,338
1023,7WOC,A,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,"S-mAb60 NRAb1 local-refined map"""" into """"Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-60",spike protein s1,C,severe acute respiratory syndrome coronavirus2,0,2.22095,0.190394,"C351,C444,C445,C449,C450,C452,C470,C472,C480,C481,C482,C483,C484,C485,C486,C490,C492,C493,C494",SARS,120
1024,7WOC,A,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,"S-mAb60 NRAb1 local-refined map"""" into """"Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-60",spike protein s1,C,severe acute respiratory syndrome coronavirus2,0,0.762215,0.675204,"C351,C444,C445,C449,C450,C452,C470,C472,C480,C481,C482,C483,C484,C485,C486,C490,C492,C493,C494",SARS,120
1025,7WOC,A,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,"S-mAb60 NRAb1 local-refined map"""" into """"Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-60",spike protein s1,C,severe acute respiratory syndrome coronavirus2,0,1.29097,1.12048,"C351,C444,C445,C449,C450,C452,C470,C472,C480,C481,C482,C483,C484,C485,C486,C490,C492,C493,C494",SARS,120
1026,7DM2,L,50,54,IGLV1-47,R,['R' 'S'],S,88.38383838383838,crystal structure of the M. tuberculosis phosphate ABC transport receptor PstS-1 in complex with Fab p4-170,phosphate-binding protein psts 1,A,mycobacterium tuberculosis h37rv,2.4,3.2836,1.62746,"A85,A87,A88,A92,A125,A174,A177,A178,A179,A181,A182,A185,A186,A189,A190,A245,A246,A247,A248,A264,A265,A267,A268,A270,A271,A272,A274,A275,A276,A279,A280,A281,A283",Mycobacterium tuberculosis,339
1027,6VC9,H,31,31,IGHV4-4,N,['S' 'N'],S,0.0,TB19 complex,"5'-nucleotidase, ecto (cd73), isoform cra_a",A,homo sapiens,2.25,0.402574,0.370813,"A121,A122,A123,A124,A125,A145,A146,A147,A148,A149,A179,A180,A182,A183,A185,A186,A187,A188,A189,A190,A191,A192,A193,A194,A195,A374,A517,A519,A520,A521,A522",Human,340
1028,6VC9,H,33,33,IGHV4-4,Y,['N' 'W' 'Y'],N,28.03030303030303,TB19 complex,"5'-nucleotidase, ecto (cd73), isoform cra_a",A,homo sapiens,2.25,3.67768,0.76655,"A121,A122,A123,A124,A125,A145,A146,A147,A148,A149,A179,A180,A182,A183,A185,A186,A187,A188,A189,A190,A191,A192,A193,A194,A195,A374,A517,A519,A520,A521,A522",Human,340
1029,6VC9,H,33,33,IGHV4-4,Y,['N' 'W' 'Y'],W,28.03030303030303,TB19 complex,"5'-nucleotidase, ecto (cd73), isoform cra_a",A,homo sapiens,2.25,8.4912,-1.10558,"A121,A122,A123,A124,A125,A145,A146,A147,A148,A149,A179,A180,A182,A183,A185,A186,A187,A188,A189,A190,A191,A192,A193,A194,A195,A374,A517,A519,A520,A521,A522",Human,340
1030,6VC9,H,50,50,IGHV4-4,R,['E' 'R' 'Y'],E,22.348484848484848,TB19 complex,"5'-nucleotidase, ecto (cd73), isoform cra_a",A,homo sapiens,2.25,4.67154,4.13039,"A121,A122,A123,A124,A125,A145,A146,A147,A148,A149,A179,A180,A182,A183,A185,A186,A187,A188,A189,A190,A191,A192,A193,A194,A195,A374,A517,A519,A520,A521,A522",Human,340
1031,6VC9,H,50,50,IGHV4-4,R,['E' 'R' 'Y'],Y,22.348484848484848,TB19 complex,"5'-nucleotidase, ecto (cd73), isoform cra_a",A,homo sapiens,2.25,3.73862,7.33408,"A121,A122,A123,A124,A125,A145,A146,A147,A148,A149,A179,A180,A182,A183,A185,A186,A187,A188,A189,A190,A191,A192,A193,A194,A195,A374,A517,A519,A520,A521,A522",Human,340
1032,4Z0X,B,50,75,IGHV1-69,G,['G' 'R'],R,83.64928909952607,Structure of Hepatitis C Virus Envelope glycoprotein E2 antigenic region 434-446 bound to the broadly neutralizing antibody HC26AM,hcv e2 antigen (residues 432-446),C,hepatitis c virus,2.0,15.3049,1.14885,"C437,C438,C439,C440,C441,C442,C443,C444,C445,C446",HCV,158
1033,4Z0X,B,54,80,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Structure of Hepatitis C Virus Envelope glycoprotein E2 antigenic region 434-446 bound to the broadly neutralizing antibody HC26AM,hcv e2 antigen (residues 432-446),C,hepatitis c virus,2.0,0.884005,-0.0340339,"C437,C438,C439,C440,C441,C442,C443,C444,C445,C446",HCV,158
1034,4Z0X,B,56,82,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Structure of Hepatitis C Virus Envelope glycoprotein E2 antigenic region 434-446 bound to the broadly neutralizing antibody HC26AM,hcv e2 antigen (residues 432-446),C,hepatitis c virus,2.0,-1.57142,-0.677422,"C437,C438,C439,C440,C441,C442,C443,C444,C445,C446",HCV,158
1035,7RP3,H,26,26,IGHV4-4,G,['G' 'S'],S,100.0,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,isoform 2b of gtpase kras,A,homo sapiens,2.0,4.49153,3.21066,"A5,A6,A7,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
1036,7RP3,H,27,27,IGHV4-4,G,['G' 'I'],I,100.0,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,isoform 2b of gtpase kras,A,homo sapiens,2.0,5.94065,7.1202,"A5,A6,A7,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
1037,7RP3,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,isoform 2b of gtpase kras,A,homo sapiens,2.0,2.54838,-0.17493,"A5,A6,A7,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
1038,7RP3,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],W,71.96969696969697,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,isoform 2b of gtpase kras,A,homo sapiens,2.0,26.1829,0.647488,"A5,A6,A7,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
1039,7RP3,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],Y,71.96969696969697,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,isoform 2b of gtpase kras,A,homo sapiens,2.0,15.9468,0.179764,"A5,A6,A7,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
1040,7RP3,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],W,71.96969696969697,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,isoform 2b of gtpase kras,A,homo sapiens,2.0,-1.5014,-1.28294,"A5,A6,A7,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
1041,7RP3,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],Y,71.96969696969697,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,isoform 2b of gtpase kras,A,homo sapiens,2.0,-1.07938,-0.52495,"A5,A6,A7,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
1042,7RP3,H,53,53,IGHV4-4,H,['H' 'T'],T,71.96969696969697,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,isoform 2b of gtpase kras,A,homo sapiens,2.0,-0.00811027,0.8717999999999932,"A5,A6,A7,A25,A32,A33,A35,A36,A37,A38,A39,A40,A41,A54,A55,A56,A65,A67,A70,A71,A74,A75",Human,95
1043,2VXQ,H,33,32,IGHV4-31,G,['G' 'S'],S,100.0,Crystal structure of the major grass pollen allergen Phl p 2 in  complex with its specific IgE-Fab,pollen allergen phl p 2,A,phleum pratense,1.9,5.01433,2.61073,"A30,A32,A34,A36,A39,A40,A41,A43,A65,A67,A68,A69,A73,A74,A75,A76,A77,A78,A79,A80,A94",Phleum pratense,341
1044,6W16,H,26,27,IGHV3-30,G,['G' 'A'],A,100.0,Crystal structure of a human metapneumovirus monomeric fusion protein complexed with 458 Fab,"fusion glycoprotein f0,envelope glycoprotein fusion",F,"human metapneumovirus, human immunodeficiencyvirus 1",3.1,3.67095,3.57424,"F56,F57,F59,F60,F61,F63,F64,F68,F69,F70,F72,F73,F75,F76,F77,F79,F80,F82,F83,F84,F86,F87,F180,F201,F202,F205,F208,F209",hMPV,342
1045,6W16,H,33,38,IGHV3-30,G,['A' 'G'],A,68.58846918489066,Crystal structure of a human metapneumovirus monomeric fusion protein complexed with 458 Fab,"fusion glycoprotein f0,envelope glycoprotein fusion",F,"human metapneumovirus, human immunodeficiencyvirus 1",3.1,1.37651,1.51736,"F56,F57,F59,F60,F61,F63,F64,F68,F69,F70,F72,F73,F75,F76,F77,F79,F80,F82,F83,F84,F86,F87,F180,F201,F202,F205,F208,F209",hMPV,342
1046,7MRZ,X,28,28,IGHV4-39,S,['S' 'Y'],Y,100.0,Structure of GDF11 bound to fused ActRIIB-ECD and Alk4-ECD with Anti-ActRIIB Fab fragment,"activin receptor type-2b,activin receptor type-1b",C,homo sapiens,3.0,-2.35513,-0.965024,"C26,C28,C30,C32,C43,C44,C45,C46,C48,C68,C69,C70,C72,C75,C88,C89,C107,C108,C109,C111,C112,C113,C114",Human,188
1047,7MRZ,X,30,30,IGHV4-39,S,['S' 'G'],G,100.0,Structure of GDF11 bound to fused ActRIIB-ECD and Alk4-ECD with Anti-ActRIIB Fab fragment,"activin receptor type-2b,activin receptor type-1b",C,homo sapiens,3.0,0.167859,0.170661,"C26,C28,C30,C32,C43,C44,C45,C46,C48,C68,C69,C70,C72,C75,C88,C89,C107,C108,C109,C111,C112,C113,C114",Human,188
1048,8DFH,H,52,52,IGHV3-30,R,['S' 'R'],S,8.548707753479125,Crystal structure of non-neutralizing / interfering human monoclonal antibody 42C3 Fab in complex with MSP1-19,merozoite surface protein 1,A,plasmodium falciparum 3d7,2.3,4.2052,0.691839,"A6,A10,A12,A13,A14,A15,A16,A17,A18,A31,A32,A33,A34,A37,A40,A41,A42,A43,A45,A69,A71,A87,A88",Malaria,343
1049,8DFH,L,50,51,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Crystal structure of non-neutralizing / interfering human monoclonal antibody 42C3 Fab in complex with MSP1-19,merozoite surface protein 1,A,plasmodium falciparum 3d7,2.3,2.23825,2.90954,"A6,A10,A12,A13,A14,A15,A16,A17,A18,A31,A32,A33,A34,A37,A40,A41,A42,A43,A45,A69,A71,A87,A88",Malaria,344
1050,8DFI,H,50,50,IGHV3-30,F,['V' 'F'],V,8.548707753479125,Crystal structure of moderately neutralizing / interfering human monoclonal antibody 42C11 Fab in complex with MSP1-19,merozoite surface protein 1,A,plasmodium falciparum 3d7,1.9,3.54924,3.03218,"A6,A10,A11,A12,A13,A14,A15,A16,A17,A31,A32,A33,A34,A37,A40,A41,A42,A43,A45,A71,A72,A73,A87,A88",Malaria,343
1051,8DFI,H,52,52,IGHV3-30,R,['S' 'R'],S,8.548707753479125,Crystal structure of moderately neutralizing / interfering human monoclonal antibody 42C11 Fab in complex with MSP1-19,merozoite surface protein 1,A,plasmodium falciparum 3d7,1.9,1.8437,0.713448,"A6,A10,A11,A12,A13,A14,A15,A16,A17,A31,A32,A33,A34,A37,A40,A41,A42,A43,A45,A71,A72,A73,A87,A88",Malaria,343
1052,8DFI,L,50,51,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Crystal structure of moderately neutralizing / interfering human monoclonal antibody 42C11 Fab in complex with MSP1-19,merozoite surface protein 1,A,plasmodium falciparum 3d7,1.9,3.08463,3.52476,"A6,A10,A11,A12,A13,A14,A15,A16,A17,A31,A32,A33,A34,A37,A40,A41,A42,A43,A45,A71,A72,A73,A87,A88",Malaria,344
1053,8D36,H,50,50,IGHV1-2,R,['R' 'W'],W,8.248730964467004,Crystal structure of SARS-CoV-2 fusion peptide in complex with neutralizing antibody COV44-62,spike protein s2 fusion peptide,F,severe acute respiratory syndrome coronavirus2,1.45,10.1095,7.50207,"F813,F814,F815,F816,F817,F818,F819,F820,F822,F823,F824,F825",SARS,345
1054,6IVZ,H,26,27,IGHV4-59,G,['G' 'S'],S,100.0,Crystal structure of 5A ScFv complexed with YFV-China sE in postfusion state,envelope protein,A,yellow fever virus,2.4,8.66204,8.81985,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A90,A99,A101,A102,A103,A104,A106,A239,A240,A241,A242,A243,A244",YFV,186
1055,6IVZ,H,27,28,IGHV4-59,G,['G' 'I'],I,100.0,Crystal structure of 5A ScFv complexed with YFV-China sE in postfusion state,envelope protein,A,yellow fever virus,2.4,1.71842,-0.933251,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A90,A99,A101,A102,A103,A104,A106,A239,A240,A241,A242,A243,A244",YFV,186
1056,6IVZ,H,30,31,IGHV4-59,Y,['S' 'Y'],S,0.0,Crystal structure of 5A ScFv complexed with YFV-China sE in postfusion state,envelope protein,A,yellow fever virus,2.4,2.13402,0.880366,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A90,A99,A101,A102,A103,A104,A106,A239,A240,A241,A242,A243,A244",YFV,186
1057,6IVZ,H,32,33,IGHV4-59,H,['Y' 'W' 'H'],Y,7.865168539325842,Crystal structure of 5A ScFv complexed with YFV-China sE in postfusion state,envelope protein,A,yellow fever virus,2.4,-0.138767,-0.589976,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A90,A99,A101,A102,A103,A104,A106,A239,A240,A241,A242,A243,A244",YFV,186
1058,6IVZ,H,32,33,IGHV4-59,H,['Y' 'W' 'H'],W,7.865168539325842,Crystal structure of 5A ScFv complexed with YFV-China sE in postfusion state,envelope protein,A,yellow fever virus,2.4,-0.409742,-0.0992045,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A90,A99,A101,A102,A103,A104,A106,A239,A240,A241,A242,A243,A244",YFV,186
1059,6IVZ,H,53,54,IGHV4-59,Y,['Y' 'T'],T,100.0,Crystal structure of 5A ScFv complexed with YFV-China sE in postfusion state,envelope protein,A,yellow fever virus,2.4,1.00416,1.48158,"A65,A66,A67,A68,A69,A70,A71,A72,A73,A74,A81,A82,A83,A84,A87,A90,A99,A101,A102,A103,A104,A106,A239,A240,A241,A242,A243,A244",YFV,186
1060,3LZF,H,33,33,IGHV2-70,G,['G' 'E'],E,100.0,Crystal Structure of Fab 2D1 in Complex with the 1918 Influenza Virus Hemagglutinin,"hemagglutinin, ha1 subunit",A,influenza a virus,2.8,0.742465,0.697849,"A124,A125,A125B,A125C,A126,A127,A128,A129,A130,A131,A157,A158,A159,A160,A161,A162,A163,A165,A166,A167,A168,A169,A171,A196,A197,A242,A246,A248",influenza,346
1061,3LZF,H,50,50,IGHV2-70,L,['L' 'R'],R,45.55555555555556,Crystal Structure of Fab 2D1 in Complex with the 1918 Influenza Virus Hemagglutinin,"hemagglutinin, ha1 subunit",A,influenza a virus,2.8,0.819737,-0.171779,"A124,A125,A125B,A125C,A126,A127,A128,A129,A130,A131,A157,A158,A159,A160,A161,A162,A163,A165,A166,A167,A168,A169,A171,A196,A197,A242,A246,A248",influenza,346
1062,6XQW,H,50,50,IGHV4-34,E,['E' 'Y'],Y,100.0,Crystal Structure of MaliM03 Fab in complex with Pfmsp1-19,pfmsp1-19,E,plasmodium falciparum,2.991,17.9509,16.2234,"E5,E6,E7,E8,E9,E10,E11,E12,E24",Malaria,347
1063,6XQW,L,50,50,IGLV1-47,R,['R' 'S'],S,88.38383838383838,Crystal Structure of MaliM03 Fab in complex with Pfmsp1-19,pfmsp1-19,E,plasmodium falciparum,2.991,1.6546,0.946856,"E5,E6,E7,E8,E9,E10,E11,E12,E24",Malaria,348
1064,3MAC,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,crystal structure of GP41-derived protein complexed with fab 8062,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.5,1.93123,2.71207,"A19,A22,A23,A24,A26,A27,A28,A30,A31,A33,A34,A35,A36,A37,A38,A50,A51,A54,A58,A61,A62,A65,A68,A69,A72,A205,A208,A209,A212,A215",HIV,349
1065,3MAC,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,crystal structure of GP41-derived protein complexed with fab 8062,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.5,1.80807,-0.0459883,"A19,A22,A23,A24,A26,A27,A28,A30,A31,A33,A34,A35,A36,A37,A38,A50,A51,A54,A58,A61,A62,A65,A68,A69,A72,A205,A208,A209,A212,A215",HIV,349
1066,7A3U,L,50,50,IGLV2-14,D,['E' 'D'],E,43.44262295081968,Crystal structure of Zika virus envelope glycoprotein in complex with the divalent F(ab')2 fragment of the broadly neutralizing human antibody EDE1 C10,envelope protein,A,zika virus,3.0,-0.926961,-1.22697,"A2,A6,A28,A44,A46,A47,A138,A140,A148,A149,A150,A151,A152,A153,A164,A278,A283,A315,A316,A329,A331,A367,A369,A370,A371,A372,A373",Zika,350
1067,7A3U,L,51,51,IGLV2-14,V,['V' 'G'],G,97.74590163934424,Crystal structure of Zika virus envelope glycoprotein in complex with the divalent F(ab')2 fragment of the broadly neutralizing human antibody EDE1 C10,envelope protein,A,zika virus,3.0,2.71449,2.04939,"A2,A6,A28,A44,A46,A47,A138,A140,A148,A149,A150,A151,A152,A153,A164,A278,A283,A315,A316,A329,A331,A367,A369,A370,A371,A372,A373",Zika,350
1068,7A3N,L,50,50,IGLV2-14,D,['E' 'D'],E,43.44262295081968,Crystal structure of Zika virus envelope glycoprotein in complex with the Fab fragment of the broadly neutralizing human antibody EDE1 C10,core protein,A,zika virus,2.1,0.783798,-0.795335,"A2,A6,A27,A28,A44,A46,A47,A138,A140,A148,A149,A150,A151,A152,A164,A276,A278,A283,A315,A316,A329,A331,A367,A369,A370,A371,A372,A373",Zika,350
1069,4I3R,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of the outer domain of HIV-1 gp120 in complex with VRC-PG04 space group P3221,outer domain of hiv-1 gp120 (ker2018 od4.2.2),G,human immunodeficiency virus,3.0,5.01291,1.23871,"G252,G254,G256,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G371,G455,G456,G457,G458,G459,G460,G461,G462,G469,G471,G472,G473,G474,G476,G477",HIV,1
1070,4I3S,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of the outer domain of HIV-1 gp120 in complex with VRC-PG04 space group P21,outer domain of hiv-1 gp120 (ker2018 od4.2.2),G,human immunodeficiency virus,2.85,4.9678,1.31363,"G252,G253,G254,G256,G275,G276,G278,G279,G280,G281,G282,G283,G365,G366,G367,G368,G371,G455,G456,G457,G458,G459,G460,G461,G462,G469,G472,G473,G474",HIV,1
1071,4ERS,L,10,10,IGKV1-17,S,['S' 'A'],A,82.26950354609927,A Molecular Basis for Negative Regulation of the Glucagon Receptor,glucagon receptor,A,homo sapiens,2.637,0.399052,0.364757,"A54,A55,A56,A102,A103,A105",Human,351
1072,4ERS,L,11,11,IGKV1-17,L,['L' 'M'],M,82.26950354609927,A Molecular Basis for Negative Regulation of the Glucagon Receptor,glucagon receptor,A,homo sapiens,2.637,0.488311,0.224637,"A54,A55,A56,A102,A103,A105",Human,351
1073,7N4I,H,74,75,IGHV5-51,S,['S' 'P'],P,100.0,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2057.,spike protein s1,C,severe acute respiratory syndrome coronavirus2,2.284,0.564294,0.819542,"C353,C355,C357,C454,C457,C458,C459,C462,C463,C464,C465,C466,C467,C468,C469,C470,C471,C472,C473,C474,C479,C480,C481,C482,C491,C516,C518",SARS,352
1074,7N4N,D,58,218,IGHV3-74,T,['S' 'T'],S,7.361963190184049,BACE-2 in complex with ligand 36,beta-secretase 2,A,homo sapiens,1.41,0.439539,-0.0900965,"A75,A77,A78,A79,A81,A98,A100,A110,A112,A113,A114,A140,A147,A148,A150,A154,A157,A158,A159,A161,A162,A163,A164",Human,106
1075,7N4L,H,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2125.,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.601,9.70077,-0.0766906,"A415,A417,A421,A453,A455,A456,A473,A474,A475,A476,A477,A478,A484,A485,A486,A487,A489,A493,A505",SARS,353
1076,7N4L,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2125.,spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.601,3.22502,2.12465,"A415,A417,A421,A453,A455,A456,A473,A474,A475,A476,A477,A478,A484,A485,A486,A487,A489,A493,A505",SARS,353
1077,4HKX,A,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Influenza hemagglutinin in complex with CH67 Fab,hemagglutinin ha1,E,influenza a virus,2.5,4.45286,1.56906,"E95,E131,E133,E134,E135,E136,E137,E145,E153,E155,E156,E157,E158,E159,E160,E187,E188,E189,E190,E192,E193,E194,E196,E219,E222,E225,E226",influenza,354
1078,1G9M,H,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B,envelope glycoprotein gp120,G,human immunodeficiency virus 1,2.2,0.470855,-0.271088,"G119,G120,G122,G200,G202,G203,G204,G205,G419,G420,G421,G422,G423,G432,G433,G434,G435,G437",HIV,177
1079,3MA9,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,Crystal structure of gp41 derived protein complexed with fab 8066,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.05,2.13766,1.55766,"A19,A22,A23,A24,A26,A27,A28,A29,A30,A31,A33,A34,A35,A36,A37,A38,A47,A50,A51,A53,A54,A57,A58,A61,A62,A65,A68,A69,A72,A202,A205,A208,A209,A212",HIV,349
1080,3MA9,H,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of gp41 derived protein complexed with fab 8066,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.05,3.04011,0.326637,"A19,A22,A23,A24,A26,A27,A28,A29,A30,A31,A33,A34,A35,A36,A37,A38,A47,A50,A51,A53,A54,A57,A58,A61,A62,A65,A68,A69,A72,A202,A205,A208,A209,A212",HIV,349
1081,3MA9,H,56,56,IGHV1-69,T,['T' 'I'],I,86.8878357030016,Crystal structure of gp41 derived protein complexed with fab 8066,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.05,1.09834,-1.019,"A19,A22,A23,A24,A26,A27,A28,A29,A30,A31,A33,A34,A35,A36,A37,A38,A47,A50,A51,A53,A54,A57,A58,A61,A62,A65,A68,A69,A72,A202,A205,A208,A209,A212",HIV,349
1082,3MA9,H,73,73,IGHV1-69,E,['E' 'K'],K,54.58135860979463,Crystal structure of gp41 derived protein complexed with fab 8066,transmembrane glycoprotein,A,human immunodeficiency virus 1,2.05,0.296098,-0.669896,"A19,A22,A23,A24,A26,A27,A28,A29,A30,A31,A33,A34,A35,A36,A37,A38,A47,A50,A51,A53,A54,A57,A58,A61,A62,A65,A68,A69,A72,A202,A205,A208,A209,A212",HIV,349
1083,5SY8,H,50,50,IGHV3-15,R,['R' 'C'],C,100.0,Crystal structure of the complex of 10E8 Fab light chain mutant1 and T117v2 HIV-1 MPER scaffold,10e8 epitope scaffold t117v2,O,synthetic construct,1.62,2.67502,2.55741,"O64,O65,O66,O73,O78,O79,O99,O100,O101,O118,O119,O120,O121,O124,O125,O127,O128,O130,O131,O134,O135",Synthetic,38
1084,7YE5,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,6.75,0.563265,0.542007,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,200
1085,7YE5,H,54,55,IGHV1-69,L,['F' 'L'],F,15.323854660347552,SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,6.75,3.67294,-0.292056,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,200
1086,7YE5,H,56,57,IGHV1-69,I,['T' 'I'],T,13.11216429699842,SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,6.75,1.37697,0.940042,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,200
1087,7YE5,H,73,74,IGHV1-69,K,['E' 'K'],E,45.41864139020537,SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,6.75,0.488571,0.21604,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,200
1088,7YE5,L,69,71,IGLV1-40,T,['T' 'A'],A,99.57081545064378,SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs,spike glycoprotein | spike glycoprotein,A | B,severe acute respiratory syndrome coronavirus2  | severe acute respiratory syndrome coronavirus2,6.75,-0.885588,-0.450759,"A340,A344,A345,A346,A348,A351,A352,A353,A354,A355,A356,A357,A359,A396,A449,A450,A452,A457,A462,A463,A464,A465,A466,A467,A468,A469,A470,A471,A472,A481,A482,A484,A490,A492,A493,A494,B14,B132,B134,B160,B161,B162,B163,B164,B165,B166,B167",SARS,201
1089,6AXK,A,35,35,IGHV3-33,H,['H' 'Y'],Y,99.69788519637464,Crystal structure of Fab311 complex,ace-asn-pro-asn-ala-asn-pro-asn-ala-asn-pro-asn,E,plasmodium falciparum,2.103,2.6445,2.50279,"E2,E3,E4,E5,E6,E7,E8,E9,E10,E12",Malaria,48
1090,6AXK,A,52,52,IGHV3-33,W,['W' 'S'],S,97.2809667673716,Crystal structure of Fab311 complex,ace-asn-pro-asn-ala-asn-pro-asn-ala-asn-pro-asn,E,plasmodium falciparum,2.103,3.5984,1.55242,"E2,E3,E4,E5,E6,E7,E8,E9,E10,E12",Malaria,48
1091,6AXK,A,94,94,IGHV3-33,R,['R' 'K'],K,92.14501510574016,Crystal structure of Fab311 complex,ace-asn-pro-asn-ala-asn-pro-asn-ala-asn-pro-asn,E,plasmodium falciparum,2.103,-0.080151,0.0181176,"E2,E3,E4,E5,E6,E7,E8,E9,E10,E12",Malaria,48
1092,7SWP,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,G32Q4 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.8,8.81817,8.8286,"A369,A377,A378,A379,A380,A381,A382,A383,A384,A385,A386,A403,A405,A406,A408,A409,A411,A412,A413,A414,A415,A416,A417,A420,A427,A428,A429,A430,A503,A504,A505",SARS,13
1093,7SWP,H,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,G32Q4 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction),spike protein s1,A,severe acute respiratory syndrome coronavirus2,3.8,-2.35142,-1.10867,"A369,A377,A378,A379,A380,A381,A382,A383,A384,A385,A386,A403,A405,A406,A408,A409,A411,A412,A413,A414,A415,A416,A417,A420,A427,A428,A429,A430,A503,A504,A505",SARS,13
1094,6Q0O,Z,31,31,IGHV4-4,S,['S' 'N'],N,100.0,human antibody H2227 lineage 652 in complex with influenza hemagglutinin head domain of A/Solomon Islands/3/2006(H1N1),hemagglutinin head domain,A,influenza a virus,3.0,1.84419,0.952646,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
1095,6Q0O,Z,32,32,IGHV4-4,S,['S' 'W' 'Y'],W,71.96969696969697,human antibody H2227 lineage 652 in complex with influenza hemagglutinin head domain of A/Solomon Islands/3/2006(H1N1),hemagglutinin head domain,A,influenza a virus,3.0,22.3926,-0.199656,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
1096,6Q0O,Z,32,32,IGHV4-4,S,['S' 'W' 'Y'],Y,71.96969696969697,human antibody H2227 lineage 652 in complex with influenza hemagglutinin head domain of A/Solomon Islands/3/2006(H1N1),hemagglutinin head domain,A,influenza a virus,3.0,19.4848,0.162287,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
1097,6Q0O,Z,34,34,IGHV4-4,W,['W' 'S'],S,100.0,human antibody H2227 lineage 652 in complex with influenza hemagglutinin head domain of A/Solomon Islands/3/2006(H1N1),hemagglutinin head domain,A,influenza a virus,3.0,1.43305,1.46433,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
1098,6Q0O,Z,53,54,IGHV4-4,H,['H' 'T'],T,71.96969696969697,human antibody H2227 lineage 652 in complex with influenza hemagglutinin head domain of A/Solomon Islands/3/2006(H1N1),hemagglutinin head domain,A,influenza a virus,3.0,1.0349,0.93604,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A186,A187,A189,A190,A192,A193,A194,A196,A198,A222,A225,A226,A227,A228",influenza,202
1099,7SWO,H,54,54,IGHV3-66,G,['G' 'C'],C,100.0,C98C7 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction),spike protein s1,A,severe acute respiratory syndrome coronavirus2,4.1,-0.895971,0.221449,"A403,A405,A406,A408,A409,A414,A415,A416,A417,A420,A421,A449,A453,A455,A456,A457,A458,A459,A460,A473,A474,A475,A476,A477,A486,A487,A489,A493,A494,A495,A496,A498,A500,A501,A502,A503,A504,A505",SARS,9
1100,6Q0I,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,Inferred intermediate I-7 (I-7-6) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.702,0.765286,0.0481419,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A225,A226,A227",influenza,202
1101,6Q0I,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],W,71.96969696969697,Inferred intermediate I-7 (I-7-6) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.702,29.4258,0.694971,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A225,A226,A227",influenza,202
1102,6Q0I,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],Y,71.96969696969697,Inferred intermediate I-7 (I-7-6) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.702,36.7242,-0.147953,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A225,A226,A227",influenza,202
1103,6Q0I,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],W,71.96969696969697,Inferred intermediate I-7 (I-7-6) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.702,-2.10687,-1.42663,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A225,A226,A227",influenza,202
1104,6Q0I,H,33,33,IGHV4-4,N,['N' 'W' 'Y'],Y,71.96969696969697,Inferred intermediate I-7 (I-7-6) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.702,-1.20545,-0.882663,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A225,A226,A227",influenza,202
1105,6Q0I,H,34,34,IGHV4-4,W,['W' 'S'],S,100.0,Inferred intermediate I-7 (I-7-6) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.702,2.21145,1.52114,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A225,A226,A227",influenza,202
1106,6Q0I,H,53,54,IGHV4-4,H,['H' 'T'],T,71.96969696969697,Inferred intermediate I-7 (I-7-6) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.702,-0.270093,1.23623,"A95,A131,A133,A134,A135,A136,A137,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A225,A226,A227",influenza,202
1107,6Q0H,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,Inferred intermediate I-7 (I-7-0) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.75,1.19545,-0.0827131,"A95,A131,A133,A134,A135,A136,A137,A143,A144,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1108,6Q0H,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],W,71.96969696969697,Inferred intermediate I-7 (I-7-0) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.75,3.94973,0.727094,"A95,A131,A133,A134,A135,A136,A137,A143,A144,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1109,6Q0H,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],Y,71.96969696969697,Inferred intermediate I-7 (I-7-0) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.75,13.1697,0.469814,"A95,A131,A133,A134,A135,A136,A137,A143,A144,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1110,6Q0H,H,34,34,IGHV4-4,W,['W' 'S'],S,100.0,Inferred intermediate I-7 (I-7-0) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.75,3.21449,3.27477,"A95,A131,A133,A134,A135,A136,A137,A143,A144,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1111,6Q0H,H,53,54,IGHV4-4,H,['H' 'T'],T,71.96969696969697,Inferred intermediate I-7 (I-7-0) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.75,0.45799999999997,1.4139999999999873,"A95,A131,A133,A134,A135,A136,A137,A143,A144,A145,A153,A155,A156,A158,A159,A160,A183,A185,A186,A187,A189,A190,A192,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1112,6Q0E,H,31,31,IGHV4-4,S,['S' 'N'],N,100.0,Inferred precursor (UCA) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.15,-0.699361,-0.60721,"A95,A131,A133,A134,A135,A136,A137,A144,A145,A153,A155,A156,A158,A159,A183,A185,A186,A187,A189,A190,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1113,6Q0E,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],W,71.96969696969697,Inferred precursor (UCA) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.15,3.51824,-0.108453,"A95,A131,A133,A134,A135,A136,A137,A144,A145,A153,A155,A156,A158,A159,A183,A185,A186,A187,A189,A190,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1114,6Q0E,H,32,32,IGHV4-4,S,['S' 'W' 'Y'],Y,71.96969696969697,Inferred precursor (UCA) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.15,1.22332,-0.590268,"A95,A131,A133,A134,A135,A136,A137,A144,A145,A153,A155,A156,A158,A159,A183,A185,A186,A187,A189,A190,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1115,6Q0E,H,53,54,IGHV4-4,H,['H' 'T'],T,71.96969696969697,Inferred precursor (UCA) of the human antibody lineage 652 in complex with influenza hemagglutinin head domain of A/Beijing/262/95(H1N1),hemagglutinin,A,influenza a virus (a/beijing/262/1995(h1n1)),2.15,0.291092,0.0473324,"A95,A131,A133,A134,A135,A136,A137,A144,A145,A153,A155,A156,A158,A159,A183,A185,A186,A187,A189,A190,A193,A194,A196,A222,A225,A226,A227,A228",influenza,202
1116,7CWO,H,33,33,IGHV3-30,A,['A' 'G'],G,31.41153081510934,SARS-CoV-2 spike protein RBD and P17 fab complex,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.9,-0.859123,-0.929754,"A351,A446,A449,A450,A452,A455,A456,A470,A471,A472,A479,A480,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,249
1117,7CWO,H,50,50,IGHV3-30,V,['V' 'F'],F,91.45129224652086,SARS-CoV-2 spike protein RBD and P17 fab complex,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.9,5.42792,5.1691,"A351,A446,A449,A450,A452,A455,A456,A470,A471,A472,A479,A480,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,249
1118,7CWO,H,52,52,IGHV3-30,S,['S' 'R'],R,91.45129224652086,SARS-CoV-2 spike protein RBD and P17 fab complex,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.9,10.3449,-0.155985,"A351,A446,A449,A450,A452,A455,A456,A470,A471,A472,A479,A480,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,249
1119,7CWO,H,94,98,IGHV3-30,R,['R' 'K'],K,46.91848906560635,SARS-CoV-2 spike protein RBD and P17 fab complex,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.9,-1.39673,-0.728642,"A351,A446,A449,A450,A452,A455,A456,A470,A471,A472,A479,A480,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A492,A493,A494",SARS,249
1120,3R1G,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Structure Basis of Allosteric Inhibition of BACE1 by an Exosite-Binding Antibody,beta-secretase 1,B,homo sapiens,2.8,12.3606,-0.932585,"B314,B315,B316,B317,B318,B319,B327,B328,B329,B330,B331,B332,B333,B334,B335,B336,B337,B339,B340,B374,B375,B377,B378,B380,B426",Human,355
1121,8E7M,H,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,"Structure of the human ACE2 receptor in complex with antibody Fab fragment, 05B04",angiotensin-converting enzyme 2,A,homo sapiens,0,6.41632,2.2331,"A17,A18,A19,A20,A21,A23,A24,A26,A27,A28,A30,A31,A79,A82,A83,A87,A89",Human,356
1122,8E7M,H,52A,53,IGHV3-23,G,['G' 'S'],S,98.3983983983984,"Structure of the human ACE2 receptor in complex with antibody Fab fragment, 05B04",angiotensin-converting enzyme 2,A,homo sapiens,0,-0.719226,-1.12064,"A17,A18,A19,A20,A21,A23,A24,A26,A27,A28,A30,A31,A79,A82,A83,A87,A89",Human,356
1123,8E7M,H,53,54,IGHV3-23,S,['S' 'G'],G,99.2992992992993,"Structure of the human ACE2 receptor in complex with antibody Fab fragment, 05B04",angiotensin-converting enzyme 2,A,homo sapiens,0,-0.525969,0.211357,"A17,A18,A19,A20,A21,A23,A24,A26,A27,A28,A30,A31,A79,A82,A83,A87,A89",Human,356
1124,8E7M,L,30,30,IGKV1-17,S,['R' 'S'],R,17.73049645390071,"Structure of the human ACE2 receptor in complex with antibody Fab fragment, 05B04",angiotensin-converting enzyme 2,A,homo sapiens,0,2.29068,1.16105,"A17,A18,A19,A20,A21,A23,A24,A26,A27,A28,A30,A31,A79,A82,A83,A87,A89",Human,357
1125,8E7M,L,32,32,IGKV1-17,Y,['D' 'Y'],D,17.73049645390071,"Structure of the human ACE2 receptor in complex with antibody Fab fragment, 05B04",angiotensin-converting enzyme 2,A,homo sapiens,0,3.94191,1.83552,"A17,A18,A19,A20,A21,A23,A24,A26,A27,A28,A30,A31,A79,A82,A83,A87,A89",Human,357
1126,7SOA,H,26,26,IGHV3-30,G,['G' 'A'],A,100.0,SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.1,5.76922,5.227,"A23,A24,A25,A26,A28,A61,A63,A65,A80,A82,A83,A84,A85,A87,A88,A108,A109,A110,A111,A113,A114,A134,A137,A232,A234,A235,A267,A268,A269,A270",SARS,25
1127,7SOA,H,52,52,IGHV3-30,R,['S' 'R'],S,8.548707753479125,SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.1,0.938735,0.702647,"A23,A24,A25,A26,A28,A61,A63,A65,A80,A82,A83,A84,A85,A87,A88,A108,A109,A110,A111,A113,A114,A134,A137,A232,A234,A235,A267,A268,A269,A270",SARS,25
1128,3D0V,B,54,54,IGHV2-5,D,['N' 'D'],N,73.74301675977654,Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide LLELDKWASLW,gp41 peptide lleldkwaslw,C,,2.05,0.73072,-0.237237,"C2,C3,C4,C5,C6,C7,C8,C9",,
1129,7LJR,S,50,69,IGHV1-69,R,['G' 'R'],G,16.350710900473935,SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.66,3.85172,0.952196,"A351,A446,A447,A449,A450,A452,A453,A456,A468,A470,A472,A473,A475,A478,A479,A480,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A491,A492,A493,A494",SARS,358
1130,7LJR,S,54,74,IGHV1-69,F,['F' 'L'],L,84.67614533965246,SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.66,0.895326,-0.120343,"A351,A446,A447,A449,A450,A452,A453,A456,A468,A470,A472,A473,A475,A478,A479,A480,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A491,A492,A493,A494",SARS,358
1131,7LJR,S,56,76,IGHV1-69,I,['T' 'I'],T,13.11216429699842,SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab,spike glycoprotein,A,severe acute respiratory syndrome coronavirus2,3.66,0.872435,0.640692,"A351,A446,A447,A449,A450,A452,A453,A456,A468,A470,A472,A473,A475,A478,A479,A480,A481,A482,A483,A484,A485,A486,A487,A488,A489,A490,A491,A492,A493,A494",SARS,358
1132,6YXK,A,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of ACPA 3F3 in complex with cit-vimentin 59-74,citrullinated vimentin (59-74),C,homo sapiens,2.0,2.4892,2.35205,"C2,C3,C4,C6,C8,C9",Human,359
1133,5T29,H,50,50,IGHV3-15,R,['R' 'C'],C,100.0,"Crystal structure of 10E8 Fab light chain mutant3, against the MPER region of the HIV-1 Env, in complex with the MPER epitope scaffold T117v2",10e8 epitope scaffold t117v2,O,synthetic construct,2.03,3.15258,2.9643,"O64,O65,O66,O73,O78,O79,O118,O119,O120,O121,O124,O125,O127,O128,O130,O131,O134,O135",Synthetic,38
1134,5T29,H,58,58,IGHV3-15,D,['D' 'N'],N,99.45054945054945,"Crystal structure of 10E8 Fab light chain mutant3, against the MPER region of the HIV-1 Env, in complex with the MPER epitope scaffold T117v2",10e8 epitope scaffold t117v2,O,synthetic construct,2.03,-0.0350896,0.120951,"O64,O65,O66,O73,O78,O79,O118,O119,O120,O121,O124,O125,O127,O128,O130,O131,O134,O135",Synthetic,38
1135,4XMP,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC08 in complex with HIV-1 clade A strain Q842.d12 gp120,"envelope glycoprotein gp160,envelope glycoprotein gp160,envelope glycoprotein gp160",G,human immunodeficiency virus 1,1.7831,2.62474,1.9156,"G49,G96,G97,G99,G102,G103,G105,G106,G109,G124,G198,G275,G276,G278,G279,G280,G281,G282,G283,G353,G357,G365,G366,G367,G368,G371,G425,G426,G427,G429,G430,G455,G456,G457,G458,G459,G460,G461,G465,G466,G467,G469,G474,G476,G480",HIV,1
1136,7NCS,H,50,50,IGHV3-21,Y,['S' 'Y'],S,0.0,"Lateral-open conformation of the lid-locked BAM complex (BamA E435C S665C, BamBDCE) bound by a bactericidal Fab fragment",outer membrane protein assembly factor bama,A,escherichia coli k-12,7.1,1.41935,0.706267,"A550,A551,A552,A553,A554,A555,A556,A557,A558,A559,A560,A562,A563,A564,A565,A643,A644,A645,A675,A752,A753,A754",E Coli,360
1137,3NPS,B,54,54,IGHV1-69,F,['F' 'L'],L,84.67614533965246,Crystal structure of membrane-type serine protease 1 (MT-SP1) in complex with the Fab Inhibitor S4,suppressor of tumorigenicity 14 protein,A,homo sapiens,1.5,0.325502,0.56992,"A41,A42,A57,A58,A60A,A60B,A60C,A60D,A60G,A96,A97,A98,A99,A143,A146,A147,A148,A150,A173,A174,A175,A189,A190,A191,A192,A193,A195,A213,A215,A216,A217,A219,A220,A221A",Human,361
1138,5IQ7,H,50,50,IGHV3-15,R,['R' 'C'],C,100.0,Crystal structure of 10E8-S74W Fab in complex with an HIV-1 gp41 peptide.,gp41 mper peptide,P,human immunodeficiency virus 1,3.2869,1.45118,0.704654,"P667,P670,P671,P672,P673,P676,P677,P679,P680,P682,P683",HIV,215
1139,5OCK,L,50,51,IGLV1-51,D,['D' 'E'],E,83.18318318318319,Crystal structure of ACPA E4 in complex with CEP1,cep1 peptide (from enolase),A,homo sapiens,1.6,-0.113518,0.201673,"A2,A3,A4,A5,A9,A10,A11,A13,A14,A15,A16,A18",Human,362
1140,7WTG,H,33,33,IGHV1-69,A,['A' 'T'],T,95.260663507109,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,-0.0848544,0.830805,"E403,E408,E416,E417,E421,E449,E452,E453,E455,E456,E457,E473,E475,E476,E478,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E501,E505",SARS,363
1141,7WTG,H,50,50,IGHV1-69,G,['G' 'R'],R,83.64928909952607,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,5.0313,0.767392,"E403,E408,E416,E417,E421,E449,E452,E453,E455,E456,E457,E473,E475,E476,E478,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E501,E505",SARS,363
1142,7WTG,H,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,0.45403,0.172653,"E403,E408,E416,E417,E421,E449,E452,E453,E455,E456,E457,E473,E475,E476,E478,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E501,E505",SARS,363
1143,7WTG,H,56,57,IGHV1-69,T,['T' 'I'],I,86.8878357030016,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,-1.17648,-0.72687,"E403,E408,E416,E417,E421,E449,E452,E453,E455,E456,E457,E473,E475,E476,E478,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E501,E505",SARS,363
1144,7WTG,L,30,30,IGKV1-17,R,['R' 'S'],S,82.26950354609927,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,1.59583,0.29509,"E403,E408,E416,E417,E421,E449,E452,E453,E455,E456,E457,E473,E475,E476,E478,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E501,E505",SARS,364
1145,7WTG,L,32,32,IGKV1-17,D,['D' 'Y'],Y,82.26950354609927,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,0.385431,-0.0112145,"E403,E408,E416,E417,E421,E449,E452,E453,E455,E456,E457,E473,E475,E476,E478,E483,E484,E485,E486,E487,E488,E489,E490,E492,E493,E494,E496,E498,E501,E505",SARS,364
1146,7WTH,H,54,56,IGHV2-5,D,['N' 'D'],N,73.74301675977654,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv264,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,0.601121,-0.0120959,"E345,E346,E437,E439,E440,E441,E442,E443,E444,E445,E446,E447,E448,E449,E450,E498,E499,E500,E501,E502,E503,E506,E509",SARS,79
1147,7WTH,L,32,34,IGLV2-14,Y,['Y' 'L'],L,97.74590163934424,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv264,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,-0.0060875,-0.148398,"E345,E346,E437,E439,E440,E441,E442,E443,E444,E445,E446,E447,E448,E449,E450,E498,E499,E500,E501,E502,E503,E506,E509",SARS,84
1148,7WTH,L,50,52,IGLV2-14,E,['E' 'D'],D,56.55737704918033,SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv264,spike protein s1,E,severe acute respiratory syndrome coronavirus2,0,0.289374,0.764062,"E345,E346,E437,E439,E440,E441,E442,E443,E444,E445,E446,E447,E448,E449,E450,E498,E499,E500,E501,E502,E503,E506,E509",SARS,84
1149,6H2Y,H,54,55,IGHV1-69,F,['F' 'L'],L,84.67614533965246,human Fab 1E6 bound to fHbp variant 3 from Neisseria meningitidis serogroup B,lipoprotein gna1870,D,neisseria meningitidis,2.65,0.288953,0.0500078,"D51,D53,D54,D55,D56,D57,D58,D79,D82,D83,D84,D85,D86,D88,D97,D100,D101,D102,D117,D119,D120,D130,D132,D134,D166,D168,D169,D191",Meningococcus,365
1150,6H2Y,L,50,49,IGLV3-21,Y,['Y' 'D'],D,33.71757925072046,human Fab 1E6 bound to fHbp variant 3 from Neisseria meningitidis serogroup B,lipoprotein gna1870,D,neisseria meningitidis,2.65,1.85144,0.973836,"D51,D53,D54,D55,D56,D57,D58,D79,D82,D83,D84,D85,D86,D88,D97,D100,D101,D102,D117,D119,D120,D130,D132,D134,D166,D168,D169,D191",Meningococcus,366
1151,3SO3,C,50,50,IGHV3-23,A,['A' 'V'],V,99.2992992992993,Structures of Fab-Protease Complexes Reveal a Highly Specific Non-Canonical Mechanism of Inhibition.,suppressor of tumorigenicity 14 protein,A,homo sapiens,2.1,-2.05028,-1.40549,"A57,A60,A60A,A60B,A60C,A94,A95,A96,A97,A98,A99,A100,A146,A170,A171,A172,A173,A174,A175,A176,A177,A178,A179,A189,A190,A191,A192,A195,A213,A214,A215,A216,A217,A219,A220,A224,A226",Human,367
1152,3SO3,C,52,52,IGHV3-23,S,['S' 'Y'],Y,98.3983983983984,Structures of Fab-Protease Complexes Reveal a Highly Specific Non-Canonical Mechanism of Inhibition.,suppressor of tumorigenicity 14 protein,A,homo sapiens,2.1,31.7348,0.675355,"A57,A60,A60A,A60B,A60C,A94,A95,A96,A97,A98,A99,A100,A146,A170,A171,A172,A173,A174,A175,A176,A177,A178,A179,A189,A190,A191,A192,A195,A213,A214,A215,A216,A217,A219,A220,A224,A226",Human,367
1153,3SO3,C,52A,52A,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Structures of Fab-Protease Complexes Reveal a Highly Specific Non-Canonical Mechanism of Inhibition.,suppressor of tumorigenicity 14 protein,A,homo sapiens,2.1,1.19893,1.30388,"A57,A60,A60A,A60B,A60C,A94,A95,A96,A97,A98,A99,A100,A146,A170,A171,A172,A173,A174,A175,A176,A177,A178,A179,A189,A190,A191,A192,A195,A213,A214,A215,A216,A217,A219,A220,A224,A226",Human,367
1154,3SO3,C,53,53,IGHV3-23,S,['S' 'G'],G,99.2992992992993,Structures of Fab-Protease Complexes Reveal a Highly Specific Non-Canonical Mechanism of Inhibition.,suppressor of tumorigenicity 14 protein,A,homo sapiens,2.1,1.16841,-0.406371,"A57,A60,A60A,A60B,A60C,A94,A95,A96,A97,A98,A99,A100,A146,A170,A171,A172,A173,A174,A175,A176,A177,A178,A179,A189,A190,A191,A192,A195,A213,A214,A215,A216,A217,A219,A220,A224,A226",Human,367
1155,3SO3,C,55,55,IGHV3-23,G,['G' 'S'],S,98.3983983983984,Structures of Fab-Protease Complexes Reveal a Highly Specific Non-Canonical Mechanism of Inhibition.,suppressor of tumorigenicity 14 protein,A,homo sapiens,2.1,-0.268365,-0.652753,"A57,A60,A60A,A60B,A60C,A94,A95,A96,A97,A98,A99,A100,A146,A170,A171,A172,A173,A174,A175,A176,A177,A178,A179,A189,A190,A191,A192,A195,A213,A214,A215,A216,A217,A219,A220,A224,A226",Human,367
1156,3SE8,H,50,50,IGHV1-2,W,['R' 'W'],R,91.751269035533,Crystal structure of broadly and potently neutralizing antibody VRC03 in complex with HIV-1 gp120,hiv-1 clade ae strain 93th057 gp120,G,human immunodeficiency virus 1,1.895,3.27758,1.6233,"G97,G123,G124,G198,G199,G257,G276,G278,G279,G280,G281,G282,G283,G357,G365,G366,G367,G368,G370,G371,G375,G425,G426,G427,G429,G430,G431,G455,G456,G457,G458,G459,G460,G461,G462,G463,G465,G466,G467,G469,G472,G473,G474",HIV,1
